


**CUMULATIVE  
SUPPLEMENT 11  
NOVEMBER 2017**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**37th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2017**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**37<sup>th</sup> EDITION**

**Cumulative Supplement 11  
November 2017**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content .....	vi
1.3 Applicant Name Changes .....	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition .....	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend .....	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List .....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**37<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 11  
November 2017**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37<sup>th</sup> Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12<sup>th</sup> Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

mail to: FDA/CDER Orange Book Staff  
Office of Generic Drugs  
7620 Standish Place  
Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
JAI PHARMA LTD (JAI PHARMA LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
TG UNITED LABS LLC (TG UNITED LABS)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)

### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-

counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a



particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

#### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2016</u>	<u>MAR 2017</u>	<u>JUN 2017</u>	<u>SEP 2017</u>	<u>DEC 2017</u>
DRUG PRODUCTS	18130	18391	18711	19012	
LISTED SINGLE	2646	2688	2708	2721	
SOURCE	(14.6%)	(14.6%)	(14.5%)	(14.3%)	
MULTISOURCE	15484	15703	16003	16291	
	(85.4%)	(85.4%)	(85.5%)	(85.7%)	
THERAPEUTICALLY	15335	15581	15882	16180	
EQUIVALENT	(84.7%)	(84.7%)	(84.9%)	(85.1%)	
NOT THERAPEUTICALLY	129	122	121	111	
EQUIVALENT	(0.7%)	(0.7%)	(0.6%)	(0.6%)	
EXCEPTIONS <sup>1</sup>	73	73	73	73	
	(0.4%)	(0.4%)	(0.4%)	(0.4%)	
NEW MOLECULAR	7	14	17	14	
ENTITIES APPROVED					
NUMBER OF	1051	1053	1050	1054	
APPLICANTS					

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

#### 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code

for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**\*\*Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

TABLET;ORAL

ABACAVIR SULFATE

>A>	AB	CIPLA LTD	EQ 300MG BASE	A078119	001	Nov 21, 2017	Nov NEWA
-----	----	-----------	---------------	---------	-----	--------------	----------

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB		AUROBINDO PHARMA LTD	EQ 600MG BASE;300MG	A206151	001	Mar 28, 2017	Mar NEWA
AB		CIPLA LTD	EQ 600MG BASE;300MG	A091144	001	Mar 28, 2017	Mar NEWA
AB		LUPIN LTD	EQ 600MG BASE;300MG	A204990	001	Mar 28, 2017	Mar NEWA

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS

TYMLOS

+	!	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743	001	Apr 28, 2017	Apr NEWA
---	---	-------------------	------------------------	---------	-----	--------------	----------

ABEMACICLIB

TABLET;ORAL

VERZENIO

+		ELI LILLY AND CO	50MG	N208716	001	Sep 28, 2017	Sep NEWA
+			100MG	N208716	002	Sep 28, 2017	Sep NEWA
+			150MG	N208716	003	Sep 28, 2017	Sep NEWA
+	!		200MG	N208716	004	Sep 28, 2017	Sep NEWA

ABIRATERONE ACETATE

TABLET;ORAL

ZYTIGA

+		JANSSEN BIOTECH	500MG	N202379	002	Apr 14, 2017	May NEWA
---	--	-----------------	-------	---------	-----	--------------	----------

ACALABRUTINIB

CAPSULE;ORAL

CALQUENCE

>D>	+	!	ACERTA PHARMA BV	100MG	N210259	001	Oct 31, 2017	Nov CAHN
	+	!		100MG	N210259	001	Oct 31, 2017	Oct NEWA
>A>	+	!	ASTRAZENECA	100MG	N210259	001	Oct 31, 2017	Nov CAHN

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB		ZYDUS PHARMS USA INC	333MG	A205995	001	May 26, 2017	May NEWA
----	--	----------------------	-------	---------	-----	--------------	----------

ACETAMINOPHEN

SOLUTION;IV (INFUSION)

ACETAMINOPHEN

AP		CUSTOPHARM INC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Jan CAHN
----	--	----------------	---------------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA		TEDOR PHARMA INC	300MG;50MG	A207635	001	Jun 05, 2017	May NEWA
----	--	------------------	------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AB		TEDOR PHARMA INC	300MG;50MG;40MG	A206615	001	Aug 04, 2017	Jul NEWA
----	--	------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	Apr CTNA
AA		MALLINCKRODT INC	325MG;50MG;40MG	A087804	001	Jan 24, 1985	Mar CAHN
@		NOVAST LABS LTD	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Sep CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

>D>	AB		HIKMA INTL PHARMS	325MG;50MG;40MG;30MG	A075618	001	Mar 23, 2001	Nov DISC
>A>		@		325MG;50MG;40MG;30MG	A075618	001	Mar 23, 2001	Nov DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

## SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ ALLIED PHARMA INC 120MG/5ML;12MG/5ML

A 086366 001

Jul CAHN

## SUSPENSION;ORAL

CAPITAL AND CODEINE

@ VALEANT PHARMS LLC 120MG/5ML;12MG/5ML

A 086024 001

Aug DISC

## TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

&gt;A&gt; @ ANDA REPOSITORY

300MG;15MG

A 089673 002 Feb 10, 1988

Nov CMS1

&gt;A&gt; @

300MG;30MG

A 089673 003 Feb 10, 1988

Nov CMS1

@

300MG;60MG

A 089673 001 Feb 10, 1988

Sep CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

## SOLUTION;ORAL

ZYFREL

&gt;D&gt;

&gt;D&gt; AA CYPRESS PHARM INC

325MG/15ML;7.5MG/15ML

A 090468 001 Apr 14, 2016

Nov DISC

&gt;A&gt;

@

325MG/15ML;7.5MG/15ML

A 090468 001 Apr 14, 2016

Nov DISC

## TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA ABHAI LLC

300MG;5MG

A 209036 001 Jun 21, 2017

Jun NEWA

AA

300MG;7.5MG

A 209036 002 Jun 21, 2017

Jun NEWA

AA

300MG;10MG

A 209036 003 Jun 21, 2017

Jun NEWA

AA

325MG;5MG

A 209037 001 Jun 21, 2017

Jun NEWA

AA

325MG;7.5MG

A 209037 002 Jun 21, 2017

Jun NEWA

AA

325MG;10MG

A 209037 003 Jun 21, 2017

Jun NEWA

AA

AMNEAL PHARMS NY

300MG;5MG

A 206869 001 Jun 23, 2017

Jun NEWA

AA

LANNETT HOLDINGS INC

300MG;5MG

A 207171 001 Jun 20, 2017

Jun NEWA

AA

300MG;7.5MG

A 207171 002 Jun 20, 2017

Jun NEWA

AA

300MG;10MG

A 207171 003 Jun 20, 2017

Jun NEWA

AA

325MG;5MG

A 207172 001 Jun 22, 2017

Jun NEWA

AA

325MG;7.5MG

A 207172 002 Jun 22, 2017

Jun NEWA

AA

325MG;10MG

A 207172 003 Jun 22, 2017

Jun NEWA

AA

MALLINCKRODT INC

300MG;5MG

A 206718 001 Mar 31, 2017

Mar NEWA

AA

300MG;7.5MG

A 206718 002 Mar 31, 2017

Mar NEWA

AA

300MG;10MG

A 206718 003 Mar 31, 2017

Mar NEWA

AA

! MIKART

300MG;7.5MG

A 040658 002 Mar 24, 2006

May CHRS

AA

300MG;7.5MG

A 040658 002 Mar 24, 2006

Apr CMS1

AA

!

300MG;10MG

A 040658 003 Jun 23, 2004

May CHRS

AA

300MG;10MG

A 040658 003 Jun 23, 2004

Apr CMS1

AA

UPSHER-SMITH LABS

325MG;5MG

A 206484 001 Mar 24, 2017

Jun CAHN

AA

325MG;5MG

A 206484 001 Mar 24, 2017

Mar NEWA

AA

325MG;7.5MG

A 206484 002 Mar 24, 2017

Jun CAHN

AA

325MG;7.5MG

A 206484 002 Mar 24, 2017

Mar NEWA

AA

325MG;10MG

A 206484 003 Mar 24, 2017

Jun CAHN

AA

325MG;10MG

A 206484 003 Mar 24, 2017

Mar NEWA

AA

WES PHARMA INC

325MG;5MG

A 210211 001 Oct 30, 2017

Oct NEWA

AA

325MG;7.5MG

A 210211 002 Oct 30, 2017

Oct NEWA

AA

325MG;10MG

A 210211 003 Oct 30, 2017

Oct NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

## TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA AMNEAL PHARMS

325MG;5MG

A 040777 001 Nov 27, 2007

May CAHN

AA

ASCENT PHARMS INC

325MG;2.5MG

A 207419 001 Mar 22, 2017

Mar NEWA

AA

325MG;5MG

A 207419 002 Mar 22, 2017

Mar NEWA

AA

325MG;7.5MG

A 207419 003 Mar 22, 2017

Mar NEWA

AA

325MG;10MG

A 207419 004 Mar 22, 2017

Mar NEWA

&gt;D&gt; AA CEROVENE INC

325MG;5MG

A 207574 001 Dec 13, 2016

Nov CAHN

&gt;A&gt; AA

CHEMO RESEARCH SL

325MG;5MG

A 207574 001 Dec 13, 2016

Nov CAHN

AA

LANNETT HOLDINGS INC

325MG;5MG

A 207333 001 Sep 25, 2017

Sep NEWA

AA

325MG;10MG

A 207333 002 Sep 25, 2017

Sep NEWA

AA

NOVEL LABS INC

325MG;2.5MG

A 204407 001 Feb 24, 2017

Feb NEWA

AA

325MG;5MG

A 204407 002 Feb 24, 2017

Feb NEWA

AA

325MG;7.5MG

A 204407 003 Feb 24, 2017

Feb NEWA

AA

325MG;10MG

A 204407 004 Feb 24, 2017

Feb NEWA

PERCOCET

AA

!

VINTAGE PHARMS LLC

325MG;7.5MG

A 040330 003 Nov 23, 2001

Jan CMS1

AA

!

325MG;10MG

A 040330 004 Nov 23, 2001

Jan CMS1

TABLET, EXTENDED RELEASE;ORAL  
XARTEMIS XR

+ @ MALLINCKRODT INC 325MG;7.5MG N204031 001 Mar 11, 2014 Aug DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>A>	AB	ALKEM LABS LTD	325MG;37.5MG	A202076	001	Mar 30, 2012	Nov CAHN
>D>	AB	APOGEE PHARMA	325MG;37.5MG	A202076	001	Mar 30, 2012	Nov CAHN
	AB		325MG;37.5MG	A202076	001	Mar 30, 2012	Sep CAHN
	AB	AUROBINDO PHARMA LTD	325MG;37.5MG	A207152	001	Mar 22, 2017	Mar NEWA
		@ CSPC OUYI PHARM CO	325MG;37.5MG	A076914	001	Jul 26, 2006	Oct CAHN
	AB	MACLEODS PHARMS LTD	325MG;37.5MG	A206885	001	May 02, 2017	Apr NEWA

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

>A>	AB	STRIDES PHARMA	125MG	A209734	001	Nov 20, 2017	Nov NEWA
>A>	AB		250MG	A209734	002	Nov 20, 2017	Nov NEWA
	AB	SUN PHARM INDUSTRIES	125MG	A089753	002	Jun 22, 1988	Jul CMS1

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP		PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	Jun NEWA
----	--	----------------------	--------------------	---------	-----	--------------	----------

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT		ICU MEDICAL INC	250MG/100ML	N017656	001		Feb CAHN
----	--	-----------------	-------------	---------	-----	--	----------

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

		@ BAUSCH AND LOMB	2%;0.79%	A040063	001	Feb 25, 1994	Oct DISC
--	--	-------------------	----------	---------	-----	--------------	----------

ACETOHEXAMIDE

TABLET;ORAL

ACETOHEXAMIDE

		@ WATSON LABS TEVA	250MG	A071893	001	Nov 25, 1987	May CAHN
		@	500MG	A071894	001	Nov 25, 1987	May CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP		SAGENT PHARMS	6GM/30ML (200MG/ML)	A091684	001	Oct 31, 2017	Oct NEWA
----	--	---------------	---------------------	---------	-----	--------------	----------

ACITRETIN

CAPSULE;ORAL

ACITRETIN

		@ MYLAN PHARMS INC	17.5MG	A203707	001	Sep 10, 2015	Oct DISC
		@	22.5MG	A203707	002	Sep 10, 2015	Oct DISC

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

		+! AUXILIUM PHARMS LLC	8MG;60MG	N019806	001	Mar 25, 1994	May CAHN
--	--	------------------------	----------	---------	-----	--------------	----------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB	!	APOTEX INC	200MG	A075677	001	Sep 28, 2005	Oct CHRS
AB		BOSCOGEN	200MG	A075090	001	Jan 26, 1999	May CAHN
AB		CARLSBAD TECHNOLOGY	200MG	A206261	001	Aug 16, 2017	Aug NEWA
		@ CHARTWELL MOLECULES	200MG	A074872	001	Apr 22, 1997	Jan CAHN
		@ MYLAN	200MG	A074727	001	Apr 22, 1997	Jun DISC
		ZOVIRAX					
AB	+	MYLAN PHARMS INC	200MG	N018828	001	Jan 25, 1985	Oct CHRS
		OINTMENT;TOPICAL					
		ACYCLOVIR					
AB		G AND W LABS INC	5%	A205591	001	Nov 13, 2017	Oct NEWA
AB		GLENMARK PHARMS LTD	5%	A205510	001	Jul 31, 2017	Jul NEWA

OINTMENT; TOPICAL							
ACYCLOVIR							
AB	TOLMAR	5%	A206437	001	Jul 31, 2017	Jul	NEWA
SUSPENSION; ORAL							
ZOVIRAX							
AB	+! MYLAN PHARMS INC	200MG/5ML	N019909	001	Dec 22, 1989	Jan	CAHN
TABLET; BUCCAL							
SITAVIG							
	+! EPI HLTH	50MG	N203791	001	Apr 12, 2013	Jun	CAHN
TABLET; ORAL							
ACYCLOVIR							
	@ CHARTWELL MOLECULES	400MG	A074834	001	Apr 24, 1997	Jan	CAHN
	@	800MG	A074834	002	Apr 24, 1997	Jan	CAHN
AB	HERITAGE PHARMS INC	400MG	A074891	001	Oct 31, 1997	Apr	CMFD
AB		800MG	A074891	002	Oct 31, 1997	Apr	CMFD
AB	MYLAN PHARMS INC	400MG	A075211	001	Sep 28, 1998	Mar	CAHN
AB		800MG	A075211	002	Sep 28, 1998	Mar	CAHN
ZOVIRAX							
AB	+ MYLAN PHARMS INC	400MG	N020089	001	Apr 30, 1991	Jan	CAHN
AB	+!	800MG	N020089	002	Apr 30, 1991	Jan	CAHN
<u>ACYCLOVIR SODIUM</u>							
INJECTABLE; INJECTION							
ACYCLOVIR SODIUM							
	@ ATHENEX INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar	CAHN
	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar	CAHN
AP	! HIKMA PHARMS	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Mar	CTEC
AP	ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017	May	NEWA
AP		EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017	May	NEWA
<u>ADENOSINE</u>							
INJECTABLE; INJECTION							
ADENOSINE							
AP	WEST-WARD PHARMS INT	3MG/ML	A076404	001	Jun 16, 2004	Jan	CAHN
AP		3MG/ML	A076500	001	Jun 16, 2004	Jan	CAHN
	@	3MG/ML	A076501	001	Jun 16, 2004	Jan	CAHN
SOLUTION; IV (INFUSION)							
ADENOSINE							
AP	AUROBINDO PHARMA LTD	60MG/20ML (3MG/ML)	A205331	001	Nov 02, 2017	Oct	NEWA
AP		90MG/30ML (3MG/ML)	A205331	002	Nov 02, 2017	Oct	NEWA
>A> AP	FRESENIUS KABI USA	60MG/20ML (3MG/ML)	A077897	001	Nov 27, 2017	Nov	NEWA
>A> AP		90MG/30ML (3MG/ML)	A077897	002	Nov 27, 2017	Nov	NEWA
<u>ALBENDAZOLE</u>							
TABLET; ORAL							
ALBENZA							
	+! IMPAX LABS INC	200MG	N020666	001	Jun 11, 1996	Jun	CAHN
<u>ALBUTEROL SULFATE</u>							
AEROSOL, METERED; INHALATION							
PROVENTIL-HFA							
BX	+! 3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May	CAHN
SOLUTION; INHALATION							
ALBUTEROL SULFATE							
AN	AUROBINDO PHARMA LTD	EQ 0.083% BASE	A206224	001	Oct 17, 2017	Oct	NEWA
AN	SUN PHARMA GLOBAL	EQ 0.083% BASE	A207857	001	Jul 21, 2017	Jul	NEWA
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>							
SOLUTION; INHALATION							
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE							
>A> AN	SUN PHARMA GLOBAL	EQ 0.083% BASE; 0.017%	A207875	001	Aug 07, 2017	Nov	CMS1
>D> AN		EQ 0.083% BASE; 0.17%	A207875	001	Aug 07, 2017	Nov	CMS1
AN		EQ 0.083% BASE; 0.17%	A207875	001	Aug 07, 2017	Jul	NEWA
AN	WATSON LABS TEVA	EQ 0.083% BASE; 0.017%	A077063	001	Dec 31, 2007	Feb	CAHN
<u>ALENDRONATE SODIUM</u>							
SOLUTION; ORAL							
FOSAMAX							
	+ @ MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Sep	CRLD

## TABLET;ORAL

## ALENDRONATE SODIUM

@ UPSHER-SMITH LABS

EQ 5MG BASE

A075871 001 Apr 22, 2009 Jun CAHN

@

EQ 10MG BASE

A075871 002 Apr 22, 2009 Jun CAHN

@

EQ 35MG BASE

A075871 004 Apr 22, 2009 Jun CAHN

@

EQ 40MG BASE

A075871 003 Apr 22, 2009 Jun CAHN

@

EQ 70MG BASE

A075871 005 Apr 22, 2009 Jun CAHN

ALISKIREN HEMIFUMARATE

&gt;A&gt; CAPSULE, PELLET;ORAL

&gt;A&gt; TEKTRNA

&gt;A&gt; +! NODEN PHARMA EQ 37.5MG BASE N210709 001 Nov 14, 2017 Nov NEWA

ALLOPURINOL

## TABLET;ORAL

## ALLOPURINOL

&gt;A&gt; AB SUN PHARM INDUSTRIES

100MG

A071450 002 Jan 09, 1987 Nov CMS1

AB ZYDUS PHARMS USA INC

100MG

A210117 001 Oct 12, 2017 Oct NEWA

AB 300MG

A210117 002 Oct 12, 2017 Oct NEWA

## ZYLOPRIM

AB + CASPER PHARMA LLC

100MG

N016084 001 Jul CAHN

AB +! 300MG

N016084 002 Jul CAHN

ALLOPURINOL; LESINURAD

## TABLET;ORAL

## DUZALLO

+ ARDEA BIOSCIENCES

200MG;200MG

N209203 001 Aug 18, 2017 Aug NEWA

+! 300MG;200MG

N209203 002 Aug 18, 2017 Aug NEWA

+ IRONWOOD PHARMS INC

200MG;200MG

N209203 001 Aug 18, 2017 Sep CAHN

+! 300MG;200MG

N209203 002 Aug 18, 2017 Sep CAHN

ALOSETRON HYDROCHLORIDE

## TABLET;ORAL

## ALOSETRON HYDROCHLORIDE

AB AMNEAL PHARMS

EQ 0.5MG BASE

A206647 001 Dec 22, 2016 May CAHN

AB EQ 1MG BASE

A206647 002 Dec 22, 2016 May CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

## INJECTABLE;INJECTION

## INFUVITE ADULT

+! SANDOZ INC

2 IU/ML;40MG/ML;12MCG/ML;40  
IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG  
/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;66  
0 IU/ML;0.03MG/ML

N021163 001 May 18, 2000 May CAHN

## INJECTABLE;IV (INFUSION)

## INFUVITE ADULT

+! SANDOZ INC

2 IU/ML;40MG/ML;12MCG/ML;40  
IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG  
/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;66  
0 IU/ML;30MCG/ML

N021559 001 Jun 16, 2003 May CAHN

ALPRAZOLAM

## TABLET;ORAL

## ALPRAZOLAM

AB ACTAVIS ELIZABETH

0.25MG

A074342 001 Oct 31, 1993 Apr CAHN

AB 0.5MG

A074342 002 Oct 31, 1993 Apr CAHN

AB 1MG

A074342 003 Oct 31, 1993 Apr CAHN

AB 2MG

A074342 004 Oct 31, 1993 Apr CAHN

&gt;D&gt; AB MYLAN PHARMS INC

0.25MG

A074046 001 Oct 19, 1993 Nov DISC

&gt;A&gt; @ 0.25MG

A074046 001 Oct 19, 1993 Nov DISC

&gt;D&gt; AB 0.5MG

A074046 002 Oct 19, 1993 Nov DISC

&gt;A&gt; @ 0.5MG

A074046 002 Oct 19, 1993 Nov DISC

&gt;D&gt; AB 1MG

A074046 003 Oct 19, 1993 Nov DISC

&gt;A&gt; @ 1MG

A074046 003 Oct 19, 1993 Nov DISC

&gt;D&gt; AB 2MG

A074046 004 May 07, 1997 Nov DISC

&gt;A&gt; @ 2MG

A074046 004 May 07, 1997 Nov DISC

## TABLET, EXTENDED RELEASE;ORAL

## ALPRAZOLAM

AB AUROBINDO PHARMA LTD

0.5MG

A090871 001 Jun 07, 2011 Jan CAHN

AB 1MG

A090871 002 Jun 07, 2011 Jan CAHN

AB 2MG

A090871 003 Jun 07, 2011 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL  
ALPRAZOLAM

AB		3MG	A090871	004	Jun 07, 2011	Jan CAHN	
>D>	AB	MYLAN	0.5MG	A077391	002	Jan 26, 2006	Nov DISC
>A>	@	0.5MG	A077391	002	Jan 26, 2006	Nov DISC	
>D>	AB	1MG	A077391	003	Jan 26, 2006	Nov DISC	
>A>	@	1MG	A077391	003	Jan 26, 2006	Nov DISC	
>D>	AB	2MG	A077391	004	Jan 26, 2006	Nov DISC	
>A>	@	2MG	A077391	004	Jan 26, 2006	Nov DISC	
>D>	AB	3MG	A077391	001	Jan 26, 2006	Nov DISC	
>A>	@	3MG	A077391	001	Jan 26, 2006	Nov DISC	

TABLET, ORALLY DISINTEGRATING;ORAL  
ALPRAZOLAM

AB	ACTAVIS ELIZABETH	0.25MG	A078561	001	Mar 16, 2010	Sep CAHN
AB		0.5MG	A078561	002	Mar 16, 2010	Sep CAHN
AB		1MG	A078561	003	Mar 16, 2010	Sep CAHN
AB		2MG	A078561	004	Mar 16, 2010	Sep CAHN

ALPROSTADIL

INJECTABLE;INJECTION  
EDEX

	@ AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	May CAHN
AP	+	0.01MG/VIAL	N020649	002	Jun 12, 1997	May CAHN
	+	0.01MG/VIAL	N020649	005	Jul 30, 1998	May CAHN
AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	May CAHN
	+	0.02MG/VIAL	N020649	006	Jul 30, 1998	May CAHN
AP	+	0.04MG/VIAL	N020649	004	Jun 12, 1997	May CAHN
	+	0.04MG/VIAL	N020649	007	Jul 30, 1998	May CAHN

SUPPOSITORY;URETHRAL  
MUSE

+	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Mar CAHN
+		0.25MG	N020700	002	Nov 19, 1996	Mar CAHN
+		0.5MG	N020700	003	Nov 19, 1996	Mar CAHN
+		1MG	N020700	004	Nov 19, 1996	Mar CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	100MG	A208966	001	Jun 21, 2017	Jun NEWA
AB	HERITAGE PHARMA	100MG	A209171	001	Jun 12, 2017	May NEWA
AB	LANNETT HOLDINGS INC	100MG	A209221	001	Jun 15, 2017	May NEWA
AB	STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	May NEWA
AB	USL PHARMA	100MG	A070589	001	Aug 05, 1986	Jun CAHN

CAPSULE, EXTENDED RELEASE;ORAL  
GOCOVRI

+	ADAMAS PHARMA	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug NEWA
+		EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug NEWA

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

AA	!	CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002	Apr CAHN
AA	!	PHARM ASSOC	50MG/5ML	A074509	001	Jul 17, 1995	May CAHN

SYMMETREL

+	@ ENDO PHARMS	50MG/5ML	N016023	002		Jan CRLD
---	---------------	----------	---------	-----	--	----------

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

AB	NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Jan NEWA	
AB	STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	May NEWA	
AB	!	USL PHARMA	100MG	A076186	001	Dec 16, 2002	Jun CAHN

AMCINONIDE

CREAM;TOPICAL

CYCLOCORT

+	@ ASTELLAS	0.025%	N018116	001		Jun CRLD
+	@	0.1%	N018116	002		Jun CRLD

LOTION;TOPICAL

CYCLOCORT

+	@ ASTELLAS	0.1%	N019729	001	Jun 13, 1988	Jun CRLD
---	------------	------	---------	-----	--------------	----------

OINTMENT;TOPICAL

CYCLOCORT

+	@ ASTELLAS	0.1%	N018498	001		Jun CRLD
---	------------	------	---------	-----	--	----------



AMIFOSTINE

INJECTABLE; INJECTION  
AMIFOSTINE

AP	MYLAN LABS LTD	500MG/VIAL	A204363	001	Jul 17, 2017	Jul NEWA
AP	SUN PHARMA GLOBAL	500MG/VIAL	A077126	001	Mar 14, 2008	Apr CAHN

AMILORIDE HYDROCHLORIDE

TABLET; ORAL  
AMILORIDE HYDROCHLORIDE

AB	WINDLAS HLTHCARE	5MG	A204180	001	Aug 07, 2015	Jul CAHN
----	------------------	-----	---------	-----	--------------	----------

AMINO ACIDS

INJECTABLE; INJECTION  
AMINOSYN 10%

ICU MEDICAL INC	10% (10GM/100ML)	N017673	003		Feb CAHN
-----------------	------------------	---------	-----	--	----------

AMINOSYN 10% (PH6)	ICU MEDICAL INC	10% (10GM/100ML)	N017673	008	Nov 18, 1985	Feb CAHN
--------------------	-----------------	------------------	---------	-----	--------------	----------

AMINOSYN 3.5%	ICU MEDICAL INC	3.5% (3.5GM/100ML)	N017789	004		Feb CAHN
---------------	-----------------	--------------------	---------	-----	--	----------

AMINOSYN 5%	ICU MEDICAL INC	5% (5GM/100ML)	N017673	001		Feb CAHN
-------------	-----------------	----------------	---------	-----	--	----------

AMINOSYN 7%	ICU MEDICAL INC	7% (7GM/100ML)	N017673	002		Feb CAHN
-------------	-----------------	----------------	---------	-----	--	----------

AMINOSYN 7% (PH6)	ICU MEDICAL INC	7% (7GM/100ML)	N017673	006	Nov 18, 1985	Feb CAHN
-------------------	-----------------	----------------	---------	-----	--------------	----------

AMINOSYN 8.5%	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	004		Feb CAHN
---------------	-----------------	--------------------	---------	-----	--	----------

AMINOSYN 8.5% (PH6)	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985	Feb CAHN
---------------------	-----------------	--------------------	---------	-----	--------------	----------

AMINOSYN II 10%	ICU MEDICAL INC	10% (10GM/100ML)	N019438	005	Apr 03, 1986	Feb CAHN
-----------------	-----------------	------------------	---------	-----	--------------	----------

AMINOSYN II 10% IN PLASTIC CONTAINER	ICU MEDICAL INC	10% (10GM/100ML)	N020015	001	Dec 19, 1991	Feb CAHN
--------------------------------------	-----------------	------------------	---------	-----	--------------	----------

AMINOSYN II 15% IN PLASTIC CONTAINER	ICU MEDICAL INC	15% (15GM/100ML)	N020041	001	Dec 19, 1991	Feb CAHN
--------------------------------------	-----------------	------------------	---------	-----	--------------	----------

AMINOSYN II 3.5%	@ ICU MEDICAL INC	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986	Feb CAHN
------------------	-------------------	--------------------	---------	-----	--------------	----------

AMINOSYN II 5%	@ ICU MEDICAL INC	5% (5GM/100ML)	N019438	002	Apr 03, 1986	Feb CAHN
----------------	-------------------	----------------	---------	-----	--------------	----------

AMINOSYN II 7%	ICU MEDICAL INC	7% (7GM/100ML)	N019438	003	Apr 03, 1986	Feb CAHN
----------------	-----------------	----------------	---------	-----	--------------	----------

AMINOSYN II 8.5%	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986	Feb CAHN
------------------	-----------------	--------------------	---------	-----	--------------	----------

AMINOSYN-HBC 7%	ICU MEDICAL INC	7% (7GM/100ML)	N019374	001	Jul 12, 1985	Feb CAHN
-----------------	-----------------	----------------	---------	-----	--------------	----------

AMINOSYN-HF 8%	ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996	Jun CAHN
----------------	-----------------	----------------	---------	-----	--------------	----------

AMINOSYN-PF 10%	ICU MEDICAL INC	10% (10GM/100ML)	N019492	002	Oct 17, 1986	Feb CAHN
-----------------	-----------------	------------------	---------	-----	--------------	----------

AMINOSYN-PF 7%	ICU MEDICAL INC	7% (7GM/100ML)	N019398	001	Sep 06, 1985	Feb CAHN
----------------	-----------------	----------------	---------	-----	--------------	----------

AMINOSYN-RF 5.2%	ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429	001		Apr CAHN
------------------	-----------------	--------------------	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION  
AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	N017789	003		Feb CAHN
-----------------	--	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION  
AMINOSYN 3.5% M

@ ICU MEDICAL INC	3.5%; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017789	005		Feb CAHN
-------------------	--	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC	10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	004	Apr 03, 1986	Apr CAHN
-----------------	--	---------	-----	--------------	----------

AMINOSYN II 7% W/ ELECTROLYTES

@ ICU MEDICAL INC	7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	006	Apr 03, 1986	Apr CAHN
-------------------	---	---------	-----	--------------	----------

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	005	Apr 03, 1986	Apr CAHN
-----------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M

@ ICU MEDICAL INC	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N019437	007	Apr 03, 1986	Apr CAHN
-------------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 7% W/ ELECTROLYTES

ICU MEDICAL INC	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789	002		Feb CAHN
-----------------	--	---------	-----	--	----------

AMINOSYN 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673	005		Feb CAHN
-----------------	--	---------	-----	--	----------

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION;ORAL

GLEOLAN

+! NXDC	1.5GM/VIAL	N208630	001	Jun 06, 2017	Jun NEWA
---------	------------	---------	-----	--------------	----------

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	50MG/ML	A204550	001	Oct 25, 2017	Oct NEWA
----	----------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

AB	MAYNE PHARMA INC	200MG	A075389	001	Jan 25, 2001	Jan CAHN
	@ MYLAN	200MG	A075188	001	Feb 24, 1999	Mar DISC
AB	! SANDOZ	200MG	A075315	001	Dec 23, 1998	Mar CHRS
AB	TARO PHARM	100MG	A075424	002	Dec 18, 2002	Mar CAHN
AB		200MG	A075424	001	Mar 30, 2001	Mar CAHN
		300MG	A076362	002	Dec 02, 2003	Mar CAHN
AB		400MG	A076362	001	Nov 29, 2002	Mar CAHN
	PACERONE					
AB	UPSHER-SMITH LABS	100MG	A075135	002	Apr 12, 2005	Jun CAHN
AB		200MG	A075135	001	Apr 30, 1998	Jun CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	10MG	A210086	001	Oct 06, 2017	Sep NEWA
AB		25MG	A210086	002	Oct 06, 2017	Sep NEWA
AB		50MG	A210086	003	Oct 06, 2017	Sep NEWA
AB		75MG	A210086	004	Oct 06, 2017	Sep NEWA
AB		100MG	A210086	005	Oct 06, 2017	Sep NEWA
AB		150MG	A210086	006	Oct 06, 2017	Sep NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@ ANDA REPOSITORY	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Sep CAHN
@	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Sep CAHN
@ WATSON LABS TEVA	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988	May CAHN

AMLODIPINE BESYLATE

## TABLET; ORAL

## AMLODIPINE BESYLATE

AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A076418	001	Oct 03, 2005	Mar CAHN
	@	EQ 2.5MG BASE	A078224	001	Feb 27, 2008	May DISC
AB		EQ 5MG BASE	A076418	002	Oct 03, 2005	Mar CAHN
	@	EQ 5MG BASE	A078224	002	Feb 27, 2008	May DISC
AB		EQ 10MG BASE	A076418	003	Oct 03, 2005	Mar CAHN
	@	EQ 10MG BASE	A078224	003	Feb 27, 2008	May DISC
	@ SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015	Sep DISC
	@	EQ 5MG BASE	A204900	002	Jul 23, 2015	Sep DISC
	@	EQ 10MG BASE	A204900	003	Jul 23, 2015	Sep DISC
AB	UPSHER-SMITH LABS	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Jun CAHN
AB		EQ 5MG BASE	A077759	002	Jul 09, 2007	Jun CAHN
AB		EQ 10MG BASE	A077759	003	Jul 09, 2007	Jun CAHN
AB	VIVIMED GLOBAL	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Aug CAHN
AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Aug CAHN
AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Aug CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

## TABLET; ORAL

## AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;20MG	A207073	001	Jul 17, 2017	Jul NEWA
AB		EQ 5MG BASE;40MG	A207073	002	Jul 17, 2017	Jul NEWA
AB		EQ 10MG BASE;20MG	A207073	003	Jul 17, 2017	Jul NEWA
AB		EQ 10MG BASE;40MG	A207073	004	Jul 17, 2017	Jul NEWA
AB	ALKEM LABS LTD	EQ 5MG BASE;20MG	A209042	001	Aug 14, 2017	Jul NEWA
AB		EQ 5MG BASE;40MG	A209042	002	Aug 14, 2017	Jul NEWA
AB		EQ 10MG BASE;20MG	A209042	003	Aug 14, 2017	Jul NEWA
AB		EQ 10MG BASE;40MG	A209042	004	Aug 14, 2017	Jul NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;20MG	A206906	001	May 15, 2017	May NEWA
AB		EQ 5MG BASE;40MG	A206906	002	May 15, 2017	May NEWA
AB		EQ 10MG BASE;20MG	A206906	003	May 15, 2017	May NEWA
AB		EQ 10MG BASE;40MG	A206906	004	May 15, 2017	May NEWA
AB	GLENMARK PHARMS LTD	EQ 5MG BASE;20MG	A207807	001	Jul 05, 2017	Jun NEWA
AB		EQ 5MG BASE;40MG	A207807	002	Jul 05, 2017	Jun NEWA
AB		EQ 10MG BASE;20MG	A207807	003	Jul 05, 2017	Jun NEWA
AB		EQ 10MG BASE;40MG	A207807	004	Jul 05, 2017	Jun NEWA
AB	JUBILANT GENERICS	EQ 5MG BASE;20MG	A207450	001	May 15, 2017	May NEWA
AB		EQ 5MG BASE;40MG	A207450	002	May 15, 2017	May NEWA
AB		EQ 10MG BASE;20MG	A207450	003	May 15, 2017	May NEWA
AB		EQ 10MG BASE;40MG	A207450	004	May 15, 2017	May NEWA
AB	MICRO LABS	EQ 5MG BASE;20MG	A207435	001	Nov 02, 2017	Oct NEWA
AB		EQ 5MG BASE;40MG	A207435	002	Nov 02, 2017	Oct NEWA
AB		EQ 10MG BASE;20MG	A207435	003	Nov 02, 2017	Oct NEWA
AB		EQ 10MG BASE;40MG	A207435	004	Nov 02, 2017	Oct NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Apr CAHN
AB		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Apr CAHN
AB		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Apr CAHN
AB		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Apr CAHN
AB	ZYDUS PHARMS USA INC	EQ 5MG BASE;20MG	A207771	001	Sep 22, 2017	Sep NEWA
AB		EQ 5MG BASE;40MG	A207771	002	Sep 22, 2017	Sep NEWA
AB		EQ 10MG BASE;20MG	A207771	003	Sep 22, 2017	Sep NEWA
AB		EQ 10MG BASE;40MG	A207771	004	Sep 22, 2017	Sep NEWA

AMMONIA N-13

## INJECTABLE; INTRAVENOUS

## AMMONIA N 13

AP	GEN HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	May CAHN
----	----------	------------------------------------	---------	-----	--------------	----------

AMMONIUM LACTATE

## LOTION; TOPICAL

## LAC-HYDRIN

	+ @ RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Jan CRLD
--	-------------	-------------	---------	-----	--------------	----------

AMOXAPINE

## TABLET; ORAL

## AMOXAPINE

@ UPSHER-SMITH LABS

@

@

@

25MG

50MG

100MG

150MG

A072943 001 Jun 28, 1991 Jun CAHN

A072944 001 Jun 28, 1991 Jun CAHN

A072878 001 Jun 28, 1991 Jun CAHN

A072879 001 Jun 28, 1991 Jun CAHN

## TABLET;ORAL

## AMOXAPINE

@ WATSON PHARMS TEVA

25MG

A072418 001 May 11, 1989 Feb CAHN

@

50MG

A072419 001 May 11, 1989 Feb CAHN

@

100MG

A072420 001 May 11, 1989 Feb CAHN

@

150MG

A072421 001 May 11, 1989 Feb CAHN

AMOXICILLIN

## FOR SUSPENSION;ORAL

## AMOXIL

+ @ DR REDDYS LABS INC

200MG/5ML

N050760 001 Apr 15, 1999 Sep CRLD

@

200MG/5ML

N050760 001 Apr 15, 1999 Feb DISC

+ @

400MG/5ML

N050760 002 Apr 15, 1999 Sep CRLD

@

400MG/5ML

N050760 002 Apr 15, 1999 Feb DISC

## TABLET, CHEWABLE;ORAL

## AMOXICILLIN

TEVA

125MG

A064013 002 Sep 11, 1995 Feb CTEC

!

250MG

A064013 001 Dec 22, 1992 Feb CTEC

AMOXICILLIN; CLAVULANATE POTASSIUM

## FOR SUSPENSION;ORAL

## AUGMENTIN '125'

&gt;D&gt; AB

+ DR REDDYS LABS INC

125MG/5ML;EQ 31.25MG BASE/5ML

N050575 001 Aug 06, 1984 Nov CTEC

&gt;A&gt;

+ DR REDDYS LABS INC

125MG/5ML;EQ 31.25MG BASE/5ML

N050575 001 Aug 06, 1984 Nov CTEC

## AUGMENTIN '200'

+ @ DR REDDYS LABS INC

200MG/5ML;EQ 28.5MG BASE/5ML

N050725 001 May 31, 1996 Feb DISC

## AUGMENTIN '400'

+ @ DR REDDYS LABS INC

400MG/5ML;EQ 57MG BASE/5ML

N050725 002 May 31, 1996 Feb DISC

## AUGMENTIN ES-600

+ @ DR REDDYS LABS INC

600MG/5ML;EQ 42.9MG BASE/5ML

N050755 001 Jun 22, 2001 Feb DISC

## TABLET;ORAL

## AMOXICILLIN AND CLAVULANATE POTASSIUM

AB

! SANDOZ

250MG;EQ 125MG BASE

A065189 001 Aug 23, 2005 Feb CHRS

AB

!

875MG;EQ 125MG BASE

A065063 001 Mar 14, 2002 Oct CHRS

AB

! SANDOZ INC

500MG;EQ 125MG BASE

A065117 001 Nov 27, 2002 Feb CHRS

## AUGMENTIN '875'

AB

+ DR REDDYS LABS INC

875MG;EQ 125MG BASE

N050720 001 Feb 13, 1996 Oct CHRS

## TABLET, CHEWABLE;ORAL

## AMOXICILLIN AND CLAVULANATE POTASSIUM

TEVA

200MG;EQ 28.5MG BASE

A065205 001 Feb 09, 2005 Feb CTEC

!

400MG;EQ 57MG BASE

A065205 002 Feb 09, 2005 Feb CTEC

## AUGMENTIN '200'

+ @ DR REDDYS LABS INC

200MG;EQ 28.5MG BASE

N050726 001 May 31, 1996 Feb DISC

## AUGMENTIN '400'

+ @ DR REDDYS LABS INC

400MG;EQ 57MG BASE

N050726 002 May 31, 1996 Feb DISC

AMPHETAMINE

## SUSPENSION, EXTENDED RELEASE;ORAL

## ADZENYS ER

+! NEOS THERAPS INC

EQ 1.25MG BASE/ML

N204325 001 Sep 15, 2017 Sep NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

## CAPSULE, EXTENDED RELEASE;ORAL

## MYDAYIS

+ SHIRE DEV LLC

3.125MG;3.125MG;3.125MG;3.125MG

N022063 001 Jun 20, 2017 Jun NEWA

+

6.25MG;6.25MG;6.25MG;6.25MG

N022063 002 Jun 20, 2017 Jun NEWA

+

9.375MG;9.375MG;9.375MG;9.375MG

N022063 003 Jun 20, 2017 Jun NEWA

+

12.5MG;12.5MG;12.5MG;12.5MG

N022063 004 Jun 20, 2017 Jun NEWA

## TABLET;ORAL

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB

ALVOGEN MALTA

1.25MG;1.25MG;1.25MG;1.25MG

A207388 001 Jul 28, 2017 Jul NEWA

AB

1.875MG;1.875MG;1.875MG;1.875MG

A207388 002 Jul 28, 2017 Jul NEWA

AB

2.5MG;2.5MG;2.5MG;2.5MG

A207388 003 Jul 28, 2017 Jul NEWA

AB

3.125MG;3.125MG;3.125MG;3.125MG

A207388 004 Jul 28, 2017 Jul NEWA

AB

3.75MG;3.75MG;3.75MG;3.75MG

A207388 005 Jul 28, 2017 Jul NEWA

AB

5MG;5MG;5MG;5MG

A207388 006 Jul 28, 2017 Jul NEWA

AB

7.5MG;7.5MG;7.5MG;7.5MG

A207388 007 Jul 28, 2017 Jul NEWA

AB

EPIC PHARMA LLC

1.25MG;1.25MG;1.25MG;1.25MG

A040444 001 Jun 19, 2002 May CAHN

AB

1.875MG;1.875MG;1.875MG;1.875MG

A040444 005 Nov 03, 2014 May CAHN

AB

2.5MG;2.5MG;2.5MG;2.5MG

A040444 002 Jun 19, 2002 May CAHN

AB

3.125MG;3.125MG;3.125MG;3.125MG

A040444 006 Nov 03, 2014 May CAHN

AB

3.75MG;3.75MG;3.75MG;3.75MG

A040444 007 Nov 03, 2014 May CAHN

## TABLET;ORAL

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002	May CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002	May CAHN
AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017	Oct NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017	Oct NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017	Oct NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017	Oct NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017	Oct NEWA
AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017	Oct NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017	Oct NEWA

AMPHOTERICIN B

## INJECTABLE, LIPID COMPLEX;INJECTION

## ABELCET

>A>	+	LEADIANT BIOSCI INC	5MG/ML	N050724	001	Nov 20, 1995	Nov CAHN
>D>	+	SIGMA TAU	5MG/ML	N050724	001	Nov 20, 1995	Nov CAHN

AMPICILLIN SODIUM

## INJECTABLE;INJECTION

## AMPICILLIN SODIUM

	@	HANFORD GC	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993	Oct CMS1
AP			EQ 250MG BASE/VIAL	A062772	006	Apr 15, 1993	Oct CMS1
AP			EQ 500MG BASE/VIAL	A062772	007	Apr 15, 1993	Oct CMS1
	@		EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993	Oct CMS1
	@		EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993	Oct CMS1
AP			EQ 2GM BASE/VIAL	A062772	003	Apr 15, 1993	Oct CMS1
	@		EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993	Oct CMS1
	@	WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A062692	001	Jun 24, 1986	Jan CAHN
	@		EQ 250MG BASE/VIAL	A062692	002	Jun 24, 1986	Jan CAHN
	@		EQ 500MG BASE/VIAL	A062692	003	Jun 24, 1986	Jan CAHN
	@		EQ 1GM BASE/VIAL	A062692	004	Jun 24, 1986	Jan CAHN
	@		EQ 2GM BASE/VIAL	A062692	005	Jun 24, 1986	Jan CAHN
	@		EQ 10GM BASE/VIAL	A062692	006	Jun 24, 1986	Jan CAHN
		PENBRITIN-S					
	+	@ WYETH AYERST	EQ 125MG BASE/VIAL	N050072	001		Jun CRLD
	+	@	EQ 250MG BASE/VIAL	N050072	002		Jun CRLD
	+	@	EQ 500MG BASE/VIAL	N050072	003		Jun CRLD
	+	@	EQ 1GM BASE/VIAL	N050072	004		Jun CRLD
	+	@	EQ 2GM BASE/VIAL	N050072	005		Jun CRLD
	+	@	EQ 4GM BASE/VIAL	N050072	006		Jun CRLD

AMPICILLIN SODIUM; SULBACTAM SODIUM

## INJECTABLE;INJECTION

## AMPICILLIN AND SULBACTAM

AP		ANTIBIOTICE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201406	001	Dec 07, 2015	Jul CAHN
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201406	002	Dec 07, 2015	Jul CAHN
AP		WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Jan CAHN
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Jan CAHN
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076	001	Mar 19, 2002	Jan CAHN

ANAGRELIDE HYDROCHLORIDE

## CAPSULE;ORAL

## ANAGRELIDE HYDROCHLORIDE

	@	MYLAN PHARMS INC	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	May DISC
AB			EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Mar CAHN
	@		EQ 0.5MG BASE	A077613	001	Jun 27, 2006	May DISC
	@		EQ 1MG BASE	A076811	002	Apr 18, 2005	May DISC
AB			EQ 1MG BASE	A076811	002	Apr 18, 2005	Mar CAHN
	@		EQ 1MG BASE	A077613	002	Jun 27, 2006	May DISC
AB		TORRENT PHARMS LTD	EQ 0.5MG BASE	A209151	001	Jun 30, 2017	Jun NEWA
AB			EQ 1MG BASE	A209151	002	Jun 30, 2017	Jun NEWA
	@	UPSHER-SMITH LABS	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Jun CAHN
	@		EQ 1MG BASE	A076683	002	Apr 18, 2005	Jun CAHN

ANASTROZOLE

## TABLET;ORAL

## ANASTROZOLE

	@	SUN PHARM INDS LTD	1MG	A091177	001	Jul 15, 2011	Sep DISC
	@	WATSON LABS TEVA	1MG	A078984	001	Jun 28, 2010	May CAHN

TABLET;ORAL  
ARIMIDEX

AB +! ASTRAZENECA PHARMS 1MG N020541 001 Dec 27, 1995 May CAHN

APREPITANT

CAPSULE;ORAL  
APREPITANT

AB GLENMARK PHARMS LTD 40MG A207777 001 Oct 12, 2017 Oct NEWA  
AB 80MG A207777 002 Oct 12, 2017 Oct NEWA  
AB 125MG A207777 003 Oct 12, 2017 Oct NEWA

>A> EMULSION;IV (INFUSION)

>A> CINVANTI

>A> +! HERON THERAPS INC 130MG/18ML (7.2MG/ML) N209296 001 Nov 09, 2017 Nov NEWA

ARGATROBAN

INJECTABLE;INJECTION  
ARGATROBAN

+! HIKMA PHARM CO LTD 50MG/50ML (1MG/ML) N203049 002 Sep 30, 2016 Feb NEWA  
AP +! NOVARTIS PHARMS CORP 250MG/2.5ML (100MG/ML) N020883 001 Jun 30, 2000 Jun CAHN

INJECTABLE;IV (INFUSION)  
ARGATROBAN IN SODIUM CHLORIDE

AP GLAND PHARMA LTD 125MG/125ML (1MG/ML) A205570 001 May 22, 2017 May NEWA  
AP +! SANDOZ 125MG/125ML (1MG/ML) N022485 001 May 09, 2011 May CFTG

ARIPIPRAZOLE

>A> TABLET;ORAL

>A> ABILIFY MYCITE KIT

>A> + OTSUKA PHARM CO LTD 2MG N207202 001 Nov 13, 2017 Nov NEWA  
>A> +! 5MG N207202 002 Nov 13, 2017 Nov NEWA  
>A> + 10MG N207202 003 Nov 13, 2017 Nov NEWA  
>A> + 15MG N207202 004 Nov 13, 2017 Nov NEWA  
>A> + 20MG N207202 005 Nov 13, 2017 Nov NEWA  
>A> + 30MG N207202 006 Nov 13, 2017 Nov NEWA

ARIPIPRAZOLE

AB ORCHID HLTHCARE 2MG A202683 001 May 23, 2017 May NEWA  
AB 5MG A202683 002 May 23, 2017 May NEWA  
AB 10MG A202683 003 May 23, 2017 May NEWA  
AB 15MG A202683 004 May 23, 2017 May NEWA  
AB 20MG A202683 005 May 23, 2017 May NEWA  
AB 30MG A202683 006 May 23, 2017 May NEWA  
>A> AB PRINSTON INC 2MG A205363 001 Dec 04, 2017 Nov NEWA  
>A> AB 5MG A205363 002 Dec 04, 2017 Nov NEWA  
>A> AB 10MG A205363 003 Dec 04, 2017 Nov NEWA  
>A> AB 15MG A205363 004 Dec 04, 2017 Nov NEWA  
>A> AB 20MG A205363 005 Dec 04, 2017 Nov NEWA  
>A> AB 30MG A205363 006 Dec 04, 2017 Nov NEWA  
AB SANTOS BIOTECH 2MG A091279 001 Jan 09, 2017 May CAHN  
AB 5MG A091279 002 Jan 09, 2017 May CAHN  
AB 10MG A091279 003 Jan 09, 2017 May CAHN  
AB 15MG A091279 004 Jan 09, 2017 May CAHN  
AB 20MG A091279 005 Jan 09, 2017 May CAHN  
AB 30MG A091279 006 Jan 09, 2017 May CAHN

TABLET, ORALLY DISINTEGRATING;ORAL  
ARIPIPRAZOLE

>D> ! ALEMBIC PHARMS LTD 10MG A202102 001 Apr 28, 2015 Nov CTEC  
>A> AB ! 10MG A202102 001 Apr 28, 2015 Nov CTEC  
>D> 15MG A202102 002 Apr 28, 2015 Nov CTEC  
>A> AB 15MG A202102 002 Apr 28, 2015 Nov CTEC  
>A> AB ORCHID HLTHCARE 10MG A202547 001 Dec 11, 2017 Nov NEWA  
>A> AB 15MG A202547 002 Dec 11, 2017 Nov NEWA

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR  
ARISTADA

+ ALKERMES INC 1064MG/3.9ML (272.82MG/ML) N207533 004 Jun 05, 2017 Jun NEWA

ARMODAFINIL

TABLET;ORAL  
ARMODAFINIL

NATCO PHARMA LTD 100MG A202768 004 Sep 28, 2017 Sep NEWA  
AB 200MG A202768 005 Sep 28, 2017 Sep NEWA

ARSENIC TRIOXIDEINJECTABLE; INJECTION  
TRISENOX

+! CEPHALON 2MG/ML N021248 002 Oct 13, 2017 Oct NEWA

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATEINJECTABLE; INJECTION  
SEPTOCAINEAP +! DEPROCO 4%;EQ 0.0085MG BASE/1.7ML (4%;EQ N022010 001 Mar 30, 2006 Jun CFTG  
0.005MG BASE/ML)AP ULTACAN  
HANSAMED INC 4%;EQ 0.0085MG BASE/1.7ML (4%; EQ A201751 001 Jul 11, 2017 Jun NEWA  
0.005MG BASE/ML)AP ULTACAN FORTE  
HANSAMED INC 4%;EQ 0.017MG BASE/1.7ML (4%; EQ A201750 001 Jul 11, 2017 Jun NEWA  
0.01MG BASE/ML)ASCORBIC ACIDSOLUTION; IV (INFUSION)  
ASCOR

+! MCGUFF 25,000MG/50ML (500MG/ML) N209112 001 Oct 02, 2017 Oct NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN KINJECTABLE; IV (INFUSION)  
INFUVITE PEDIATRIC+! SANDOZ INC 80MG/VIAL; 0.02MG/VIAL; 400 N021265 001 Feb 21, 2001 May CAHN  
IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14  
MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/V  
IAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300  
IU/VIAL; 0.2MG/VIALINFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)  
+! SANDOZ INC 80MG/VIAL; 0.02MG/VIAL; 400 N021646 001 Jan 29, 2004 May CAHN  
IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14  
MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/V  
IAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300  
IU/VIAL; 0.2MG/VIALASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

>D> M.V.I.-12 (WITHOUT VITAMIN K)  
>D> + @ HOSPIRA 20MG/ML; 0.006MG/ML; 0.05MCG/ML; 1.5M N008809 006 Sep 09, 2004 Nov CTNA  
G/ML; 0.0005MG/ML; 0.06MG/ML; 4MG/ML;  
0.6MG/ML; 0.36MG/ML; 0.6MG/ML; 0.1MG/  
ML; 1MG/ML+ @ 20MG/ML; 0.006MG/ML; 0.05MCG/ML; 1.5M N008809 006 Sep 09, 2004 Aug DISC  
G/ML; 0.0005MG/ML; 0.06MG/ML; 4MG/ML;  
0.6MG/ML; 0.36MG/ML; 0.6MG/ML; 0.1MG/  
ML; 1MG/ML>A> M.V.I.-12 ADULT  
>A> @ HOSPIRA 10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG N008809 004 Aug 08, 1985 Nov CTNA  
/ML; 20  
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.  
36MG/ML; 0.3MG/ML; 330 UNITS/ML; 1>A> + @ 20MG/ML; 0.006MG/ML; 0.05MCG/ML; 1.5M N008809 006 Sep 09, 2004 Nov CTNA  
G/ML; 0.0005MG/ML; 0.06MG/ML; 4MG/ML;  
0.6MG/ML; 0.36MG/ML; 0.6MG/ML; 0.1MG/  
ML; 1MG/MLASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

>D> M.V.I.-12  
>D> @ HOSPIRA 10MG/ML; 0.006MG/ML; 0.5UGM/ML; 1.5MG N008809 004 Aug 08, 1985 Nov CTNA  
/ML; 20IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.  
36MG/ML; 0.3MG/ML; 330 UNITS/ML; 1ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

>D> M.V.I.-12  
>D> @ HOSPIRA 20MG/ML; 0.006MG/ML; 0.5UGM/ML; 1.5MG N008809 005 Apr 22, 2004 Nov CTNA  
/ML; 20

IU/ML; 0.6MG/ML; 4MG/ML; 0.4MG/ML; 0.3

INJECTABLE; INJECTION						
>D>	M.V.I.-12					
		UNITS/ML; 1 IU/ML				
>A>	M.V.I.-12 ADULT					
>A>	@ HOSPIRA	20MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG /ML; 20 IU/ML; 0.6MG/ML; 4MG/ML; 0.4MG/ML; 0.3 6MG/ML; 0.6MG/ML; 330 UNITS/ML; 1	N008809	005	Apr 22, 2004	Nov CTNA
<u>ASPIRIN; BUTALBITAL; CAFFEINE</u>						
TABLET; ORAL						
FIORINAL						
	+ @ ALLERGAN SALES LLC	325MG; 50MG; 40MG	N017534	003	Apr 16, 1986	Jan CRLD
<u>ASPIRIN; CARISOPRODOL</u>						
TABLET; ORAL						
CARISOPRODOL AND ASPIRIN						
AB	NOVAST LABS LTD	325MG; 200MG	A040832	001	Jan 07, 2010	Sep CAHN
<u>ASPIRIN; DIPYRIDAMOLE</u>						
CAPSULE, EXTENDED RELEASE; ORAL						
ASPIRIN AND DIPYRIDAMOLE						
AB	AMNEAL PHARMS	25MG; 200MG	A206392	001	Mar 08, 2016	May CAHN
AB	IMPAX LABS INC	25MG; 200MG	A206964	001	Jan 18, 2017	Jan NEWA
AB	PAR PHARM INC	25MG; 200MG	A207944	001	Jan 18, 2017	Jan NEWA
AB	SANDOZ INC	25MG; 200MG	A206739	001	Jan 18, 2017	Jan NEWA
AB	ZYDUS PHARMS USA INC	25MG; 200MG	A206753	001	Aug 29, 2017	Aug NEWA
<u>ASPIRIN; MEPROBAMATE</u>						
TABLET; ORAL						
EQUAGESIC						
	@ SUN PHARM INDUSTRIES	325MG; 200MG	N011702	003	Dec 29, 1983	Oct CAHN
<u>ATENOLOL</u>						
TABLET; ORAL						
ATENOLOL						
AB	UNIQUE PHARM LABS	25MG	A077443	001	Sep 13, 2006	Aug CAHN
AB		50MG	A077443	002	Sep 13, 2006	Aug CAHN
AB		100MG	A077443	003	Sep 13, 2006	Aug CAHN
	@ WATSON LABS TEVA	100MG	A073353	001	Dec 27, 1991	May CAHN
<u>ATENOLOL; CHLORTHALIDONE</u>						
TABLET; ORAL						
ATENOLOL AND CHLORTHALIDONE						
>A> AB	SUN PHARM INDUSTRIES	50MG; 25MG	A073582	002	Apr 29, 1993	Nov CMS1
<u>ATOMOXETINE HYDROCHLORIDE</u>						
CAPSULE; ORAL						
ATOMOXETINE HYDROCHLORIDE						
AB	APOTEX INC	10MG	A078983	001	May 30, 2017	May NEWA
AB		18MG	A078983	002	May 30, 2017	May NEWA
AB		25MG	A078983	003	May 30, 2017	May NEWA
AB		40MG	A078983	004	May 30, 2017	May NEWA
AB		60MG	A078983	005	May 30, 2017	May NEWA
AB		80MG	A078983	006	May 30, 2017	May NEWA
AB		100MG	A078983	007	May 30, 2017	May NEWA
AB	AUROBINDO PHARMA LTD	10MG	A079016	001	May 30, 2017	May NEWA
AB		18MG	A079016	002	May 30, 2017	May NEWA
AB		25MG	A079016	003	May 30, 2017	May NEWA
AB		40MG	A079016	004	May 30, 2017	May NEWA
AB		60MG	A079016	005	May 30, 2017	May NEWA
AB		80MG	A079016	006	May 30, 2017	May NEWA
AB		100MG	A079016	007	May 30, 2017	May NEWA
AB	GLENMARK PHARMS LTD	10MG	A079019	001	May 30, 2017	May NEWA
AB		18MG	A079019	002	May 30, 2017	May NEWA
AB		25MG	A079019	003	May 30, 2017	May NEWA
AB		40MG	A079019	004	May 30, 2017	May NEWA
AB		60MG	A079019	005	May 30, 2017	May NEWA
AB		80MG	A079019	006	May 30, 2017	May NEWA
AB		100MG	A079019	007	May 30, 2017	May NEWA
AB	TEVA PHARMS USA	10MG	A079022	001	May 30, 2017	May NEWA
AB		18MG	A079022	002	May 30, 2017	May NEWA
AB		25MG	A079022	003	May 30, 2017	May NEWA



## CAPSULE;ORAL

## ATOMOXETINE HYDROCHLORIDE

AB		40MG	A079022	004	May 30, 2017	May NEWA
AB		60MG	A079022	005	May 30, 2017	May NEWA
AB		80MG	A079022	006	May 30, 2017	May NEWA
AB		100MG	A079022	007	May 30, 2017	May NEWA

## STRATTERA

AB	+	LILLY	10MG	N021411	002	Nov 26, 2002	May CFTG
AB	+		18MG	N021411	003	Nov 26, 2002	May CFTG
AB	+		25MG	N021411	004	Nov 26, 2002	May CFTG
AB	+		40MG	N021411	005	Nov 26, 2002	May CFTG
AB	+	!	60MG	N021411	006	Nov 26, 2002	May CFTG
AB	+		80MG	N021411	007	Feb 14, 2005	May CFTG
AB	+		100MG	N021411	008	Feb 14, 2005	May CFTG

ATORVASTATIN CALCIUM

## TABLET;ORAL

## ATORVASTATIN CALCIUM

AB		TEVA PHARMS USA	EQ 10MG BASE	A205300	001	Mar 27, 2017	Mar NEWA
AB			EQ 20MG BASE	A205300	002	Mar 27, 2017	Mar NEWA
AB			EQ 40MG BASE	A205300	003	Mar 27, 2017	Mar NEWA
AB			EQ 80MG BASE	A205300	004	Mar 27, 2017	Mar NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

## TABLET;ORAL

## EZETIMIBE AND ATORVASTATIN CALCIUM

		WATSON LABS TEVA	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Apr NEWA
			EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Apr NEWA
			EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Apr NEWA
	!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Apr NEWA

ATOVAQUONE

## SUSPENSION;ORAL

## ATOVAQUONE

AB		APOTEX INC	750MG/5ML	A209750	001	Oct 11, 2017	Oct NEWA
AB		PADDOK LLC	750MG/5ML	A207833	001	Apr 28, 2017	Apr NEWA

ATRACURIUM BESYLATE

## INJECTABLE;INJECTION

## ATRACURIUM BESYLATE

AP		MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017	Jun NEWA
	@	WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998	Feb CAHN
		ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP		MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017	Mar NEWA
		TRACRIUM					
	+	@ HOSPIRA	10MG/ML	N018831	002	Jun 20, 1985	Apr CMS1
		TRACRIUM PRESERVATIVE FREE					
	+	@ HOSPIRA	10MG/ML	N018831	001	Nov 23, 1983	Apr CMS1

ATROPINE SULFATE

## SOLUTION;INTRAVENOUS

## ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE

+	!	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	004	Aug 17, 2017	Aug NEWA
+	!		1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Aug NEWA

## SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL

## ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+	!	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Aug CDFR
+	!		0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Aug CDFR
+	!		1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Aug NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

## SOLUTION;ORAL

## DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D>	AA	!	WEST-WARD PHARMS INT	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Nov CTEC
>A>		!		0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Nov CTEC

## TABLET;ORAL

## DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		ANI PHARMS INC	0.025MG;2.5MG	A086727	001		Jun CMFD
----	--	----------------	---------------	---------	-----	--	----------

>D> ATROPINE SULFATE; EDROPHONIUM CHLORIDE

&gt;D&gt; INJECTABLE;INJECTION

&gt;D&gt; ENLON-PLUS

&gt;D&gt; +! MYLAN INSTITUTIONAL 0.14MG/ML;10MG/ML N019678 001 Nov 06, 1991 Nov DISC

&gt;A&gt; + @ 0.14MG/ML;10MG/ML N019678 001 Nov 06, 1991 Nov DISC

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

+! CEREXA EQ 0.5GM BASE;2GM/VIAL N206494 001 Feb 25, 2015 May CAHN

AZACITIDINE

POWDER;IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

AP ACTAVIS LLC 100MG/VIAL N208216 001 Apr 29, 2016 Mar CTEC

AP DR REDDYS LABS LTD 100MG/VIAL A201537 001 Sep 16, 2013 Mar CDFR

AP MYLAN INSTITUTIONAL 100MG/VIAL A204949 001 Apr 28, 2016 Mar CDFR

AP NATCO PHARMA LTD 100MG/VIAL A207234 001 Jun 23, 2017 Jun NEWA

AP SHILPA MEDICARE 100MG/VIAL A207518 001 Sep 29, 2016 Mar CDFR

VIDAZA

AP +! CELGENE 100MG/VIAL N050794 001 May 19, 2004 Mar CDFR

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

IMURAN

+ @ CASPER PHARMA LLC EQ 100MG BASE/VIAL N017391 001 Jul CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT SANDOZ INC 0.05% A202305 001 May 31, 2012 Feb CAHN

OPTIVAR

AT +! MYLAN SPECIALITY LP 0.05% N021127 001 May 22, 2000 Mar CAHN

SPRAY, METERED;NASAL

ASTELIN

AB +! MYLAN SPECIALITY LP EQ 0.125MG BASE/SPRAY N020114 001 Nov 01, 1996 Mar CAHN

ASTEPRO

@ MYLAN SPECIALITY LP EQ 0.125MG BASE/SPRAY N022203 001 Oct 15, 2008 Mar CAHN

AB +! EQ 0.1876MG BASE/SPRAY N022203 002 Aug 31, 2009 Mar CAHN

AZELASTINE HYDROCHLORIDE

AB ALKEM LABS LTD EQ 0.125MG BASE/SPRAY A208156 001 Aug 18, 2017 Aug NEWA

AB AMNEAL PHARMS LLC EQ 0.125MG BASE/SPRAY A204660 001 Aug 28, 2017 Aug NEWA

AB BRECKENRIDGE PHARM EQ 0.125MG BASE/SPRAY A090176 001 Jul 28, 2015 Feb CAHN

AB UPSHER-SMITH LABS EQ 0.125MG BASE/SPRAY A202609 001 Mar 17, 2017 Jun CAHN

AB EQ 0.125MG BASE/SPRAY A202609 001 Mar 17, 2017 Mar NEWA

AB WEST-WARD PHARMS INT EQ 0.1876MG BASE/SPRAY A207243 001 Sep 22, 2017 Sep NEWA

AB ZYDUS PHARMS USA INC EQ 0.125MG BASE/SPRAY A091409 001 Aug 14, 2017 Jul NEWA

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB APOTEX INC EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY A207712 001 Apr 28, 2017 Apr NEWA

DYMISTA

AB +! MYLAN SPECIALITY LP EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY N202236 001 May 01, 2012 Apr CFTG

+! EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY N202236 001 May 01, 2012 Mar CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB LUPIN LTD EQ 100MG BASE/5ML A065488 001 May 15, 2015 Aug CTEC

AB EQ 200MG BASE/5ML A065488 002 May 15, 2015 Aug CTEC

INJECTABLE;INJECTION

AZITHROMYCIN

@ CSPC OUYI PHARM CO EQ 500MG BASE/VIAL A065265 001 Jan 18, 2007 Oct CAHN

AP MYLAN LABS LTD EQ 500MG BASE/VIAL A204732 001 Jan 26, 2017 Jan NEWA

TABLET;ORAL

AZITHROMYCIN

@ MYLAN EQ 250MG BASE A065365 001 May 30, 2007 Jun DISC

@ EQ 500MG BASE A065366 001 May 30, 2007 May DISC

TABLET;ORAL  
ZITHROMAX

AB	+	PFIZER	EQ 250MG BASE	N050711	001	Jul 18, 1996	Apr CRLD
AB	+		EQ 500MG BASE	N050784	001	May 24, 2002	Apr CRLD

BACITRACIN

INJECTABLE;INJECTION  
BACITRACIN

AP		AKORN	50,000 UNITS/VIAL	A206719	001	Oct 20, 2017	Oct NEWA
----	--	-------	-------------------	---------	-----	--------------	----------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL  
CORTISPORIN

+	!	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984	Feb CAHN
---	---	----------------	--	---------	-----	--------------	----------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC  
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

>D>	AT	PERRIGO CO TENNESSEE	400 UNITS/GM;EQ 3.5MG BASE;10,000 UNITS/GM	A060764	002		Nov CPOT
>A>	AT		400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Nov CPOT
		NEOSPORIN					
AT	+	CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		Apr CMFD

BACLOFEN

INJECTABLE;INTRATHECAL  
BACLOFEN

AP		EMERALD INTL LTD	0.05MG/ML	A091193	001	May 03, 2016	Mar CAHN
AP			0.5MG/ML	A091193	002	May 03, 2016	Mar CAHN
AP			2MG/ML	A091193	003	May 03, 2016	Mar CAHN
		GABLOFEN					
		+	!	MALLINCKRODT INC	1MG/ML	N022462	004 Jun 22, 2012 Mar CRLD
AP		PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Apr CAHN
AP			0.5MG/ML	N022462	002	Nov 19, 2010	Apr CAHN
		+	!		1MG/ML	N022462	004 Jun 22, 2012 Apr CAHN
AP			2MG/ML	N022462	003	Nov 19, 2010	Apr CAHN

TABLET;ORAL  
BACLOFEN

		@ MYLAN	10MG	A077181	001	Jul 29, 2005	May DISC
AB		OXFORD PHARMS	10MG	A077088	002	Oct 31, 2007	Apr CMS1
>A>		RUBICON RES PVT LTD	5MG	A209102	001	Nov 28, 2017	Nov NEWA
>A>	AB		10MG	A209102	002	Nov 28, 2017	Nov NEWA
>A>	AB		20MG	A209102	003	Nov 28, 2017	Nov NEWA
>A>	AB	SUN PHARM INDS INC	10MG	A077862	001	Aug 14, 2006	Nov CMS1
AB		USL PHARMA	10MG	A074584	001	Aug 19, 1996	Jun CAHN
AB			20MG	A074584	002	Aug 19, 1996	Jun CAHN

BALSALAZIDE DISODIUM

CAPSULE;ORAL  
BALSALAZIDE DISODIUM

AB		WEST-WARD PHARMS INT	750MG	A077806	001	Dec 28, 2007	Jul CTEC
BX			750MG	A077806	001	Dec 28, 2007	Apr CTEC

BARIUM SULFATE

FOR SUSPENSION;ORAL

>D>		E-Z-CAT DRY					
>D>		+	!	BRACCO	40% (9GM/POUCH)	N208036	003 Jan 03, 2017 Nov DISC
>A>		+	@		40% (9GM/POUCH)	N208036	003 Jan 03, 2017 Nov DISC
		+	!		40% (9GM/POUCH)	N208036	003 Jan 03, 2017 Aug NEWA
		E-Z-HD					
		+	!	BRACCO	98% (334GM/BOTTLE)	N208036	001 Jan 11, 2016 Apr CPOT
		E-Z-PAQUE					
		+	!	BRACCO	96% (169GM/BOTTLE)	N208036	002 Apr 07, 2017 Apr NEWA
		SUSPENSION;ORAL					
		LIQUID E-Z-PAQUE					
		+	!	BRACCO	60% (213GM/355ML)	N208143	003 Mar 01, 2017 Mar NEWA
		READI-CAT 2 SMOOTHIES					
>D>		+		BRACCO	2% (9GM/450ML)	N208143	002 Jan 15, 2016 Nov CHRS
>A>		+	!		2% (9GM/450ML)	N208143	002 Jan 15, 2016 Nov CHRS

## SUSPENSION;ORAL

## TAGITOL V

+	!	BRACCO	40% (8GM/20ML)	N208143	005	Aug 04, 2017	Aug	NEWA
VARIBAR NECTAR								
+	!	BRACCO	40% (96GM/240ML)	N208143	004	Jul 07, 2017	Jul	NEWA

BECLOMETHASONE DIPROPIONATE

## AEROSOL, METERED;INHALATION

## QVAR REDHALER

+		NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017	Aug	NEWA
+	!		0.08MG/INH	N207921	002	Aug 03, 2017	Aug	NEWA

BENAZEPRIL HYDROCHLORIDE

## TABLET;ORAL

## BENAZEPRIL HYDROCHLORIDE

AB		AMNEAL PHARMS	5MG	A076820	001	Feb 03, 2006	Apr	CAHN
AB			10MG	A076820	002	Feb 03, 2006	Apr	CAHN
AB			20MG	A076820	003	Feb 03, 2006	Apr	CAHN
AB			40MG	A076820	004	Feb 03, 2006	Apr	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

## TABLET;ORAL

## LOTENSIN HCT

+	@	US PHARMS HOLDINGS I	5MG;6.25MG	N020033	001	May 19, 1992	May	DISC
---	---	----------------------	------------	---------	-----	--------------	-----	------

BENDROFLUMETHIAZIDE; NADOLOL

## TABLET;ORAL

## CORZIDE

AB	+	KING PHARMS LLC	5MG;40MG	N018647	001	May 25, 1983	Mar	CAHN
AB	+	!	5MG;80MG	N018647	002	May 25, 1983	Mar	CAHN

## NADOLOL AND BENDROFLUMETHIAZIDE

>D>	AB	MYLAN	5MG;40MG	A078688	001	Feb 15, 2008	Nov	DISC
>A>		@	5MG;40MG	A078688	001	Feb 15, 2008	Nov	DISC
>D>	AB		5MG;80MG	A078688	002	Feb 15, 2008	Nov	DISC
>A>		@	5MG;80MG	A078688	002	Feb 15, 2008	Nov	DISC

BENZNIDAZOLE

## TABLET;ORAL

## BENZNIDAZOLE

+		CHEMO RESEARCH SL	12.5MG	N209570	001	Aug 29, 2017	Aug	NEWA
+	!		100MG	N209570	002	Aug 29, 2017	Aug	NEWA

BENZONATATE

## CAPSULE;ORAL

## TESSALON

AA	+	PFIZER	100MG	N011210	001		Apr	CRLD
----	---	--------	-------	---------	-----	--	-----	------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

## GEL;TOPICAL

## CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB		TOLMAR	5%;EQ 1% BASE	A204087	001	Jun 27, 2017	Jun	NEWA
----	--	--------	---------------	---------	-----	--------------	-----	------

BENZPHETAMINE HYDROCHLORIDE

## TABLET;ORAL

## BENZPHETAMINE HYDROCHLORIDE

AA		ANDA REPOSITORY	50MG	A040578	001	Apr 17, 2006	Sep	CAHN
		@ EPIC PHARMA LLC	50MG	A040714	001	Oct 29, 2007	May	CAHN
AA		TWI PHARMS INC	50MG	A040578	001	Apr 17, 2006	Mar	CAHN

BENZTROPINE MESYLATE

## TABLET;ORAL

## BENZTROPINE MESYLATE

		@ ANDA REPOSITORY	1MG	A081264	001	Jan 23, 1992	Sep	CAHN
		@	2MG	A081265	001	Jan 23, 1992	Sep	CAHN
AA		EPIC PHARMA LLC	0.5MG	A072264	001	Feb 27, 1989	May	CAHN
AA			1MG	A072265	001	Feb 27, 1989	May	CAHN
AA			2MG	A072266	001	Feb 27, 1989	May	CAHN
		OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008	May	CMS1
			1MG	A040706	003	Feb 14, 2008	May	CMS1
AA	!	UPSHER-SMITH LABS	0.5MG	A040103	001	Dec 12, 1996	Feb	CAHN
AA	!		1MG	A040103	002	Dec 12, 1996	Feb	CAHN
AA	!		2MG	A040103	003	Dec 12, 1996	Feb	CAHN

TABLET;ORAL							
BENZTROPINE MESYLATE							
AA	!	USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Jun CAHN
AA	!		1MG	A040103	002	Dec 12, 1996	Jun CAHN
AA	!		2MG	A040103	003	Dec 12, 1996	Jun CAHN
<u>BETAINE HYDROCHLORIDE</u>							
FOR SOLUTION;ORAL							
CYSTADANE							
+!		ORPHAN EUROPE	1GM/SCOOPFUL	N020576	001	Oct 25, 1996	Jul CAHN
<u>BETAMETHASONE DIPROPIONATE</u>							
LOTION;TOPICAL							
BETAMETHASONE DIPROPIONATE							
AB	!	FOUGERA PHARMS INC	EQ 0.05% BASE	A070275	001	Aug 12, 1985	Jan CAHN
	@	TARO	EQ 0.05% BASE	A074272	001	Sep 30, 1994	Apr CAHN
DIPROSONE							
+	@	SCHERING	EQ 0.05% BASE	N017781	001		Jan CRLD
OINTMENT;TOPICAL							
BETAMETHASONE DIPROPIONATE							
AB	+!	FOUGERA PHARMS INC	EQ 0.05% BASE	N019141	001	Sep 04, 1984	Aug CAHN
AB		TARO	EQ 0.05% BASE	A074271	001	Sep 15, 1994	Apr CAHN
OINTMENT, AUGMENTED;TOPICAL							
BETAMETHASONE DIPROPIONATE							
AB		TELIGENT PHARMA INC	EQ 0.05% BASE	A206118	001	Nov 09, 2017	Oct NEWA
<u>BETAMETHASONE VALERATE</u>							
AEROSOL, FOAM;TOPICAL							
BETAMETHASONE VALERATE							
AB		PERRIGO UK FINCO	0.12%	A078337	001	Nov 26, 2012	Apr CAHN
AB		RICONPHARMA LLC	0.12%	A207144	001	May 24, 2017	May NEWA
AB		TARO PHARM	0.12%	A208204	001	May 24, 2017	May NEWA
LUXIQ							
AB	+!	MYLAN PHARMS INC	0.12%	N020934	001	Feb 28, 1999	Jan CAHN
CREAM;TOPICAL							
BETAMETHASONE VALERATE							
AB	+!	FOUGERA PHARMS INC	EQ 0.1% BASE	N018861	001	Aug 31, 1983	Aug CAHN
LOTION;TOPICAL							
BETAMETHASONE VALERATE							
AB	+!	FOUGERA PHARMS INC	EQ 0.1% BASE	N018866	001	Aug 31, 1983	Aug CAHN
OINTMENT;TOPICAL							
BETAMETHASONE VALERATE							
AB	+!	FOUGERA PHARMS INC	EQ 0.1% BASE	N018865	001	Aug 31, 1983	Aug CAHN
<u>BETAXOLOL HYDROCHLORIDE</u>							
SOLUTION/DROPS;OPHTHALMIC							
BETAXOLOL HYDROCHLORIDE							
AT		MEDIMETRIKS PHARMS	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Sep CAHN
AT		TELIGENT	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Apr CAHN
<u>BETHANECHOL CHLORIDE</u>							
TABLET;ORAL							
BETHANECHOL CHLORIDE							
AA		ECI PHARMS LLC	5MG	A040725	001	Oct 26, 2007	Sep CAHN
AA			10MG	A040726	001	Oct 26, 2007	Sep CAHN
AA			25MG	A040727	001	Oct 26, 2007	Sep CAHN
AA			50MG	A040728	001	Oct 26, 2007	Sep CAHN
	@	IMPAX LABS	5MG	A040721	001	Nov 01, 2006	Jan CMS1
	@		10MG	A040721	002	Nov 01, 2006	Jan CMS1
	@		25MG	A040721	003	Nov 01, 2016	Jan CMS1
AA		LANNETT HOLDINGS INC	5MG	A040677	002	Mar 27, 2008	May CMS1
AA			10MG	A040677	003	Mar 27, 2008	May CMS1
AA			25MG	A040677	004	Mar 27, 2008	May CMS1
AA		UPSHER-SMITH LABS	5MG	A040633	001	Jun 01, 2005	Jun CAHN
AA			10MG	A040634	001	Jun 01, 2005	Jun CAHN
AA			25MG	A040635	001	Jun 01, 2005	Jun CAHN
AA			50MG	A040636	001	Jun 01, 2005	Jun CAHN

BETRIXABANCAPSULE;ORAL  
BEVYXXA

+	PORTOLA PHARMS INC	40MG	N208383	001	Jun 23, 2017	Jun NEWA
+	!	80MG	N208383	002	Jun 23, 2017	Jun NEWA

BICALUTAMIDETABLET;ORAL  
BICALUTAMIDE

AB	SANTOS BIOTECH	50MG	A091011	001	Jun 10, 2015	May CAHN	
AB	WATSON LABS TEVA	50MG	A078634	001	Aug 28, 2009	May CAHN	
CASODEX							
AB	+	! ASTRAZENECA PHARMS	50MG	N020498	001	Oct 04, 1995	May CAHN

BIMATOPROSTSOLUTION/DROPS;OPHTHALMIC  
BIMATOPROST

AT	SANDOZ INC	0.03%	A202565	001	May 05, 2015	Mar CAHN
----	------------	-------	---------	-----	--------------	----------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDETABLET, CHEWABLE, TABLET, CAPSULE;ORAL  
HELIDAC

+	@ CASPER PHARMA LLC	262.4MG,N/A,N/A,N/A,250MG,N/A,N/A, N/A,500MG	N050719	001	Aug 15, 1996	Jul CAHN
---	---------------------	---	---------	-----	--------------	----------

BISOPROLOL FUMARATETABLET;ORAL  
BISOPROLOL FUMARATE

	@ ANDA REPOSITORY	5MG	A075474	001	Oct 25, 2002	Sep CAHN
	@	10MG	A075474	002	Oct 25, 2002	Sep CAHN
AB	ORIT LABS LLC	5MG	A204891	001	Jan 11, 2017	Jan NEWA
AB		10MG	A204891	002	Jan 11, 2017	Jan NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDETABLET;ORAL  
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@ WATSON LABS TEVA	2.5MG;6.25MG	A075469	001	Sep 25, 2000	May CAHN	
	@	5MG;6.25MG	A075469	002	Sep 25, 2000	May CAHN	
	@	10MG;6.25MG	A075469	003	Sep 25, 2000	May CAHN	
ZIAC							
AB	+	TEVA BRANDED PHARM	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Jan CAHN
AB	+		5MG;6.25MG	N020186	001	Mar 26, 1993	Jan CAHN
AB	+	!	10MG;6.25MG	N020186	002	Mar 26, 1993	Jan CAHN

BIVALIRUDININJECTABLE;INTRAVENOUS  
BIVALIRUDIN

>A>	AP	ACCORD HLTHCARE	250MG/VIAL	A206551	001	Nov 22, 2017	Nov NEWA
	AP	APOTEX INC	250MG/VIAL	A204876	001	Jul 06, 2017	Jun NEWA
	AP	DR REDDYS LABS LTD	250MG/VIAL	A201577	001	May 26, 2017	May NEWA

BORTEZOMIBPOWDER;INTRAVENOUS  
BORTEZOMIB

>A>		FRESENIUS KABI USA	3.5MG/VIAL	N205004	001	Nov 06, 2017	Nov NEWA
-----	--	--------------------	------------	---------	-----	--------------	----------

BOSENTANTABLET, FOR SUSPENSION;ORAL  
TRACLEER

+	!	ACTELION PHARMS	32MG	N209279	001	Sep 05, 2017	Sep NEWA
---	---	-----------------	------	---------	-----	--------------	----------

BOSUTINIB MONOHYDRATETABLET;ORAL  
BOSULIF

+	PF PRISM CV	EQ 400MG BASE	N203341	003	Oct 27, 2017	Oct NEWA
---	-------------	---------------	---------	-----	--------------	----------

BRETYLIUM TOSYLATEINJECTABLE; INJECTION  
BRETYLIUM TOSYLATE

@ WEST-WARD PHARMS INT 50MG/ML

A070545 001 May 14, 1986 Jan CAHN

BREXPIRAZOLETABLET; ORAL  
REXULTI+! OTSUKA PHARM CO LTD 2MG  
+ 4MGN205422 004 Jul 10, 2015 Aug CHRS  
N205422 006 Jul 10, 2015 Aug CHRSBRIGATINIBTABLET; ORAL  
ALUNBRIG+ ARIAD 30MG  
+! 90MG  
+ 180MGN208772 001 Apr 28, 2017 Apr NEWA  
N208772 002 Apr 28, 2017 Apr NEWA  
N208772 003 Oct 02, 2017 Oct NEWABRIMONIDINE TARTRATESOLUTION/DROPS; OPHTHALMIC  
BRIMONIDINE TARTRATEAT SANDOZ INC 0.2%  
AT 0.2%A076254 001 Sep 16, 2003 Feb CAHN  
A078075 001 Jan 30, 2008 Mar CAHNQOLIANA  
AT SANDOZ INC 0.15%

N021764 001 May 22, 2006 Mar CAHN

BROMFENAC SODIUMSOLUTION/DROPS; OPHTHALMIC  
BROMFENAC SODIUMAT1 AMRING PHARMS EQ 0.09% ACID  
AT1 ! APOTEX INC EQ 0.09% ACID  
AT2 ! HI-TECH PHARMACAL EQ 0.09% ACIDA202030 001 Jan 09, 2013 Mar CAHN  
A202435 001 Jun 19, 2014 Feb CHRS  
A203395 001 Jan 22, 2014 Mar CHRSBROMPHENIRAMINE MALEATE

TABLET; ORAL

BROMPHENIRAMINE MALEATE  
@ UPSHER-SMITH LABS 4MG

A083215 001 Jun CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA TARO PHARM 2MG/5ML; 10MG/5ML; 30MG/5ML

A205112 001 Feb 27, 2017 Feb NEWA

BUDESONIDECAPSULE; ORAL  
BUDESONIDEAB AMNEAL PHARMS 3MG  
AB APPCO PHARMA LLC 3MG  
AB SCIECURE PHARMA INC 3MG  
AB ZYDUS PHARMS USA INC 3MGA206200 001 Jul 31, 2017 Jul NEWA  
A207367 001 Apr 07, 2017 Mar NEWA  
A209041 001 Sep 28, 2017 Sep NEWA  
A206134 001 May 04, 2017 Apr NEWASUSPENSION; INHALATION  
BUDESONIDEAN CIPLA LTD 0.25MG/2ML  
AN 0.5MG/2ML  
AN 1MG/2MLA205710 001 Nov 16, 2017 Oct NEWA  
A205710 002 Nov 16, 2017 Oct NEWA  
A205710 003 Nov 16, 2017 Oct NEWABUMETANIDEINJECTABLE; INJECTION  
BUMETANIDEAP ! ATHENEX INC 0.25MG/ML  
AP WEST-WARD PHARMS INT 0.25MG/MLA074441 001 Jan 27, 1995 Mar CAHN  
A079196 001 Apr 30, 2008 Jan CAHNBUMEX  
+ @ VALIDUS PHARMS 0.25MG/ML

N018226 001 Feb 28, 1983 Jun CAHN

TABLET; ORAL

BUMETANIDE

AB AMNEAL PHARMS CO 0.5MG  
AB 1MG  
AB 2MGA209724 001 Oct 18, 2017 Oct NEWA  
A209724 002 Oct 18, 2017 Oct NEWA  
A209724 003 Oct 18, 2017 Oct NEWA

BUMEX

AB + VALIDUS PHARMS 0.5MG  
AB + 1MGN018225 002 Feb 28, 1983 Jun CAHN  
N018225 001 Feb 28, 1983 Jun CAHN

TABLET;ORAL							
BUMEX							
AB	+	2MG	N018225	003	Jun 14, 1985	Jun	CAHN
<u>BUPIVACAINE HYDROCHLORIDE</u>							
INJECTABLE;SPINAL							
BUPIVACAINE HYDROCHLORIDE							
AP	BAXTER HLTHCARE CORP	0.75%	A207266	001	Jul 25, 2016	Aug	CAHN
<u>BUPRENORPHINE</u>							
>A>	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS						
>A>	SUBLOCADE						
>A>	+	INDIVIOR INC	100MG/0.5ML (100MG/0.5ML)	N209819	001	Nov 29, 2017	Nov NEWA
>A>	+	!	300MG/1.5ML (200MG/ML)	N209819	002	Nov 29, 2017	Nov NEWA
<u>BUPRENORPHINE HYDROCHLORIDE</u>							
FILM;BUCCAL							
BELBUCA							
+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan	CAHN
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan	CAHN
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan	CAHN
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan	CAHN
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan	CAHN
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan	CAHN
+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan	CAHN
TABLET;SUBLINGUAL							
BUPRENORPHINE HYDROCHLORIDE							
AB	RHODES PHARMS	EQ 2MG BASE	A207276	001	Mar 27, 2017	Mar	NEWA
AB		EQ 8MG BASE	A207276	002	Mar 27, 2017	Mar	NEWA
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE</u>							
TABLET;SUBLINGUAL							
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
AB	AMNEAL PHARMS	EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	May	CAHN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
AB	AMNEAL PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	May	CAHN
ZUBSOLV							
+	OREXO US INC	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jan	CHRS
+	!	EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jan	CHRS
<u>BUPROPION HYDROCHLORIDE</u>							
TABLET;ORAL							
BUPROPION HYDROCHLORIDE							
AB	INVAGEN PHARMS	75MG	A207389	001	Sep 18, 2017	Sep	NEWA
AB		100MG	A207389	002	Sep 18, 2017	Sep	NEWA
WELLBUTRIN							
+	@ GLAXOSMITHKLINE	50MG	N018644	001	Dec 30, 1985	Sep	CRLD
+	@	75MG	N018644	002	Dec 30, 1985	Sep	CRLD
+	@	100MG	N018644	003	Dec 30, 1985	Sep	CRLD
TABLET, EXTENDED RELEASE;ORAL							
BUPROPION HYDROCHLORIDE							
AB3	ANBISON LAB CO LTD	150MG	A207224	001	Jun 30, 2017	Jun	NEWA
AB3		300MG	A207224	002	Jun 30, 2017	Jun	NEWA
AB3	JUBILANT GENERICS	150MG	A207459	001	Jun 30, 2017	Jun	NEWA
AB3		300MG	A207459	002	Jun 30, 2017	Jun	NEWA
AB3	LUPIN LTD	150MG	A090693	001	Apr 06, 2017	Mar	NEWA
AB3		300MG	A090693	002	Apr 06, 2017	Mar	NEWA
AB3	SCIEGEN PHARMS INC	150MG	A207479	001	Apr 12, 2017	Mar	NEWA
AB3		300MG	A207479	002	Apr 12, 2017	Mar	NEWA
AB3	SINOTHERAPEUTICS INC	150MG	A208652	001	Aug 21, 2017	Aug	NEWA
AB3		300MG	A208652	002	Aug 21, 2017	Aug	NEWA
AB2	TECH ORGANIZED	150MG	A206122	001	Aug 17, 2016	Sep	CAHN
AB3	TWI PHARMS INC	150MG	A210081	001	Nov 03, 2017	Oct	NEWA
AB3		300MG	A210081	002	Nov 03, 2017	Oct	NEWA
FORFIVO XL							
+	! ALVOGEN	450MG	N022497	001	Nov 10, 2011	Jan	CAHN



BUSPIRONE HYDROCHLORIDE

## TABLET; ORAL

## BUSPIRONE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	May NEWA
AB		7.5MG	A208829	002	May 24, 2017	May NEWA
AB		10MG	A208829	003	May 24, 2017	May NEWA
AB		15MG	A208829	004	May 24, 2017	May NEWA
AB		30MG	A208829	005	May 24, 2017	May NEWA
	@ MYLAN	5MG	A075467	001	Feb 28, 2002	Jun DISC
	@	10MG	A075467	003	Feb 28, 2002	Jun DISC
	@	15MG	A075467	004	Feb 28, 2002	Jun DISC
AB	STRIDES PHARMA	5MG	A202330	001	Aug 25, 2014	Apr CAHN
AB		7.5MG	A202330	005	Feb 17, 2017	Sep NEWA
AB		10MG	A202330	002	Aug 25, 2014	Apr CAHN
AB		15MG	A202330	003	Aug 25, 2014	Apr CAHN
AB		30MG	A202330	004	Aug 25, 2014	Apr CAHN

BUSULFAN

## INJECTABLE; INJECTION

## BUSULFAN

>A>	AP	ACTAVIS LLC	6MG/ML	A205139	001	Dec 08, 2017	Nov NEWA
	AP	PHARMASCIENCE INC	6MG/ML	A207050	001	Mar 24, 2017	Mar NEWA
	AP	SANDOZ INC	6MG/ML	A205106	001	Jul 07, 2017	Jun NEWA
>A>		MYLERAN					
>A>	AP	ASPEN GLOBAL INC	6MG/ML	A208536	001	Nov 20, 2017	Nov NEWA

BUTABARBITAL SODIUM

## TABLET; ORAL

## BUTISOL SODIUM

	@ MYLAN SPECIALITY LP	15MG	N000793	002		Mar CAHN
+	!	30MG	N000793	004		Mar CAHN
	@	50MG	N000793	003		Mar CAHN
	@	100MG	N000793	005		Mar CAHN

BUTORPHANOL TARTRATE

## INJECTABLE; INJECTION

## BUTORPHANOL TARTRATE

	@ BAXTER HLTHCARE CORP	2MG/ML	A075697	001	Oct 23, 2001	Aug CAHN
		BUTORPHANOL TARTRATE PRESERVATIVE FREE				
	@ BAXTER HLTHCARE CORP	1MG/ML	A075695	001	Oct 23, 2001	Aug CAHN
	@	2MG/ML	A075695	002	Oct 23, 2001	Aug CAHN
AP	WEST-WARD PHARMS INT	1MG/ML	A075045	001	Aug 12, 1998	Jan CAHN
AP		2MG/ML	A075045	002	Aug 12, 1998	Jan CAHN

CALCIPOTRIENE

## AEROSOL, FOAM; TOPICAL

## SORILUX

+	!	MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010	Jan CAHN
---	---	--------------	--------	---------	-----	--------------	----------

## OINTMENT; TOPICAL

## CALCIPOTRIENE

!		GLENMARK PHARMS INC	0.005%	A090633	001	Mar 24, 2010	May CAHN
---	--	---------------------	--------	---------	-----	--------------	----------

CALCITONIN SALMON

## SPRAY, METERED; NASAL

## CALCITONIN-SALMON

AB	!	APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Apr CHRS
		MIACALCIN					
	+	@ MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Apr DISC

CALCITONIN SALMON RECOMBINANT

## SPRAY, METERED; NASAL

## FORTICAL

	@ UPSHER-SMITH LABS	200 IU/SPRAY	N021406	001	Aug 12, 2005	Jun CAHN
--	---------------------	--------------	---------	-----	--------------	----------

CALCITRIOL

## CAPSULE; ORAL

## CALCITRIOL

AB		AMNEAL PHARMS	0.25MCG	A203289	002	Jun 14, 2017	May NEWA
AB			0.5MCG	A203289	001	Jun 14, 2017	May NEWA

INJECTABLE; INJECTION									
CALCIJEX									
	+ @	ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	May	CRLD	
	+ @		0.002MG/ML	N018874	002	Sep 25, 1986	May	CRLD	
CALCITRIOL									
	!	AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	May	CHRS	
<u>CALCIUM ACETATE</u>									
CAPSULE; ORAL									
CALCIUM ACETATE									
AB		CHARTWELL RX	667MG	A091312	001	Jun 01, 2012	Mar	CAHN	
TABLET; ORAL									
CALCIUM ACETATE									
AB	!	PADDOCK LLC	667MG	A091561	001	Apr 13, 2011	Apr	CHRS	
ELIPHOS									
AB		CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008	Apr	CHRS	
<u>CALCIUM CHLORIDE</u>									
INJECTABLE; INJECTION									
CALCIUM CHLORIDE 10%									
AP		LUITPOLD PHARMS INC	100MG/ML	A209088	001	Jul 27, 2017	Jul	NEWA	
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER									
AP	+	HOSPIRA	100MG/ML	N021117	001	Jan 28, 2000	Jul	CFTG	
<u>CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>									
INJECTABLE; INJECTION									
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER									
	@	HOSPIRA	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N018254	001		Aug	DISC	
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER									
	B	BRAUN	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N020000	001	Apr 17, 1992	Aug	CTEC	
<u>CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE</u>									
INJECTABLE; INJECTION									
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
AP		ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017608	001		Feb	CAHN	
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
	@	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685	005	Oct 17, 1988	Feb	CAHN	
	@		20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685	006	Oct 17, 1988	Feb	CAHN	
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
	@	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685	007	Oct 17, 1988	Feb	CAHN	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
AP		ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685	002	Oct 17, 1988	Feb	CAHN	
AP			20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685	008	Oct 17, 1988	Feb	CAHN	
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
	@	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685	003	Oct 17, 1988	Feb	CAHN	
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
AP		ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685	004	Oct 17, 1988	Feb	CAHN	
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
	@	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685	001	Oct 17, 1988	Feb	CAHN	
<u>CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>									
INJECTABLE; INJECTION									
RINGER'S IN PLASTIC CONTAINER									
AP		ICU MEDICAL INC	33MG/100ML; 30MG/100ML; 860MG/100ML	N018251	001		Feb	CAHN	
SOLUTION; IRRIGATION									
RINGER'S IN PLASTIC CONTAINER									
AT		ICU MEDICAL INC	33MG/100ML; 30MG/100ML; 860MG/100ML	N017635	001		Feb	CAHN	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION							
LACTATED RINGER'S IN PLASTIC CONTAINER							
AP	ICU MEDICAL INC	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017641	001			Feb CAHN
SOLUTION; IRRIGATION							
LACTATED RINGER'S IN PLASTIC CONTAINER							
AT	+! ICU MEDICAL INC	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019416	001	Jan 17, 1986		Feb CAHN

CALCIUM GLUCONATE

SOLUTION; IV (INFUSION)							
CALCIUM GLUCONATE							
	+! FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017		Jun NEWA
	+!	5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017		Jun NEWA
	+!	10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017		Jun NEWA

CANDESARTAN CILEXETIL

TABLET; ORAL							
CANDESARTAN CILEXETIL							
AB	ALEMBIC PHARMS LTD	32MG	A209119	001	Jun 20, 2017		Jun NEWA
AB	ZYDUS PHARMS USA INC	4MG	A091390	001	Aug 23, 2017		Aug NEWA
AB		8MG	A091390	002	Aug 23, 2017		Aug NEWA
AB		16MG	A091390	003	Aug 23, 2017		Aug NEWA
AB		32MG	A091390	004	Aug 23, 2017		Aug NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL							
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE							
AB	MYLAN PHARMS INC	16MG; 12.5MG	A090704	001	Dec 04, 2012		May CAHN
AB		32MG; 12.5MG	A090704	002	Dec 04, 2012		May CAHN
AB		32MG; 25MG	A090704	003	Dec 04, 2012		May CAHN
>A> AB	ZYDUS PHARMS USA INC	16MG; 12.5MG	A203466	001	Nov 27, 2017		Nov NEWA
>A> AB		32MG; 12.5MG	A203466	002	Nov 27, 2017		Nov NEWA
>A> AB		32MG; 25MG	A203466	003	Nov 27, 2017		Nov NEWA

CAPECITABINE

TABLET; ORAL							
CAPECITABINE							
>A> AB	ALKEM LABS LTD	150MG	A207652	001	Nov 24, 2017		Nov NEWA
>A> AB		500MG	A207652	002	Nov 24, 2017		Nov NEWA
AB	AMNEAL PHARMS	150MG	A204741	001	Feb 28, 2017		Feb NEWA
AB		500MG	A204741	002	Feb 28, 2017		Feb NEWA

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION							
CAPASTAT SULFATE							
>D>	+! AKORN	EQ 1GM BASE/VIAL	N050095	001			Nov CFTG
>A> AP	+!	EQ 1GM BASE/VIAL	N050095	001			Nov CFTG
>A>	CAPREOMYCIN SULFATE						
>A> AP	MYLAN LABS LTD	EQ 1GM BASE/VIAL	A202634	001	Nov 27, 2017		Nov NEWA

CAPTOPRIL

TABLET; ORAL							
CAPTOPRIL							
	@ BOSCOGEN	12.5MG	A074677	004	May 30, 1997		May CAHN
	@	25MG	A074677	002	May 30, 1997		May CAHN
	@	50MG	A074677	001	May 30, 1997		May CAHN
	@	100MG	A074677	003	May 30, 1997		May CAHN
AB	MYLAN PHARMS INC	12.5MG	A074434	001	Feb 13, 1996		Mar CAHN
AB		25MG	A074434	002	Feb 13, 1996		Mar CAHN
AB		50MG	A074434	003	Feb 13, 1996		Mar CAHN
AB	!	100MG	A074434	004	Feb 13, 1996		Mar CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL							
EQUETRO							
	+ VALIDUS PHARMS	100MG	N021710	001	Dec 10, 2004		Jun CAHN
	+	200MG	N021710	002	Dec 10, 2004		Jun CAHN
	+!	300MG	N021710	003	Dec 10, 2004		Jun CAHN

	SOLUTION;IV (INFUSION)						
	CARNEXIV						
	+! LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jan	CAHN
	SUSPENSION;ORAL						
	TERIL						
AB	TARO PHARM	100MG/5ML	A076729	001	Sep 20, 2004	Mar	CAHN
	<u>CARBIDOPA</u>						
	TABLET;ORAL						
	CARBIDOPA						
AB	NOVEL LABS INC	25MG	A204763	001	Oct 20, 2017	Oct	NEWA
	<u>CARBIDOPA; LEVODOPA</u>						
	TABLET;ORAL						
	CARBIDOPA AND LEVODOPA						
	IDT AUSTRALIA LTD	10MG;100MG	A073587	002	Jun 29, 1995	Jul	CMS1
		25MG;250MG	A073587	003	Jun 29, 1995	Jul	CMS1
	<u>CARBOPLATIN</u>						
	INJECTABLE;INJECTION						
	CARBOPLATIN						
	@ WATSON LABS TEVA	50MG/VIAL	A076162	001	Oct 14, 2004	May	CAHN
	@	150MG/VIAL	A076162	002	Oct 14, 2004	May	CAHN
	@	450MG/VIAL	A076162	003	Oct 14, 2004	May	CAHN
	INJECTABLE;IV (INFUSION)						
	CARBOPLATIN						
AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	Jan	NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	Jan	NEWA
AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Apr	NEWA
AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Apr	NEWA
AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Apr	NEWA
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Apr	NEWA
	<u>CARISOPRODOL</u>						
	CAPSULE;ORAL						
	SOMA						
	@ MYLAN SPECIALITY LP	250MG	N011792	003		Mar	CAHN
	TABLET;ORAL						
	CARISOPRODOL						
	@ EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000	May	CAHN
AA	HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Apr	CMFD
AB	NOSTRUM LABS INC	250MG	A207237	001	May 11, 2017	Apr	NEWA
	@ SUN PHARM INDS LTD	350MG	A040755	001	Feb 27, 2007	Sep	DISC
	SOMA						
AB	+! MYLAN SPECIALITY LP	250MG	N011792	004	Sep 13, 2007	Mar	CAHN
AA	+	350MG	N011792	001		Mar	CAHN
	<u>CARTEOLOL HYDROCHLORIDE</u>						
	SOLUTION/DROPS;OPHTHALMIC						
	CARTEOLOL HYDROCHLORIDE						
AT	! SANDOZ INC	1%	A075476	001	Jan 03, 2000	May	CHRS
AT		1%	A075476	001	Jan 03, 2000	Mar	CAHN
	OCUPRESS						
	+ @ NOVARTIS	1%	N019972	001	May 23, 1990	May	DISC
	<u>CARVEDILOL</u>						
	TABLET;ORAL						
	CARVEDILOL						
	@ PLIVA HRVATSKA DOO	3.125MG	A078240	001	Oct 30, 2007	Jul	DISC
	@	6.25MG	A078240	002	Oct 30, 2007	Jul	DISC
	@	12.5MG	A078240	003	Oct 30, 2007	Jul	DISC
	@	25MG	A078240	004	Oct 30, 2007	Jul	DISC

CARVEDILOL PHOSPHATECAPSULE, EXTENDED RELEASE;ORAL  
CARVEDILOL PHOSPHATE

AB	SUN PHARM INDUSTRIES	10MG	A090132	001	Oct 25, 2017	Oct	NEWA
AB		20MG	A090132	002	Oct 25, 2017	Oct	NEWA
AB		40MG	A090132	003	Oct 25, 2017	Oct	NEWA
AB		80MG	A090132	004	Oct 25, 2017	Oct	NEWA

COREG CR

AB	+ SMITHKLINE BEECHAM	10MG	N022012	001	Oct 20, 2006	Oct	CFTG
AB	+	20MG	N022012	002	Oct 20, 2006	Oct	CFTG
AB	+!	40MG	N022012	003	Oct 20, 2006	Oct	CFTG
AB	+	80MG	N022012	004	Oct 20, 2006	Oct	CFTG

CASPOFUNGIN ACETATEPOWDER;IV (INFUSION)  
CANCIDAS

AP	+! MERCK	50MG/VIAL	N021227	001	Jan 26, 2001	Mar	CDFR
AP	+!	70MG/VIAL	N021227	002	Jan 26, 2001	Mar	CDFR

CASPOFUNGIN ACETATE

AP	GLAND PHARMA LTD	50MG/VIAL	A207092	001	Sep 29, 2017	Sep	NEWA
AP		70MG/VIAL	A207092	002	Sep 29, 2017	Sep	NEWA
AP	MYLAN LABS LTD	50MG/VIAL	A207650	001	Sep 29, 2017	Sep	NEWA
AP		70MG/VIAL	A207650	002	Sep 29, 2017	Sep	NEWA

CEFACLORFOR SUSPENSION;ORAL  
CEFACLOR

>D> AB	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012	Nov	CTEC
>A>		EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012	Nov	CTEC
>D> AB		EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012	Nov	CTEC
>A>		EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012	Nov	CTEC
>D> AB		EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012	Nov	CTEC
>A>		EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012	Nov	CTEC
>D> AB	!	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Nov	CTEC
>A>	!	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Nov	CTEC

CEFADROXIL/CEFADROXIL HEMIHYDRATECAPSULE;ORAL  
CEFADROXIL

AB	CSPC OUYI PHARM CO	EQ 500MG BASE	A205072	001	Jul 28, 2017	Jul	NEWA
----	--------------------	---------------	---------	-----	--------------	-----	------

CEFAZOLIN SODIUMINJECTABLE;INJECTION  
CEFAZOLIN SODIUM

!	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014	Oct	CHRS
@	FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Oct	DISC
@		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Oct	DISC
@		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Oct	DISC
@		EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Oct	DISC

CEFDINIRCAPSULE;ORAL  
OMNICEF

+ @	ABBVIE	300MG	N050739	001	Dec 04, 1997	Jan	CRLD
-----	--------	-------	---------	-----	--------------	-----	------

FOR SUSPENSION;ORAL  
OMNICEF

+ @	ABBVIE	125MG/5ML	N050749	001	Dec 04, 1997	Jan	CRLD
+ @		250MG/5ML	N050749	002	Jul 29, 2004	Jan	CRLD

CEFIXIMEFOR SUSPENSION;ORAL  
CEFIXIME

AB	BELCHER PHARMS LLC	100MG/5ML	A206938	001	Feb 06, 2017	Jan	NEWA
AB		200MG/5ML	A206938	002	Feb 06, 2017	Jan	NEWA
AB		500MG/5ML	A206939	001	Feb 06, 2017	Jan	NEWA
>A> AB	SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017	Nov	NEWA
>A> AB		200MG/5ML	A206144	002	Nov 17, 2017	Nov	NEWA

SUPRAX

AB	+! LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Jan	CFTG
----	--------------	-----------	---------	-----	--------------	-----	------

CEFOTAXIME SODIUMINJECTABLE;INJECTION  
CLAFORAN

@	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987	Aug DISC
@		EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987	Aug DISC

CEFOTETAN DISODIUMINJECTABLE;INJECTION  
CEFOTAN

AP	+	TELIGENT	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Apr CAHN
AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Apr CAHN
	@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Apr CAHN
		CEFOTAN IN PLASTIC CONTAINER					
	@	TELIGENT	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Apr CAHN
	@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Apr CAHN

CEFOXITIN SODIUMINJECTABLE;INJECTION  
CEFOXITIN

	@	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	Oct DISC
	@		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	Oct DISC
	@		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	Oct DISC
AP		WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Jan CAHN
AP			EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Jan CAHN
AP			EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Jan CAHN
		MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
	+	@ MERCK	EQ 20MG BASE/ML	N050581	003	Sep 20, 1984	Sep CRLD
	+	@	EQ 40MG BASE/ML	N050581	004	Sep 20, 1984	Sep CRLD
		MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	+	@ MERCK	EQ 20MG BASE/ML	N050581	002	Sep 20, 1984	Sep CRLD
	+	@	EQ 40MG BASE/ML	N050581	001	Sep 20, 1984	Sep CRLD

CEFPROZILTABLET;ORAL  
CEFPROZIL

AB		AUROBINDO PHARMA LTD	250MG	A065340	001	May 24, 2007	Jan CAHN
AB			500MG	A065340	002	May 24, 2007	Jan CAHN

CEFTAZIDIMEINJECTABLE;INJECTION  
FORTAZ

AP	+	TELIGENT	500MG/VIAL	N050578	001	Jul 19, 1985	Apr CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Apr CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Apr CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Apr CAHN

CEFTAZIDIME SODIUMINJECTABLE;INJECTION  
FORTAZ IN PLASTIC CONTAINER

	@	TELIGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	May CAHN
	+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	May CAHN
	+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	May CAHN

CEFTRIAXONE SODIUMINJECTABLE;INJECTION  
CEFTRIAXONE

	@	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Oct DISC
		CEFTRIAXONE SODIUM					
AP		HIKMA FARMACEUTICA	EQ 10GM BASE/VIAL	A090701	001	Oct 04, 2017	Sep NEWA
AP		SAGENT PHARMS	EQ 10GM BASE/VIAL	A091117	001	Jan 20, 2017	Jan NEWA
		ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER					
	+	@ HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987	Jan CRLD
	+	@	EQ 20MG BASE/ML	N050624	002	Feb 11, 1987	Jan CRLD
	+	@	EQ 40MG BASE/ML	N050624	003	Feb 11, 1987	Jan CRLD

CEFUROXIME AXETILTABLET;ORAL  
CEFUROXIME AXETIL

AB		AUROBINDO PHARMA LTD	EQ 125MG BASE	A065308	001	Mar 29, 2006	Jan CAHN
AB			EQ 250MG BASE	A065308	002	Mar 29, 2006	Jan CAHN
AB			EQ 500MG BASE	A065308	003	Mar 29, 2006	Jan CAHN

CEFUROXIME SODIUMINJECTABLE;INJECTION  
CEFUROXIME SODIUM

AP	ACS DOBFAR SPA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Sep CAHN
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Sep CAHN
	ZINACEF					
AP	+! TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	May CAHN
AP	+!	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	May CAHN
	ZINACEF IN PLASTIC CONTAINER					
	@ TELIGENT	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May CAHN
	+!	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May CAHN
	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
	CEFUROXIME SODIUM					
AB	ACS DOBFAR SPA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Sep CAHN
	ZINACEF					
AB	+! TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	May CAHN

CELECOXIBCAPSULE;ORAL  
CELECOXIB

AB	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Mar NEWA
AB		100MG	A207061	002	Apr 04, 2017	Mar NEWA
AB		200MG	A207061	003	Apr 04, 2017	Mar NEWA
AB		400MG	A207061	004	Apr 04, 2017	Mar NEWA

CEPHALEXINCAPSULE;ORAL  
CEPHALEXIN

AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A065253	001	Nov 16, 2005	Jan CAHN
AB		EQ 500MG BASE	A065253	002	Nov 16, 2005	Jan CAHN
	FOR SUSPENSION;ORAL					
	CEPHALEXIN					
AB	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065336	001	Jul 25, 2007	Aug CMFD
AB		EQ 250MG BASE/5ML	A065336	002	Jul 25, 2007	Aug CMFD

CEPHAPIRIN SODIUMINJECTABLE;INJECTION  
CEPHAPIRIN SODIUM

	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987	Jan CAHN
	@	EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987	Jan CAHN
	@	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987	Jan CAHN
	@	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987	Jan CAHN

CETIRIZINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
ZERVIAE

	+! EYEVANCE PHARMS	EQ 0.24% BASE	N208694	001	May 30, 2017	Oct CAHN
	+! NICOX OPHTHALMICS	EQ 0.24% BASE	N208694	001	May 30, 2017	May NEWA
	SYRUP;ORAL					
	CETIRIZINE HYDROCHLORIDE					
AA	ALLIED PHARMA INC	5MG/5ML	A090191	001	Nov 12, 2009	Apr CAHN

CEVIMELINE HYDROCHLORIDECAPSULE;ORAL  
CEVIMELINE HYDROCHLORIDE

AB	RISEING PHARMS INC	30MG	A203775	001	Jun 04, 2014	May CAHN
----	--------------------	------	---------	-----	--------------	----------

CHENODIOLTABLET;ORAL  
CHENIX

	+ @ LEADIANT BIOSCI INC	250MG	N018513	002	Jul 28, 1983	Feb CAHN
--	-------------------------	-------	---------	-----	--------------	----------

CHLORAMPHENICOL SODIUM SUCCINATEINJECTABLE;INJECTION  
CHLOROMYCETIN

	+ @ PARKEDALE	EQ 1GM BASE/VIAL	N050155	001		Mar CRLD
--	---------------	------------------	---------	-----	--	----------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

@ UPSHER-SMITH LABS	5MG	A 084678	001		Jun CAHN
@	5MG	A 084919	001		Aug CAHN
@	10MG	A 084041	001		Jun CAHN
@	10MG	A 084920	001		Aug CAHN
@	25MG	A 084679	002		Jun CAHN
@	25MG	A 084823	001		Aug CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

PERIOGARD

AT	COLGATE PALMOLIVE CO	0.12%	A 073695	001	Jan 14, 1994	May CAHN
----	----------------------	-------	----------	-----	--------------	----------

CHLOROPROCAINE HYDROCHLORIDE

SOLUTION; INTRATHECAL

CLOROTEKAL

+	SINTETICA SA	50MG/5ML (10MG/ML)	N 208791	001	Sep 26, 2017	Sep NEWA
---	--------------	--------------------	----------	-----	--------------	----------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN

+	@ SANOFI AVENTIS US	EQ 300MG BASE	N 006002	001		Sep DISC	
AA	!	NATCO PHARMA LTD	EQ 300MG BASE	A 090612	001	Jan 21, 2011	Sep CHRS

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

!	MYLAN	250MG	A 084217	002		Sep CMS1
---	-------	-------	----------	-----	--	----------

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

@	PAMLAB LLC	400MG	N 014217	002		Mar CAHN
---	------------	-------	----------	-----	--	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA	ACELLA PHARMS LLC	4MG/5ML; 5MG/5ML	A 206891	001	Jun 09, 2017	May NEWA
	@ TRIS PHARMA INC	4MG/5ML; 5MG/5ML	A 206438	001	Jan 27, 2015	Sep DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	BIO-PHARM INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A 206660	001	May 15, 2017	May NEWA
	@ TRIS PHARMA INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A 203838	001	Nov 26, 2014	Sep DISC

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

	USL PHARMA	10MG	A 083386	001		Jun CAHN
		10MG	A 083386	001		May CTEC
!		25MG	A 084112	001		Jun CAHN
!		25MG	A 084112	001		May CHRS
		50MG	A 084113	001		Jun CAHN
		50MG	A 084113	001		May CTEC
!		100MG	A 084114	001		Jun CAHN
!		100MG	A 084114	001		May CHRS
		200MG	A 084115	001		Jun CAHN
		200MG	A 084115	001		May CTEC
	THORAZINE					
@	GLAXOSMITHKLINE	10MG	N 009149	002		May CRLD
@		25MG	N 009149	007		May CRLD
@		50MG	N 009149	013		May CRLD
@		100MG	N 009149	018		May CRLD
@		200MG	N 009149	020		May CRLD



CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ ANI PHARMS INC

250MG

A087353 001

Jan CAHN

@ WATSON LABS TEVA

250MG

A088826 001

Sep 26, 1984

May CAHN

GLUCAMIDE

AB ANI PHARMS INC

250MG

A088641 001

Oct 11, 1984

Jul CMFD

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB RICONPHARMA LLC

25MG

A206904 001

Mar 30, 2017

Mar NEWA

AB 50MG

A206904 002

Mar 30, 2017

Mar NEWA

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE LIGHT

AB ZYDUS PHARMS USA INC

EQ 4GM RESIN/SCOOPFUL

A202902 001

Apr 25, 2017

Aug CTNA

AB EQ 4GM RESIN/SCOOPFUL

A202902 001

Apr 25, 2017

Apr NEWA

PREVALITE

AB UPSHER-SMITH LABS

EQ 4GM RESIN/PACKET

A073263 001

Feb 22, 1996

Jun CAHN

AB EQ 4GM RESIN/SCOOPFUL

A073263 002

Oct 30, 1997

Jun CAHN

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

&gt;A&gt; AP UCSF RODIOPHARM

4-33.1mCi/ML

A208444 001

Nov 20, 2017

Nov NEWA

UNIV TX MD ANDERSON

4-100mCi/ML

A205690 001

Oct 29, 2015

Jul CPOT

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB ALEMBIC PHARMS LTD

EQ 45MG FENOFIBRIC ACID

A208705 001

May 12, 2017

May NEWA

AB EQ 135MG FENOFIBRIC ACID

A208705 002

May 12, 2017

May NEWA

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+! ASTRAZENECA PHARMS

0.08MG/INH

N021658 002

Jan 10, 2008

Jul CAHN

+! 0.16MG/INH

N021658 003

Jan 10, 2008

Jul CAHN

AEROSOL, METERED; NASAL

ZETONNA

+! ASTRAZENECA PHARMS

0.037MG/INH

N202129 001

Jan 20, 2012

Jul CAHN

SPRAY, METERED; NASAL

OMNARIS

+! ASTRAZENECA PHARMS

0.05MG/INH

N022004 001

Oct 20, 2006

Jul CAHN

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB PERRIGO NEW YORK

0.77%

A077364 001

Mar 03, 2006

Apr CAHN

GEL; TOPICAL

CICLOPIROX

AB +! CNTY LINE PHARMS

0.77%

N020519 001

Jul 21, 1997

Sep CTNA

SHAMPOO; TOPICAL

CICLOPIROX

AT PERRIGO CO

1%

A078594 001

Feb 16, 2010

Apr CAHN

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB CHARTWELL RX

50MG

A077722 001

Sep 24, 2012

Sep CAHN

AB 100MG

A077831 001

Sep 24, 2012

Sep CAHN

@ EPIC PHARMA LLC

50MG

A077150 001

Mar 11, 2005

May CAHN

@ 100MG

A077022 001

Nov 23, 2004

May CAHN

@ MYLAN

50MG

A077323 002

Apr 20, 2006

May DISC

@ 100MG

A077323 001

Apr 20, 2006

May DISC

@ MYLAN PHARMS INC

50MG

A077019 001

Nov 23, 2004

Mar DISC

@ 100MG

A077019 002

Nov 23, 2004

Mar DISC

@ PLIVA HRVATSKA DOO

50MG

A077898 001

Oct 29, 2007

Mar DISC

TABLET;ORAL  
CILOSTAZOL

@	100MG	A077898	002	Oct 29, 2007	Mar DISC
PLETAL					
+ @ OTSUKA	50MG	N020863	001	Jan 15, 1999	Jan CRLD
+ @	100MG	N020863	002	Jan 15, 1999	Jan CRLD

CIMETIDINE

TABLET;ORAL  
CIMETIDINE

@ CHARTWELL MOLECULES	200MG	A074281	001	May 17, 1994	Jan CAHN
@	300MG	A074281	002	May 17, 1994	Jan CAHN
@	400MG	A074281	003	May 17, 1994	Jan CAHN
@	800MG	A074329	001	May 17, 1994	Jan CAHN
@ SANDOZ INC	200MG	A074250	001	Jun 29, 1995	Mar CAHN
@	300MG	A074250	002	Jun 29, 1995	Mar CAHN
@	400MG	A074250	003	Jun 29, 1995	Mar CAHN
@	800MG	A074250	004	Jun 29, 1995	Mar CAHN
@ UPSHER-SMITH LABS	200MG	A074506	001	Jan 24, 1996	Jun CAHN
@	300MG	A074506	002	Jan 24, 1996	Jun CAHN
@	400MG	A074506	003	Jan 24, 1996	Jun CAHN
@	800MG	A074506	004	Jan 24, 1996	Jun CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION  
CIMETIDINE HYDROCHLORIDE

>D> AP	DAVA PHARMS INC	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996	Nov CTEC
>A>		EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996	Nov CTEC

## SOLUTION;ORAL

## CIMETIDINE HYDROCHLORIDE

AA	PHARM ASSOC	EQ 300MG BASE/5ML	A074553	001	Jan 27, 1997	May CAHN
----	-------------	-------------------	---------	-----	--------------	----------

CIPROFLOXACIN

INJECTABLE;INJECTION  
CIPRO

+ @ BAYER HLTHCARE	400MG/40ML (10MG/ML)	N019847	001	Dec 26, 1990	Feb DISC
+ @	200MG/20ML (10MG/ML)	N019847	002	Dec 26, 1990	Feb DISC
	CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER				
+ @ BAYER HLTHCARE	200MG/100ML	N019857	001	Dec 26, 1990	Feb DISC
+ @	400MG/200ML	N019857	002	Dec 26, 1990	Feb DISC

## CIPROFLOXACIN

AP	!	BAXTER HLTHCARE CORP	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Aug CAHN
AP	!		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Aug CAHN
AP	!	CLARIS	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Feb CHRS
AP	!		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Feb CHRS

## CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE CORP	200MG/100ML	A078024	001	Mar 18, 2008	Aug CAHN
AP			400MG/200ML	A078024	002	Mar 18, 2008	Aug CAHN
AP	!	HOSPIRA	200MG/100ML	A077753	001	Mar 18, 2008	Feb CHRS
AP	!		400MG/200ML	A077753	002	Mar 18, 2008	Feb CHRS

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
CIPROFLOXACIN HYDROCHLORIDE

AT	@ AMRING PHARMS	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Oct DISC
AT		EQ 0.3% BASE	A078598	001	Jan 16, 2008	Mar CAHN
AT	TELIGENT	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Apr CAHN

## TABLET;ORAL

## CIPROFLOXACIN HYDROCHLORIDE

	@ MYLAN	EQ 250MG BASE	A075685	002	Jun 09, 2004	Aug DISC
	@	EQ 500MG BASE	A075685	003	Jun 09, 2004	Aug DISC
	@	EQ 750MG BASE	A075685	001	Jun 09, 2004	Aug DISC
AB	TARO PHARM	EQ 100MG BASE	A076912	001	Feb 18, 2005	Mar CAHN
AB		EQ 250MG BASE	A076912	002	Oct 06, 2004	Mar CAHN
AB		EQ 500MG BASE	A076912	003	Oct 06, 2004	Mar CAHN
AB		EQ 750MG BASE	A076912	004	Oct 06, 2004	Mar CAHN
AB	UNIQUE PHARM LABS	EQ 250MG BASE	A076639	001	Sep 10, 2004	Aug CAHN
AB		EQ 500MG BASE	A076639	002	Sep 10, 2004	Aug CAHN
AB		EQ 750MG BASE	A076639	003	Sep 10, 2004	Aug CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Jun NEWA
AP	JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A209334	001	Aug 30, 2017	Aug NEWA
	CISATRACURIUM BESYLATE	PRESERVATIVE FREE				
AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Jun NEWA
AP		EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Jun NEWA
AP	JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Jan NEWA
>A> AP		EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Nov CAIN

>D> CISATRACURIUM BESYLATE PRESERVATIVE FREE

&gt;D&gt; INJECTABLE;INJECTION

&gt;D&gt; CISATRACURIUM BESYLATE PRESERVATIVE FREE

>D> AP	JIANGSU HENGRUI MED	EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Nov CAIN
AP		EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Sep NEWA

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

AP	GLAND PHARMA LTD	1MG/ML	A207323	001	Mar 17, 2017	Mar NEWA
AP	+ HQ SPCLT PHARMA	1MG/ML	N018057	004	Nov 08, 1988	Mar CRLD
	PLATINOL					
	+ @ HQ SPCLT PHARMA	10MG/VIAL	N018057	001		Mar CRLD
	+ @	50MG/VIAL	N018057	002		Mar CRLD
	PLATINOL-AQ					
	+ @ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Mar CRLD

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

@ MYLAN PHARMS INC EQ 10MG BASE

A077668 001 Feb 28, 2007 Mar DISC

@ EQ 20MG BASE

A077668 002 Feb 28, 2007 Mar DISC

@ EQ 40MG BASE

A077668 003 Feb 28, 2007 Mar DISC

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

AA	AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	A077812	001	Aug 28, 2006	Jan CAHN
----	----------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

@ EPIC PHARMA LLC EQ 10MG BASE

A077036 001 Oct 28, 2004 May CAHN

@ EQ 20MG BASE

A077036 002 Oct 28, 2004 May CAHN

@ EQ 40MG BASE

A077036 003 Oct 28, 2004 May CAHN

@ MYLAN EQ 10MG BASE

A077039 001 Feb 03, 2005 Jun DISC

@ EQ 20MG BASE

A077039 002 Feb 03, 2005 Jun DISC

@ EQ 40MG BASE

A077039 003 Feb 03, 2005 Jun DISC

@ MYLAN PHARMS INC EQ 10MG BASE

A077037 001 Nov 05, 2004 May DISC

@ EQ 20MG BASE

A077037 002 Nov 05, 2004 May DISC

@ EQ 40MG BASE

A077037 003 Nov 05, 2004 May DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

PREPOPIK

+!	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACK ET	N202535	001	Jul 16, 2012	Mar CAHN
----	--------------------	---------------------------------------	---------	-----	--------------	----------

SOLUTION;ORAL

CLENPIQ

>A>						
>A>	+!	FERRING PHARMS INC	12GM/160ML;3.5GM/160ML;10MG/160ML	N209589	001	Nov 28, 2017
						Nov NEWA

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

@ MYLAN 250MG

A065195 001 Mar 11, 2005 May DISC

@ 500MG

A065195 002 Mar 11, 2005 May DISC

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

@ SANDOZ 2.68MG

A073459 001 Oct 31, 1993 Feb DISC

! TEVA 2.68MG

A073283 001 Jan 31, 1992 Feb CTEC

CLINDAMYCIN HYDROCHLORIDE

## CAPSULE;ORAL

## CLINDAMYCIN HYDROCHLORIDE

AB	EPIC PHARMA LLC	EQ 150MG BASE	A065194	001	Mar 22, 2004	May CAHN
AB		EQ 300MG BASE	A065194	002	Mar 22, 2004	May CAHN
AB	LANNETT	EQ 75MG BASE	A065243	002	Aug 12, 2005	Aug CMS1
	@ MYLAN PHARMS INC	EQ 75MG BASE	A091225	001	May 31, 2011	May DISC
	@	EQ 150MG BASE	A091225	002	May 31, 2011	May DISC
	@	EQ 300MG BASE	A091225	003	May 31, 2011	May DISC
	CLINDAMYCIN HYDROCHLORIDE					
AB	LANNETT	EQ 150MG BASE	A065243	003	Aug 12, 2005	Aug CMS1

CLINDAMYCIN PALMITATE HYDROCHLORIDE

## FOR SOLUTION;ORAL

## CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	INVAGEN PHARMS	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Apr NEWA
AA	ORIT LABS LLC	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Jun CAHN
AA	PADDOCK LLC	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Apr CAHN

CLINDAMYCIN PHOSPHATE

## AEROSOL, FOAM;TOPICAL

## EVOCLIN

AT	+! MYLAN PHARMS INC	1%	N050801	001	Oct 22, 2004	Jan CAHN
----	---------------------	----	---------	-----	--------------	----------

## INJECTABLE;INJECTION

## CLINDAMYCIN PHOSPHATE

AP	MYLAN LABS LTD	EQ 150MG BASE/ML	A204748	001	Oct 10, 2017	Sep NEWA
AP		EQ 150MG BASE/ML	A204749	001	Oct 10, 2017	Sep NEWA
AP	SAGENT PHARMS	EQ 150MG BASE/ML	A090109	001	Sep 30, 2011	Apr CAHN
AP	WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Jan CAHN
	CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE CORP	EQ 6MG BASE/ML	A208084	001	Jun 28, 2017	Jul CAHN
AP		EQ 12MG BASE/ML	A208084	002	Jun 28, 2017	Jul CAHN
AP		EQ 18MG BASE/ML	A208084	003	Jun 28, 2017	Jul CAHN
AP	CELERITY PHARMS	EQ 6MG BASE/ML	A208084	001	Jun 28, 2017	Jun NEWA
AP		EQ 12MG BASE/ML	A208084	002	Jun 28, 2017	Jun NEWA
AP		EQ 18MG BASE/ML	A208084	003	Jun 28, 2017	Jun NEWA

## SOLUTION;IV (INFUSION)

## CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

+!	BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017	May CAHN
+!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017	May CAHN
+!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017	May CAHN
+!	CELERITY PHARMS	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017	Apr NEWA
+!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017	Apr NEWA
+!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017	Apr NEWA

## SOLUTION;TOPICAL

## CLINDAMYCIN PHOSPHATE

AT	FOUGERA PHARMS INC	EQ 1% BASE	A064159	001	Jun 05, 1997	Jan CAHN
	@ NOVAST LABS LTD	EQ 1% BASE	A064108	001	Sep 27, 1996	Sep CAHN

## SWAB;TOPICAL

## CLINDETS

AT	PERRIGO CO	EQ 1% BASE	A064136	001	Sep 30, 1996	Apr CAHN
----	------------	------------	---------	-----	--------------	----------

CLOBAZAM

## SUSPENSION;ORAL

## ONFI

+!	LUNDBECK PHARMS LLC	2.5MG/ML	N203993	001	Dec 14, 2012	Jan CAHN
----	---------------------	----------	---------	-----	--------------	----------

## TABLET;ORAL

## ONFI

	@ LUNDBECK PHARMS LLC	5MG	N202067	001	Oct 21, 2011	Jan CAHN
+		10MG	N202067	002	Oct 21, 2011	Jan CAHN
+!		20MG	N202067	003	Oct 21, 2011	Jan CAHN

CLOBETASOL PROPIONATE

## AEROSOL, FOAM; TOPICAL

## CLOBETASOL PROPIONATE

AB1	INGENUS PHARMS LLC	0.05%	A206805	001	Jul 31, 2017	Jul	NEWA
-----	--------------------	-------	---------	-----	--------------	-----	------

## OLUX

AB1	+! MYLAN PHARMS INC	0.05%	N021142	001	May 26, 2000	Jan	CAHN
-----	---------------------	-------	---------	-----	--------------	-----	------

## OLUX E

AB2	+! MYLAN PHARMS INC	0.05%	N022013	001	Jan 12, 2007	Jan	CAHN
-----	---------------------	-------	---------	-----	--------------	-----	------

## CREAM; TOPICAL

## CLOBETASOL PROPIONATE

AB1	FOUGERA PHARMS INC	0.05%	A074392	001	Sep 30, 1996	Jan	CAHN
-----	--------------------	-------	---------	-----	--------------	-----	------

AB1	MYLAN PHARMS INC	0.05%	A075338	001	Feb 09, 2001	May	CMFD
-----	------------------	-------	---------	-----	--------------	-----	------

## @

		0.05%	A075338	001	Feb 09, 2001	Jan	CAHN
--	--	-------	---------	-----	--------------	-----	------

AB1	TARO	0.05%	A074249	001	Jul 08, 1996	Apr	CAHN
-----	------	-------	---------	-----	--------------	-----	------

## CLOBETASOL PROPIONATE (EMOLLIENT)

## @ NOVAST LABS LTD

		0.05%	A075733	001	Aug 22, 2001	Sep	CAHN
--	--	-------	---------	-----	--------------	-----	------

AB2	TELIGENT PHARMA INC	0.05%	A209411	001	Aug 21, 2017	Aug	NEWA
-----	---------------------	-------	---------	-----	--------------	-----	------

&gt;A&gt;

## IMPOYZ

&gt;A&gt;

## +! PROMIUS PHARMA LLC

		0.025%	N209483	001	Nov 28, 2017	Nov	NEWA
--	--	--------	---------	-----	--------------	-----	------

## GEL; TOPICAL

## CLOBETASOL PROPIONATE

AB	PERRIGO CO	0.05%	A075027	001	Oct 31, 1997	Apr	CAHN
----	------------	-------	---------	-----	--------------	-----	------

AB	TARO	0.05%	A075279	001	May 28, 1999	Apr	CAHN
----	------	-------	---------	-----	--------------	-----	------

AB	TELIGENT PHARMA INC	0.05%	A208881	001	Mar 06, 2017	Feb	NEWA
----	---------------------	-------	---------	-----	--------------	-----	------

## LOTION; TOPICAL

## CLOBETASOL PROPIONATE

AB	LUPIN LTD	0.05%	A209147	001	Sep 22, 2017	Sep	NEWA
----	-----------	-------	---------	-----	--------------	-----	------

## OINTMENT; TOPICAL

## CLOBETASOL PROPIONATE

AB	GLENMARK PHARMS	0.05%	A208933	001	Mar 20, 2017	Mar	NEWA
----	-----------------	-------	---------	-----	--------------	-----	------

>D> AB1	MYLAN PHARMS INC	0.05%	A075057	001	Aug 12, 1998	Nov	CTEC
---------	------------------	-------	---------	-----	--------------	-----	------

>A> AB		0.05%	A075057	001	Aug 12, 1998	Nov	CTEC
--------	--	-------	---------	-----	--------------	-----	------

AB1		0.05%	A075057	001	Aug 12, 1998	May	CMFD
-----	--	-------	---------	-----	--------------	-----	------

## @

		0.05%	A075057	001	Aug 12, 1998	Jan	CAHN
--	--	-------	---------	-----	--------------	-----	------

AB	TARO	0.05%	A074248	001	Jul 12, 1996	Apr	CAHN
----	------	-------	---------	-----	--------------	-----	------

AB	ZYDUS PHARMS USA INC	0.05%	A210199	001	Oct 27, 2017	Oct	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

## TEMOVATE

## + @ FOUGERA PHARMS

		0.05%	N019323	001	Dec 27, 1985	Jan	CRLD
--	--	-------	---------	-----	--------------	-----	------

## SHAMPOO; TOPICAL

## CLOBETASOL PROPIONATE

AB	HI-TECH PHARMACAL	0.05%	A209871	001	Oct 27, 2017	Oct	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

## SOLUTION; TOPICAL

## CLOBETASOL PROPIONATE

AT	MACLEODS PHARMS LTD	0.05%	A209361	001	Oct 25, 2017	Oct	NEWA
----	---------------------	-------	---------	-----	--------------	-----	------

AT	TARO	0.05%	A075224	001	Nov 16, 1998	Apr	CAHN
----	------	-------	---------	-----	--------------	-----	------

## SPRAY; TOPICAL

## CLOBETASOL PROPIONATE

AT	AKORN	0.05%	A207218	001	Apr 28, 2017	Apr	NEWA
----	-------	-------	---------	-----	--------------	-----	------

AT	ZYDUS PHARMS USA INC	0.05%	A206378	001	Feb 16, 2017	Feb	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

CLOFARABINE

## INJECTABLE; IV (INFUSION)

## CLOFARABINE

AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	Apr	NEWA
----	-----------------	--------------------	---------	-----	--------------	-----	------

AP	AMNEAL PHARMS CO	20MG/20ML (1MG/ML)	A208857	001	Nov 06, 2017	Oct	NEWA
----	------------------	--------------------	---------	-----	--------------	-----	------

AP	DR REDDYS LABS LTD	20MG/20ML (1MG/ML)	A205375	001	Nov 06, 2017	Oct	NEWA
----	--------------------	--------------------	---------	-----	--------------	-----	------

>A> AP	MSN LABS PVT LTD	20MG/20ML (1MG/ML)	A209775	001	Dec 06, 2017	Nov	NEWA
--------	------------------	--------------------	---------	-----	--------------	-----	------

AP	MYLAN LABS LTD	20MG/20ML (1MG/ML)	A208860	001	Nov 06, 2017	Oct	NEWA
----	----------------	--------------------	---------	-----	--------------	-----	------

## CLOLAR

AP	+! GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Apr	CFTG
----	------------	--------------------	---------	-----	--------------	-----	------

CLOFAZIMINE

## CAPSULE; ORAL

## LAMPRENE

	+ @ NOVARTIS	50MG	N019500	002	Dec 15, 1986	Aug	DISC
--	--------------	------	---------	-----	--------------	-----	------

CLOFIBRATE

CAPSULE;ORAL

CLOFIBRATE

@ USL PHARMA	500MG	A070531	001	Jun 16, 1986	Jun CAHN
--------------	-------	---------	-----	--------------	----------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	SANDOZ	25MG	A074953	001	Jun 25, 1997	Feb CMFD
AB		50MG	A074953	002	Jun 25, 1997	Feb CMFD
AB		75MG	A074953	003	Jun 25, 1997	Feb CMFD

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

@	MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997	Mar DISC
@		1MG	A074940	002	Oct 30, 1997	Mar DISC
@		2MG	A074940	003	Oct 30, 1997	Mar DISC
AB	PRINSTON INC	0.5MG	A077856	001	Jun 28, 2006	Feb CAHN
AB		1MG	A077856	002	Jun 28, 2006	Feb CAHN
AB		2MG	A077856	003	Jun 28, 2006	Feb CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988	Jul CMS1
		0.2MG	A071785	003	Apr 05, 1988	Jul CMS1
@		0.3MG	A071785	001	Apr 05, 1988	Feb CAHN
AB	PRINSTON INC	0.1MG	A077901	001	Mar 09, 2007	Feb CAHN
AB		0.2MG	A077901	002	Mar 09, 2007	Feb CAHN
AB		0.3MG	A077901	003	Mar 09, 2007	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	Apr CAHN
AB1		0.1MG	A203320	001	May 15, 2015	Apr CAHN
@		0.2MG	A202792	002	May 15, 2015	Apr CAHN
@		0.2MG	A203320	002	May 15, 2015	Apr CAHN
>A> AB1	AJANTA PHARMA LTD	0.1MG	A209686	001	Nov 20, 2017	Nov NEWA
>A> AB1	AMNEAL PHARMS NY	0.1MG	A210052	001	Nov 20, 2017	Nov NEWA
AB1	LUPIN LTD	0.1MG	A209285	001	Oct 23, 2017	Oct NEWA
>A> AB1	XIAMEN LP PHARM CO	0.1MG	A209757	001	Nov 20, 2017	Nov NEWA

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	ACME LABS	EQ 75MG BASE	A078004	001	May 17, 2012	Jul CAHN
AB	ALLIED PHARMA INC	EQ 75MG BASE	A078004	001	May 17, 2012	Mar CAHN
AB	CSPC OUYI PHARM CO	EQ 75MG BASE	A204359	001	Feb 02, 2017	Jan NEWA

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

AUROLIFE PHARMA LLC	3.75MG	A072112	002	Aug 11, 2017	Aug CMS1
	7.5MG	A072112	003	Aug 11, 2017	Aug CMS1

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

@	SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Oct DISC
@		7.5MG	A076911	002	Sep 29, 2004	Oct DISC
@		15MG	A076911	003	Sep 29, 2004	Oct DISC
AB	TARO PHARM	3.75MG	A075731	003	Apr 27, 2000	Mar CAHN
AB		7.5MG	A075731	002	Apr 27, 2000	Mar CAHN
AB		15MG	A075731	001	Apr 27, 2000	Mar CAHN

CLOTRIMAZOLE

SOLUTION;TOPICAL

CLOTRIMAZOLE

AT	! TARO	1%	A074580	001	Jul 29, 1996	Apr CAHN
	LOTRIMIN					
	+ @ SCHERING PLOUGH	1%	N017613	001		Jul CRLD

CLOZAPINESUSPENSION;ORAL  
VERSACLOZ

+! TASMAN PHARMA 50MG/ML

N203479 001 Feb 06, 2013 Sep CAHN

TABLET;ORAL  
CLOZAPINE

AB MAYNE PHARMA 50MG

A203807 003 Aug 22, 2017 Aug NEWA

AB 200MG

A203807 004 Aug 22, 2017 Aug NEWA

AB SUN PHARM INDS INC 200MG

A075713 004 Nov 07, 2017 Oct NEWA

&gt;A&gt; AB ZYDUS PHARMS USA INC 25MG

A209480 001 Dec 06, 2017 Nov NEWA

&gt;A&gt; AB 50MG

A209480 002 Dec 06, 2017 Nov NEWA

&gt;A&gt; AB 100MG

A209480 003 Dec 06, 2017 Nov NEWA

&gt;A&gt; AB 200MG

A209480 004 Dec 06, 2017 Nov NEWA

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

@ PHARM ASSOC 10MG/5ML;6.25MG/5ML

A089647 001 Dec 22, 1988 May CAHN

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

@ WEST-WARD PHARMS INT 30MG/5ML

N202245 001 Jun 30, 2011 Jan CAHN

TABLET;ORAL

CODEINE SULFATE

AB + WEST-WARD PHARMS INT 15MG

N022402 001 Jul 16, 2009 Jan CAHN

AB + 30MG

N022402 002 Jul 16, 2009 Jan CAHN

AB +! 60MG

N022402 003 Jul 16, 2009 Jan CAHN

COLESTIPOL HYDROCHLORIDE

GRANULE;ORAL

COLESTID

&gt;D&gt; AB + PHARMACIA AND UPJOHN 5GM/SCOOPFUL

N017563 003 Sep 22, 1995 Nov CAHN

&gt;D&gt; AB +! 5GM/PACKET

N017563 004 Sep 22, 1995 Nov CAHN

&gt;A&gt; AB + PHARMACIA UPJOHN 5GM/SCOOPFUL

N017563 003 Sep 22, 1995 Nov CAHN

&gt;A&gt; AB +! 5GM/PACKET

N017563 004 Sep 22, 1995 Nov CAHN

FLAVORED COLESTID

&gt;D&gt; + PHARMACIA AND UPJOHN 5GM/PACKET

N017563 001 Nov CAHN

&gt;D&gt; + 5GM/SCOOPFUL

N017563 002 Nov CAHN

&gt;A&gt; + PHARMACIA UPJOHN 5GM/PACKET

N017563 001 Nov CAHN

&gt;A&gt; + 5GM/SCOOPFUL

N017563 002 Nov CAHN

TABLET;ORAL

COLESTID

&gt;D&gt; AB +! PHARMACIA AND UPJOHN 1GM

N020222 001 Jul 19, 1994 Nov CAHN

&gt;A&gt; AB +! PHARMACIA UPJOHN 1GM

N020222 001 Jul 19, 1994 Nov CAHN

COPANLISIB DIHYDROCHLORIDE

POWDER;IV (INFUSION)

ALIQOPA

+! BAYER HEALTHCARE 60MG/VIAL

N209936 001 Sep 14, 2017 Sep NEWA

COPPER

INTRAUTERINE DEVICE;INTRAUTERINE

PARAGARD T 380A

&gt;A&gt; +! COOPERSURGICAL 309MG/COPPER

N018680 001 Nov 15, 1984 Nov CAHN

&gt;D&gt; +! TEVA WOMENS 309MG/COPPER

N018680 001 Nov 15, 1984 Nov CAHN

CORTICOTROPIN

INJECTABLE;INJECTION

PURIFIED CORTROPHIN GEL

@ ANI PHARMS INC 40 UNITS/ML

N008975 001 May CAHN

@ 80 UNITS/ML

N008975 002 May CAHN

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE;INJECTION

CORTROPHIN-ZINC

@ ANI PHARMS INC 40 UNITS/ML

N009854 001 May CAHN

COSYNTROPINSOLUTION; INTRAVENOUS  
COSYNTROPIN

@ SANDOZ INC	0.25MG/ML (0.25MG/ML)	N022028	001	Feb 21, 2008	May CAHN
--------------	-----------------------	---------	-----	--------------	----------

CROMOLYN SODIUMCONCENTRATE; ORAL  
CROMOLYN SODIUM

AA	AILEX PHARMS LLC	100MG/5ML	A209264	001	Oct 16, 2017	Oct NEWA
AA	RISING PHARMS INC	100MG/5ML	A202583	001	Oct 27, 2011	Oct CAHN
GASTROCROM						
AA	+! MYLAN SPECIALITY LP	100MG/5ML	N020479	001	Feb 29, 1996	Mar CAHN
SOLUTION; INHALATION						
CROMOLYN SODIUM						
AN	AILEX PHARMS LLC	10MG/ML	A209453	001	Oct 16, 2017	Oct NEWA
	@ BAUSCH AND LOMB	10MG/ML	A075585	001	Dec 21, 2000	Jul DISC
AN		10MG/ML	A075585	001	Dec 21, 2000	Feb CAHN
INTAL						
	+ @ KING PHARMS LLC	10MG/ML	N018596	001	May 28, 1982	Sep CRLD
	@	10MG/ML	N018596	001	May 28, 1982	May CAHN
SOLUTION/DROPS; OPHTHALMIC						
CROLOM						
	@ BAUSCH AND LOMB	4%	A074443	001	Jan 30, 1995	Oct DISC

CYANOCOBALAMININJECTABLE; INJECTION  
CYANOCOBALAMIN

AP	MYLAN LABS LTD	1MG/ML	A204829	001	Jun 05, 2017	May NEWA
	DODEX					
	@ ACCORD HLTHCARE	1MG/ML	A083022	001		Jun CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	JUBILANT CADISTA	7.5MG	A077563	003	Aug 25, 2017	Aug NEWA
AB	OXFORD PHARMS	5MG	A077209	002	Feb 03, 2006	May CMS1
AB	PRINSTON INC	5MG	A077797	001	Feb 28, 2007	Feb CAHN
AB		10MG	A077797	002	Feb 28, 2007	Feb CAHN
AB	RUBICON RES PVT LTD	5MG	A208170	001	May 31, 2017	May NEWA
AB		7.5MG	A208170	002	May 31, 2017	May NEWA
AB		10MG	A208170	003	May 31, 2017	May NEWA
	@ UPSHER-SMITH LABS	5MG	A072854	002	Feb 03, 2006	Jun CAHN
	@	10MG	A072854	001	Nov 19, 1991	Jun CAHN

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

+	WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Jan CAHN
+	!	50MG	N203856	002	Sep 16, 2013	Jan CAHN

INJECTABLE; INJECTION

CYTOXAN (LYOPHILIZED)

+	@ BAXTER HLTHCARE	500MG/VIAL	N012142	003		Feb CRLD
+	@	1GM/VIAL	N012142	004	Aug 30, 1982	Feb CRLD
+	@	2GM/VIAL	N012142	005	Aug 30, 1982	Feb CRLD

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	BIO-PHARM INC	2MG/5ML	A204823	001	Dec 27, 2016	Sep CAHN
AA	SILARX PHARMS INC	2MG/5ML	A203191	001	Jul 13, 2017	Jul NEWA
PERIACTIN						
	+ @ MERCK	2MG/5ML	N013220	002		Jan CRLD

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	AILEX PHARMS LLC	4MG	A207555	001	Jan 31, 2017	Sep CAHN
AA	APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Jan NEWA
AA	IMPAX LABS INC	4MG	A040537	001	Sep 30, 2003	Feb CAHN
AA	SANTOS BIOTECH	4MG	A040644	001	May 30, 2006	May CAHN
AA	ZYDUS PHARMS USA INC	4MG	A208938	001	May 19, 2017	May NEWA



CYSTEAMINE BITARTRATECAPSULE, DELAYED RELEASE;ORAL  
PROCYSBI

+	HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013	Mar CAHN
+	!	EQ 75MG BASE	N203389	002	Apr 30, 2013	Mar CAHN

CYSTEAMINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
CYSTARAN

+	!	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012	Feb CAHN
---	---	---------------------	---------------	---------	-----	--------------	----------

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

>A>	AP	HONG KONG	20MG/ML	A206190	001	Nov 09, 2017	Nov CAHN
	AP	MYLAN LABS LTD	20MG/ML	A200915	001	Dec 13, 2011	Mar CAHN
>D>	AP	SAGENT PHARMS	20MG/ML	A206190	001	Nov 09, 2017	Nov CAHN
	AP		20MG/ML	A206190	001	Nov 09, 2017	Oct NEWA
		WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Mar CTEC
	!		500MG/VIAL	A071472	001	Aug 02, 1989	Mar CHRS
	!		1GM/VIAL	A074245	001	Aug 31, 1994	Mar CHRS
	!		2GM/VIAL	A074245	002	Aug 31, 1994	Mar CHRS
		CYTOSAR-U					
	@	TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998	Mar DISC
	@		500MG/VIAL	A075206	002	Dec 30, 1998	Mar DISC
	@		1GM/VIAL	A075206	004	Dec 30, 1998	Mar DISC
	@		2GM/VIAL	A075206	003	Dec 30, 1998	Mar DISC

CYTARABINE; DAUNORUBICIN

>D>		POWDER; INTRAVENOUS					
>D>		VYXEOS					
>D>	+	!	CELATOR PHARMS	100MG; 44MG	N209401	001	Aug 03, 2017
	+	!		100MG; 44MG	N209401	001	Aug 03, 2017
>A>		POWDER; IV (INFUSION)					
>A>		VYXEOS					
>A>	+	!	CELATOR PHARMS	100MG; 44MG	N209401	001	Aug 03, 2017

DACARBAZINE

INJECTABLE;INJECTION

DACARBAZINE

>D>	AP	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999	Nov CTEC
>A>		!		100MG/VIAL	A075371	001	Aug 27, 1999	Nov CTEC
	AP	!		100MG/VIAL	A075371	001	Aug 27, 1999	Feb CHRS
	AP	!		200MG/VIAL	A075371	002	Aug 27, 1999	Feb CHRS
			DTIC-DOME					
	+	@	BAYER HLTHCARE	100MG/VIAL	N017575	001		Apr DISC
	+	@		200MG/VIAL	N017575	002		Apr DISC

DACTINOMYCIN

INJECTABLE;INJECTION

DACTINOMYCIN

AP		MYLAN LABS LTD	0.5MG/VIAL	A203385	001	Nov 09, 2017	Oct NEWA
----	--	----------------	------------	---------	-----	--------------	----------

DALBAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

DALVANCE

+	!	ALLERGAN SALES LLC	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Aug CAHN
---	---	--------------------	--------------------	---------	-----	--------------	----------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

AMPYRA

AB	+	!	ACORDA	10MG	N022250	001	Jan 22, 2010	Jan CFTG
			DALFAMPRIDINE					
AB			ACTAVIS LABS FL INC	10MG	A206836	001	Jan 23, 2017	Jan NEWA
AB			AUROBINDO PHARMA LTD	10MG	A206811	001	Jan 23, 2017	Jan NEWA

DANTROLENE SODIUMINJECTABLE; INJECTION  
DANTROLENE SODIUM

AP	HIKMA PHARMS	20MG/VIAL	A204762	001	Jun 19, 2017	Jun	NEWA
----	--------------	-----------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
XIGDUO XR

+	ASTRAZENECA AB	EQ 2.5MG BASE; 1GM	N205649	005	Jul 28, 2017	Jul	NEWA
---	----------------	--------------------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDETABLET; ORAL  
QTERN

+	ASTRAZENECA AB	EQ 10MG BASE; EQ 5MG BASE	N209091	001	Feb 27, 2017	Feb	NEWA
---	----------------	---------------------------	---------	-----	--------------	-----	------

DAPSONEGEL; TOPICAL  
ACZONE

AB	+	ALLERGAN	5%	N021794	001	Jul 07, 2005	Oct	CFTG
----	---	----------	----	---------	-----	--------------	-----	------

DAPSONE

AB		TARO	5%	A209506	001	Oct 16, 2017	Oct	NEWA
----	--	------	----	---------	-----	--------------	-----	------

TABLET; ORAL  
DAPSONE

AB		ACTAVIS LLC	25MG	A204380	001	Mar 23, 2017	Mar	NEWA
AB			100MG	A204380	002	Mar 23, 2017	Mar	NEWA
AB		NOVITIUM PHARMA	25MG	A206505	001	Dec 01, 2016	Oct	CAHN
AB			100MG	A206505	002	Dec 01, 2016	Oct	CAHN
AB		VIRTUS PHARMS	25MG	A204074	001	May 10, 2016	Sep	CAHN
AB			100MG	A204074	002	May 10, 2016	Sep	CAHN

DAPTOMYCIN>D> POWDER; INTRAVENOUS  
>D> DAPTOMYCIN

>D>	+	SAGENT PHARMS	350MG/VIAL	N208385	001	Sep 12, 2017	Nov	CDFR
	+		350MG/VIAL	N208385	001	Sep 12, 2017	Sep	NEWA

>A> POWDER; IV (INFUSION)  
>A> DAPTOMYCIN

>A>	+	SAGENT PHARMS	350MG/VIAL	N208385	001	Sep 12, 2017	Nov	CDFR
	+	XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017	Oct	NEWA

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL  
DARIFENACIN

AB		MACLEODS PHARMS LTD	EQ 7.5MG BASE	A207302	001	Jul 28, 2017	Jul	NEWA
AB			EQ 15MG BASE	A207302	002	Jul 28, 2017	Jul	NEWA

DARIFENACIN HYDROBROMIDE

>A>	AB	ALEMBIC PHARMS LTD	EQ 7.5MG BASE	A207681	001	Dec 08, 2017	Nov	NEWA
>A>	AB		EQ 15MG BASE	A207681	002	Dec 08, 2017	Nov	NEWA

DARUNAVIR ETHANOLATE

TABLET; ORAL

>A> DARUNAVIR ETHANOLATE  
>A> AB TEVA PHARMS USA  
PREZISTA

A202118	001	Nov 21, 2017	Nov	NEWA
---------	-----	--------------	-----	------

&gt;D&gt; + JANSSEN PRODS EQ 600MG BASE

N021976	002	Feb 25, 2008	Nov	CFTG
---------	-----	--------------	-----	------

&gt;A&gt; AB + EQ 600MG BASE

N021976	002	Feb 25, 2008	Nov	CFTG
---------	-----	--------------	-----	------

DECITABINEINJECTABLE; INTRAVENOUS  
DECITABINE

AP		ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Feb	NEWA
AP		CHEMI SPA	50MG/VIAL	A206033	001	Sep 22, 2017	Sep	NEWA
>A>	AP	CIPLA LTD	50MG/VIAL	A208601	001	Nov 16, 2017	Nov	NEWA
AP		PHARMASCIENCE INC	50MG/VIAL	A204607	001	May 31, 2017	May	NEWA

DEFERASIROXGRANULE;ORAL  
JADENU SPRINKLE

+	NOVARTIS PHARMS CORP	90MG	N207968	001	May 18, 2017	May NEWA
+		180MG	N207968	002	May 18, 2017	May NEWA
+	!	360MG	N207968	003	May 18, 2017	May NEWA

DEFEROXAMINE MESYLATEINJECTABLE;INJECTION  
DEFEROXAMINE MESYLATE

AP	GLAND PHARMA LTD	500MG/VIAL	A207384	001	Sep 29, 2017	Sep NEWA
AP		2GM/VIAL	A207384	002	Sep 29, 2017	Sep NEWA

DEFLAZACORTSUSPENSION;ORAL  
EMFLAZA

+	MARATHON PHARMS LLC	22.75MG/ML	N208685	001	Feb 09, 2017	Feb NEWA
+	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr CAHN

TABLET;ORAL

EMFLAZA

+	MARATHON PHARMS LLC	6MG	N208684	001	Feb 09, 2017	Feb NEWA
+		18MG	N208684	002	Feb 09, 2017	Feb NEWA
+		30MG	N208684	003	Feb 09, 2017	Feb NEWA
+	!	36MG	N208684	004	Feb 09, 2017	Feb NEWA
+	PTC THERAP	6MG	N208684	001	Feb 09, 2017	Apr CAHN
+		18MG	N208684	002	Feb 09, 2017	Apr CAHN
+		30MG	N208684	003	Feb 09, 2017	Apr CAHN
+	!	36MG	N208684	004	Feb 09, 2017	Apr CAHN

DELAFLORACIN MEGLUMINEPOWDER;IV (INFUSION)  
BAXDELA

>A>	+	MELINTA	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017	Nov CAHN
>D>	+	MELINTA THERAPS INC	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017	Nov CAHN
	+		EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017	Jun NEWA

TABLET;ORAL

BAXDELA

>A>	+	MELINTA	EQ 450MG BASE	N208610	001	Jun 19, 2017	Nov CAHN
>D>	+	MELINTA THERAPS INC	EQ 450MG BASE	N208610	001	Jun 19, 2017	Nov CAHN
	+		EQ 450MG BASE	N208610	001	Jun 19, 2017	Jun NEWA

DESIPRAMINE HYDROCHLORIDETABLET;ORAL  
DESIPRAMINE HYDROCHLORIDE

AB	IMPAX LABS INC	10MG	A205153	001	Oct 28, 2016	Feb CAHN
AB		25MG	A205153	002	Oct 28, 2016	Feb CAHN
AB		50MG	A205153	003	Oct 28, 2016	Feb CAHN
AB		75MG	A205153	004	Oct 28, 2016	Feb CAHN
AB		100MG	A205153	005	Oct 28, 2016	Feb CAHN
AB		150MG	A205153	006	Oct 28, 2016	Feb CAHN

DESMETHYL PIROXICAMCAPSULE;ORAL  
PIROXICAM

	SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008	Mar CMS1
--	----------------------	------	---------	-----	--------------	----------

DESMOPRESSIN ACETATEINJECTABLE;INJECTION  
DESMOPRESSIN ACETATE

	@ HOSPIRA	0.004MG/ML	A075220	001	Aug 28, 2000	Jul DISC
AP	SAGENT PHARMS	0.004MG/ML	A204695	001	Aug 22, 2017	Aug NEWA
AP		0.004MG/ML	A204751	001	Aug 22, 2017	Aug NEWA
	@ TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Jul DISC

SPRAY, METERED;NASAL

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB	ZYDUS PHARMS USA INC	0.01MG/SPRAY	A091345	001	Oct 03, 2017	Sep NEWA
	NOCTIVA					
+	AVADEL SPECLT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Oct CAHN
+	!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Oct CAHN
+	SERENITY PHARMS LLC	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Mar NEWA
+	!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Mar NEWA

SPRAY, METERED;NASAL  
STIMATE

	@ FERRING PHARMS INC	0.15MG/SPRAY	N020355	001	Mar 07, 1994	Jun CAHN
	STIMATE (NEEDS NO REFRIGERATION)					
	+! FERRING PHARMS INC	0.15MG/SPRAY	N020355	002	Oct 24, 2007	Jun CAHN
	TABLET;ORAL					
	DESMOPRESSIN ACETATE					
AB	HERITAGE PHARMA	0.1MG	A207880	001	May 26, 2017	May NEWA
AB		0.1MG	A207880	001	May 26, 2017	May CAHN
AB		0.2MG	A207880	002	May 26, 2017	May NEWA
AB		0.2MG	A207880	002	May 26, 2017	May CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	ACCORD HLTHCARE	0.15MG,N/A;0.02MG,0.01MG	A209170	001	Jun 05, 2017	May NEWA
AB	AUROBINDO PHARMA LTD	0.15MG,N/A;0.02MG,0.01MG	A206853	001	Mar 22, 2017	Mar NEWA
	ISIBLOOM					
>A> AB	LABS LEON FARMA	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Nov CAHN
>D> AB	SANDOZ INC	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Nov CAHN
	KALLIGA					
AB	AUROBINDO PHARMA LTD	0.15MG;0.03MG	A207081	001	May 17, 2017	May NEWA
	VOLNEA					
>A> AB	LABS LEON FARMA	0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016	Nov CAHN
>D> AB	SANDOZ INC	0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016	Nov CAHN

DESONIDE

CREAM;TOPICAL

DESONIDE

AB	GLENMARK PHARMS	0.05%	A209729	001	Jul 24, 2017	Jul NEWA
	LOTION;TOPICAL					
	DESONIDE					
AB	GLENMARK PHARMS	0.05%	A209494	001	Sep 26, 2017	Sep NEWA
AB	TELLIGENT PHARMA INC	0.05%	A207855	001	Sep 28, 2017	Sep NEWA
	OINTMENT;TOPICAL					
	DESONIDE					
AB	GLENMARK PHARMS LTD	0.05%	A209996	001	Sep 15, 2017	Sep NEWA
AB	HI-TECH PHARMACAL	0.05%	A208836	001	Mar 27, 2017	Mar NEWA

DESOXIMETASONE

CREAM;TOPICAL

TOPICORT

AB	! TARO	0.05%	A073210	001	Nov 30, 1990	Apr CAHN
AB	!	0.25%	A073193	001	Nov 30, 1990	Apr CAHN
	+ @	0.25%	N017856	001		May CAHN
	TOPICORT LP					
	+ @ TARO	0.05%	N018309	001		May CAHN
	GEL;TOPICAL					
	DESOXIMETASONE					
AB	RISING PHARMS INC	0.05%	A204675	001	Aug 12, 2016	May CAHN
	TOPICORT					
AB	! TARO	0.05%	A074904	001	Jul 14, 1998	Apr CAHN
	+ @	0.05%	N018586	001	Mar 29, 1982	May CAHN
	+ @ TARO PHARMS NORTH	0.05%	N018586	001	Mar 29, 1982	Jan CRLD
	OINTMENT;TOPICAL					
	DESOXIMETASONE					
AB	RISING PHARMS INC	0.25%	A204272	001	Nov 30, 2016	May CAHN
AB	ZYDUS PHARMS USA INC	0.25%	A205206	001	Sep 19, 2017	Sep NEWA
	TOPICORT					
AB	+! TARO	0.05%	N018594	001	Jan 17, 1985	May CAHN
AB	!	0.25%	A074286	001	Jun 07, 1996	Apr CAHN
	+ @	0.25%	N018763	001	Sep 30, 1983	May CAHN
	SPRAY;TOPICAL					
	DESOXIMETASONE					
AT	PERRIGO ISRAEL	0.25%	A206441	001	Jan 20, 2017	Jan NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL  
DESVENLAFAXINE SUCCINATE

AB	ACTAVIS LABS FL	EQ 25MG BASE	A204065	001	Jul 29, 2016	May CAHN
AB		EQ 50MG BASE	A204065	002	Jul 29, 2016	May CAHN
AB		EQ 100MG BASE	A204065	003	Jul 29, 2016	May CAHN
AB	WEST-WARD PHARMS INT	EQ 25MG BASE	A204082	002	Aug 28, 2017	Aug NEWA
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A204020	001	Oct 11, 2017	Sep NEWA
AB		EQ 100MG BASE	A204020	002	Oct 11, 2017	Sep NEWA

DEUTETRABENAZINE

TABLET;ORAL  
AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Apr NEWA
+		9MG	N208082	002	Apr 03, 2017	Apr NEWA
+	!	12MG	N208082	003	Apr 03, 2017	Apr NEWA

DEXAMETHASONE

TABLET;ORAL

	DEXAMETHASONE					
AB	LARKEN LABS INC	1.5MG	A201270	001	Jul 17, 2017	Jul NEWA
BP	PAR PHARM	6MG	A088481	001	Nov 28, 1983	May CHRS
	@ UPSHER SMITH	0.75MG	A087534	001		Jun CAHN
	@	1.5MG	A087533	001		Jun CAHN
BP	XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983	Aug CAHN
BP		1.5MG	A088237	001	Apr 28, 1983	Jul CAHN
	HEXADROL					
	@ ASPEN GLOBAL INC	0.5MG	N012675	004		Oct CAHN
	@	0.75MG	N012675	007		Oct CAHN
	@	1.5MG	N012675	009		Oct CAHN
	@	4MG	N012675	010		Oct CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

	DEXAMETHASONE SODIUM PHOSPHATE					
AP	WEST-WARD PHARMS INT	EQ 4MG PHOSPHATE/ML	A084282	001		Aug CMFD
	SOLUTION/DROPS;OPHTHALMIC, OTIC					
	DEXAMETHASONE SODIUM PHOSPHATE					
AT	! SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	Feb CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OPHTHALMIC

	MAXITROL					
AT	SANDOZ INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062341	001	May 22, 1984	Feb CAHN

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL  
DEXILANT

AB	+! TAKEDA PHARMS USA	60MG	N022287	002	Jan 30, 2009	Apr CFTG
	DEXLANSOPRAZOLE					
AB	PAR PHARM INC	60MG	A202294	001	Apr 19, 2017	Apr NEWA
	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL					
	DEXILANT SOLUTAB					
	+ @ TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Aug DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

	DEXMEDETOMIDINE HYDROCHLORIDE							
AP	ACCORD HLTHCARE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Mar	CAHN	
AP	JIANGSU HENGRUI MED	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Sep	NEWA	
AP	LUITPOLD PHARMS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	May	CAHN	
AP	PHARMAFORCE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	May	NEWA	
AP	TEVA PHARMS USA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205272	001	Nov 28, 2017	Nov	NEWA	
AP	WEST-WARD PHARMS INT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205046	001	Apr 26, 2017	Apr	NEWA	

DEXMETHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	IMPAX LABS INC	25MG	A203614	001	Jul 05, 2017	Jun NEWA
AB		35MG	A203614	002	Jul 05, 2017	Jun NEWA
AB	TEVA PHARMS USA	25MG	A202731	001	Jul 05, 2017	Jun NEWA
AB		35MG	A202731	004	Jul 05, 2017	Jun NEWA

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	LANNETT CO INC	2.5MG	A209468	001	Sep 25, 2017	Sep NEWA
AB		5MG	A209468	002	Sep 25, 2017	Sep NEWA
AB		10MG	A209468	003	Sep 25, 2017	Sep NEWA
>A> AB	RHODES PHARMS	2.5MG	A208756	001	Nov 20, 2017	Nov NEWA
>A> AB		5MG	A208756	002	Nov 20, 2017	Nov NEWA
>A> AB		10MG	A208756	003	Nov 20, 2017	Nov NEWA

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE;ORAL  
DEXEDRINE

AB	+ IMPAX LABS INC	5MG	N017078	001		Aug CAHN
AB	+	10MG	N017078	002		Aug CAHN
AB	+!	15MG	N017078	003		Aug CAHN

DEXTROAMPHETAMINE SULFATE

AB	NESHER PHARMS	5MG	A209111	001	Jun 27, 2017	Jun NEWA
AB		10MG	A209111	002	Jun 27, 2017	Jun NEWA
AB		15MG	A209111	003	Jun 27, 2017	Jun NEWA
AB	VINTAGE PHARMS	5MG	A205673	001	Oct 31, 2017	Oct NEWA
AB		10MG	A205673	002	Oct 31, 2017	Oct NEWA
AB		15MG	A205673	003	Oct 31, 2017	Oct NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

	@ EPIC PHARMA LLC	5MG	A090652	001	Mar 07, 2014	May CAHN
	@	10MG	A090652	002	Mar 07, 2014	May CAHN
AA	SUNRISE PHARM INC	5MG	A210059	001	Oct 18, 2017	Oct NEWA
AA		10MG	A210059	002	Oct 18, 2017	Oct NEWA

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB	ACTAVIS ELIZABETH	20MG;10MG	A202934	001	Oct 10, 2017	Sep NEWA
AB	+! AVANIR PHARMS	20MG;10MG	N021879	001	Oct 29, 2010	Sep CFTG

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	+! ICU MEDICAL INC	10GM/100ML	N018080	001		Feb CAHN
----	--------------------	------------	---------	-----	--	----------

DEXTROSE 20% IN PLASTIC CONTAINER

AP	+! ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982	Feb CAHN
----	--------------------	------------	---------	-----	--------------	----------

DEXTROSE 30% IN PLASTIC CONTAINER

AP	+! ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985	Feb CAHN
----	--------------------	------------	---------	-----	--------------	----------

DEXTROSE 40% IN PLASTIC CONTAINER

AP	+! ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982	May CAHN
----	--------------------	------------	---------	-----	--------------	----------

DEXTROSE 5% IN PLASTIC CONTAINER

AP	+! ICU MEDICAL INC	50MG/ML	N016367	002		Feb CAHN
----	--------------------	---------	---------	-----	--	----------

DEXTROSE 50% IN PLASTIC CONTAINER

AP	+! ICU MEDICAL INC	50GM/100ML	N018563	001	Mar 23, 1982	Feb CAHN
----	--------------------	------------	---------	-----	--------------	----------

@ 50GM/100ML

DEXTROSE 60% IN PLASTIC CONTAINER

>D> AP	+! BAXTER HLTHCARE	60GM/100ML	N017521	005	Mar 26, 1982	Nov CTEC
--------	--------------------	------------	---------	-----	--------------	----------

>A>	+!	60GM/100ML	N017521	005	Mar 26, 1982	Nov CTEC
-----	----	------------	---------	-----	--------------	----------

DEXTROSE 70% IN PLASTIC CONTAINER

AP	+! ICU MEDICAL INC	70GM/100ML	N018561	001	Mar 23, 1982	Apr CAHN
----	--------------------	------------	---------	-----	--------------	----------

AP	+!	70GM/100ML	N019893	001	Dec 26, 1989	Feb CAHN
----	----	------------	---------	-----	--------------	----------

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;21MG/100ML;128MG/100ML;2	N017610	001		
	34MG/100ML				

Feb CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;30MG/100ML;141MG/100ML;1	N019513	001	May 08, 1986	
	5MG/100ML;260MG/100ML;25MG/100ML				

Feb CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;22	N019844	001	Jun 10, 1993	
	0MG/100ML;140MG/100ML				

Aug DISC

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;30MG/100ML;37MG/100ML;22	N017609	001		
	2MG/100ML;526MG/100ML;502MG/100ML				

Feb CAHN

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634	004	
---	-----------------	----------------------	---------	-----	--

Sep CRLD

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	5GM/100ML;150MG/100ML	N017634	001	
----	---	-----------------	-----------------------	---------	-----	--

Sep CRLD

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634	003	
----	---	-----------------	-----------------------	---------	-----	--

Sep CRLD

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	5GM/100ML;300MG/100ML	N017634	002	
----	---	-----------------	-----------------------	---------	-----	--

Sep CRLD

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;149MG/100ML	N018371	001		
-----------------	-----------------------	---------	-----	--	--

Apr CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	5GM/100ML;224MG/100ML	N018371	003	
----	--	-----------------	-----------------------	---------	-----	--

Apr CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;298MG/100ML	N018371	002		
-----------------	-----------------------	---------	-----	--	--

Apr CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;	N019870	001	Jun 10, 1993	
	280MG/100ML;91MG/100ML				

Aug DISC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	001	Jan 17, 1986	
-----------------	------------------------------------	---------	-----	--------------	--

Jun CAHN

	5GM/100ML;149MG/100ML;300MG/100ML	N018876	006	Mar 28, 1988	
--	-----------------------------------	---------	-----	--------------	--

Jun CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	005	Mar 28, 1988	Feb CAHN
----	--	-----------------	------------------------------------	---------	-----	--------------	----------

AP			5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	009	Jul 05, 1983	Feb CAHN
----	--	--	------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	002	Mar 24, 1988	Apr CAHN
----	--	-----------------	------------------------------------	---------	-----	--------------	----------

AP			5GM/100ML;149MG/100ML;900MG/100ML	N019691	004	Mar 24, 1988	Apr CAHN
----	--	--	-----------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N018365	008	Mar 28, 1988	
-----------------	-----------------------------------	---------	-----	--------------	--

Feb CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876	007	Mar 28, 1988	
-----------------	-----------------------------------	---------	-----	--------------	--

Jun CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	5GM/100ML;224MG/100ML;450MG/100ML	N018362	006	Mar 28, 1988	Feb CAHN
----	--	-----------------	-----------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML	N019691	006	Mar 24, 1988	Apr CAHN
----	--	-----------------	-----------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876	008	Mar 28, 1988	
-----------------	-----------------------------------	---------	-----	--------------	--

Jun CAHN

## INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML;149MG/100ML;450MG/100ML	N018362	010	Jul 05, 1983	Feb CAHN
AP		5GM/100ML;298MG/100ML;450MG/100ML	N018362	007	Mar 28, 1988	Feb CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML;149MG/100ML;900MG/100ML	N019691	005	Mar 24, 1988	Apr CAHN
AP		5GM/100ML;298MG/100ML;900MG/100ML	N019691	008	Mar 24, 1988	Apr CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML	N018876	002	Jan 17, 1986	Jun CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N018365	003	Jul 05, 1983	Feb CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876	003	Jan 17, 1986	Jun CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML;224MG/100ML;450MG/100ML	N018362	002		Feb CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML	N019691	007	Mar 24, 1988	Apr CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML	N018365	004	Jul 05, 1983	Feb CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876	004	Mar 28, 1988	Jun CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML;298MG/100ML;450MG/100ML	N018362	003		Feb CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML;298MG/100ML;900MG/100ML	N019691	009	Mar 24, 1988	Apr CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	005	Mar 28, 1988	Feb CAHN
		5GM/100ML;149MG/100ML;225MG/100ML	N018365	007	Mar 28, 1988	Feb CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	005	Mar 28, 1988	Jun CAHN
		5GM/100ML;149MG/100ML;300MG/100ML	N018876	009	Mar 28, 1988	Jun CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988	Feb CAHN
AP		5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988	Feb CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988	Apr CAHN
AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988	Apr CAHN

DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	10GM/100ML;900MG/100ML	N019631	015	Feb 24, 1988	Aug CTEC
>D> AP	BAXTER HLTHCARE	10GM/100ML;900MG/100ML	N016696	001		Nov DISC
>A>	@	10GM/100ML;900MG/100ML	N016696	001		Nov DISC
	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
+!	ICU MEDICAL INC	5GM/100ML;225MG/100ML	N017606	001		Feb CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
+!	ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001		Feb CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML;450MG/100ML	N017607	001		Feb CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	+! ICU MEDICAL INC	5GM/100ML;900MG/100ML	N017585	001		Aug CRLD
AP		5GM/100ML;900MG/100ML	N017585	001		Feb CAHN

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

## INJECTABLE; INJECTION

	MD-76R					
+ @	LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989	Aug DISC
	RENOGRAFIN-76					
+!	BRACCO	66%;10%	N010040	001		Aug CTEC

DIAZEPAM

## TABLET; ORAL

## DIAZEPAM

@	UPSHER-SMITH LABS	2MG	A070302	001	Dec 20, 1985	Jun CAHN
@		5MG	A070303	001	Dec 20, 1985	Jun CAHN
@		10MG	A070304	001	Dec 20, 1985	Jun CAHN
@	VIRTUS PHARMS	2MG	A070462	001	Feb 25, 1986	Feb CAHN
@		5MG	A070463	001	Feb 25, 1986	Feb CAHN
@		10MG	A070464	001	Feb 25, 1986	Feb CAHN



DICHLORPHENAMIDETABLET;ORAL  
KEVEYIS

+! STRONGBRIDGE US 50MG N011366 002 Aug 07, 2015 Aug CRLD

DICLOFENAC POTASSIUM

TABLET;ORAL

DICLOFENAC POTASSIUM

@ WATSON LABS TEVA 50MG A075152 001 Nov 27, 1998 May CAHN

DICLOFENAC SODIUM

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AT ANDA REPOSITORY 1.5% A202393 001 Nov 24, 2014 Sep CAHN

AT ! APOTEX INC 1.5% A202027 001 May 27, 2014 Jul CHRS

AT RICONPHARMA LLC 1.5% A206715 001 Aug 07, 2017 Jul NEWA

AT TWI PHARMS INC 1.5% A202393 001 Nov 24, 2014 Mar CAHN

PENNSAID

+! HORIZON PHARMA 2%

AT +! 2% N204623 001 Jan 16, 2014 Oct CTEC

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

AT SANDOZ INC 0.1% A078031 001 Feb 06, 2008 Feb CAHN

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

@ ALLIED PHARMA INC 50MG A074986 001 Feb 26, 1999 Apr CAHN

@ 75MG A074986 002 Feb 26, 1999 Apr CAHN

AB UNIQUE PHARM LABS 25MG A090066 001 Dec 01, 2010 Aug CAHN

AB 50MG A090066 002 Dec 01, 2010 Aug CAHN

AB 75MG A077863 003 Jun 08, 2007 Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

@ ACTAVIS ELIZABETH 100MG A075910 001 Jan 07, 2002 Apr DISC

AB ! DEXCEL LTD 100MG A076201 001 Nov 06, 2002 Apr CHRS

VOLTAREN-XR

+ @ NOVARTIS 100MG N020254 001 Mar 08, 1996 Jul CRLD

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB EAGLE PHARMS 50MG;0.2MG A200540 001 Mar 14, 2014 Jan CAHN

AB 75MG;0.2MG A200540 002 Mar 14, 2014 Jan CAHN

AB EXELA HOLDINGS 50MG;0.2MG A200540 001 Mar 14, 2014 Mar CAHN

AB 75MG;0.2MG A200540 002 Mar 14, 2014 Mar CAHN

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE

AP LUITPOLD PHARMS INC 10MG/ML A208353 001 Feb 17, 2017 Feb NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

@ MYLAN PHARMS INC 125MG A090788 001 Apr 08, 2010 May DISC

@ 200MG A090788 002 Apr 08, 2010 May DISC

@ 250MG A090788 003 Apr 08, 2010 May DISC

@ 400MG A090788 004 Apr 08, 2010 May DISC

FOR SOLUTION;ORAL

DIDANOSINE

@ AUROBINDO PHARMA 10MG/ML A078112 001 Mar 08, 2007 Jul DISC

VIDEX

+! BRISTOL-MYERS SQUIBB 10MG/ML N020156 001 Oct 09, 1991 Jul CTEC

TABLET, FOR SUSPENSION;ORAL

DIDANOSINE

@ AUROBINDO 100MG A077275 001 Aug 14, 2012 Jul DISC

@ 150MG A077275 002 Aug 14, 2012 Jul DISC

@ 200MG A077275 003 Aug 14, 2012 Jul DISC

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL

NATAZIA

+	!	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	N022252	001	May 06, 2010	Apr CTEC
			G, N/A				

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

@ EPIC PHARMA LLC

25MG

A040828 001 Nov 05, 2008 May CAHN

DIFLORASONE DIACETATE

CREAM; TOPICAL

PSORCON

+ @ TARO PHARMS NORTH 0.05%

N020205 001 Nov 20, 1992 Sep CRLD

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB RICONPHARMA LLC 0.05%

A207440 001 Feb 27, 2017 Feb NEWA

AB ! TARO 0.05%

A075331 001 May 14, 1999 Apr CAHN

PSORCON

+ @ PHARMACIA AND UPJOHN 0.05%

N019260 001 Aug 28, 1985 Mar CRLD

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

@ ALLIED PHARMA INC

250MG

A073562 001 Nov 27, 1992 Jul CAHN

@

500MG

A073563 001 Nov 27, 1992 Jul CAHN

AB ZYDUS PHARMS USA INC 500MG

A203547 001 Jun 16, 2017 Jun NEWA

DIGOXIN

ELIXIR; ORAL

DIGOXIN

+! WEST-WARD PHARMS INT 0.05MG/ML

N021648 001 Aug 26, 2004 Jan CAHN

INJECTABLE; INJECTION

DIGOXIN

AP SANDOZ INC 0.25MG/ML

A040481 001 Aug 21, 2003 Mar CAHN

AP WEST-WARD PHARMS INT 0.25MG/ML

A083391 001 Jul CAHN

LANOXIN

AP +! COVIS PHARMA BV 0.25MG/ML

N009330 002 May CAHN

LANOXIN PEDIATRIC

+! COVIS PHARMA BV 0.1MG/ML

N009330 004 May CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

DIHYDROERGOTAMINE MESYLATE

AP HIKMA PHARMS 1MG/ML

A206621 001 Sep 15, 2017 Sep NEWA

AP WEST-WARD PHARMS INT 1MG/ML

A040453 001 Jun 09, 2003 Jan CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB3 SUN PHARM INDS LTD 120MG

A203023 001 Jun 08, 2017 May NEWA

AB3 180MG

A203023 002 Jun 08, 2017 May NEWA

AB3 240MG

A203023 003 Jun 08, 2017 May NEWA

AB3 300MG

A203023 004 Jun 08, 2017 May NEWA

AB3 360MG

A203023 005 Jun 08, 2017 May NEWA

AB3 ZYDUS PHARMS USA INC 120MG

A206534 001 Aug 08, 2017 Jul NEWA

AB4 120MG

A206641 001 Aug 11, 2017 Jul NEWA

AB3 180MG

A206534 002 Aug 08, 2017 Jul NEWA

AB4 180MG

A206641 002 Aug 11, 2017 Jul NEWA

AB3 240MG

A206534 003 Aug 08, 2017 Jul NEWA

AB4 240MG

A206641 003 Aug 11, 2017 Jul NEWA

AB3 300MG

A206534 004 Aug 08, 2017 Jul NEWA

AB4 300MG

A206641 004 Aug 11, 2017 Jul NEWA

AB3 360MG

A206534 005 Aug 08, 2017 Jul NEWA

AB4 360MG

A206641 005 Aug 11, 2017 Jul NEWA

AB4 420MG

A206641 006 Aug 11, 2017 Jul NEWA

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

AP ! ATHENEX INC 5MG/ML

A074617 001 Feb 28, 1996 Mar CAHN

AP WEST-WARD PHARMS INT 5MG/ML

A078538 001 Dec 17, 2008 Jan CAHN

## TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

@ CHARTWELL MOLECULES 30MG  
 @ 60MG  
 @ 90MG  
 @ 120MG

A074093 001 Nov 05, 1992 Feb CAHN  
 A074093 002 Nov 05, 1992 Feb CAHN  
 A074093 003 Nov 05, 1992 Feb CAHN  
 A074093 004 Nov 05, 1992 Feb CAHN

DIMENHYDRINATE

INJECTABLE;INJECTION

DIMENHYDRINATE

@ WATSON LABS TEVA 50MG/ML

A080615 001 May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

! PHARM ASSOC 12.5MG/5ML

A087513 001 Feb 10, 1982 May CAHN

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@ WATSON LABS TEVA 10MG/ML

A080873 001 May CAHN

@ 50MG/ML

A080873 002 May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@ WATSON LABS TEVA 50MG/ML

A080873 003 May CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP ! ATHENEX INC 5MG/ML

A074939 001 Apr 13, 1998 Mar CAHN

TABLET;ORAL

DIPYRIDAMOLE

IDT AUSTRALIA LTD 50MG

A086944 001 Feb 25, 1992 Aug CMS1

75MG

A086944 003 Feb 25, 1992 Aug CMS1

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

AB MAYNE PHARMA EQ 150MG BASE

A070173 002 May 31, 1985 Sep CMS1

CAPSULE, EXTENDED RELEASE;ORAL

NORPACE CR

&gt;D&gt; AB +! GD SEARLE LLC EQ 150MG BASE

N018655 002 Jul 20, 1982 Nov CTEC

&gt;A&gt; +! EQ 150MG BASE

N018655 002 Jul 20, 1982 Nov CTEC

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB CHARTWELL MOLECULES 250MG

A091563 001 Dec 31, 2012 Jan CAHN

AB 500MG

A091563 002 Dec 31, 2012 Jan CAHN

@ WATSON LABS TEVA 500MG

A086890 001 May CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

AB PRINSTON INC EQ 125MG VALPROIC ACID

A090210 001 Nov 30, 2009 Feb CAHN

AB EQ 250MG VALPROIC ACID

A090210 002 Nov 30, 2009 Feb CAHN

AB EQ 500MG VALPROIC ACID

A090210 003 Nov 30, 2009 Feb CAHN

AB UPSHER-SMITH LABS EQ 125MG VALPROIC ACID

A078182 001 Jul 29, 2008 Jun CAHN

AB EQ 250MG VALPROIC ACID

A078182 002 Jul 29, 2008 Jun CAHN

AB EQ 500MG VALPROIC ACID

A078182 003 Jul 29, 2008 Jun CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTREX

+ @ LILLY EQ 12.5MG BASE/ML

N017820 002 Aug CRLD

DOCETAXEL

INJECTABLE;INJECTION

DOCEFREZ

+ @ SUN PHARMA GLOBAL 20MG/VIAL

N022534 001 May 03, 2011 Aug DISC

+ @ 80MG/VIAL

N022534 002 May 03, 2011 Aug DISC

DOCETAXEL

AP ACTAVIS LLC 20MG/ML (20MG/ML)

N203551 001 Apr 12, 2013 Feb CAHN

AP 80MG/4ML (20MG/ML)

N203551 002 Apr 12, 2013 Feb CAHN

INJECTABLE; INJECTION  
DOCETAXEL

		140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013	Feb CAHN
AP	DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017	Jan NEWA
AP		80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017	Jan NEWA
		200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017	Jan NEWA
	+ @ HOSPIRA INC	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016	Aug DISC
	+	160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017	Jan NEWA
AP	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Aug NEWA
AP		80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Aug NEWA
AP		160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Aug NEWA
AP	JIANGSU HENGRUI MED	20MG/ML (20MG/ML)	A207252	001	Aug 09, 2017	Jul NEWA
	!	40MG/ML	A203170	001	Feb 15, 2017	Jan NEWA
AP		80MG/4ML (20MG/ML)	A207252	002	Aug 09, 2017	Jul NEWA
AP		160MG/8ML (20MG/ML)	A207252	003	Aug 09, 2017	Jul NEWA
	@ PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Jan DISC
	@	80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Jan DISC
	@	130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Jan DISC
	@	200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Jan DISC

DOFETILIDE

CAPSULE; ORAL  
DOFETILIDE

AB	MAYNE PHARMA INC	0.125MG	A207058	001	Jun 06, 2016	Feb CAHN
AB		0.25MG	A207058	002	Jun 06, 2016	Feb CAHN
AB		0.5MG	A207058	003	Jun 06, 2016	Feb CAHN

DOLASETRON MESYLATE

INJECTABLE; INJECTION  
ANZEMET

	+ @ US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Oct DISC
	+ @	100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Oct DISC

TABLET; ORAL

ANZEMET

	+ @ US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997	Oct DISC
	+ @	100MG	N020623	002	Sep 11, 1997	Oct DISC

>A> DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

>A> TABLET; ORAL

>A> JULUCA

>A>	+! VIIV HLTHCARE	EQ 50MG BASE; EQ 25MG BASE	N210192	001	Nov 21, 2017	Nov NEWA
-----	------------------	----------------------------	---------	-----	--------------	----------

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	5MG	A078662	001	May 31, 2011	Jun CAHN
AB		10MG	A078662	002	May 31, 2011	Jun CAHN
AB	ALLIED PHARMA INC	5MG	A078662	001	May 31, 2011	Mar CAHN
AB		10MG	A078662	002	May 31, 2011	Mar CAHN
AB	CADILA PHARMS LTD	5MG	A204609	001	Sep 19, 2017	Sep NEWA
AB		10MG	A204609	002	Sep 19, 2017	Sep NEWA
AB	VIVIMED GLOBAL	5MG	A090551	001	May 31, 2011	Aug CAHN
AB		10MG	A090551	002	May 31, 2011	Aug CAHN
AB	ZHEJIANG HISUN PHARM	23MG	A202410	001	Mar 24, 2017	Mar NEWA
AB	ZYDUS PHARMS USA INC	23MG	A203162	001	Aug 31, 2017	Aug NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB	AMNEAL PHARMS	10MG; 14MG	A208328	001	Jan 27, 2017	Jan NEWA
AB		10MG; 28MG	A208328	002	Jan 27, 2017	Jan NEWA
	NAMZARIC					
AB	+ FOREST LABS LLC	10MG; 14MG	N206439	001	Dec 23, 2014	Jan CFTG
AB	+!	10MG; 28MG	N206439	002	Dec 23, 2014	Jan CFTG

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

>D> AP	!	LUITPOLD	160MG/ML	A070826	001	Feb 11, 1987	Nov CTEC
>A>	!		160MG/ML	A070826	001	Feb 11, 1987	Nov CTEC
	@	TELIGENT	40MG/ML	N018656	001	Jun 28, 1983	May CAHN

DORIPENEM

INJECTABLE;IV (INFUSION)  
DORIBAX

+ @ SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010	Sep DISC
+ @	500MG/VIAL	N022106	001	Oct 12, 2007	Sep DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE

AT	SANDOZ INC	EQ 2% BASE	A078748	001	Nov 06, 2008	Mar CAHN
AT		EQ 2% BASE	A078981	001	Apr 13, 2009	Feb CAHN
>D> AT	ZAMBON SPA	EQ 2% BASE	A091034	001	Dec 04, 2013	Nov DISC
>A>	@	EQ 2% BASE	A091034	001	Dec 04, 2013	Nov DISC
AT		EQ 2% BASE	A091034	001	Dec 04, 2013	Sep CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	SANDOZ INC	EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009	Mar CAHN
AT	ZAMBON SPA	EQ 2% BASE;EQ 0.5% BASE	A091180	001	Dec 04, 2013	Sep CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION  
DOXAPRAM HYDROCHLORIDE

AP	ATHENEX INC	20MG/ML	A076266	001	Jan 10, 2003	Mar CAHN
----	-------------	---------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET;ORAL  
DOXAZOSIN MESYLATE

AB	ZYDUS PHARMS USA INC	EQ 1MG BASE	A208719	001	Jul 07, 2017	Jun NEWA
AB		EQ 2MG BASE	A208719	002	Jul 07, 2017	Jun NEWA
AB		EQ 4MG BASE	A208719	003	Jul 07, 2017	Jun NEWA
AB		EQ 8MG BASE	A208719	004	Jul 07, 2017	Jun NEWA

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL  
DOXEPIIN HYDROCHLORIDE

AB	AMNEAL PHARMS CO	EQ 10MG BASE	A207482	001	Jun 28, 2017	Jun NEWA
AB		EQ 25MG BASE	A207482	002	Jun 28, 2017	Jun NEWA
AB		EQ 50MG BASE	A207482	003	Jun 28, 2017	Jun NEWA
AB		EQ 75MG BASE	A207482	004	Jun 28, 2017	Jun NEWA
AB		EQ 100MG BASE	A207482	005	Jun 28, 2017	Jun NEWA
	@ WATSON LABS TEVA	EQ 50MG BASE	A072987	001	Mar 29, 1991	May CAHN

CREAM;TOPICAL  
ZONALON

+! MYLAN PHARMS INC	5%	N020126	001	Apr 01, 1994	Jan CAHN
---------------------	----	---------	-----	--------------	----------

TABLET;ORAL  
DOXEPIIN HYDROCHLORIDE

>D> AB	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Nov DISC
>A>	@	EQ 3MG BASE	A202337	001	Jan 20, 2016	Nov DISC
>D> AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Nov DISC
>A>	@	EQ 6MG BASE	A202337	002	Jan 20, 2016	Nov DISC

DOXERCALCIFEROL

INJECTABLE;INJECTION  
DOXERCALCIFEROL

AP	AMNEAL PHARMS CO	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	May NEWA
AP		4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	May NEWA
AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	May NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION  
DOXORUBICIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	20MG/VIAL	A208888	001	Feb 17, 2017	Feb NEWA
AP		50MG/VIAL	A208888	002	Feb 17, 2017	Feb NEWA
AP	GLAND PHARMA LTD	2MG/ML	A209825	001	Aug 11, 2017	Jul NEWA

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	DR REDDYS LABS LTD	20MG/10ML (2MG/ML)	A208657	001	May 15, 2017	May NEWA
AB		50MG/25ML (2MG/ML)	A208657	002	May 15, 2017	May NEWA

DOXYCYCLINECAPSULE;ORAL  
DOXYCYCLINE

AB	ALEMBIC PHARMS LTD	EQ 75MG BASE	A209165	001	Jul 28, 2017	Jul NEWA
AB		EQ 100MG BASE	A209165	002	Jul 28, 2017	Jul NEWA
AB	MAYNE PHARMA INC	EQ 50MG BASE	A209396	001	Sep 29, 2017	Sep NEWA
AB		EQ 75MG BASE	A209396	002	Sep 29, 2017	Sep NEWA
AB		EQ 100MG BASE	A209396	003	Sep 29, 2017	Sep NEWA

TABLET;ORAL  
DOXYCYCLINE

AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A209582	001	Sep 28, 2017	Sep NEWA
AB		EQ 75MG BASE	A209582	002	Sep 28, 2017	Sep NEWA
AB		EQ 100MG BASE	A209582	003	Sep 28, 2017	Sep NEWA
AB		EQ 150MG BASE	A209582	004	Sep 28, 2017	Sep NEWA

DOXYCYCLINE HYCLATE

&gt;A&gt; CAPSULE;ORAL

&gt;A&gt; PERIOSTAT

&gt;A&gt; + @ COLLAGENEX EQ 20MG BASE N050744 001 Sep 30, 1998 Nov CDFR

CAPSULE, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

@ MEDICIS EQ 75MG BASE A065281 001 Dec 21, 2005 Jul DISC

@ EQ 100MG BASE A065281 002 Dec 21, 2005 Jul DISC

INJECTABLE;INJECTION

DOXY 200

&gt;D&gt; ! FRESENIUS KABI USA EQ 200MG BASE/VIAL A062475 002 Dec 09, 1983 Nov CTEC

&gt;A&gt; AP ! EQ 200MG BASE/VIAL A062475 002 Dec 09, 1983 Nov CTEC

DOXYCYCLINE

AP ZYDUS PHARMS USA INC EQ 100MG BASE/VIAL A207757 001 Sep 28, 2017 Sep NEWA

AP EQ 200MG BASE/VIAL A207757 002 Sep 28, 2017 Sep NEWA

VIBRAMYCIN

+ @ PFIZER EQ 100MG BASE/VIAL N050442 002 Jan CRLD

+ @ EQ 200MG BASE/VIAL N050442 001 Jan CRLD

TABLET;ORAL

ACTICLATE

AB + AQUA PHARMS LLC EQ 75MG BASE N205931 001 Jul 25, 2014 Jun CFTG

AB +! EQ 150MG BASE N205931 002 Jul 25, 2014 Jun CFTG

DOXYCYCLINE HYCLATE

AB AMNEAL PHARMS CO EQ 75MG BASE A209372 001 Oct 06, 2017 Sep NEWA

AB EQ 150MG BASE A209372 002 Oct 06, 2017 Sep NEWA

CARIBE HOLDINGS EQ 50MG BASE A062269 003 Mar CMFD

@ EQ 50MG BASE A062269 003 Jan CAHN

AB EQ 100MG BASE A062269 002 Nov 08, 1982 Jan CAHN

@ EPIC PHARMA LLC EQ 20MG BASE A065182 001 May 13, 2005 May CAHN

AB LUPIN LTD EQ 75MG BASE A208818 001 Sep 27, 2017 Sep NEWA

AB EQ 150MG BASE A208818 002 Sep 27, 2017 Sep NEWA

AB MAYNE PHARMA INC EQ 75MG BASE A208765 001 Jun 14, 2017 May NEWA

AB EQ 150MG BASE A208765 002 Jun 14, 2017 May NEWA

AB NOVEL LABS INC EQ 100MG BASE A207558 001 Sep 06, 2017 Aug NEWA

AB ZYDUS PHARMS USA INC EQ 100MG BASE A207773 001 Oct 30, 2017 Oct NEWA

&gt;D&gt; PERIOSTAT

&gt;D&gt; + @ COLLAGENEX EQ 20MG BASE N050744 001 Sep 30, 1998 Nov CDFR

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

&gt;A&gt; AB PAR PHARM INC 10MG;10MG A208518 001 Dec 06, 2017 Nov NEWA

DRONABINOL

SOLUTION;ORAL

SYNDROS

+! INSYS DEV CO INC 5MG/ML N205525 001 Mar 23, 2017 Mar NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB PII 3MG;0.02MG A203291 001 Jul 18, 2017 Jul NEWA

LORYNA

&gt;A&gt; AB LABS LEON FARMA 3MG;0.02MG A079221 001 Mar 28, 2011 Nov CAHN

&gt;D&gt; AB SANDOZ 3MG;0.02MG A079221 001 Mar 28, 2011 Nov CAHN

## TABLET;ORAL-28

## SYEDA

>A>	AB	LABS LEON FARMA	3MG;0.03MG	A090114	001	Mar 28, 2011	Nov CAHN
>D>	AB	SANDOZ	3MG;0.03MG	A090114	001	Mar 28, 2011	Nov CAHN

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

## TABLET;ORAL

## TYDEMY

>A>	AB	LUPIN LTD	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	A205948	001	Dec 12, 2017	Nov NEWA
-----	----	-----------	------------------------------------	---------	-----	--------------	----------

DULOXETINE HYDROCHLORIDE

## CAPSULE, DELAYED REL PELLETS;ORAL

## DULOXETINE HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	EQ 20MG BASE	A204815	001	Mar 23, 2017	Mar NEWA
AB			EQ 30MG BASE	A204815	002	Mar 23, 2017	Mar NEWA
AB			EQ 60MG BASE	A204815	003	Mar 23, 2017	Mar NEWA
AB		PRINSTON INC	EQ 20MG BASE	A206653	001	May 18, 2017	May NEWA
AB			EQ 30MG BASE	A206653	002	May 18, 2017	May NEWA
AB			EQ 60MG BASE	A206653	003	May 18, 2017	May NEWA
AB		ZYDUS HLTHCARE	EQ 20MG BASE	A090739	001	Jan 08, 2014	Apr CAHN
AB			EQ 30MG BASE	A090739	002	Jan 08, 2014	Apr CAHN
AB			EQ 60MG BASE	A090739	003	Jan 08, 2014	Apr CAHN

DUTASTERIDE

## CAPSULE;ORAL

## DUTASTERIDE

AB		AMNEAL PHARMS	0.5MG	A203118	001	Nov 20, 2015	May CAHN
AB		HAUPT PHARMA	0.5MG	A207935	001	Oct 13, 2017	Oct NEWA
>A>	AB	HUMANWELL PURACAP	0.5MG	A209909	001	Nov 21, 2017	Nov NEWA
AB		MARKSANS PHARMA	0.5MG	A204376	001	Apr 07, 2017	Mar NEWA
AB		ZYDUS PHARMS USA INC	0.5MG	A204373	001	Oct 04, 2017	Sep NEWA

DYPHYLLINE

## TABLET;ORAL

## LUFYLLIN

## @ MYLAN SPECIALITY LP

## @

200MG

400MG

A084566 001

A084566 002

Mar CAHN

Mar CAHN

ECONAZOLE NITRATE

## AEROSOL, FOAM;TOPICAL

## ECOZA

+! CHEMO RESEARCH SL 1%

N205175 001 Oct 24, 2013 May CAHN

## CREAM;TOPICAL

## SPECTAZOLE

AB + ALVOGEN MALTA 1%

N018751 001 Dec 23, 1982 Sep CMFD

+ @ 1%

N018751 001 Dec 23, 1982 Mar CMS1

EDARAVONE

## SOLUTION;IV (INFUSION)

## RADICAVA

+! MITSUBISHI TANABE 30MG/100ML (0.3MG/ML)

N209176 001 May 05, 2017 May NEWA

EDROPHONIUM CHLORIDE

## INJECTABLE;INJECTION

## TENSILON

+ @ TELIGENT 10MG/ML

N007959 001

Apr CAHN

## TENSILON PRESERVATIVE FREE

+ @ TELIGENT 10MG/ML

N007959 002

Apr CAHN

ELETRIPTAN HYDROBROMIDE

## TABLET;ORAL

## ELETRIPTAN HYDROBROMIDE

AB		AJANTA PHARMA LTD	EQ 20MG BASE	A205186	001	Aug 29, 2017	Aug NEWA
AB			EQ 40MG BASE	A205186	002	Aug 29, 2017	Aug NEWA
AB		MYLAN PHARMS INC	EQ 20MG BASE	A205152	001	Aug 11, 2017	Jul NEWA
AB			EQ 40MG BASE	A205152	002	Aug 11, 2017	Jul NEWA
AB		TEVA PHARMS USA	EQ 20MG BASE	A202040	001	Jun 27, 2017	Jun NEWA
AB			EQ 40MG BASE	A202040	002	Jun 27, 2017	Jun NEWA
AB		ZYDUS PHARMS USA INC	EQ 20MG BASE	A206409	001	Jun 16, 2017	Jun NEWA
AB			EQ 40MG BASE	A206409	002	Jun 16, 2017	Jun NEWA

TABLET;ORAL								
RELPAK								
AB	+	PFIZER IRELAND	EQ 20MG BASE	N021016	001	Dec 26, 2002	Jun CFTG	
AB	+	!	EQ 40MG BASE	N021016	002	Dec 26, 2002	Jun CFTG	
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE</u>								
TABLET;ORAL								
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE								
AB		TEVA PHARMS USA	200MG;300MG	A090894	001	Jun 08, 2017	May NEWA	
TRUVADA								
AB	+	!	GILEAD	200MG;300MG	N021752	001	Aug 02, 2004	May CFTG
<u>ENALAPRIL MALEATE</u>								
SOLUTION;ORAL								
EPANED								
	+	!	SILVERGATE PHARMS	1MG/ML	N208686	001	Sep 20, 2016	Jul CRLD
<u>ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE</u>								
TABLET;ORAL								
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE								
	@	UPSHER-SMITH LABS	5MG;12.5MG	A076116	001	Sep 19, 2001	Jun CAHN	
	@		10MG;25MG	A076116	002	Sep 19, 2001	Jun CAHN	
<u>ENALAPRILAT</u>								
INJECTABLE;INJECTION								
ENALAPRILAT								
AP	!	ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Mar CAHN	
VASOTEC								
	+	@	BIOVAIL LABS INTL	1.25MG/ML	N019309	001	Feb 09, 1988	Mar CRLD
<u>ENASIDENIB MESYLATE</u>								
TABLET;ORAL								
IDHIFA								
	+		CELGENE CORP	EQ 50MG BASE	N209606	001	Aug 01, 2017	Aug NEWA
	+	!		EQ 100MG BASE	N209606	002	Aug 01, 2017	Aug NEWA
<u>ENTACAPONE</u>								
TABLET;ORAL								
ENTACAPONE								
AB		AJANTA PHARMA LTD	200MG	A205792	001	Aug 31, 2017	Aug NEWA	
AB		MACLEODS PHARMS LTD	200MG	A207210	001	Jun 05, 2017	May NEWA	
	@	MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013	May DISC	
<u>ENTECAVIR</u>								
TABLET;ORAL								
ENTECAVIR								
AB		ACCORD HLTHCARE	0.5MG	A205824	001	Aug 25, 2017	Aug NEWA	
AB			1MG	A205824	002	Aug 25, 2017	Aug NEWA	
AB		PRINSTON INC	0.5MG	A208782	001	Oct 10, 2017	Sep NEWA	
AB			1MG	A208782	002	Oct 10, 2017	Sep NEWA	
AB		SANDOZ INC	0.5MG	A206672	001	May 11, 2017	May NEWA	
AB			1MG	A206672	002	May 11, 2017	May NEWA	
AB		ZYDUS PHARMS USA INC	0.5MG	A206745	001	Jun 23, 2017	Jun NEWA	
AB			1MG	A206745	002	Jun 23, 2017	Jun NEWA	
<u>EPHEDRINE SULFATE</u>								
SOLUTION;INTRAVENOUS								
AKOVAZ								
AP	+	!	FLAMEL IRELAND LTD	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Mar CTEC
EPHEDRINE SULFATE								
AP		AKORN INC	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Mar NEWA	
AP		SANDOZ INC	50MG/ML (50MG/ML)	A209784	001	Aug 23, 2017	Aug NEWA	
SOLUTION;IV (INFUSION)								
CORPHEDRA								
		PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Jan NEWA	



EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
EPINASTINE HYDROCHLORIDE

AT	AKORN	0.05%	A204055	001	May 05, 2017	Apr NEWA
AT	SANDOZ INC	0.05%	A203384	001	Dec 07, 2016	Mar CAHN

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS  
ADRENALIN

BX	+	IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	Jun CAHN
BX	+		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	Jun CAHN
>D>		AUVI-Q					
>D> BX	+	KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Nov CDFR
>D> BX	+		EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Nov CDFR
		TWINJECT 0.15					
		@ IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	Jun CAHN
		TWINJECT 0.3					
		@ IMPAX LABS INC	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	Jun CAHN
		SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
		ADRENALIN					
	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Aug CDFR
	+		EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Aug CDFR
		AUVI-Q					
>A>	+	KALEO INC	EQ 0.1MG/DELIVERY	N201739	003	Nov 17, 2017	Nov NEWA
>A> BX	+		EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Nov CDFR
>A> BX	+		EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Nov CDFR
		SYMJEPI					
	+	ADAMIS PHARMS CORP	0.3MG/ML (0.3MG/ML)	N207534	001	Jun 15, 2017	Jun NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION  
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

	@	BELMORA LLC	0.01MG/ML;2%	A080504	004	Oct 19, 1983	Feb CAHN
	@		0.02MG/ML;2%	A080504	005	Oct 19, 1983	Feb CAHN
	@	WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Mar CAHN
	@		0.01MG/ML;2%	A080406	002		Mar CAHN
		XYLOCAINE W/ EPINEPHRINE					
>D> AP	+	FRESENIUS KABI USA	0.005MG/ML;1%	N006488	018	Nov 13, 1986	Nov CTEC
>A>	+		0.005MG/ML;1%	N006488	018	Nov 13, 1986	Nov CTEC

EPLERENONE

TABLET;ORAL  
EPLERENONE

AB	ACCORD HLTHCARE	25MG	A206922	001	Jul 13, 2017	Jul NEWA
AB		50MG	A206922	002	Jul 13, 2017	Jul NEWA
AB	MYLAN PHARMS INC	25MG	A203896	001	Feb 02, 2017	Jan NEWA
AB		50MG	A203896	002	Feb 02, 2017	Jan NEWA

EPTIFIBATIDE

INJECTABLE;INJECTION  
EPTIFIBATIDE

AP	ACCORD HLTHCARE	2MG/ML	A205557	001	Nov 06, 2017	Oct NEWA
AP		75MG/100ML	A205557	002	Nov 06, 2017	Oct NEWA
AP	AKORN	2MG/ML	A204589	001	Apr 18, 2017	Apr NEWA
AP		75MG/100ML	A204589	002	Apr 18, 2017	Apr NEWA
AP	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016	May CAHN
AP		75MG/100ML	A205581	002	Dec 08, 2016	May CAHN

ERGOLOID MESYLATES

TABLET;ORAL  
ERGOLOID MESYLATES

!	SUN PHARM INDUSTRIES	1MG	A081113	001	Oct 31, 1991	May CHRS
	HYDERGINE					
+	@ NOVARTIS	1MG	N017993	001		May DISC

ERYTHROMYCIN

GEL; TOPICAL					
E-GLADES					
	@ MYLAN PHARMS INC	2%	A065009	001	Mar 18, 2002 Jan CAHN
ERYGEL					
AT	+! MYLAN PHARMS INC	2%	N050617	001	Oct 21, 1987 Jan CAHN
ERYTHROMYCIN					
AT	PERRIGO CO	2%	A063211	001	Jan 29, 1993 Apr CAHN
AT	TELIGENT PHARMA INC	2%	A208154	001	Jul 19, 2017 Jul NEWA
OINTMENT; TOPICAL					
AKNE-MYCIN					
	+ @ DOW PHARM	2%	N050584	001	Jan 10, 1985 Oct DISC
SOLUTION; TOPICAL					
A/T/S					
	@ TARO	2%	A062405	001	Nov 18, 1982 Apr CAHN
ERYTHRA-DERM					
	@ SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988 Oct CAHN
ERYTHROMYCIN					
	@ FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997 Aug DISC
AT	! PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991 Aug CHRS
>A> AT	TELIGENT PHARMA INC	2%	A208100	001	Nov 20, 2017 Nov NEWA
SWAB; TOPICAL					
ERYCETTE					
	+ @ JOHNSON AND JOHNSON	2%	N050594	001	Feb 15, 1985 Sep CRLD
ERYTHROMYCIN					
	@ MYLAN PHARMS INC	2%	A064128	001	Jul 03, 1996 Jan CAHN
AT	! PERRIGO CO	2%	A064126	001	Jul 03, 1996 Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL					
E.E.S.					
	+ ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	001	Oct CTEC
ERYPED					
	+ ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987 Oct CTEC

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL					
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL					
	@ BARR	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	A062759	001	May 20, 1988 Jul DISC

ESCITALOPRAM OXALATE

TABLET; ORAL					
ESCITALOPRAM OXALATE					
AB	AMNEAL PHARMS	EQ 5MG BASE	A205619	001	May 17, 2017 May NEWA
AB		EQ 10MG BASE	A205619	002	May 17, 2017 May NEWA
AB		EQ 20MG BASE	A205619	003	May 17, 2017 May NEWA
>D> AB	MYLAN PHARMS INC	EQ 5MG BASE	A077550	001	May 14, 2015 Nov DISC
>A>	@	EQ 5MG BASE	A077550	001	May 14, 2015 Nov DISC
>D> AB		EQ 10MG BASE	A077550	002	May 14, 2015 Nov DISC
>A>	@	EQ 10MG BASE	A077550	002	May 14, 2015 Nov DISC
>D> AB		EQ 20MG BASE	A077550	003	May 14, 2015 Nov DISC
>A>	@	EQ 20MG BASE	A077550	003	May 14, 2015 Nov DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL					
ESOMEPRAZOLE MAGNESIUM					
AB	ALKEM LABS LTD	EQ 20MG BASE	A208333	001	Oct 20, 2017 Oct NEWA
AB		EQ 40MG BASE	A208333	002	Oct 20, 2017 Oct NEWA
AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A205563	001	Sep 01, 2017 Aug NEWA
AB		EQ 40MG BASE	A205563	002	Sep 01, 2017 Aug NEWA
FOR SUSPENSION, DELAYED RELEASE; ORAL					
NEXIUM					
	+ ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008 May CRLD

ESOMEPRAZOLE SODIUMINJECTABLE;INTRAVENOUS  
ESOMEPRAZOLE SODIUM

AP	!	AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	May CHRS
AP			EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Aug CHRS
AP	!		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	May CHRS
AP		DEVA HOLDING AS	EQ 40MG BASE/VIAL	A207181	001	Mar 06, 2017	Feb NEWA
AP		MYLAN LABS LTD	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	May NEWA
AP			EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	May NEWA
		NEXIUM IV					
	+	@ ASTRAZENECA PHARMS	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	May DISC
AP	+	!	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Aug CMFD
	+	@	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	May DISC

ESTRADIOLFILM, EXTENDED RELEASE;TRANSDERMAL  
ESTRADERM

	+	@ NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986	May DISC
	+	@	0.1MG/24HR	N019081	003	Sep 10, 1986	May DISC
		VIVELLE					
		@ NOVARTIS	0.05MG/24HR	N020323	002	Oct 28, 1994	May DISC
		@	0.1MG/24HR	N020323	004	Oct 28, 1994	May DISC

GEL, METERED;TRANSDERMAL  
ELESTRIN

	+	!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Mar CAHN
			SPRAY;TRANSDERMAL					
			EVAMIST					
	+	!	PERRIGO PHARMA INTL	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May CAHN

TABLET;VAGINAL  
ESTRADIOL

AB		TEVA PHARMS USA	10MCG	A206388	001	Jul 21, 2017	Jul NEWA
----	--	-----------------	-------	---------	-----	--------------	----------

ESTRADIOL ACETATETABLET;ORAL  
FEMTRACE

	+	@ APIL	0.45MG	N021633	001	Aug 20, 2004	Jun DISC
	+	@	0.9MG	N021633	002	Aug 20, 2004	Jun DISC
	+	@	1.8MG	N021633	003	Aug 20, 2004	Jun DISC

ESTRADIOL VALERATEINJECTABLE;INJECTION  
ESTRADIOL VALERATE

	@	SANDOZ INC	10MG/ML	A040628	001	Oct 04, 2007	Apr CAHN
	@		20MG/ML	A040628	002	Oct 04, 2007	Apr CAHN
	@		40MG/ML	A040628	003	Oct 04, 2007	Apr CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB		MYLAN LABS LTD	0.5MG;0.1MG	A207261	001	Feb 10, 2017	Jan NEWA
AB			1MG;0.5MG	A207261	002	Feb 10, 2017	Jan NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET;ORAL

CENESTIN

	+	@ TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Aug CRLD
	+	@	0.45MG	N020992	005	Feb 05, 2004	Aug CRLD
	+	@	0.625MG	N020992	002	Mar 24, 1999	Aug CRLD
	+	@	0.9MG	N020992	003	Mar 24, 1999	Aug CRLD
	+	@	1.25MG	N020992	004	Mar 13, 2000	Aug CRLD

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL

ENJUVIA

	@	TEVA BRANDED PHARM	0.3MG	N021443	001	Dec 20, 2004	Aug DISC
			0.3MG	N021443	001	Dec 20, 2004	Apr CAHN
	@		0.45MG	N021443	002	Dec 20, 2004	Aug DISC
			0.45MG	N021443	002	Dec 20, 2004	Apr CAHN
	@		0.625MG	N021443	003	May 10, 2004	Apr CAHN
	@		0.9MG	N021443	005	Apr 27, 2007	Aug DISC
			0.9MG	N021443	005	Apr 27, 2007	Apr CAHN

## TABLET;ORAL

ENJUVA

@

1.25MG

N021443

004

May 10, 2004

Apr CAHN

ESTROGENS, ESTERIFIED

## TABLET;ORAL

MENEST

MONARCH PHARMS

0.3MG

A084951

001

Jun CAHN

0.625MG

A084948

001

Jun CAHN

1.25MG

A084950

001

Jun CAHN

!

2.5MG

A084949

001

Jun CAHN

ESTRONE

## INJECTABLE;INJECTION

ESTRONE

@ WATSON LABS TEVA

5MG/ML

A085239

001

May CAHN

ESTROPIPATE

## TABLET;ORAL

ESTROPIPATE

@ BARR

0.75MG

A040135

001

Nov 27, 1996

May DISC

@

1.5MG

A040135

002

Nov 27, 1996

May DISC

@

3MG

A040135

003

Nov 27, 1996

May DISC

! WATSON LABS TEVA

3MG

A081215

001

Sep 23, 1993

May CHRS

AB

3MG

A081215

001

Sep 23, 1993

Feb CAHN

OGEN .625

@ PHARMACIA AND UPJOHN

0.75MG

A083220

001

May DISC

OGEN 1.25

@ PHARMACIA AND UPJOHN

1.5MG

A083220

002

May DISC

OGEN 2.5

@ PHARMACIA AND UPJOHN

3MG

A083220

003

May DISC

ETELCALCETIDE

## SOLUTION;INTRAVENOUS

PARSABIV

+! KAI PHARMS INC

2.5MG/0.5ML (2.5MG/0.5ML)

N208325

001

Feb 07, 2017

Feb NEWA

+!

5MG/ML (5MG/ML)

N208325

002

Feb 07, 2017

Feb NEWA

+!

10MG/2ML (5MG/ML)

N208325

003

Feb 07, 2017

Feb NEWA

ETHACRYNATE SODIUM

## INJECTABLE;INJECTION

ETHACRYNATE SODIUM

&gt;A&gt; AP

ZYDUS PHARMS USA INC

EQ 50MG BASE/VIAL

A207758

001

Nov 17, 2017

Nov NEWA

ETHACRYNIC ACID

## TABLET;ORAL

ETHACRYNIC ACID

AB

PAR PHARM INC

25MG

A208501

001

Jul 21, 2017

Jul NEWA

AB

WEST-WARD PHARMS INT

25MG

A207262

001

Feb 23, 2017

Feb NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

## TABLET;ORAL-21

ZOVIA 1/35E-21

@ WATSON PHARMS TEVA

0.035MG;1MG

A072720

001

Dec 30, 1991

Mar CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

## TABLET;ORAL

INTROVALE

&gt;A&gt; AB

LABS LEON FARMA

0.03MG;0.15MG

A079064

001

Sep 27, 2010

Nov CAHN

&gt;D&gt; AB

SANDOZ

0.03MG;0.15MG

A079064

001

Sep 27, 2010

Nov CAHN

LO SIMPESSE

AB

AUROBINDO PHARMA LTD

0.02MG,0.01MG;0.01MG,N/A

A206852

001

Apr 28, 2017

Apr NEWA

SIMPESSE

AB

AUROBINDO PHARMA LTD

0.03MG,0.01MG;0.15MG,N/A

A206851

001

Apr 07, 2017

Mar NEWA

## TABLET;ORAL-28

ALTAVERA

&gt;A&gt; AB

LABS LEON FARMA

0.03MG;0.15MG

A079102

001

Aug 03, 2010

Nov CAHN

&gt;D&gt; AB

SANDOZ

0.03MG;0.15MG

A079102

001

Aug 03, 2010

Nov CAHN

ELIFEMME

AB

LABS LEON FARMA

0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG

A202507

001

Dec 04, 2015

Feb CAHN

## TABLET;ORAL-28

## VIENVA

>A>	AB1	LABS LEON FARMA	0.02MG;0.1MG	A201088	001	May 21, 2015	Nov CAHN
>D>	AB1	SANDOZ INC	0.02MG;0.1MG	A201088	001	May 21, 2015	Nov CAHN

ETHINYL ESTRADIOL; NORELGESTROMIN

## FILM, EXTENDED RELEASE;TRANSDERMAL

## XULANE

>D>	AB	!	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Nov CTEC
>A>		!		0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Nov CTEC
	AB	!		0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Mar CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

## TABLET;ORAL-21

## NORETHIN 1/35E-21

@ WATSON PHARMS TEVA 0.035MG;1MG

A071480 001 Apr 12, 1988 Mar CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL

@ WATSON PHARMS TEVA 0.035MG;1MG

A070685 001 Jan 29, 1987 Mar CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

@ WATSON LABS TEVA 0.035MG,0.035MG;0.5MG,1MG

A071041 001 Sep 24, 1991 May CAHN

## TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

AB ACCORD HLTHCARE 0.035MG;1MG

A206864 001 Apr 28, 2017 Apr NEWA

@ MYLAN LABS LTD 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG

A200486 001 Dec 28, 2015 Oct DISC

@ 0.035MG;0.5MG

A200488 001 Oct 21, 2015 Sep DISC

@ 0.035MG;1MG

A200489 001 Oct 21, 2015 Sep DISC

AB WATSON LABS TEVA 0.035MG;1MG

A070687 001 Jan 29, 1987 May CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS TEVA 0.035MG,0.035MG;0.5MG,1MG

A071044 001 Apr 01, 1988 May CAHN

## TABLET, CHEWABLE;ORAL

## NEXESTA FE

AB AUROBINDO PHARMA LTD 0.035MG;0.4MG

A207535 001 Feb 02, 2017 Jan NEWA

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB ACCORD HLTHCARE 0.035MG;0.4MG

A207066 001 Mar 29, 2017 Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

## TABLET;ORAL

## AUROVELA 24 FE

AB AUROBINDO PHARMA LTD 0.02MG;1MG

A207504 001 Jun 15, 2017 Jun NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB MYLAN LABS LTD 0.0025MG;0.5MG

A207260 001 Feb 02, 2017 Jan NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

&gt;A&gt; AB GLENMARK PHARMS LTD 0.02MG;1MG

A204847 001 Nov 17, 2017 Nov NEWA

## TABLET;ORAL-21

## AUROVELA 1.5/30

AB AUROBINDO PHARMA LTD 0.03MG;1.5MG

A207581 001 Jun 26, 2017 Jun NEWA

## AUROVELA 1/20

AB AUROBINDO PHARMA LTD 0.02MG;1MG

A207506 001 Jun 16, 2017 Jun NEWA

## TABLET;ORAL-28

## AUROVELA FE 1.5/30

AB AUROBINDO PHARMA LTD 0.03MG;1.5MG

A207580 001 Jun 15, 2017 May NEWA

## AUROVELA FE 1/20

AB AUROBINDO PHARMA LTD 0.02MG;1MG

A207505 001 Jun 16, 2017 Jun NEWA

&gt;A&gt; HAILEY FE 1/20

&gt;A&gt; AB GLENMARK PHARMS LTD 0.02MG;1MG

A206597 001 Nov 21, 2017 Nov NEWA

## LOESTRIN FE 1/20

AB + APIL 0.02MG;1MG

N017354 001 Jul CRLD

## TABLET, CHEWABLE;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB AMNEAL PHARMS 0.02MG;1MG

A207514 001 Sep 11, 2017 Aug NEWA

AB MYLAN LABS LTD 0.02MG;1MG

A206120 001 Sep 12, 2017 Sep NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

## TABLET;ORAL-28

## ESTARYLLA

&gt;A&gt; AB LABS LEON FARMA 0.035MG;0.25MG

A090794 001 Jan 30, 2013 Nov CAHN

&gt;D&gt; AB SANDOZ 0.035MG;0.25MG

A090794 001 Jan 30, 2013 Nov CAHN

NORGESTIMATE AND ETHINYL ESTRADIOL

AB AMNEAL PHARMS 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG

A203873 001 May 12, 2016 Sep CAHN

## TABLET;ORAL-28

## TRI-ESTARYLLA

>A>	AB	LABS LEON FARMA	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A 090793	001	Jan 30, 2013	Nov CAHN
>D>	AB	SANDOZ	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A 090793	001	Jan 30, 2013	Nov CAHN
TRI-LO-ESTARYLLA							
>A>	AB	LABS LEON FARMA	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A 091232	001	Jun 29, 2015	Nov CAHN
>D>	AB	SANDOZ INC	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A 091232	001	Jun 29, 2015	Nov CAHN

ETHINYL ESTRADIOL; NORGESTREL

## TABLET;ORAL-28

## NORGESTREL AND ETHINYL ESTRADIOL

		@ MYLAN LABS LTD	0.03MG;0.3MG	A 201828	001	Jun 21, 2016	Oct DISC
		@	0.05MG;0.5MG	A 202875	001	May 08, 2017	Oct DISC
AB			0.05MG;0.5MG	A 202875	001	May 08, 2017	Apr NEWA
OGESTREL 0.5/50-28							
	!	WATSON LABS	0.05MG;0.5MG	A 075406	002	Dec 15, 1999	Oct CTEC
AB	!		0.05MG;0.5MG	A 075406	002	Dec 15, 1999	May CTEC

ETHOSUXIMIDE

## SYRUP;ORAL

## ETHOSUXIMIDE

AA		PHARM ASSOC	250MG/5ML	A 040253	001	Nov 22, 2000	May CAHN
		ZARONTIN					
AA	!	PARKE-DAVIS	250MG/5ML	A 080258	001		Mar CAHN

ETIDRONATE DISODIUM

## TABLET;ORAL

## DIDRONEL

	+	@ APIL	200MG	N 017831	001		Jun DISC
	+	@	400MG	N 017831	002		Jun DISC
ETIDRONATE DISODIUM							
		MYLAN	200MG	A 075800	001	Jan 24, 2003	Jun CTEC
	!		400MG	A 075800	002	Jan 24, 2003	Jun CHRS

ETODOLAC

## CAPSULE;ORAL

## ETODOLAC

		@ CHARTWELL MOLECULES	200MG	A 074842	001	Jul 17, 1997	Mar CAHN
		@	300MG	A 074842	002	Jul 17, 1997	Mar CAHN
		@ CHARTWELL PHARMS LLC	200MG	A 074842	001	Jul 17, 1997	Jan CAHN
		@	300MG	A 074842	002	Jul 17, 1997	Jan CAHN
		@ ECI PHARMS LLC	300MG	A 074929	001	Jan 30, 1998	Apr CAHN
LODINE							
	+	@ WYETH PHARMS INC	300MG	N 018922	003	Jan 31, 1991	Jul CRLD
TABLET;ORAL							
ETODOLAC							
		@ CHARTWELL MOLECULES	400MG	A 074841	001	Jun 27, 1997	Jan CAHN
		@ MYLAN PHARMS INC	400MG	A 075104	001	Feb 06, 1998	May DISC
AB			400MG	A 075104	001	Feb 06, 1998	Mar CAHN
		@	500MG	A 075104	002	Nov 20, 1998	May DISC
AB			500MG	A 075104	002	Nov 20, 1998	Mar CAHN

ETOMIDATE

## INJECTABLE;INJECTION

## ETOMIDATE

AP		AUROBINDO PHARMA LTD	2MG/ML	A 206126	001	Feb 24, 2017	Feb NEWA
AP		GLAND PHARMA LTD	2MG/ML	A 209058	001	Apr 18, 2017	Apr NEWA
AP		MYLAN LABS LTD	2MG/ML	A 201044	001	Feb 07, 2017	Jan NEWA
AP		WEST-WARD PHARMS INT	2MG/ML	A 074593	001	Nov 04, 1996	Jan CAHN

ETOPOSIDE

## CAPSULE;ORAL

## VEPESID

	+	@ DAVA PHARMS INC	50MG	N 019557	001	Dec 30, 1986	Sep CRLD
	+	@	100MG	N 019557	002	Dec 30, 1986	Sep CRLD

## INJECTABLE;INJECTION

## ETOPOSIDE

>A>	AP	MYLAN LABS LTD	20MG/ML	A 203507	001	Nov 20, 2017	Nov NEWA
	AP		20MG/ML	A 204927	001	Oct 31, 2017	Oct NEWA

EXAMETAZIMEPOWDER; INTRAVENOUS  
DRAX EXAMETAZIME

AP	JUBILANT DRAXIMAGE	0.5MG/VIAL	N208870	001	Aug 17, 2017	Aug NEWA
----	--------------------	------------	---------	-----	--------------	----------

EXEMESTANETABLET; ORAL  
EXEMESTANE

AB	MYLAN PHARMS INC	25MG	A203315	001	Mar 10, 2017	Feb NEWA
AB	UPSHER-SMITH LABS	25MG	A209208	001	Jul 26, 2017	Aug CAHN
AB		25MG	A209208	001	Jul 26, 2017	Jul NEWA

EXENATIDESUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS  
BYDUREON BCISE

+	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017	Oct NEWA
---	----------------	-------------------------	---------	-----	--------------	----------

EZETIMIBETABLET; ORAL  
EZETIMIBE

AB	AMNEAL PHARMS CO	10MG	A208803	001	Jun 12, 2017	May NEWA
AB	APOTEX INC	10MG	A208332	001	Jun 12, 2017	May NEWA
AB	AUROBINDO PHARMA LTD	10MG	A209838	001	Aug 25, 2017	Aug NEWA
AB	OHM LABS INC	10MG	A207311	001	Jun 12, 2017	May NEWA
AB	SANDOZ INC	10MG	A203931	001	Jun 12, 2017	May NEWA
AB	TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017	May NEWA
AB	WATSON LABS INC	10MG	A200831	001	Jun 12, 2017	May NEWA
AB	ZYDUS PHARMS USA INC	10MG	A204331	001	Jun 12, 2017	May NEWA

EZETIMIBE; SIMVASTATINTABLET; ORAL  
EZETIMIBE AND SIMVASTATIN

>A>	AB	AMNEAL PHARMS CO	10MG; 10MG	A208831	001	Nov 21, 2017	Nov NEWA
>A>	AB		10MG; 20MG	A208831	002	Nov 21, 2017	Nov NEWA
>A>	AB		10MG; 40MG	A208831	003	Nov 21, 2017	Nov NEWA
>A>	AB		10MG; 80MG	A208831	004	Nov 21, 2017	Nov NEWA
	AB	DR REDDYS LABS INTL	10MG; 10MG	A200909	001	Apr 26, 2017	Apr NEWA
	AB		10MG; 20MG	A200909	002	Apr 26, 2017	Apr NEWA
	AB		10MG; 40MG	A200909	003	Apr 26, 2017	Apr NEWA
	AB		10MG; 80MG	A200909	004	Apr 26, 2017	Apr NEWA
	AB	DR REDDYS LABS SA	10MG; 10MG	A200909	001	Apr 26, 2017	May CAHN
	AB		10MG; 20MG	A200909	002	Apr 26, 2017	May CAHN
	AB		10MG; 40MG	A200909	003	Apr 26, 2017	May CAHN
	AB		10MG; 80MG	A200909	004	Apr 26, 2017	May CAHN
	AB	IMPAX LABS INC	10MG; 10MG	A201890	001	Apr 26, 2017	Apr NEWA
	AB		10MG; 20MG	A201890	002	Apr 26, 2017	Apr NEWA
	AB		10MG; 40MG	A201890	003	Apr 26, 2017	Apr NEWA
	AB		10MG; 80MG	A201890	004	Apr 26, 2017	Apr NEWA
	AB	WATSON LABS INC	10MG; 10MG	A202968	001	Apr 26, 2017	Apr NEWA
	AB		10MG; 20MG	A202968	002	Apr 26, 2017	Apr NEWA
	AB		10MG; 40MG	A202968	003	Apr 26, 2017	Apr NEWA
	AB		10MG; 80MG	A202968	004	Apr 26, 2017	Apr NEWA
		VYTORIN					
AB	+	MSD INTL	10MG; 10MG	N021687	001	Jul 23, 2004	Apr CFTG
AB	+		10MG; 20MG	N021687	002	Jul 23, 2004	Apr CFTG
AB	+		10MG; 40MG	N021687	003	Jul 23, 2004	Apr CFTG
AB	+		10MG; 80MG	N021687	004	Jul 23, 2004	Apr CFTG

FAMCICLOVIRTABLET; ORAL  
FAMCICLOVIR

AB	!	TEVA PHARMS	500MG	A077487	003	Aug 24, 2007	Jan CHRS
		FAMVIR					
	+	@ NOVARTIS	125MG	N020363	003	Dec 11, 1995	Jan DISC
	+	@	250MG	N020363	001	Apr 26, 1996	Jan DISC
	+	@	500MG	N020363	002	Jun 29, 1994	Jan DISC

FAMOTIDINE

>A>	FOR SUSPENSION;ORAL						
>A>	FAMOTIDINE						
>A> AB	NOVEL LABS INC	40MG/5ML	A201695	001	Dec 17, 2012	Nov	CDFR
	INJECTABLE;INJECTION						
	FAMOTIDINE						
AP	ATHENEX INC	10MG/ML	A075651	001	Apr 16, 2001	Mar	CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Mar	CAHN
	@ WEST-WARD PHARMS INT	10MG/ML	A075799	001	Apr 30, 2002	Aug	CAHN
	FAMOTIDINE PRESERVATIVE FREE						
AP	ATHENEX INC	10MG/ML	A075622	001	Apr 16, 2001	Mar	CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Mar	CAHN
	@ WEST-WARD PHARMS INT	10MG/ML	A075789	001	Apr 30, 2002	Aug	CAHN
	FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER						
>D> AP	! BAXTER HLTHCARE	0.4MG/ML	A075591	001	May 10, 2001	Nov	CTEC
>A>	!	0.4MG/ML	A075591	001	May 10, 2001	Nov	CTEC
>D>	SUSPENSION;ORAL						
>D>	FAMOTIDINE						
>D> AB	NOVEL LABS INC	40MG/5ML	A201695	001	Dec 17, 2012	Nov	CDFR
	TABLET;ORAL						
	FAMOTIDINE						
AB	PERRIGO R AND D	20MG	A077352	002	Jul 27, 2005	Apr	CAHN
AB		40MG	A077352	001	Jul 27, 2005	Apr	CAHN

FELBAMATE

	SUSPENSION;ORAL						
	FELBAMATE						
AB	TARO PHARM	600MG/5ML	A206314	001	Jun 16, 2017	Jun	NEWA
	FELBATOL						
AB	+! MYLAN SPECIALITY LP	600MG/5ML	N020189	003	Jul 29, 1993	Mar	CAHN
	TABLET;ORAL						
	FELBAMATE						
AB	IMPAX LABS INC	400MG	A202284	001	Nov 04, 2015	Feb	CAHN
AB		600MG	A202284	002	Nov 04, 2015	Feb	CAHN
AB	TARO PHARM	400MG	A207093	001	Apr 20, 2017	Apr	NEWA
AB		600MG	A207093	002	Apr 20, 2017	Apr	NEWA
AB	ZYDUS PHARMS USA INC	400MG	A208970	001	May 30, 2017	May	NEWA
AB		600MG	A208970	002	May 30, 2017	May	NEWA
	FELBATOL						
AB	+ MYLAN SPECIALITY LP	400MG	N020189	001	Jul 29, 1993	Mar	CAHN
AB	+!	600MG	N020189	002	Jul 29, 1993	Mar	CAHN

FENOFIBRATE

	CAPSULE;ORAL						
	FENOFIBRATE (MICRONIZED)						
>A> AB	CNTY LINE PHARMS	67MG	A207805	001	Nov 16, 2017	Nov	NEWA
>A> AB		134MG	A207805	002	Nov 16, 2017	Nov	NEWA
>A> AB		200MG	A207805	003	Nov 16, 2017	Nov	NEWA
AB	GLENMARK PHARMS LTD	67MG	A205566	001	Apr 07, 2017	Mar	NEWA
AB		134MG	A205566	002	Apr 07, 2017	Mar	NEWA
AB		200MG	A205566	003	Apr 07, 2017	Mar	NEWA
AB	! IMPAX LABS	200MG	A075868	003	Oct 27, 2003	Jun	CHRS
AB	INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar	NEWA
AB		134MG	A207378	002	Mar 28, 2017	Mar	NEWA
AB		200MG	A207378	003	Mar 28, 2017	Mar	NEWA
AB	RHODES PHARMS	200MG	A075753	003	Apr 09, 2002	Jun	CHRS
	TABLET;ORAL						
	FENOFIBRATE						
AB	! IMPAX LABS	160MG	A076509	002	Mar 26, 2008	Mar	CHRS
AB	RHODES PHARMS	160MG	A076433	002	May 13, 2005	Mar	CHRS
AB	SUN PHARM INDS LTD	48MG	A200884	001	Sep 07, 2017	Aug	NEWA
AB		145MG	A200884	002	Sep 07, 2017	Aug	NEWA
	TRICOR						
+ @	ABBVIE INC	54MG	N021203	001	Sep 04, 2001	Aug	CAHN
+ @		160MG	N021203	003	Sep 04, 2001	Aug	CAHN



FENOLDOPAM MESYLATEINJECTABLE; INJECTION  
FENOLDOPAM MESYLATE

AP	SANDOZ INC	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	Mar CAHN
----	------------	-----------------	---------	-----	--------------	----------

FENOPROFEN CALCIUMCAPSULE; ORAL  
NALFON

+	!	XSPIRE PHARMA	EQ 200MG BASE	N017604	003		Aug CAHN
		@	EQ 300MG BASE	N017604	002		Aug CAHN
+			EQ 400MG BASE	N017604	004	Jul 21, 2009	Aug CAHN

TABLET; ORAL

FENOPROFEN CALCIUM

!	XSPIRE PHARMA	EQ 600MG BASE	A072267	001	Aug 17, 1988	Aug CAHN
---	---------------	---------------	---------	-----	--------------	----------

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB	3M DRUG DELIVERY	100MCG/HR	A202097	005	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007	Mar CAHN

FENTANYL-12

AB	3M DRUG DELIVERY	12.5MCG/HR	A202097	001	Nov 04, 2016	Mar CAHN
----	------------------	------------	---------	-----	--------------	----------

FENTANYL-25

AB	3M DRUG DELIVERY	25MCG/HR	A202097	002	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007	Mar CAHN

FENTANYL-37

>A>	AB	AVEVA	37.5MCG/HR	A077449	006	Dec 06, 2017	Nov NEWA
-----	----	-------	------------	---------	-----	--------------	----------

FENTANYL-50

AB	3M DRUG DELIVERY	50MCG/HR	A202097	003	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007	Mar CAHN

FENTANYL-62

>A>	AB	AVEVA	62.5MCG/HR	A077449	007	Dec 06, 2017	Nov NEWA
-----	----	-------	------------	---------	-----	--------------	----------

FENTANYL-75

AB	3M DRUG DELIVERY	75MCG/HR	A202097	004	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007	Mar CAHN

FENTANYL-87

>A>	AB	AVEVA	87.5MCG/HR	A077449	008	Dec 06, 2017	Nov NEWA
-----	----	-------	------------	---------	-----	--------------	----------

SPRAY; SUBLINGUAL

SUBSYS

+	INSYS DEV CO INC	0.1MG	N202788	001	Jan 04, 2012	May CAHN
+		0.2MG	N202788	002	Jan 04, 2012	May CAHN
+	!	0.4MG	N202788	003	Jan 04, 2012	May CAHN
+		0.6MG	N202788	004	Jan 04, 2012	May CAHN
+		0.8MG	N202788	005	Jan 04, 2012	May CAHN
+		1.2MG	N202788	006	Aug 30, 2012	May CAHN
+		1.6MG	N202788	007	Aug 30, 2012	May CAHN

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

>D>	+	DEPOMED INC	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Nov CAHN
>D>	+		EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Nov CAHN
>D>	+	!	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Nov CAHN
>A>	+	ELEFSEE PHARMS INTL	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Nov CAHN
>A>	+		EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Nov CAHN
>A>	+	!	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Nov CAHN

TABLET; SUBLINGUAL

ABSTRAL

>D>	+	SENTYNL THERAPS INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Nov CFTG
>A>	AB	+	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Nov CFTG
>D>	+		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Nov CFTG
>A>	AB	+	EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Nov CFTG
>D>	+		EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Nov CFTG
>A>	AB	+	EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Nov CFTG
>D>	+	!	EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Nov CFTG
>A>	AB	+	EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Nov CFTG
>D>	+		EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Nov CFTG

TABLET;SUBLINGUAL  
ABSTRAL

>A>	AB	+	EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Nov CFTG
>D>		+	EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Nov CFTG
>A>	AB	+	EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Nov CFTG
>A>			FENTANYL CITRATE				
>A>	AB		ACTAVIS LABS FL INC EQ 0.1MG BASE	A207338	001	Nov 17, 2017	Nov NEWA
>A>	AB		EQ 0.2MG BASE	A207338	002	Nov 17, 2017	Nov NEWA
>A>	AB		EQ 0.3MG BASE	A207338	003	Nov 17, 2017	Nov NEWA
>A>	AB		EQ 0.4MG BASE	A207338	004	Nov 17, 2017	Nov NEWA
>A>	AB		EQ 0.6MG BASE	A207338	005	Nov 17, 2017	Nov NEWA
>A>	AB		EQ 0.8MG BASE	A207338	006	Nov 17, 2017	Nov NEWA

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL  
FESOTERODINE FUMARATE

AB	AUROBINDO PHARMA LTD	4MG	A205007	001	Feb 17, 2017	Feb NEWA
AB		8MG	A205007	002	Feb 17, 2017	Feb NEWA
AB	ZYDUS PHARMS USA INC	4MG	A204946	001	Oct 03, 2017	Sep NEWA
AB		8MG	A204946	002	Oct 03, 2017	Sep NEWA

FINASTERIDE

TABLET;ORAL  
FINASTERIDE

AB	ACCORD HLTHCARE	1MG	A091643	001	Nov 05, 2013	Mar CAHN
AB	ACTAVIS TOTOWA TEVA	5MG	A077914	001	Mar 28, 2007	May CAHN

FLECAINIDE ACETATE

TABLET;ORAL  
FLECAINIDE ACETATE

AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Nov 03, 2017	Oct NEWA
AB		100MG	A202821	002	Nov 03, 2017	Oct NEWA
AB		150MG	A202821	003	Nov 03, 2017	Oct NEWA

FLOXURIDINE

INJECTABLE;INJECTION  
FLOXURIDINE

>A>	AP	PHARMAFORCE	500MG/VIAL	A203008	001	Nov 22, 2017	Nov NEWA
-----	----	-------------	------------	---------	-----	--------------	----------

FLUCONAZOLE

FOR SUSPENSION;ORAL  
FLUCONAZOLE

AB	AUROBINDO PHARMA LTD	50MG/5ML	A079150	001	Sep 18, 2009	Jan CAHN
AB		200MG/5ML	A079150	002	Sep 18, 2009	Jan CAHN

INJECTABLE;INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @ PFIZER 200MG/100ML (2MG/ML)

N019950 003 Sep 29, 1992 Mar DISC

+ @ 400MG/200ML (2MG/ML)

N019950 005 Jul 08, 1994 Mar DISC

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+ @ PFIZER 200MG/100ML (2MG/ML)

N019950 001 Jan 29, 1990 Mar DISC

+ @ 400MG/200ML (2MG/ML)

N019950 006 Jan 29, 1990 Mar DISC

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ @ PFIZER 200MG/100ML (2MG/ML)

N019950 002 Jan 29, 1990 Mar DISC

+ @ 400MG/200ML (2MG/ML)

N019950 004 Jan 29, 1990 Mar DISC

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP ! HOSPIRA 200MG/100ML (2MG/ML)

A076304 001 Jul 29, 2004 Mar CHRS

AP ! 400MG/200ML (2MG/ML)

A076304 002 Jul 29, 2004 Mar CHRS

AP RENAISSANCE SSA LLC 200MG/100ML (2MG/ML)

A077988 001 May 26, 2010 Aug CAHN

AP 400MG/200ML (2MG/ML)

A077988 002 May 26, 2010 Aug CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP BAXTER HLTHCARE CORP 200MG/100ML (2MG/ML)

A077947 001 May 26, 2010 Aug CAHN

AP 400MG/200ML (2MG/ML)

A077947 002 May 26, 2010 Aug CAHN

WEST-WARD PHARMS INT 100MG/50ML (2MG/ML)

A076087 002 Sep 26, 2008 Jan CAHN

AP 200MG/100ML (2MG/ML)

A076087 001 Jul 29, 2004 Jan CAHN

AP 400MG/200ML (2MG/ML)

A076087 003 Jul 29, 2004 Jan CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP ! ACS DOBFAR INFO SA 200MG/100ML (2MG/ML)

A079104 001 Jul 30, 2009 Mar CHRS

AP ! 400MG/200ML (2MG/ML)

A079104 002 Jul 30, 2009 Mar CHRS

RENAISSANCE SSA LLC 100MG/50ML (2MG/ML)

A077909 003 Apr 20, 2015 Aug CAHN

AP 200MG/100ML (2MG/ML)

A077909 001 May 26, 2010 Aug CAHN

AP 400MG/200ML (2MG/ML)

A077909 002 May 26, 2010 Aug CAHN

AP WEST-WARD PHARMS INT 200MG/100ML (2MG/ML)

A078107 001 Jul 30, 2008 Jan CAHN

## INJECTABLE;INJECTION

## FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jan CAHN
----	--	----------------------	---------	-----	--------------	----------

## TABLET;ORAL

## FLUCONAZOLE

AB	UNIQUE PHARM LABS	50MG	A076957	001	Sep 28, 2005	Aug CAHN
AB		100MG	A076957	002	Sep 28, 2005	Aug CAHN
AB		150MG	A076957	004	Feb 27, 2017	Aug CAHN
AB		150MG	A076957	004	Feb 27, 2017	Feb NEWA
AB		200MG	A076957	003	Sep 28, 2005	Aug CAHN
AB	ZYDUS PHARMS USA INC	50MG	A208963	001	Feb 16, 2017	Feb NEWA
AB		100MG	A208963	002	Feb 16, 2017	Feb NEWA
AB		150MG	A208963	003	Feb 16, 2017	Feb NEWA
AB		200MG	A208963	004	Feb 16, 2017	Feb NEWA

FLUCYTOSINE

## CAPSULE;ORAL

## FLUCYTOSINE

AB	NOVEL LABS INC	250MG	A204652	001	Jul 07, 2017	Jun NEWA
AB		500MG	A204652	002	Jul 07, 2017	Jun NEWA
AB	ROXANE	250MG	A206550	001	Oct 17, 2017	Oct NEWA
AB		500MG	A206550	002	Oct 17, 2017	Oct NEWA
AB	WEST-WARD PHARMS INT	250MG	A206550	001	Oct 17, 2017	Oct CAHN
AB		500MG	A206550	002	Oct 17, 2017	Oct CAHN

FLUDARABINE PHOSPHATE

## INJECTABLE;INJECTION

## FLUDARABINE PHOSPHATE

AP	ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Feb NEWA
AP	CUSTOPHARM INC	50MG/VIAL	A076349	001	Aug 28, 2003	Oct CAHN

FLUDEOXYGLUCOSE F-18

## INJECTABLE;INTRAVENOUS

## FLUDEOXYGLUCOSE F18

AP	JUBILANT DRAXIMAGE	20-300mCi/ML	A203920	001	Jun 23, 2015	Sep CAHN
>A> AP	SOFIE	20-300mCi/ML	A203591	001	Aug 31, 2015	Nov CAHN
>D> AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Nov CAHN

FLUMAZENIL

## INJECTABLE;INJECTION

## FLUMAZENIL

	@ BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Aug CAHN
	@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Aug CAHN
AP	SANDOZ INC	0.5MG/5ML (0.1MG/ML)	A077071	001	May 03, 2005	Apr CAHN
AP		1MG/10ML (0.1MG/ML)	A077071	002	May 03, 2005	Apr CAHN
AP	WEST-WARD PHARMS INT	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Jan CAHN
AP		0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jan CAHN
AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Jan CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jan CAHN

FLUNISOLIDE

## AEROSOL, METERED;INHALATION

## AEROSPAN HFA

+	MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006	Mar CAHN
---	---------------------	-------------	---------	-----	--------------	----------

FLUOCINOLONE ACETONIDE

## CREAM;TOPICAL

## FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.01%	A088170	001	Dec 16, 1982	Jan CAHN
AT		0.025%	A088169	001	Dec 16, 1982	Jan CAHN
	@ TARO	0.01%	A040035	001	Oct 31, 1994	Apr CAHN
	@	0.025%	A040042	001	Oct 31, 1994	Apr CAHN

## OIL/DROPS;OTIC

## FLUOCINOLONE ACETONIDE

AT	PERRIGO ISRAEL	0.01%	A202849	001	Jul 17, 2017	Jul NEWA
----	----------------	-------	---------	-----	--------------	----------

## OINTMENT;TOPICAL

## FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.025%	A088168	001	Dec 16, 1982	Jan CAHN
AT	TARO	0.025%	A040041	001	Sep 15, 1994	Apr CAHN

SOLUTION;TOPICAL									
FLUOCINOLONE ACETONIDE									
AT		FOUGERA PHARMS INC	0.01%		A088167	001	Dec 16, 1982	Jan	CAHN
<u>FLUOCINONIDE</u>									
CREAM;TOPICAL									
FLUOCINONIDE									
AB1		FOUGERA PHARMS INC	0.05%		A073030	001	Oct 17, 1994	Jan	CAHN
AB		PERRIGO ISRAEL	0.1%		A090256	001	Jan 14, 2014	Apr	CAHN
AB1		TARO	0.05%		A071500	001	Jun 10, 1987	Mar	CMFD
FLUOCINONIDE EMULSIFIED BASE									
AB2		G AND W LABS INC	0.05%		A074204	001	Jun 13, 1995	May	CMFD
GEL;TOPICAL									
FLUOCINONIDE									
AB	+	CNTY LINE PHARMS	0.05%		N017373	001		Oct	CMFD
AB		FOUGERA PHARMS INC	0.05%		A072933	001	Dec 30, 1994	Jan	CAHN
AB	!	TARO	0.05%		A074935	001	Jul 29, 1997	Apr	CAHN
OINTMENT;TOPICAL									
FLUOCINONIDE									
AB		NOVEL LABS INC	0.05%		A207538	001	Jul 31, 2017	Jul	NEWA
AB	!	TARO	0.05%		A075008	001	Jun 30, 1999	Apr	CAHN
SOLUTION;TOPICAL									
FLUOCINONIDE									
>D>	AT	FOUGERA	0.05%		A072934	001	Feb 27, 1995	Nov	CAHN
>A>	AT	FOUGERA PHARMS INC	0.05%		A072934	001	Feb 27, 1995	Nov	CAHN
	AT	NOVEL LABS INC	0.05%		A206003	001	Jul 21, 2017	Jul	NEWA
	AT	! TARO	0.05%		A074799	001	Dec 31, 1996	Apr	CAHN
LIDEX									
AT	+	CNTY LINE PHARMS	0.05%		N018849	001	Apr 06, 1984	Mar	CRLD
<u>FLUOROURACIL</u>									
CREAM;TOPICAL									
FLUOROURACIL									
AB		MYLAN PHARMS INC	0.5%		A203122	001	Apr 20, 2015	Jun	CAHN
INJECTABLE;INJECTION									
FLUOROURACIL									
AP		GLAND PHARMA LTD	500MG/10ML (50MG/ML)		A210123	001	Oct 27, 2017	Oct	NEWA
AP			1GM/20ML (50MG/ML)		A210123	002	Oct 27, 2017	Oct	NEWA
AP		SAGENT PHARMS	500MG/10ML (50MG/ML)		A203608	001	May 11, 2017	May	NEWA
AP			1GM/20ML (50MG/ML)		A203608	002	May 11, 2017	May	NEWA
	@	SANDOZ	2.5GM/50ML (50MG/ML)		A091299	001	May 02, 2011	Jul	DISC
	@		5GM/100ML (50MG/ML)		A091299	002	May 02, 2011	Jul	DISC
	+	@ SPECTRUM PHARMS	500MG/10ML (50MG/ML)		N012209	001		Jan	CRLD
	+	@	2.5GM/50ML (50MG/ML)		N012209	002	Jul 29, 2016	Aug	DISC
SOLUTION;TOPICAL									
FLUOROURACIL									
AT		TARO PHARM	2%		A076526	001	Nov 05, 2003	Mar	CAHN
AT			5%		A076526	002	Nov 05, 2003	Mar	CAHN
<u>FLUOXETINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
FLUOXETINE HYDROCHLORIDE									
	@	MYLAN	EQ 10MG BASE		A075207	001	Jan 30, 2002	Jun	DISC
	@		EQ 20MG BASE		A075207	002	Jan 30, 2002	Jun	DISC
	@		EQ 40MG BASE		A075207	003	May 25, 2007	Jun	DISC
>D>	AB1	MYLAN PHARMS INC	EQ 10MG BASE		A075577	001	Jan 29, 2002	Nov	DISC
>A>	@		EQ 10MG BASE		A075577	001	Jan 29, 2002	Nov	DISC
>D>	AB1		EQ 20MG BASE		A075577	002	Jan 29, 2002	Nov	DISC
>A>	@		EQ 20MG BASE		A075577	002	Jan 29, 2002	Nov	DISC
SOLUTION;ORAL									
FLUOXETINE HYDROCHLORIDE									
AA		AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML		A079209	001	Mar 20, 2009	Jan	CAHN
AA	!	PHARM ASSOC	EQ 20MG BASE/5ML		A076015	001	Jan 30, 2002	May	CAHN
TABLET;ORAL									
FLUOXETINE HYDROCHLORIDE									
AB		ALEMBIC PHARMS LTD	EQ 10MG BASE		A208698	001	Apr 05, 2017	Mar	NEWA
AB			EQ 20MG BASE		A208698	002	Apr 05, 2017	Mar	NEWA
AB	+	ALVOGEN	EQ 60MG BASE		N202133	001	Oct 06, 2011	Oct	CTEC
	+		EQ 60MG BASE		N202133	001	Oct 06, 2011	Jan	CAHN
>A>	AB	INVENTIA HLTHCARE	EQ 60MG BASE		A209695	001	Nov 20, 2017	Nov	NEWA
	AB	PAR PHARM INC	EQ 60MG BASE		A209419	001	Nov 16, 2017	Oct	NEWA

FLUOXYMESTERONETABLET; ORAL  
FLUOXYMESTERONE

! USL PHARMA 10MG A088342 001 Oct 21, 1983 Jun CAHN

FLUPHENAZINE DECANOATEINJECTABLE; INJECTION  
FLUPHENAZINE DECANOATE

AO AUROBINDO PHARMA LTD 25MG/ML A207739 001 Oct 17, 2017 Oct NEWA

FLUPHENAZINE HYDROCHLORIDECONCENTRATE; ORAL  
FLUPHENAZINE HYDROCHLORIDE

@ ANI PHARMS INC 5MG/ML A073058 001 Aug 30, 1991 Jan CAHN

! PHARM ASSOC 5MG/ML A074725 001 Sep 16, 1996 May CAHN

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

! PHARM ASSOC 2.5MG/5ML A040146 001 Aug 21, 1996 May CAHN

PROLIXIN

+ @ APOTHECON 2.5MG/5ML N012145 003 Sep DISC

FLURANDRENOLIDECREAM; TOPICAL  
FLURANDRENOLIDE

AT CINTEX SVCS 0.05% A205342 001 Apr 13, 2016 Jun CAHN

LOTION; TOPICAL

FLURANDRENOLIDE

AT CINTEX SVCS 0.05% A205343 001 Dec 22, 2016 Jun CAHN

FLURAZEPAM HYDROCHLORIDECAPSULE; ORAL  
FLURAZEPAM HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 15MG A071717 002 Jul 31, 1991 Jan CMS1

FLUTAMIDECAPSULE; ORAL  
EULEXIN

+ @ SCHERING 125MG N018554 001 Jan 27, 1989 Sep CRLD

FLUTAMIDE

@ MYLAN 125MG A076224 001 May 09, 2003 Jun DISC

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEPOWDER; INHALATION  
TRELEGY ELLIPTA+! GLAXOSMITHKLINE 0.1MG/INH;EQ 0.0625MG BASE/INH;EQ N209482 001 Sep 18, 2017 Sep NEWA  
0.025MG BASE/INHFLUTICASONE PROPIONATEPOWDER; INHALATION  
ARMONAIR RESPICLICK

+ TEVA PHARM 0.055MG/INH N208798 001 Jan 27, 2017 Jan NEWA

+ 0.113MG/INH N208798 002 Jan 27, 2017 Jan NEWA

+! 0.232MG/INH N208798 003 Jan 27, 2017 Jan NEWA

SPRAY, METERED; NASAL

FLONASE

+ @ GLAXOSMITHKLINE 0.05MG/SPRAY N020121 001 Oct 19, 1994 Jul CRLD

FLUTICASONE PROPIONATE

AB ! WEST-WARD PHARMS INT 0.05MG/SPRAY A076504 001 Feb 22, 2006 Jul CHRS

XHANCE

+! OPTNOSE US 0.093MG N209022 001 Sep 18, 2017 Sep NEWA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEPOWDER; INHALATION  
AIRDUO RESPICLICK

+ TEVA PHARM 0.055MG/INH;EQ 0.014MG BASE/INH N208799 001 Jan 27, 2017 Jan NEWA

+ 0.113MG/INH;EQ 0.014MG BASE/INH N208799 002 Jan 27, 2017 Jan NEWA

+! 0.232MG/INH;EQ 0.014MG BASE/INH N208799 003 Jan 27, 2017 Jan NEWA

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB	!	MYLAN PHARMS INC	EQ 40MG BASE	A090595	002	Apr 11, 2012	May CHRS
		LESCOL					
	+	@ NOVARTIS	EQ 20MG BASE	N020261	001	Dec 31, 1993	May DISC
	+	@	EQ 40MG BASE	N020261	002	Dec 31, 1993	May DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB	!	ACTAVIS ELIZABETH	150MG	A091482	002	Nov 18, 2013	Apr CHRS
		LUVOX CR					
	+	@ JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Apr DISC
	+	@	150MG	N022033	002	Feb 28, 2008	Apr DISC
		TABLET; ORAL					
		FLUVOXAMINE MALEATE					
	@	ECI PHARMS LLC	25MG	A075900	001	Feb 23, 2006	May CAHN
	@		50MG	A075900	002	Feb 23, 2006	May CAHN
	@		100MG	A075900	003	Feb 23, 2006	May CAHN
	@	UPSHER-SMITH LABS	25MG	A075887	001	Jan 05, 2001	Jun CAHN
AB			25MG	A075888	001	Nov 29, 2000	Jun CAHN
	@		50MG	A075887	002	Jan 05, 2001	Jun CAHN
AB			50MG	A075888	002	Nov 29, 2000	Jun CAHN
	@		100MG	A075887	003	Jan 05, 2001	Jun CAHN
AB	!		100MG	A075888	003	Nov 29, 2000	Jun CAHN

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

	+	@ NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001	Feb DISC
--	---	------------	-------------	---------	-----	--------------	----------

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

	+	!	ASTRAZENECA PHARMS	0.0048MG/INH; 0.0090MG/INH	N208294	001	Apr 25, 2016	Mar CAHN
--	---	---	--------------------	----------------------------	---------	-----	--------------	----------

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

@	HOSPIRA	2.4GM/100ML	A077174	001	May 31, 2005	Sep DISC
	FOSCAVIR					
+!	CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Sep CTEC

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

	@	UPSHER-SMITH LABS	10MG	A076188	001	Oct 08, 2004	Jun CAHN	
AB			10MG	A076483	001	Apr 23, 2004	Jun CAHN	
	@		20MG	A076188	002	Oct 08, 2004	Jun CAHN	
AB			20MG	A076483	002	Apr 23, 2004	Jun CAHN	
	@		40MG	A076188	003	Oct 08, 2004	Jun CAHN	
AB			40MG	A076483	003	Apr 23, 2004	Jun CAHN	
		MONOPRIL						
	+	@	BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Jan CRLD
	+	@		20MG	N019915	003	May 16, 1991	Jan CRLD
	+	@		40MG	N019915	004	Mar 28, 1995	Jan CRLD

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP		FRESENIUS KABI USA	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Jun CMFD
AP		WEST-WARD PHARMS INT	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jan CAHN
AP			EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jan CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

	@	ACCORD HLTHCARE	10MG/ML	A070017	001	Dec 15, 1986	Jun CAHN
AP		BAXTER HLTHCARE CORP	10MG/ML	A202747	001	Jan 27, 2014	Aug CAHN

TABLET;ORAL  
FUROSEMIDE

AB	IPCA LABS LTD	20MG	A078010	001	Sep 18, 2006	Aug CTEC
BX		20MG	A078010	001	Sep 18, 2006	Apr CTEC
AB		40MG	A078010	002	Sep 18, 2006	Aug CTEC
BX		40MG	A078010	002	Sep 18, 2006	Apr CTEC
AB		80MG	A078010	003	Sep 18, 2006	Aug CTEC
BX		80MG	A078010	003	Sep 18, 2006	Apr CTEC
AB	PRINSTON INC	20MG	A076796	001	Mar 26, 2004	Feb CAHN
AB		40MG	A076796	002	Mar 26, 2004	Feb CAHN
AB		80MG	A076796	003	Mar 26, 2004	Feb CAHN
	@ SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014	May DISC
	@	40MG	A091258	002	Apr 01, 2014	May DISC
	@	40MG	N018790	001	Nov 29, 1983	Oct CAHN
	@	80MG	A091258	003	Apr 01, 2014	May DISC
AB	WEST-WARD PHARMS INT	20MG	N018823	001	Nov 10, 1983	Jan CAHN
AB		40MG	N018823	002	Nov 10, 1983	Jan CAHN

GABAPENTIN

CAPSULE;ORAL  
GABAPENTIN

AB	AUROBINDO PHARMA LTD	100MG	A078787	001	Jan 31, 2008	Jan CAHN
AB		300MG	A078787	002	Jan 31, 2008	Jan CAHN
AB		400MG	A078787	003	Jan 31, 2008	Jan CAHN
	@ CSPC OUYI PHARM CO	100MG	A075477	001	Mar 23, 2005	Oct CAHN
	@	300MG	A075477	002	Mar 23, 2005	Oct CAHN
	@	400MG	A075477	003	Mar 23, 2005	Oct CAHN
AB	EPIC PHARMA LLC	100MG	A207099	001	Mar 24, 2017	Mar NEWA
AB		300MG	A207099	002	Mar 24, 2017	Mar NEWA
AB		400MG	A207099	003	Mar 24, 2017	Mar NEWA
AB	JIANGSU HENGRUI MED	100MG	A091008	001	Oct 26, 2017	Oct NEWA
AB		300MG	A091008	002	Oct 26, 2017	Oct NEWA
AB		400MG	A091008	003	Oct 26, 2017	Oct NEWA

TABLET;ORAL  
GABAPENTIN

AB	CSPC OUYI PHARM CO	600MG	A207057	001	Oct 26, 2017	Oct NEWA
AB		800MG	A207057	002	Oct 26, 2017	Oct NEWA
AB	GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	May CAHN
AB		800MG	A077662	002	Aug 18, 2006	May CAHN
AB	TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Feb NEWA
AB		800MG	A205807	002	Mar 10, 2017	Feb NEWA

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS  
DOTAREM

+	GUERBET	1.8845GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017	Sep CMS1
+		1.884GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017	Aug NEWA

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

	@ MYLAN	EQ 4MG BASE	A077603	001	Aug 28, 2008	Oct DISC
	@	EQ 8MG BASE	A077603	002	Aug 28, 2008	Oct DISC
	@	EQ 12MG BASE	A077603	003	Aug 28, 2008	Oct DISC
AB	YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	Jul CMFD
AB		EQ 8MG BASE	A077604	002	Feb 06, 2009	Jul CMFD
AB		EQ 12MG BASE	A077604	003	Feb 06, 2009	Jul CMFD

GANCICLOVIR

SOLUTION;IV (INFUSION)  
GANCICLOVIR

+	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Feb NEWA
---	----------------------	----------------------	---------	-----	--------------	----------

GANCICLOVIR SODIUM

INJECTABLE;INJECTION  
GANCICLOVIR

>A>	AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017	Nov NEWA
>A>	AP	PHARMASCIENCE INC	EQ 500MG BASE/VIAL	A207645	001	Dec 08, 2017	Nov NEWA

GATIFLOXACINSOLUTION/DROPS;OPHTHALMIC  
GATIFLOXACIN

AT	SANDOZ INC	0.5%	A204227	001	Jul 11, 2016	Feb CAHN
----	------------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE;INJECTION  
GEMCITABINE HYDROCHLORIDE

AP	ACTAVIS TOTOWA	EQ 2GM BASE/VIAL	A079160	003	Jul 28, 2016	Oct NEWA
AP	APOTEX INC	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017	May NEWA
AP		1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017	May NEWA
AP		2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017	May NEWA
>A> AP	MYLAN LABS LTD	200MG/5.26ML (38MG/ML)	A205242	001	Dec 06, 2017	Nov NEWA
>A> AP		1GM/26.3ML (38MG/ML)	A205242	002	Dec 06, 2017	Nov NEWA
>A> AP		2GM/52.6ML (38MG/ML)	A205242	003	Dec 06, 2017	Nov NEWA
>D> AP	SAGENT PHARMS	EQ 200MG BASE/VIAL	A091597	001	May 07, 2013	Nov DISC
>A>	@	EQ 200MG BASE/VIAL	A091597	001	May 07, 2013	Nov DISC
>D> AP		EQ 1GM BASE/VIAL	A091597	002	May 07, 2013	Nov DISC
>A>	@	EQ 1GM BASE/VIAL	A091597	002	May 07, 2013	Nov DISC

SOLUTION;IV (INFUSION)  
GEMCITABINE HYDROCHLORIDE

+	!	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017	Aug NEWA
+	!		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017	Aug NEWA
+	!		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017	Aug NEWA
+	!		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017	Aug NEWA

GEMFIBROZILTABLET;ORAL  
GEMFIBROZIL

AB	CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007	Jan CAHN
----	-----------------	-------	---------	-----	--------------	----------

GEMIFLOXACIN MESYLATETABLET;ORAL  
FACTIVE

AB	+	!	LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Mar CAHN
----	---	---	-------------	---------------	---------	-----	--------------	----------

GENTAMICIN SULFATECREAM;TOPICAL  
GENTAMICIN SULFATE

AT	@	FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984	Jan DISC
	!	PERRIGO NEW YORK	EQ 0.1% BASE	A062307	001		Jan CHRS
	@	TARO	EQ 0.1% BASE	A062427	001	May 26, 1983	Jan DISC

OINTMENT;TOPICAL  
GENTAMICIN SULFATE

AT		FOUGERA PHARMS INC	EQ 0.1% BASE	A062533	001	Oct 05, 1984	Jan CAHN
----	--	--------------------	--------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC  
GENOPTIC

AT	!	ALLERGAN	EQ 0.3% BASE	A062452	001	Oct 10, 1984	Oct CHRS
----	---	----------	--------------	---------	-----	--------------	----------

GENTAMICIN SULFATE

AT	@	BAUSCH AND LOMB	EQ 0.3% BASE	A064048	001	May 11, 1994	Oct DISC
		SANDOZ INC	EQ 0.3% BASE	A062196	001		Mar CAHN

GLATIRAMER ACETATEINJECTABLE;SUBCUTANEOUS  
COPAXONE

AP	+	!	TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014	Sep CFTG
----	---	---	-----------------	---------	---------	-----	--------------	----------

GLATIRAMER ACETATE

AP		MYLAN PHARMS INC	20MG/ML	A091646	001	Oct 03, 2017	Sep NEWA
AP			40MG/ML	A206936	001	Oct 03, 2017	Sep NEWA

GLECAPREVIR; PIBRENTASVIRTABLET;ORAL  
MAVYRET

+	!	ABBVIE INC	100MG;40MG	N209394	001	Aug 03, 2017	Aug NEWA
---	---	------------	------------	---------	-----	--------------	----------



GLIMEPIRIDE

## TABLET; ORAL

## GLIMEPIRIDE

	@ EPIC PHARMA LLC	1MG	A077274	001	Oct 06, 2005	May	CAHN
	@	2MG	A077274	002	Oct 06, 2005	May	CAHN
	@	4MG	A077274	003	Oct 06, 2005	May	CAHN
>D> AB	MICRO LABS LTD INDIA	1MG	A091220	001	Jun 29, 2012	Nov	CAHN
>D> AB		2MG	A091220	002	Jun 29, 2012	Nov	CAHN
>D>		3MG	A091220	003	Jun 29, 2012	Nov	CAHN
>D> AB		4MG	A091220	004	Jun 29, 2012	Nov	CAHN
>D>		6MG	A091220	005	Jun 29, 2012	Nov	CAHN
>D> AB		8MG	A091220	006	Jun 29, 2012	Nov	CAHN
AB	PRINSTON INC	1MG	A077370	001	Dec 23, 2005	Feb	CAHN
AB		2MG	A077370	002	Dec 23, 2005	Feb	CAHN
AB		4MG	A077370	003	Dec 23, 2005	Feb	CAHN
AB		8MG	A077370	004	Dec 23, 2005	Feb	CAHN
>A> AB	VIVA HLTHCARE	1MG	A091220	001	Jun 29, 2012	Nov	CAHN
>A> AB		2MG	A091220	002	Jun 29, 2012	Nov	CAHN
>A>		3MG	A091220	003	Jun 29, 2012	Nov	CAHN
>A> AB		4MG	A091220	004	Jun 29, 2012	Nov	CAHN
>A>		6MG	A091220	005	Jun 29, 2012	Nov	CAHN
>A> AB		8MG	A091220	006	Jun 29, 2012	Nov	CAHN

GLIPIZIDE

## TABLET; ORAL

## GLIPIZIDE

>D> AB	MYLAN	5MG	A074438	001	Jun 20, 1995	Nov	DISC
>A>	@	5MG	A074438	001	Jun 20, 1995	Nov	DISC
>D> AB		10MG	A074438	002	Jun 20, 1995	Nov	DISC
>A>	@	10MG	A074438	002	Jun 20, 1995	Nov	DISC
AB	WATSON LABS TEVA	5MG	A074223	001	Feb 27, 1995	May	CAHN
AB		10MG	A074223	002	Feb 27, 1995	May	CAHN

## TABLET, EXTENDED RELEASE; ORAL

## GLIPIZIDE

AB	AUROBINDO PHARMA LTD	2.5MG	A206928	001	May 12, 2017	May	NEWA
AB		5MG	A206928	002	May 12, 2017	May	NEWA
AB		10MG	A206928	003	May 12, 2017	May	NEWA

GLIPIZIDE; METFORMIN HYDROCHLORIDE

## TABLET; ORAL

## GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	EPIC PHARMA LLC	2.5MG; 250MG	A077507	001	Oct 27, 2005	May	CAHN
AB		2.5MG; 500MG	A077507	002	Oct 27, 2005	May	CAHN
AB		5MG; 500MG	A077507	003	Oct 27, 2005	May	CAHN
	METAGLIP						
+ @	BRISTOL MYERS SQUIBB	2.5MG; 250MG	N021460	001	Oct 21, 2002	Jan	CRLD
+ @		2.5MG; 500MG	N021460	002	Oct 21, 2002	Jan	CRLD
+ @		5MG; 500MG	N021460	003	Oct 21, 2002	Jan	CRLD

GLUTETHIMIDE

## TABLET; ORAL

## GLUTETHIMIDE

@ UPSHER-SMITH LABS	500MG	A083234	002			Jun	CAHN
---------------------	-------	---------	-----	--	--	-----	------

GLYBURIDE

## TABLET; ORAL

## GLYBURIDE

AB1	EPIC PHARMA LLC	1.25MG	A076257	001	Jun 27, 2002	May	CAHN
AB1		2.5MG	A076257	002	Jun 27, 2002	May	CAHN
AB1		5MG	A076257	003	Jun 27, 2002	May	CAHN
AB2	IMPAX LABS INC	1.25MG	A206079	001	Sep 30, 2015	Feb	CAHN
AB2		2.5MG	A206079	002	Sep 30, 2015	Feb	CAHN
AB2		5MG	A206079	003	Sep 30, 2015	Feb	CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

## TABLET; ORAL

## GLUCOVANCE

+ @	BRISTOL MYERS SQUIBB	2.5MG; 500MG	N021178	002	Jul 31, 2000	Aug	DISC
+ @		5MG; 500MG	N021178	003	Jul 31, 2000	Aug	DISC
	GLYBURIDE AND METFORMIN HYDROCHLORIDE						
AB	! AUROBINDO PHARMA	2.5MG; 500MG	A077870	002	Nov 14, 2007	Aug	CHRS

## TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@ IMPAX LABS INC 1.25MG;250MG

A076731 001 Nov 19, 2004 Feb CAHN

@ 2.5MG;500MG

A076731 002 Nov 19, 2004 Feb CAHN

@ 5MG;500MG

A076731 003 Nov 19, 2004 Feb CAHN

GLYCINE

SOLUTION;IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

AT ICU MEDICAL INC 1.5GM/100ML

N018315 001

Feb CAHN

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

AP AMNEAL PHARMS CO 0.2MG/ML

A208973 001 Jun 15, 2017 Jun NEWA

AA FRESENIUS KABI USA 0.2MG/ML

A209328 001 Oct 27, 2017 Oct NEWA

AP SOMERSET THERAPS LLC 0.2MG/ML

A207639 001 Jun 23, 2017 Jun NEWA

POWDER;INHALATION

SEEBRI

+! SUNOVION PHARMS INC 15.6MCG/INH

N207923 001 Oct 29, 2015 Jan CAHN

TABLET;ORAL

GLYCOPYRROLATE

@ EPIC PHARMA LLC 1MG

A040568 001 Dec 22, 2004 May CAHN

@ 2MG

A040568 002 Dec 22, 2004 May CAHN

&gt;D&gt; AA NEXGEN PHARMA 1.5MG

A091522 001 Mar 12, 2012 Nov CTEC

&gt;A&gt; 1.5MG

A091522 001 Mar 12, 2012 Nov CTEC

AA SANTOS BIOTECH 1MG

A091182 001 Feb 03, 2014 May CAHN

AA 2MG

A091182 002 Feb 03, 2014 May CAHN

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER;INHALATION

UTIBRON

+! SUNOVION PHARMS INC 15.6MCG/INH;27.5MCG/INH

N207930 001 Oct 29, 2015 Jan CAHN

GONADORELIN HYDROCHLORIDE

INJECTABLE;INJECTION

FACTREL

@ WEST-WARD PHARMS INT EQ 0.1MG BASE/VIAL

N018123 001 Sep 30, 1982 Mar CAHN

@ EQ 0.2MG BASE/VIAL

N018123 002 Sep 30, 1982 Mar CAHN

@ EQ 0.5MG BASE/VIAL

N018123 003 Sep 30, 1982 Mar CAHN

GONADOTROPIN, CHORIONIC

INJECTABLE;INJECTION

CHORIONIC GONADOTROPIN

+! FERRING 5,000 UNITS/VIAL

N017016 006

Jan CMFD

GOSERELIN ACETATE

IMPLANT;IMPLANTATION

ZOLADEX

+! TERSERA THERAPS LLC EQ 3.6MG BASE

N019726 001 Dec 29, 1989 May CAHN

+! EQ 10.8MG BASE

N020578 001 Jan 11, 1996 May CAHN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT AMRING PHARMS 0.025MG/ML;EQ 1.75MG  
BASE/ML;10,000 UNITS/ML

A065187 001 Oct 28, 2005 Mar CAHN

NEOSPORIN

AT ! MONARCH PHARMS 0.025MG/ML;EQ 1.75MG  
BASE/ML;10,000 UNITS/ML

A060582 001

Apr CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

@ BAXTER HLTHCARE CORP EQ 0.1MG BASE/ML (EQ 0.1MG  
BASE/ML)

A078197 001 Dec 31, 2007 Aug CAHN

@ EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A078198 001 Jun 30, 2008 Aug CAHN

@ EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

A078198 002 Jun 30, 2008 Aug CAHN

AP MYLAN LABS LTD EQ 0.1MG BASE/ML (EQ 0.1MG  
BASE/ML)

A203454 001 Apr 04, 2017 Mar NEWA

AP EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A203454 002 Apr 04, 2017 Mar NEWA

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

A203453 001 Jan 31, 2017 Jan NEWA

AP SANDOZ INC EQ 0.1MG BASE/ML (EQ 0.1MG

A078534 001 Apr 30, 2009 Mar CAHN

## INJECTABLE; INJECTION

## GRANISETRON HYDROCHLORIDE

		BASE/ML)					
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078531	001	Apr 30, 2009	Mar	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078531	002	Apr 30, 2009	Mar	CAHN
AP	WEST-WARD PHARMS INT	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jan	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jan	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jan	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jan	CAHN

## TABLET; ORAL

## GRANISETRON HYDROCHLORIDE

	@ EPIC PHARMA LLC	EQ 1MG BASE	A078260	001	Dec 31, 2007	May	CAHN
AB	TARO PHARM	EQ 1MG BASE	A090817	001	May 28, 2010	Mar	CAHN

GRISEOFULVIN, MICROCRYSTALLINE

## TABLET; ORAL

## FULVICIN-U/F

	@ CHARTWELL RX	250MG	A060569	002		Sep	CAHN
	@	500MG	A060569	001		Sep	CAHN

GRISEOFULVIN, MICROSIZE

## SUSPENSION; ORAL

## GRISEOFULVIN

AB	CHARTWELL RX	125MG/5ML	A065200	001	Mar 02, 2005	Jun	CAHN
----	--------------	-----------	---------	-----	--------------	-----	------

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

## TABLET; ORAL

## FULVICIN P/G

	@ CHARTWELL RX	125MG	A061996	001		Sep	CAHN
	@	250MG	A061996	002		Sep	CAHN

## FULVICIN P/G 165

	@ CHARTWELL RX	165MG	A061996	003	Apr 06, 1982	Sep	CAHN
--	----------------	-------	---------	-----	--------------	-----	------

## FULVICIN P/G 330

	@ CHARTWELL RX	330MG	A061996	004	Apr 06, 1982	Sep	CAHN
--	----------------	-------	---------	-----	--------------	-----	------

GRISEOFULVIN, ULTRAMICROSIZE

## TABLET; ORAL

## GRISEOFULVIN, ULTRAMICROSIZE

AB	IMPAX LABS INC	125MG	A204371	001	Jan 09, 2014	Sep	CAHN
AB		250MG	A204371	002	Jan 09, 2014	Sep	CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

## SOLUTION; ORAL

## OBREDON

	+ @ SOVEREIGN PHARMS	200MG/5ML; 2.5MG/5ML	N205474	001	Nov 14, 2014	Aug	DISC
--	----------------------	----------------------	---------	-----	--------------	-----	------

GUANFACINE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## GUANFACINE HYDROCHLORIDE

>A>	AB	SUN PHARM INDS LTD	EQ 1MG BASE	A205689	001	Nov 16, 2017	Nov	NEWA
>A>	AB		EQ 2MG BASE	A205689	002	Nov 16, 2017	Nov	NEWA
>A>	AB		EQ 3MG BASE	A205689	003	Nov 16, 2017	Nov	NEWA
>A>	AB		EQ 4MG BASE	A205689	004	Nov 16, 2017	Nov	NEWA

HALCINONIDE

## CREAM; TOPICAL

## HALOG-E

	@ SUN PHARM INDS INC	0.1%	N018234	001		Aug	CAHN
--	----------------------	------	---------	-----	--	-----	------

## OINTMENT; TOPICAL

## HALOG

	+! SUN PHARM INDS INC	0.1%	N017824	001		Aug	CAHN
--	-----------------------	------	---------	-----	--	-----	------

## SOLUTION; TOPICAL

## HALOG

	@ SUN PHARM INDS INC	0.1%	N017823	001		Aug	CAHN
--	----------------------	------	---------	-----	--	-----	------

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	!	G AND W LABS	0.05%	A078162	001	Apr 24, 2007	Apr CHRS
		ULTRAVATE					

AB	+	SUN PHARM INDS LTD	0.05%	N019967	001	Dec 27, 1990	Apr CHRS
AB	+	!	0.05%	N019967	001	Dec 27, 1990	Mar CAHN

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB	!	G AND W LABS	0.05%	A077721	001	Sep 07, 2006	Jun CHRS
>D>		@ G AND W LABS INC	0.05%	A077109	001	Jun 14, 2005	Nov CMFD
>A>	AB		0.05%	A077109	001	Jun 14, 2005	Nov CMFD
AB		PERRIGO ISRAEL	0.05%	A076872	001	Dec 16, 2004	Apr CAHN
		ULTRAVATE					
AB	+	RANBAXY	0.05%	N019968	001	Dec 17, 1990	Jun CHRS

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@	ANDA REPOSITORY	0.5MG	A071156	001	Jan 02, 1987	Sep CAHN
@		1MG	A071157	001	Jan 02, 1987	Sep CAHN
@		2MG	A071172	001	Jan 02, 1987	Sep CAHN
@		5MG	A071212	001	Jan 07, 1988	Sep CAHN
@		10MG	A071173	001	Jan 07, 1988	Sep CAHN
@		20MG	A071177	001	Jan 07, 1988	Sep CAHN
@	FRONTIDA BIOPHARM	20MG	A071177	001	Jan 07, 1988	Feb CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO		GLAND PHARMA LTD	EQ 50MG BASE/ML	A205241	001	May 12, 2017	May NEWA
AO			EQ 100MG BASE/ML	A205241	002	May 12, 2017	May NEWA
	@	SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005	Mar CAHN
	@		EQ 100MG BASE/ML	A076463	002	Jun 24, 2005	Mar CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

AA		PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May CAHN
----	--	-------------	----------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

HALOPERIDOL

AP		AKORN	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017	Aug NEWA
	@	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Aug CAHN
	@		EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Aug CAHN
	@	SANDOZ INC	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Mar CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP		GLAND PHARMA LTD	5,000 UNITS/ML	A205323	001	Feb 06, 2017	Jan NEWA
>A>	AP	MYLAN LABS LTD	1,000 UNITS/ML	A203851	001	Nov 30, 2017	Nov NEWA
>A>	AP		5,000 UNITS/ML	A203851	002	Nov 30, 2017	Nov NEWA
>A>	AP		10,000 UNITS/ML	A203851	003	Nov 30, 2017	Nov NEWA
>A>	AP		20,000 UNITS/ML	A203852	001	Nov 30, 2017	Nov NEWA
	@	WEST-WARD PHARMS INT	1,000 UNITS/ML	N017007	001		Jul CAHN
	@		2,500 UNITS/ML	N017007	007		Jul CAHN
	@		5,000 UNITS/ML	N017007	002		Jul CAHN
	@		5,000 UNITS/0.5ML	N017007	010		Jul CAHN
	@		7,500 UNITS/ML	N017007	003		Jul CAHN
	@		10,000 UNITS/ML	N017007	004		Jul CAHN
	@		15,000 UNITS/ML	N017007	005		Jul CAHN
	@		20,000 UNITS/ML	N017007	006		Jul CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA		ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Feb NEWA
AA		BIO-PHARM INC	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Feb NEWA
AA		NOVEL LABS INC	1.5MG/5ML; 5MG/5ML	A203535	001	Feb 13, 2017	Jan NEWA
AA		PADDOCK LLC	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017	Jan NEWA

## TABLET;ORAL

## HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA	AVANTHI INC	1.5MG;5MG	A207176	001	Aug 07, 2017	Jul NEWA
	TUSSIGON					
AA	! KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985	Feb CAHN

HYDRALAZINE HYDROCHLORIDE

## TABLET;ORAL

## HYDRALAZINE HYDROCHLORIDE

	@ ANDA REPOSITORY	10MG	A089359	001	Jul 25, 1986	Sep CAHN
	@	25MG	A089258	001	May 05, 1986	Sep CAHN
	@	50MG	A089259	001	May 05, 1986	Sep CAHN
	@	100MG	A088729	001	Apr 11, 1985	Sep CAHN
>D> AA	MYLAN	10MG	A090413	001	Dec 08, 2010	Nov DISC
>A>	@	10MG	A090413	001	Dec 08, 2010	Nov DISC
>D> AA		25MG	A090413	002	Dec 08, 2010	Nov DISC
>A>	@	25MG	A090413	002	Dec 08, 2010	Nov DISC
>D> AA		50MG	A090413	003	Dec 08, 2010	Nov DISC
>A>	@	50MG	A090413	003	Dec 08, 2010	Nov DISC
>D> AA		100MG	A090413	004	Dec 08, 2010	Nov DISC
>A>	@	100MG	A090413	004	Dec 08, 2010	Nov DISC
AA	SCIEGEN PHARMS INC	10MG	A205236	001	May 26, 2017	May NEWA
AA		25MG	A205236	002	May 26, 2017	May NEWA
AA		50MG	A205236	003	May 26, 2017	May NEWA
AA		100MG	A205236	004	May 26, 2017	May NEWA
AA	TECH ORGANIZED	10MG	A205236	001	May 26, 2017	Sep CAHN
AA		25MG	A205236	002	May 26, 2017	Sep CAHN
AA		50MG	A205236	003	May 26, 2017	Sep CAHN
AA		100MG	A205236	004	May 26, 2017	Sep CAHN
	@ UPSHER-SMITH LABS	10MG	A083241	001		Jun CAHN
	@	25MG	A083560	001		Jun CAHN
	@	50MG	A083561	001		Jun CAHN
	@	50MG	A085088	001		Sep CAHN

HYDROCHLOROTHIAZIDE

## CAPSULE;ORAL

## HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG	A075907	001	Sep 17, 2002	Feb CAHN
----	--------------	--------	---------	-----	--------------	----------

## TABLET;ORAL

## HYDROCHLOROTHIAZIDE

	@ JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007	Sep DISC
	@	50MG	A040809	002	Sep 04, 2007	Sep DISC
>D> AB	MYLAN PHARMS INC	12.5MG	A040770	001	Jan 23, 2007	Nov DISC
>A>	@	12.5MG	A040770	001	Jan 23, 2007	Nov DISC
AB	PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Feb CAHN
AB		50MG	A040412	002	Mar 29, 2002	Feb CAHN
AB	TECH ORGANIZED	25MG	A203018	001	Jul 23, 2014	Sep CAHN
AB		50MG	A203018	002	Jul 23, 2014	Sep CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

## TABLET;ORAL

## IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ATLAS PHARMS LLC	12.5MG;150MG	A203036	001	Jan 15, 2016	Mar CAHN
AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Mar CAHN
AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar CAHN
AB	UNICHEM LABS LTD	12.5MG;150MG	A207018	001	Sep 19, 2017	Sep NEWA
AB		12.5MG;300MG	A207018	002	Sep 19, 2017	Sep NEWA
AB	WEST-WARD PHARMS INT	25MG;300MG	A090351	003	Jun 08, 2017	May NEWA

HYDROCHLOROTHIAZIDE; LISINAPRIL

## TABLET;ORAL

## LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;10MG	A204058	001	May 23, 2017	May NEWA
AB		12.5MG;20MG	A204058	002	May 23, 2017	May NEWA
AB		25MG;20MG	A204058	003	May 23, 2017	May NEWA

## PRINZIDE

+	@ MERCK	12.5MG;10MG	N019778	003	Nov 18, 1993	Jan CRLD
+	@	12.5MG;20MG	N019778	001	Feb 16, 1989	Jan CRLD

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

## TABLET; ORAL

## LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG; 50MG	A204901	001	Nov 06, 2017	Oct NEWA
AB		12.5MG; 100MG	A204901	002	Nov 06, 2017	Oct NEWA
AB		25MG; 100MG	A204901	003	Nov 06, 2017	Oct NEWA
AB	UNICHEM LABS LTD	12.5MG; 50MG	A204832	001	Jul 21, 2017	Jul NEWA
AB		12.5MG; 100MG	A204832	002	Jul 21, 2017	Jul NEWA
AB		25MG; 100MG	A204832	003	Jul 21, 2017	Jul NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

## TABLET; ORAL

## MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ CHARTWELL RX	12.5MG; 7.5MG	A090096	001	Sep 25, 2008	Mar CAHN
	@	12.5MG; 15MG	A090096	002	Sep 25, 2008	Mar CAHN
	@	25MG; 15MG	A090096	003	Sep 25, 2008	Mar CAHN
AB	HERITAGE PHARMS INC	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Jan CMS1
AB		12.5MG; 15MG	A202150	002	Mar 07, 2014	Jan CMS1
AB		25MG; 15MG	A202150	003	Mar 07, 2014	Jan CMS1

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

## TABLET; ORAL

## OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG; 20MG	A204233	001	Apr 24, 2017	Apr NEWA
AB		12.5MG; 40MG	A204233	002	Apr 24, 2017	Apr NEWA
AB		25MG; 40MG	A204233	003	Apr 24, 2017	Apr NEWA
AB	AUROBINDO PHARMA LTD	12.5MG; 20MG	A205391	001	Apr 24, 2017	Apr NEWA
AB		12.5MG; 40MG	A205391	002	Apr 24, 2017	Apr NEWA
AB		25MG; 40MG	A205391	003	Apr 24, 2017	Apr NEWA
AB	PRINSTON INC	12.5MG; 20MG	A207804	001	Apr 24, 2017	Apr NEWA
AB		12.5MG; 40MG	A207804	002	Apr 24, 2017	Apr NEWA
AB		25MG; 40MG	A207804	003	Apr 24, 2017	Apr NEWA
AB	TEVA PHARMS USA	12.5MG; 20MG	A200532	001	Apr 24, 2017	Apr NEWA
AB		12.5MG; 40MG	A200532	002	Apr 24, 2017	Apr NEWA
AB		25MG; 40MG	A200532	003	Apr 24, 2017	Apr NEWA
AB	TORRENT PHARMS LTD	12.5MG; 20MG	A206515	001	May 03, 2017	Apr NEWA
AB		12.5MG; 40MG	A206515	002	May 03, 2017	Apr NEWA
AB		25MG; 40MG	A206515	003	May 03, 2017	Apr NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

## TABLET; ORAL

## QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG; EQ 10MG BASE	A201356	001	Apr 20, 2011	Jun CMS1
AB		12.5MG; EQ 20MG BASE	A201356	002	Apr 20, 2011	Jun CMS1
AB		25MG; EQ 20MG BASE	A201356	003	Apr 20, 2011	Jun CMS1

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

## TABLET; ORAL

## SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

	@ UPSHER SMITH	25MG; 25MG	A087553	001		Jun CAHN
--	----------------	------------	---------	-----	--	----------

HYDROCHLOROTHIAZIDE; TELMISARTAN

## TABLET; ORAL

## TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG; 40MG	A209028	001	Nov 06, 2017	Oct NEWA
AB		12.5MG; 80MG	A209028	002	Nov 06, 2017	Oct NEWA
AB		25MG; 80MG	A209028	003	Nov 06, 2017	Oct NEWA
AB	ZYDUS PHARMS USA INC	12.5MG; 40MG	A204221	001	Aug 15, 2017	Jul NEWA
AB		12.5MG; 80MG	A204221	002	Aug 15, 2017	Jul NEWA
AB		25MG; 80MG	A204221	003	Aug 15, 2017	Jul NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

## TABLET; ORAL

## VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG; 80MG	A201662	001	Mar 21, 2013	May CAHN
AB		12.5MG; 160MG	A201662	002	Mar 21, 2013	May CAHN
AB		12.5MG; 320MG	A201662	003	Mar 21, 2013	May CAHN
AB		25MG; 160MG	A201662	004	Mar 21, 2013	May CAHN
AB		25MG; 320MG	A201662	005	Mar 21, 2013	May CAHN
AB	WATSON LABS TEVA	12.5MG; 80MG	A091519	001	Mar 21, 2013	May CAHN
AB		12.5MG; 160MG	A091519	002	Mar 21, 2013	May CAHN
AB		12.5MG; 320MG	A091519	003	Mar 21, 2013	May CAHN

## TABLET;ORAL

## VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		25MG;160MG	A091519	004	Mar 21, 2013	May CAHN
AB		25MG;320MG	A091519	005	Mar 21, 2013	May CAHN

HYDROCODONE BITARTRATE

## TABLET, EXTENDED RELEASE;ORAL

## VANTRELA ER

+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan NEWA
+		30MG	N207975	002	Jan 17, 2017	Jan NEWA
+		45MG	N207975	003	Jan 17, 2017	Jan NEWA
+		60MG	N207975	004	Jan 17, 2017	Jan NEWA
+		90MG	N207975	005	Jan 17, 2017	Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

## TABLET;ORAL

## HYDROCODONE BITARTRATE AND IBUPROFEN

AB	!	AMNEAL PHARMS NY	7.5MG;200MG	A076642	001	Oct 12, 2004	Sep CHRS
		VICOPROFEN					
	+	@ ABBVIE	7.5MG;200MG	N020716	001	Sep 23, 1997	Sep DISC

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

## SOLUTION;ORAL

## HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	TRIS PHARMA INC	5MG/5ML;60MG/5ML	A203839	001	Oct 28, 2014	Sep DISC
---	-----------------	------------------	---------	-----	--------------	----------

HYDROCORTISONE

## CREAM;TOPICAL

## HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	1%	A080693	003		Jan CAHN
AT	!		2.5%	A089414	001	Dec 16, 1986	Jan CAHN
		SYNACORT					
		@ MEDICIS	1%	A087458	001		Jul DISC
		@	2.5%	A087457	001		Jul DISC

## LOTION;TOPICAL

## STIE-CORT

		@ PERRIGO CO	1%	A089066	001	Nov 25, 1985	Apr CAHN
AT			2.5%	A089074	001	Nov 26, 1985	Apr CAHN

## OINTMENT;TOPICAL

## HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	2.5%	A081203	001	May 28, 1993	Jan CAHN
		HYDROCORTISONE IN ABSORBASE					
AT		CMP PHARMA INC	1%	A088138	001	Sep 06, 1985	Apr CAHN

## TABLET;ORAL

## HYDROCORTISONE

AB		PII	5MG	A207029	001	Apr 27, 2017	Apr NEWA
AB			10MG	A207029	002	Apr 27, 2017	Apr NEWA
AB			20MG	A207029	003	Apr 27, 2017	Apr NEWA

HYDROCORTISONE ACETATE

## AEROSOL, METERED;RECTAL

## CORTIFOAM

+	!	MYLAN SPECIALITY LP	10%	N017351	001	Feb 10, 1982	Mar CAHN
---	---	---------------------	-----	---------	-----	--------------	----------

## CREAM;TOPICAL

## HYDROCORTISONE ACETATE

@	FERNDAL LABS	2.5%	A040259	001	Jul 29, 1999	Sep DISC
---	--------------	------	---------	-----	--------------	----------

&gt;D&gt; MICORT-HC

>D>	!	SEBELA IRELAND LTD	2%	A040398	001	Mar 29, 2002	Nov DISC
-----	---	--------------------	----	---------	-----	--------------	----------

>A>	@		2%	A040398	001	Mar 29, 2002	Nov DISC
-----	---	--	----	---------	-----	--------------	----------

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

## CREAM;TOPICAL

## CORTISPORIN

+	!	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985	Feb CAHN
---	---	----------------	---------------------------------------	---------	-----	--------------	----------





HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID

AP	+	FRESENIUS KABI USA	1MG/ML	N019034	003	Apr 30, 2009	Jan CAHN
AP	+		2MG/ML	N019034	004	Apr 30, 2009	Jan CAHN
AP	+		4MG/ML	N019034	005	Apr 30, 2009	Jan CAHN

DILAUDID-HP

AP	+	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Jan CAHN
	@		250MG/VIAL	N019034	002	Aug 04, 1994	Jan CAHN

HYDROMORPHONE HYDROCHLORIDE

@ HOSPIRA 10MG/ML

A074598 001 Jun 19, 1997 Sep DISC

SOLUTION;ORAL

DILAUDID

AA	+	RHODES PHARMS	5MG/5ML	N019891	001	Dec 07, 1992	Jun CAHN
----	---	---------------	---------	---------	-----	--------------	----------

HYDROMORPHONE HYDROCHLORIDE

AA		ASCENT PHARMS INC	5MG/5ML	A210176	001	Oct 27, 2017	Oct NEWA
----	--	-------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

DILAUDID

AB	+	RHODES PHARMS	2MG	N019892	003	Nov 09, 2007	Jun CAHN
----	---	---------------	-----	---------	-----	--------------	----------

AB	+		4MG	N019892	002	Nov 09, 2007	Jun CAHN
----	---	--	-----	---------	-----	--------------	----------

AB	+		8MG	N019892	001	Dec 07, 1992	Jun CAHN
----	---	--	-----	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB		PADDOCK LLC	32MG	A204278	004	Sep 20, 2017	Sep NEWA
----	--	-------------	------	---------	-----	--------------	----------

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

HYDROXOCOBALAMIN

!	ACTAVIS LLC	1MG/ML	A085998	001			Feb CAHN
---	-------------	--------	---------	-----	--	--	----------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION

VISTARIL

+	@	PFIZER	25MG/ML	N011111	001		Jan CRLD
---	---	--------	---------	---------	-----	--	----------

+	@		50MG/ML	N011111	002		Jan CRLD
---	---	--	---------	---------	-----	--	----------

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 10MG

A087871 002 Dec 20, 1982 Jan CMS1

@ 25MG

A087871 003 Dec 20, 1982 Jan CMS1

>D>	AB	BAYSHORE PHARMS LLC	10MG	A207120	001	Mar 29, 2017	Nov CAHN
-----	----	---------------------	------	---------	-----	--------------	----------

AB			10MG	A207120	001	Mar 29, 2017	Sep CAHN
----	--	--	------	---------	-----	--------------	----------

>D>	AB		50MG	A207122	001	Mar 29, 2017	Nov CAHN
-----	----	--	------	---------	-----	--------------	----------

AB			50MG	A207122	001	Mar 29, 2017	Sep CAHN
----	--	--	------	---------	-----	--------------	----------

>A>	AB	NUVO PHARM	10MG	A207120	001	Mar 29, 2017	Nov CAHN
-----	----	------------	------	---------	-----	--------------	----------

>A>	AB		50MG	A207122	001	Mar 29, 2017	Nov CAHN
-----	----	--	------	---------	-----	--------------	----------

AB		NUVO PHARM INC	10MG	A207120	001	Mar 29, 2017	Mar NEWA
----	--	----------------	------	---------	-----	--------------	----------

AB			25MG	A207121	001	Mar 29, 2017	Mar NEWA
----	--	--	------	---------	-----	--------------	----------

AB			50MG	A207122	001	Mar 29, 2017	Mar NEWA
----	--	--	------	---------	-----	--------------	----------

AB		PRINSTON INC	10MG	A040579	001	May 27, 2005	Feb CAHN
----	--	--------------	------	---------	-----	--------------	----------

AB			25MG	A040574	001	May 27, 2005	Feb CAHN
----	--	--	------	---------	-----	--------------	----------

AB			50MG	A040580	001	May 27, 2005	Feb CAHN
----	--	--	------	---------	-----	--------------	----------

IBANDRONATE SODIUM

TABLET;ORAL

IBANDRONATE SODIUM

AB		MACLEODS PHARMS LTD	EQ 150MG BASE	A206887	001	Oct 31, 2017	Oct NEWA
----	--	---------------------	---------------	---------	-----	--------------	----------

@ MYLAN PHARMS INC EQ 150MG BASE

A078995 001 Mar 19, 2012 May DISC

AB		WATSON LABS TEVA	EQ 150MG BASE	A079003	001	Mar 20, 2012	May CAHN
----	--	------------------	---------------	---------	-----	--------------	----------

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

AB	!	ACTAVIS MID ATLANTIC	100MG/5ML	A074978	001	Mar 25, 1998	May CAHN
----	---	----------------------	-----------	---------	-----	--------------	----------

AB		TARO	100MG/5ML	A209204	001	Jun 23, 2017	Jun NEWA
----	--	------	-----------	---------	-----	--------------	----------

MOTRIN

+	@	MCNEIL CONSUMER	100MG/5ML	N019842	001	Sep 19, 1989	Jan CRLD
---	---	-----------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

@ MYLAN PHARMS INC 400MG

A070045 001 Sep 24, 1985 Mar CAHN

@ PLIVA 400MG

A071666 001 Jun 18, 1987 Aug CAHN

@ 600MG

A071667 001 Jun 18, 1987 Aug CAHN

TABLET;ORAL  
IBUPROFEN

@ 800MG A071668 001 Jun 18, 1987 Aug CAHN

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

BX @ WATSON LABS 400MG;5MG A078394 001 Nov 26, 2007 Jun DISC  
400MG;5MG A078394 001 Nov 26, 2007 Apr CTEC

ICOSAPENT ETHYL

CAPSULE;ORAL

VASCEPA

+ AMARIN PHARMS 500MG N202057 002 Feb 16, 2017 Mar NEWA

IDOXURIDINE

SOLUTION/DROPS;OPHTHALMIC

DENDRID

+ @ ALCON 0.1% N014169 001 Jul DISC

IFOSFAMIDE

INJECTABLE;INJECTION

IFOSFAMIDE

>D> AP WEST-WARD PHARMS INT 1GM/20ML (50MG/ML) A076619 001 Jun 29, 2011 Nov CMS1  
>A> AP 1GM/20ML (50MG/ML) A076619 001 Jun 29, 2011 Nov CMS1  
>D> AP 3GM/60ML (50MG/ML) A076619 002 Jun 29, 2011 Nov CMS1  
>A> AP 3GM/60ML (50MG/ML) A076619 002 Jun 29, 2011 Nov CMS1

IFOSFAMIDE; MESNA

INJECTABLE;INTRAVENOUS

IFOSFAMIDE/MESNA KIT

@ TEVA PHARMS USA 1GM/20ML;1GM/10ML (50MG/ML;100MG/ML) A075874 001 Feb 26, 2002 Mar DISC

@ 3GM/60ML;1GM/10ML (50MG/ML;100MG/ML) A075874 002 Feb 26, 2002 Mar DISC

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB MYLAN PHARMS INC EQ 100MG BASE A204644 001 Jun 21, 2017 Jun NEWA  
AB EQ 400MG BASE A204644 002 Jun 21, 2017 Jun NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB MALLINCKRODT INC 10MG A087846 002 May 22, 1984 Aug CMS1  
AB 25MG A087846 003 May 22, 1984 Aug CMS1  
OXFORD PHARMS 10MG A040751 003 Feb 28, 2008 May CMS1  
25MG A040751 002 Feb 28, 2008 May CMS1  
@ PAR PHARM 10MG A089422 001 Jul 14, 1987 Jul DISC

IMIPRAMINE PAMOATE

CAPSULE;ORAL

IMIPRAMINE PAMOATE

@ MYLAN PHARMS INC EQ 75MG HCL A202338 001 Jun 28, 2013 Jun DISC  
@ EQ 100MG HCL A202338 002 Jun 28, 2013 Jun DISC  
@ EQ 125MG HCL A202338 003 Jun 28, 2013 Jun DISC  
@ EQ 150MG HCL A202338 004 Jun 28, 2013 Jun DISC

INDACATEROL MALEATE

POWDER;INHALATION

ARCAPTA NEOHALER

+! SUNOVION PHARMS INC EQ 75MCG BASE N022383 001 Jul 01, 2011 Jan CAHN

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

>D> AB MYLAN PHARMS INC 1.25MG A075105 001 Jul 23, 1998 Nov DISC  
>A> @ 1.25MG A075105 001 Jul 23, 1998 Nov DISC  
>D> AB 2.5MG A075105 002 Jul 23, 1998 Nov DISC  
>A> @ 2.5MG A075105 002 Jul 23, 1998 Nov DISC

INDOMETHACIN

CAPSULE;ORAL							
INDOMETHACIN							
	@ CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984	Feb	CAHN
	@	50MG	A070651	001	Mar 05, 1986	Apr	CAHN
	@	50MG	N018829	001	Aug 06, 1984	Feb	CAHN
AB	JUBILANT GENERICS	25MG	A205215	001	Aug 25, 2017	Aug	NEWA
AB		50MG	A205215	002	Aug 25, 2017	Aug	NEWA
CAPSULE, EXTENDED RELEASE;ORAL							
INDOMETHACIN							
AB	CHARTWELL RX	75MG	A200529	001	Nov 30, 2010	Jun	CAHN
AB	GLENMARK PHARMS LTD	75MG	A203501	001	Jun 22, 2017	Jun	NEWA
AB	NOVAST LABS LTD	75MG	A204853	001	May 08, 2017	Apr	NEWA
	@ WATSON LABS INC	75MG	A202572	001	Dec 09, 2013	Feb	DISC
AB	ZYDUS PHARMS USA INC	75MG	A202711	001	Sep 25, 2017	Sep	NEWA

INDOMETHACIN SODIUM

INJECTABLE;INJECTION							
INDOMETHACIN SODIUM							
AP	NAVINTA LLC	EQ 1MG BASE/VIAL	A206561	001	Jul 19, 2017	Jul	NEWA

INSULIN ASPART RECOMBINANT

SOLUTION;IV (INFUSION), SUBCUTANEOUS							
FIASP							
+	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N208751	001	Sep 29, 2017	Sep	NEWA
SOLUTION;SUBCUTANEOUS							
FIASP FLEXTOUCH							
+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N208751	002	Sep 29, 2017	Sep	NEWA

IODIPAMIDE MEGLUMINE

INJECTABLE;INJECTION							
CHOLOGRAFIN MEGLUMINE							
+	@ BRACCO	52%	N009321	003		Aug	DISC

IODIXANOL

INJECTABLE;INJECTION							
VISIPAQUE 270							
	@ GE HEALTHCARE	55%	N020808	001	Aug 29, 1997	Aug	DISC

IOPAMIDOL

INJECTABLE;INJECTION							
SCANLUX-300							
AP	MYLAN IRELAND LTD	61%	A090394	001	Jun 18, 2010	Jan	CAHN
AP	SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010	Feb	CAHN
SCANLUX-370							
AP	MYLAN IRELAND LTD	76%	A090394	002	Jun 18, 2010	Jan	CAHN
AP	SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010	Feb	CAHN

IOPROMIDE

INJECTABLE;INJECTION							
ULTRAVIST 150							
+	@ BAYER HLTHCARE	31.2%	N020220	004	May 10, 1995	Aug	DISC
ULTRAVIST 300 IN PLASTIC CONTAINER							
+	@ BAYER HLTHCARE	62.3%	N020220	005	Nov 18, 2008	Aug	DISC

IPRATROPIUM BROMIDE

SOLUTION;INHALATION							
IPRATROPIUM BROMIDE							
	@ BAUSCH AND LOMB INC	0.02%	A075835	001	Oct 15, 2001	Jul	DISC

IRBESARTAN

TABLET;ORAL							
IRBESARTAN							
	@ AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015	Oct	DISC
	@	150MG	A203685	002	Dec 10, 2015	Oct	DISC
	@	300MG	A203685	003	Dec 10, 2015	Oct	DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	INGENUS PHARMS LLC	40MG/2ML (20MG/ML)	A206935	001	May 26, 2017	May NEWA
AP		100MG/5ML (20MG/ML)	A206935	002	May 26, 2017	May NEWA
AP	INTAS PHARMS USA	40MG/2ML (20MG/ML)	A203054	001	Aug 31, 2017	Aug NEWA
AP		100MG/5ML (20MG/ML)	A203054	002	Aug 31, 2017	Aug NEWA
	@ SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jul DISC
	@	100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jul DISC
AP	WEST-WARD PHARMS INT	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jan CAHN
AP		100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jan CAHN

INJECTABLE, LIPOSOMAL; IV (INFUSION)

ONIVYDE

+	IPSEN INC	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015	Apr CAHN
---	-----------	--------------------------------------	---------	-----	--------------	----------

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

!	SANDOZ INC	100MG/ML	A040648	001	Jul 05, 2005	Mar CAHN
---	------------	----------	---------	-----	--------------	----------

SYRUP; ORAL

ISONIAZID

!	CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Apr CAHN
---	----------------	----------	---------	-----	--------------	----------

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

AP	NEXUS PHARMS	0.2MG/ML	A206961	001	Aug 02, 2017	Jul NEWA
----	--------------	----------	---------	-----	--------------	----------

ISUPREL

AP	+	HOSPIRA	0.2MG/ML	N010515	001	Jul CTEC
----	---	---------	----------	---------	-----	----------

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@	WATSON LABS TEVA	5MG	A086031	001	Sep 29, 1987	May CAHN
---	------------------	-----	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

@	IMPAX LABS INC	40MG	A040723	001	Mar 17, 2008	Feb CAHN
---	----------------	------	---------	-----	--------------	----------

ISOSORBIDE MONONITRATE

TABLET; ORAL

MONOKET

>D>	AB	+	KREMERS URBAN PHARMS	10MG	N020215	002	Jun 30, 1993	Nov CAHN
>D>	AB	+	!	20MG	N020215	001	Jun 30, 1993	Nov CAHN
>A>	AB	+	LANNETT CO INC	10MG	N020215	002	Jun 30, 1993	Nov CAHN
>A>	AB	+	!	20MG	N020215	001	Jun 30, 1993	Nov CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB	ACCORD HLTHCARE	30MG	A209684	001	Oct 24, 2017	Oct NEWA
AB		60MG	A209684	002	Oct 24, 2017	Oct NEWA
AB		120MG	A209684	003	Oct 24, 2017	Oct NEWA

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

BX	+	SUN PHARM INDS INC	10MG	N021951	001	May 25, 2012	Aug CAHN
BX	+		20MG	N021951	002	May 25, 2012	Aug CAHN
	+		25MG	N021951	005	Aug 15, 2014	Aug CAHN
BX	+		30MG	N021951	003	May 25, 2012	Aug CAHN
	+		35MG	N021951	006	Aug 15, 2014	Aug CAHN
BX	+	!	40MG	N021951	004	May 25, 2012	Aug CAHN

ISOTRETINOIN

AB	AMNEAL PHARMS NY	10MG	A207792	001	Sep 29, 2017	Sep NEWA
AB		20MG	A207792	002	Sep 29, 2017	Sep NEWA
AB		30MG	A207792	003	Sep 29, 2017	Sep NEWA
AB		40MG	A207792	004	Sep 29, 2017	Sep NEWA

ISRADIPINECAPSULE;ORAL  
DYNACIRC+ @ SMITHKLINE BEECHAM 2.5MG  
+ @ 5MGN019546 001 Dec 20, 1990 Sep CRLD  
N019546 002 Dec 20, 1990 Sep CRLD

ISRADIPINE

AB WATSON LABS TEVA 2.5MG  
AB ! 5MGA077317 001 Jan 05, 2006 May CAHN  
A077317 002 Jan 05, 2006 May CAHN

TABLET, EXTENDED RELEASE;ORAL

ISRADIPINE

MYLAN PHARMS INC 5MG

A201067 001 Nov 27, 2015 Nov DISC

@ 5MG

A201067 001 Nov 27, 2015 Nov DISC

10MG

A201067 002 Nov 27, 2015 Nov DISC

@ 10MG

A201067 002 Nov 27, 2015 Nov DISC

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

AB ALKEM LABS LTD 100MG

A208591 001 Jun 12, 2017 May NEWA

AB JUBILANT GENERICS 100MG

A203445 001 Feb 23, 2017 Feb NEWA

AB ZYDUS PHARMS USA INC 100MG

A204672 001 Sep 19, 2017 Sep NEWA

KANAMYCIN SULFATE

INJECTABLE;INJECTION

KANAMYCIN

@ WEST-WARD PHARMS INT EQ 75MG BASE/2ML

A062324 001 Jan CAHN

@ EQ 500MG BASE/2ML

A062324 002 Jan CAHN

@ EQ 1GM BASE/3ML

A062324 003 Jan CAHN

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL

EXTINA

AT +! MYLAN PHARMS INC 2%

N021738 001 Jun 12, 2007 Jan CAHN

CREAM;TOPICAL

NIZORAL

+ @ JANSSEN PHARMA 2%

N019084 001 Dec 31, 1985 May CRLD

TABLET;ORAL

NIZORAL

+ @ JANSSEN PHARMS 200MG

N018533 001 Oct CRLD

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN

AB HERITAGE PHARMS INC 25MG

A074014 001 Jan 29, 1993 Feb CAHN

AB 50MG

A074014 002 Jan 29, 1993 Feb CAHN

AB 75MG

A074014 003 Jan 29, 1993 Feb CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

@ BAXTER HLTHCARE CORP 15MG/ML

A075631 002 Jun 29, 2001 Aug CAHN

@ 30MG/ML

A075631 001 Jun 29, 2001 Aug CAHN

AP CYCLE PHARMS LTD 30MG/ML

A209900 001 Sep 15, 2017 Sep NEWA

@ MYLAN LABS LTD 15MG/ML

A078299 001 Jul 16, 2007 Oct DISC

@ 15MG/ML

A201155 001 Aug 04, 2014 Oct DISC

@ 30MG/ML

A078299 002 Jul 16, 2007 Oct DISC

@ 30MG/ML

A201155 002 Aug 04, 2014 Oct DISC

@ SANDOZ INC 15MG/ML

A076271 001 Oct 06, 2004 Mar CAHN

AP 30MG/ML

A076271 002 Oct 06, 2004 Mar CAHN

SOLUTION/DROPS;OPHTHALMIC

ACUVAIL

+! ALLERGAN 0.45%

N022427 001 Jul 22, 2009 Sep CTEC

KETOROLAC TROMETHAMINE

AT SANDOZ INC 0.5%

A076583 001 Nov 05, 2009 Feb CAHN

L-GLUTAMINEFOR SOLUTION; ORAL  
ENDARI

+	EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017	Jul NEWA
	NUTRESTORE					
+	EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	Jul CAIN

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTION  
LABETALOL HYDROCHLORIDE

	@ BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002	Aug CAHN
AP	SAGENT AGILA LLC	5MG/ML	A079134	001	Feb 03, 2010	Feb CAHN

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	INNOGENIX	100MG	A075215	001	Jul 29, 1999	Sep CAHN
AB		200MG	A075215	002	Jul 29, 1999	Sep CAHN
AB		300MG	A075215	003	Jul 29, 1999	Sep CAHN
AB	ZYDUS PHARMS USA INC	100MG	A207743	001	Sep 19, 2017	Sep NEWA
AB		200MG	A207743	002	Sep 19, 2017	Sep NEWA
AB		300MG	A207743	003	Sep 19, 2017	Sep NEWA

LACOSAMIDESOLUTION; ORAL  
VIMPAT

+	UCB INC	10MG/ML	N022255	001	Apr 20, 2010	Oct CTEC
---	---------	---------	---------	-----	--------------	----------

TABLET; ORAL

VIMPAT

+	UCB INC	50MG	N022253	001	Oct 28, 2008	Oct CTEC
+		100MG	N022253	002	Oct 28, 2008	Oct CTEC
+		150MG	N022253	003	Oct 28, 2008	Oct CTEC
+		200MG	N022253	004	Oct 28, 2008	Oct CTEC

LACTULOSESOLUTION; ORAL  
LACTULOSE

AA	PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	May CAHN
----	-------------	-----------	---------	-----	--------------	----------

LAMIVUDINETABLET; ORAL  
LAMIVUDINE

AB	CIPLA LTD	150MG	A077221	001	Mar 03, 2017	Feb NEWA
AB		300MG	A077221	002	Mar 03, 2017	Feb NEWA
AB	ECI PHARMS LLC	150MG	A203586	001	Nov 21, 2016	Aug CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG; 300MG	A077558	001	May 05, 2017	Apr NEWA
BX	PHARMACARE	150MG; 300MG	N022018	001	Mar 17, 2017	Mar NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ MYLAN LABS LTD

@ 25MG

@ 100MG

@ 150MG

@ 200MG

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	GLENMARK PHARMS LTD	5MG	A079099	001	Feb 19, 2009	May CAHN
AB		25MG	A079099	002	Feb 19, 2009	May CAHN
	@ MYLAN	5MG	A076630	001	Jan 22, 2009	Jun DISC
	@	25MG	A076630	002	Jan 22, 2009	Jun DISC

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

AB	ACTAVIS ELIZABETH	250MG	A203733	001	Nov 13, 2013	Apr CAHN
AB	HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013	Jan CAHN
AB		50MG	A202887	002	Jun 17, 2013	Jan CAHN
AB		100MG	A202887	003	Jun 17, 2013	Jan CAHN
AB		200MG	A202887	004	Jun 17, 2013	Jan CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL  
LANSOPRAZOLE

AB	INVENTIA HLTHCARE	15MG	A205868	001	Aug 30, 2017	Aug NEWA
AB		30MG	A205868	002	Aug 30, 2017	Aug NEWA
AB	KREMERS URBAN PHARMS	15MG	A207156	001	Sep 28, 2017	Sep NEWA
AB		30MG	A207156	002	Sep 28, 2017	Sep NEWA

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL  
PREVACID

AB	+ TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002	Sep CTEC
AB	+!	30MG	N021428	002	Aug 30, 2002	Sep CTEC

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL  
LANSOPRAZOLE

AB	TEVA PHARMS USA	15MG	A208784	001	Sep 21, 2017	Sep NEWA
AB		30MG	A208784	002	Sep 21, 2017	Sep NEWA

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL  
FOSRENOL

AB	+ SHIRE LLC	EQ 500MG BASE	N021468	002	Oct 26, 2004	Jul CFTG
AB	+	EQ 750MG BASE	N021468	003	Nov 23, 2005	Jul CFTG
AB	+!	EQ 1GM BASE	N021468	004	Nov 23, 2005	Jul CFTG

LANTHANUM CARBONATE

AB	NATCO PHARMA LTD	EQ 500MG BASE	A090978	001	Aug 11, 2017	Jul NEWA
AB		EQ 750MG BASE	A090978	002	Aug 11, 2017	Jul NEWA
AB		EQ 1GM BASE	A090978	003	Aug 11, 2017	Jul NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC  
LATANOPROST

AT	AMRING PHARMS	0.005%	A200925	001	Mar 22, 2011	Mar CAHN
AT	SANDOZ INC	0.005%	A091449	001	Mar 22, 2011	Feb CAHN

>A> LATANOPROSTENE BUNOD

>A> SOLUTION/DROPS;OPHTHALMIC  
>A> VYZULTA

>A>	+!	BAUSCH AND LOMB	0.024%	N207795	001	Nov 02, 2017	Nov NEWA
-----	----	-----------------	--------	---------	-----	--------------	----------

>A> LETERMOVIR

>A> SOLUTION;IV (INFUSION)  
>A> PREVIMIS

>A>	+!	MERCK SHARP DOHME	240MG/12ML (20MG/ML)	N209940	001	Nov 08, 2017	Nov NEWA
>A>	+!		480MG/24ML (20MG/ML)	N209940	002	Nov 08, 2017	Nov NEWA

>A> TABLET;ORAL  
>A> PREVIMIS

>A>	+	MERCK SHARP DOHME	240MG	N209939	001	Nov 08, 2017	Nov NEWA
>A>	+!		480MG	N209939	002	Nov 08, 2017	Nov NEWA

LETROZOLE

TABLET;ORAL  
LETROZOLE

@ KREMERS URBAN PHARMS 2.5MG  
@ LANNETT HOLDINGS INC 2.5MG  
@ SUN PHARM INDS LTD 2.5MG

A091098	001	Jun 03, 2011	Jun DISC
A202048	001	Oct 29, 2014	Jun DISC
A091466	001	Jun 03, 2011	Oct DISC

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET, TABLET;ORAL  
KISQALI FEMARA CO-PACK (COPACKAGED)

+!	NOVARTIS PHARMS CORP	2.5MG,N/A;N/A,EQ 200MG BASE	N209935	001	May 04, 2017	May NEWA
----	----------------------	-----------------------------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION  
LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	!	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A040286	001	Feb 26, 1999	Oct CTEC
AP		MYLAN LABS LTD	EQ 100MG BASE/VIAL	A203800	001	May 19, 2017	May NEWA
AP			EQ 200MG BASE/VIAL	A203800	002	May 19, 2017	May NEWA
AP			EQ 350MG BASE/VIAL	A203800	003	May 19, 2017	May NEWA
AP		SAGENT PHARMS	EQ 500MG BASE/VIAL	A209110	001	Oct 26, 2017	Oct NEWA

## TABLET;ORAL

## LEUCOVORIN CALCIUM

@ EPIC PHARMA LLC

EQ 5MG BASE

A074544 001 Aug 28, 1997 May CAHN

@

EQ 25MG BASE

A074544 002 Aug 28, 1997 May CAHN

## WELLCOVORIN

+ @ GLAXOSMITHKLINE

EQ 5MG BASE

N018342 001 Jul 08, 1983 Jun CRLD

+ @

EQ 25MG BASE

N018342 002 Jul 08, 1983 Jun CRLD

LEVALBUTEROL HYDROCHLORIDE

## SOLUTION; INHALATION

## LEVALBUTEROL HYDROCHLORIDE

AN AUROBINDO PHARMA LTD EQ 0.25% BASE

A207628 001 Jan 31, 2017 Jan NEWA

LEVETIRACETAM

## INJECTABLE; IV (INFUSION)

## LEVETIRACETAM

AP JUBILANT GENERICS 500MG/5ML (100MG/ML)

A206838 001 Jun 02, 2016 Jul CAHN

## LEVETIRACETAM IN SODIUM CHLORIDE

AP GLAND PHARMA LTD 500MG/100ML (5MG/ML)

A206880 001 Oct 25, 2017 Oct NEWA

AP 1000MG/100ML (10MG/ML)

A206880 002 Oct 25, 2017 Oct NEWA

AP 1500MG/100ML (15MG/ML)

A206880 003 Oct 25, 2017 Oct NEWA

## SOLUTION; ORAL

## LEVETIRACETAM

AA ALLIED PHARMA INC 100MG/ML

A078582 001 Jan 15, 2009 Mar CAHN

AA AUROBINDO PHARMA LTD 100MG/ML

A079063 001 Jan 15, 2009 Jan CAHN

## TABLET; ORAL

## LEVETIRACETAM

AB ACI HEALTHCARE LTD 250MG

A078042 001 Jan 15, 2009 Jun CAHN

AB 500MG

A078042 002 Jan 15, 2009 Jun CAHN

AB 750MG

A078042 003 Jan 15, 2009 Jun CAHN

AB 1GM

A078042 004 Jan 15, 2009 Jun CAHN

AB ACIC PHARMS 250MG

A090767 001 Jul 28, 2010 Sep CAHN

AB 500MG

A090767 002 Jul 28, 2010 Sep CAHN

AB 750MG

A090767 003 Jul 28, 2010 Sep CAHN

AB 1GM

A090767 004 Jul 28, 2010 Sep CAHN

AB ALLIED PHARMA INC 250MG

A078042 001 Jan 15, 2009 Mar CAHN

AB 500MG

A078042 002 Jan 15, 2009 Mar CAHN

AB 750MG

A078042 003 Jan 15, 2009 Mar CAHN

AB 1GM

A078042 004 Jan 15, 2009 Mar CAHN

## ROWEEPRA

AB LOTUS PHARM CO LTD 250MG

A090906 002 Oct 31, 2016 Apr NEWA

AB 500MG

A090906 001 Nov 05, 2010 Apr CTNA

AB 750MG

A090906 003 Oct 31, 2016 Apr NEWA

AB 1GM

A090906 004 Oct 31, 2016 Apr NEWA

## TABLET, EXTENDED RELEASE; ORAL

## LEVETIRACETAM

AB ECI PHARMS LLC 500MG

A204754 001 Aug 26, 2016 Mar CAHN

AB 750MG

A204754 002 Aug 26, 2016 Mar CAHN

@ MYLAN PHARMS INC

500MG

A200475 001 Dec 19, 2011 Apr DISC

@

750MG

A200475 002 Dec 19, 2011 Apr DISC

@

1GM

A200475 003 Dec 07, 2015 Apr DISC

AB PHARMTAK INC 500MG

A207175 001 Sep 28, 2017 Sep NEWA

AB 750MG

A207175 002 Sep 28, 2017 Sep NEWA

AB PRINSTON INC 500MG

A202533 001 Jul 20, 2012 Feb CAHN

AB 750MG

A202533 002 Jul 20, 2012 Feb CAHN

AB VIRTUS PHARMS 500MG

A091291 001 Sep 12, 2011 Feb CAHN

AB 750MG

A091291 002 Sep 12, 2011 Feb CAHN

## TABLET, FOR SUSPENSION; ORAL

## SPRITAM

&gt;A&gt; + APRECIA PHARMS 250MG

N207958 001 Jul 31, 2015 Nov CAHN

&gt;A&gt; + 500MG

N207958 002 Jul 31, 2015 Nov CAHN

&gt;A&gt; + 750MG

N207958 003 Jul 31, 2015 Nov CAHN

&gt;A&gt; +! 1GM

N207958 004 Jul 31, 2015 Nov CAHN

&gt;D&gt; + APRECIA PHARMS CO 250MG

N207958 001 Jul 31, 2015 Nov CAHN

&gt;D&gt; + 500MG

N207958 002 Jul 31, 2015 Nov CAHN

&gt;D&gt; + 750MG

N207958 003 Jul 31, 2015 Nov CAHN

&gt;D&gt; +! 1GM

N207958 004 Jul 31, 2015 Nov CAHN



LEVOBUNOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
LEVOBUNOLOL HYDROCHLORIDE

	@ BAUSCH AND LOMB	0.25%	A074307	001	Mar 04, 1994	Jul DISC
AT	SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	Feb CAHN

LEVOCARNITINEINJECTABLE;INJECTION  
CARNITOR

AP	+! LEADIANT BIOSCI INC	200MG/ML	N020182	001	Dec 16, 1992	Mar CAHN
	SOLUTION;ORAL					
	CARNITOR					
	@ LEADIANT BIOSCI INC	1GM/10ML	N018948	002	Apr 27, 1988	Mar CAHN
AA	+!	1GM/10ML	N019257	001	Apr 10, 1986	Mar CAHN
	CARNITOR SF					
AA	+ LEADIANT BIOSCI INC	1GM/10ML	N019257	002	Mar 28, 2007	Mar CAHN
	TABLET;ORAL					
	CARNITOR					
AB	+! LEADIANT BIOSCI INC	330MG	N018948	001	Dec 27, 1985	Mar CAHN
	LEVOCARNITINE					
AB	IMPAX LABS INC	330MG	A076858	001	Sep 20, 2004	Feb CAHN
AB	RISING PHARMS INC	330MG	A076858	001	Sep 20, 2004	Oct CAHN

LEVOCETIRIZINE DIHYDROCHLORIDESOLUTION;ORAL  
LEVOCETIRIZINE DIHYDROCHLORIDE

>D> AA	SILARX PHARMS INC	2.5MG/ML	A204599	001	May 15, 2017	Nov CPOT
>A> AA		2.5MG/5ML	A204599	001	May 15, 2017	Nov CPOT
AA		2.5MG/ML	A204599	001	May 15, 2017	May NEWA
	XYZAL					
AA	+! SANOFI-AVENTIS US	2.5MG/5ML	N022157	001	Jan 28, 2008	Jul CAHN
	TABLET;ORAL					
	LEVOCETIRIZINE DIHYDROCHLORIDE					
>D> AB	ALLIED PHARMA INC	5MG	A202046	001	Sep 17, 2013	Nov CAHN
AB		5MG	A202046	001	Sep 17, 2013	Sep CAHN
AB		5MG	A204323	001	Dec 20, 2016	Apr CAHN
>A> AB	MICRO LABS LTD INDIA	5MG	A202046	001	Sep 17, 2013	Nov CAHN
	XYZAL					
AB	+! SANOFI-AVENTIS US	5MG	N022064	001	May 25, 2007	Jul CAHN

LEVOFLOXACININJECTABLE;INJECTION  
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	+ @ JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan CRLD
	+ @	EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan CRLD
	+ @	EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan CRLD
	LEVOFLOXACIN					
AP	BAXTER HLTHCARE CORP	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Aug CAHN
AP	SAGENT AGILA LLC	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun CAHN
AP		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun CAHN
AP	ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	May NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	May NEWA
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE CORP	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Aug CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Aug CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Aug CAHN
>D> AP	HIKMA FARMACEUTICA	EQ 500MG/100ML (EQ 5MG/ML)	A091375	002	Sep 16, 2011	Nov CMS1
>A> AP		EQ 500MG/100ML (EQ 5MG/ML)	A091375	002	Sep 16, 2011	Nov CMS1

SOLUTION;ORAL

LEVAQUIN

	+ @ JANSSEN PHARMS	250MG/10ML	N021721	001	Oct 21, 2004	Aug DISC
	LEVOFLOXACIN					
	! HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	Aug CHRS
	SOLUTION/DROPS;OPHTHALMIC					
	LEVOFLOXACIN					
>A> AT	MYLAN LABS LTD	0.5%	A204899	001	Dec 08, 2017	Nov NEWA
AT	WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011	Feb CAHN
	TABLET;ORAL					
	LEVOFLOXACIN					
	@ MYLAN	250MG	A076276	001	Jun 20, 2011	Jul DISC

TABLET;ORAL  
LEVOFLOXACIN

@	500MG	A076276	002	Jun 20, 2011	Jul DISC
@	750MG	A077097	001	Jun 20, 2011	Jun DISC

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)  
LEVOLEUCOVORIN CALCIUM

AP	ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	Jan NEWA
	+	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	May CRLD
AP	AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Jan NEWA
SOLUTION;IV (INFUSION)						
LEVOLEUCOVORIN CALCIUM						
AP	AMNEAL PHARMS CO	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	Aug NEWA

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION  
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

@ SEPTODONT INC	0.05MG/ML;2%	A084697	001		May CAHN
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN					
@ BELMORA LLC	0.05MG/ML;2%	A084850	002	Oct 21, 1983	Feb CAHN

LEVONORGESTREL

TABLET;ORAL  
LEVONORGESTREL

>A>	@ FDN CONSUMER	0.75MG	A078665	001	Aug 28, 2009	Nov CAHN
>D>	@ WATSON LABS	0.75MG	A078665	001	Aug 28, 2009	Nov CAHN
PLAN B						
>A>	+ @ FDN CONSUMER	0.75MG	N021045	001	Jul 28, 1999	Nov CAHN
>A>	+ @	0.75MG	N021045	002	Aug 24, 2006	Nov CAHN
>D>	+ @ TEVA BRANDED PHARM	0.75MG	N021045	001	Jul 28, 1999	Nov CAHN
>D>	+ @	0.75MG	N021045	002	Aug 24, 2006	Nov CAHN

LEVOTHYROXINE SODIUM

CAPSULE;ORAL  
TIROSINT

+	INSTITUT BIOCHIMIQUE	0.175MG	N021924	011	Apr 25, 2017	Sep NEWA
+		0.200MG	N021924	012	Apr 25, 2017	Sep NEWA

SOLUTION;ORAL  
TIROSINT-SOL

+	@ INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jun DISC
+	@	25MCG/ML	N206977	002	Dec 15, 2016	Jun DISC
+	@	50MCG/ML	N206977	003	Dec 15, 2016	Jun DISC
+	@	75MCG/ML	N206977	004	Dec 15, 2016	Jun DISC
+	@	88MCG/ML	N206977	005	Dec 15, 2016	Jun DISC
+	@	100MCG/ML	N206977	006	Dec 15, 2016	Jun DISC
+	@	112MCG/ML	N206977	007	Dec 15, 2016	Jun DISC
+	@	125MCG/ML	N206977	008	Dec 15, 2016	Jun DISC
+	@	137MCG/ML	N206977	009	Dec 15, 2016	Jun DISC
+	@	150MCG/ML	N206977	010	Dec 15, 2016	Jun DISC
+	@	175MCG/ML	N206977	011	Dec 15, 2016	Jun DISC
+	@	200MCG/ML	N206977	012	Dec 15, 2016	Jun DISC

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL  
LEVOLET

@ GENUS LIFESCIENCES	0.025MG	N021137	001	Jun 06, 2003	Sep CAHN
@	0.05MG	N021137	002	Jun 06, 2003	Sep CAHN
@	0.075MG	N021137	003	Jun 06, 2003	Sep CAHN
@	0.088MG	N021137	004	Jun 06, 2003	Sep CAHN
@	0.1MG	N021137	005	Jun 06, 2003	Sep CAHN
@	0.112MG	N021137	006	Jun 06, 2003	Sep CAHN
@	0.125MG	N021137	007	Jun 06, 2003	Sep CAHN
@	0.137MG	N021137	008	Jun 06, 2003	Sep CAHN
@	0.15MG	N021137	009	Jun 06, 2003	Sep CAHN
@	0.175MG	N021137	010	Jun 06, 2003	Sep CAHN
@	0.2MG	N021137	011	Jun 06, 2003	Sep CAHN
@	0.3MG	N021137	012	Jun 06, 2003	Sep CAHN

## LEVOXYL

AB1, +	KING PHARMS	0.025MG	N021301	001	May 25, 2001	May CAHN
--------	-------------	---------	---------	-----	--------------	----------

TABLET;ORAL  
LEVOXYL

AB3									
AB1, +	0.05MG	N021301	002	May 25, 2001	May	CAHN			
AB3									
AB1, +	0.075MG	N021301	003	May 25, 2001	May	CAHN			
AB3									
AB1, +	0.088MG	N021301	004	May 25, 2001	May	CAHN			
AB3									
AB1, +	0.1MG	N021301	005	May 25, 2001	May	CAHN			
AB3									
AB1, +	0.112MG	N021301	006	May 25, 2001	May	CAHN			
AB3									
AB1, +	0.125MG	N021301	007	May 25, 2001	May	CAHN			
AB3									
AB1, +	0.137MG	N021301	008	May 25, 2001	May	CAHN			
AB3									
AB1, +	0.15MG	N021301	009	May 25, 2001	May	CAHN			
AB3									
AB1, +	0.175MG	N021301	010	May 25, 2001	May	CAHN			
AB3									
AB1, +!	0.2MG	N021301	011	May 25, 2001	May	CAHN			
AB3									
+ @	0.3MG	N021301	012	May 25, 2001	May	CAHN			
THYRO-TABS									
+ @ LLOYD	0.025MG	N021116	001	Oct 24, 2002	Sep	CTNA			
+ @	0.05MG	N021116	002	Oct 24, 2002	Sep	CTNA			
+ @	0.075MG	N021116	003	Oct 24, 2002	Sep	CTNA			
+ @	0.088MG	N021116	010	Oct 24, 2002	Sep	CTNA			
+ @	0.1MG	N021116	004	Oct 24, 2002	Sep	CTNA			
+ @	0.112MG	N021116	011	Oct 24, 2002	Sep	CTNA			
+ @	0.125MG	N021116	005	Oct 24, 2002	Sep	CTNA			
+ @	0.137MG	N021116	012	Dec 07, 2004	Sep	CTNA			
+ @	0.15MG	N021116	006	Oct 24, 2002	Sep	CTNA			
+ @	0.175MG	N021116	007	Oct 24, 2002	Sep	CTNA			
+ @	0.2MG	N021116	008	Oct 24, 2002	Sep	CTNA			
+ @	0.3MG	N021116	009	Oct 24, 2002	Sep	CTNA			

LIDOCAINE

OINTMENT;TOPICAL  
LIDOCAINE

AT	ALKEM LABS LTD	5%	A207810	001	Mar 10, 2017	Feb	NEWA		
AT	! FOUGERA PHARMS INC	5%	A080198	001		Jan	CAHN		
AT	RICONPHARMA LLC	5%	A208604	001	Sep 20, 2017	Sep	NEWA		
AT	VITRUVIAS THERAP	5%	A208822	001	Sep 25, 2017	Sep	NEWA		
XYLOCAINE									
+ @	ASTRAZENECA	5%	N008048	001		Jan	CRLD		

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION  
LIDOCAINE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	1%	A207182	001	Oct 30, 2017	Oct	NEWA		
AP		2%	A207182	002	Oct 30, 2017	Oct	NEWA		
	@ BELMORA LLC	2%	A080504	001		Feb	CAHN		
>D> AP	MYLAN LABS LTD	0.5%	A091056	001	Dec 08, 2010	Nov	DISC		
>A>	@	0.5%	A091056	001	Dec 08, 2010	Nov	DISC		
>D> AP		0.5%	A091058	001	Sep 30, 2010	Nov	DISC		
>A>	@	0.5%	A091058	001	Sep 30, 2010	Nov	DISC		
>D> AP		1%	A091056	002	Dec 08, 2010	Nov	DISC		
>A>	@	1%	A091056	002	Dec 08, 2010	Nov	DISC		
>D> AP		1%	A091058	002	Sep 30, 2010	Nov	DISC		
>A>	@	1%	A091058	002	Sep 30, 2010	Nov	DISC		
>D> AP		2%	A202242	001	Apr 11, 2014	Nov	DISC		
>A>	@	2%	A202242	001	Apr 11, 2014	Nov	DISC		
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE									
>D> AP	MYLAN LABS LTD	2%	A090665	001	Sep 27, 2010	Nov	DISC		
>A>	@	2%	A090665	001	Sep 27, 2010	Nov	DISC		

LIDOCAINE; TETRACAINE

CREAM;TOPICAL  
PLIAGLIS

+!	TARO PHARMS	7%;7%	N021717	001	Jun 29, 2006	May	CAHN		
----	-------------	-------	---------	-----	--------------	-----	------	--	--

LINACLOTIDECAPSULE;ORAL  
LINZESS

+ FOREST LABS LLC 72MCG N202811 003 Jan 25, 2017 Jan NEWA

LINEZOLIDSOLUTION;IV (INFUSION)  
LINEZOLID

AP	HQ SPCLT PHARMA	200MG/100ML (2MG/ML)	A207001	001	Jul 07, 2017	Jun NEWA
AP		600MG/300ML (2MG/ML)	A207001	002	Jul 07, 2017	Jun NEWA
>A> AP	MYLAN LABS LTD	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	Nov NEWA
>A> AP		600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	Nov NEWA
AP	SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	Feb NEWA
AP		600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	Feb NEWA

TABLET;ORAL  
LINEZOLID

AB ZYDUS PHARMS USA INC 600MG A206097 001 Feb 22, 2017 Feb NEWA

LIOTHYRONINE SODIUMTABLET;ORAL  
CYTOMEL

AB	+ KING PHARMS	EQ 0.005MG BASE	N010379	001		Mar CAHN
AB	+	EQ 0.025MG BASE	N010379	002		Mar CAHN
AB	+	EQ 0.05MG BASE	N010379	003		Mar CAHN

LISDEXAMFETAMINE DIMESYLATETABLET, CHEWABLE;ORAL  
VYVANSE

+	SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017	Jan NEWA
+		20MG	N208510	002	Jan 28, 2017	Jan NEWA
+		30MG	N208510	003	Jan 28, 2017	Jan NEWA
+		40MG	N208510	004	Jan 28, 2017	Jan NEWA
+		50MG	N208510	005	Jan 28, 2017	Jan NEWA
+		60MG	N208510	006	Jan 28, 2017	Apr CHRS
+		60MG	N208510	006	Jan 28, 2017	Jan NEWA

LISINOPRILTABLET;ORAL  
LISINOPRIL

AB	PRINSTON INC	2.5MG	A075743	001	Jul 01, 2002	Feb CAHN
AB		5MG	A075743	002	Jul 01, 2002	Feb CAHN
AB		10MG	A075743	003	Jul 01, 2002	Feb CAHN
AB		20MG	A075743	004	Jul 01, 2002	Feb CAHN
AB		30MG	A075743	005	Jul 01, 2002	Feb CAHN
AB		40MG	A075743	006	Jul 01, 2002	Feb CAHN

LITHIUM CARBONATECAPSULE;ORAL  
LITHIUM CARBONATE

AB	MYLAN PHARMS INC	150MG	A076243	002	Feb 24, 2003	Jan CAHN
AB		300MG	A076243	001	Jun 27, 2002	Jan CAHN
AB		600MG	A078763	001	Apr 15, 2008	Jan CAHN
AB	+ WEST-WARD PHARMS INT	150MG	N017812	002	Jan 28, 1987	Jan CAHN
AB	+	300MG	N017812	001		Jan CAHN
AB	+	600MG	N017812	003	Jan 28, 1987	Jan CAHN

TABLET;ORAL  
LITHIUM CARBONATE

AB +! WEST-WARD PHARMS INT 300MG N018558 001 Jan 29, 1982 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL  
LITHIUM CARBONATE

AB UNIQUE PHARM LABS 450MG A205663 001 Jun 05, 2017 May NEWA

LITHIUM CITRATESYRUP;ORAL  
LITHIUM CITRATE

AA +! WEST-WARD PHARMS INT EQ 300MG CARBONATE/5ML N018421 001 Jan CAHN

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM

AA	SAPTALIS PHARMS	2MG/ML	A 079244	001	Apr 28, 2009	Oct	CAHN
----	-----------------	--------	----------	-----	--------------	-----	------

INJECTABLE;INJECTION

LORAZEPAM

@ WEST-WARD PHARMS INT 2MG/ML

A 074496 001 Sep 28, 1998 Mar CAHN

@ 4MG/ML

A 074496 002 Sep 28, 1998 Mar CAHN

TABLET;ORAL

LORAZEPAM

@ ANDA REPOSITORY 0.5MG

A 072553 001 Mar 29, 1991 Sep CAHN

@ 1MG

A 072554 001 Mar 29, 1991 Sep CAHN

@ 2MG

A 072555 001 Mar 29, 1991 Sep CAHN

>D> AB	MYLAN	2MG	A 071591	001	Oct 13, 1987	Nov	DISC
--------	-------	-----	----------	-----	--------------	-----	------

>A>	@	2MG	A 071591	001	Oct 13, 1987	Nov	DISC
-----	---	-----	----------	-----	--------------	-----	------

>D> AB	SANDOZ	0.5	A 071141	002	Apr 21, 1987	Nov	CMS1
--------	--------	-----	----------	-----	--------------	-----	------

>A> AB		0.5MG	A 071141	002	Apr 21, 1987	Nov	CMS1
--------	--	-------	----------	-----	--------------	-----	------

AB		0.5	A 071141	002	Apr 21, 1987	Apr	CMS1
----	--	-----	----------	-----	--------------	-----	------

AB		1MG	A 071141	003	Apr 21, 1987	Apr	CMS1
----	--	-----	----------	-----	--------------	-----	------

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB	HETERO LABS LTD V	25MG	A 203835	001	Aug 12, 2015	Jul	CTEC
----	-------------------	------	----------	-----	--------------	-----	------

AB		50MG	A 203835	002	Aug 12, 2015	Jul	CTEC
----	--	------	----------	-----	--------------	-----	------

AB		100MG	A 203835	003	Aug 12, 2015	Jul	CTEC
----	--	-------	----------	-----	--------------	-----	------

AB	UPSHER-SMITH LABS	25MG	A 090544	001	Oct 06, 2010	Jun	CAHN
----	-------------------	------	----------	-----	--------------	-----	------

AB		50MG	A 090544	002	Oct 06, 2010	Jun	CAHN
----	--	------	----------	-----	--------------	-----	------

AB		100MG	A 090544	003	Oct 06, 2010	Jun	CAHN
----	--	-------	----------	-----	--------------	-----	------

AB	VIVA HLTHCARE	25MG	A 091541	001	Sep 24, 2012	Sep	CAHN
----	---------------	------	----------	-----	--------------	-----	------

AB		50MG	A 091541	002	Sep 24, 2012	Sep	CAHN
----	--	------	----------	-----	--------------	-----	------

AB		100MG	A 091541	003	Sep 24, 2012	Sep	CAHN
----	--	-------	----------	-----	--------------	-----	------

AB	VIVIMED GLOBAL	25MG	A 090382	001	Oct 06, 2010	Aug	CAHN
----	----------------	------	----------	-----	--------------	-----	------

AB		50MG	A 090382	002	Oct 06, 2010	Aug	CAHN
----	--	------	----------	-----	--------------	-----	------

AB		100MG	A 090382	003	Oct 06, 2010	Aug	CAHN
----	--	-------	----------	-----	--------------	-----	------

LOVASTATIN

TABLET;ORAL

LOVASTATIN

@ MYLAN 10MG

A 075935 001 Dec 17, 2001 Mar DISC

@ 20MG

A 075935 002 Dec 17, 2001 Mar DISC

@ 40MG

A 075935 003 Dec 17, 2001 Mar DISC

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

@ COVIS PHARMA BV 10MG

N 021316 001 Jun 26, 2002 Apr CAHN

+ 20MG

N 021316 002 Jun 26, 2002 Apr CAHN

+ 40MG

N 021316 003 Jun 26, 2002 Apr CAHN

+! 60MG

N 021316 004 Jun 26, 2002 Apr CAHN

LOXAPINE

POWDER;INHALATION

ADASUVE

+! GALEN UK 10MG

N 022549 001 Dec 21, 2012 Sep CAHN

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

AT	NOVAST LABS LTD	5%	A 206716	001	Jul 31, 2017	Sep	CAHN
----	-----------------	----	----------	-----	--------------	-----	------

AT	RICONPHARMA LLC	5%	A 206716	001	Jul 31, 2017	Jul	NEWA
----	-----------------	----	----------	-----	--------------	-----	------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

ICU MEDICAL INC 30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML

N 017586 001 Feb CAHN

SOLUTION;IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

ICU MEDICAL INC 30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML

N 017637 002 Jul 08, 1982 Feb CAHN

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

>D>	AP	+	HOSPIRA	40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Nov CMS1
>A>	AP	+		40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Nov CMS1
>A>	AP		HQ SPCLT PHARMA	2GM/50ML (40MG/ML)	A207350	001	Dec 06, 2017	Nov NEWA
>A>	AP			4GM/100ML (40MG/ML)	A207350	002	Dec 06, 2017	Nov NEWA
>A>	AP			4GM/50ML (80MG/ML)	A207350	003	Dec 06, 2017	Nov NEWA
>A>	AP			20GM/500ML (40MG/ML)	A207350	004	Dec 06, 2017	Nov NEWA
>A>	AP			40GM/1000ML (40MG/ML)	A207350	005	Dec 06, 2017	Nov NEWA

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA			NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	Feb NEWA
			SUPREP BOWEL PREP KIT					
AA	+	!	BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	Feb CFTG

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA			NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	May CAIN
			SUPREP BOWEL PREP KIT					
AA	+	!	BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	May CAIN

MALATHION

LOTION;TOPICAL

OVIDE

AT	+	!	TARO PHARM	0.5%	N018613	001	Aug 02, 1982	May CAHN
----	---	---	------------	------	---------	-----	--------------	----------

MANGAFODIPIR TRISODIUM

INJECTABLE;INJECTION

TESLASCAN

>D>			@ GE HEALTHCARE	37.9MG/ML	N020652	001	Nov 26, 1997	Nov CAHN
>A>			@ IC TARGETS	37.9MG/ML	N020652	001	Nov 26, 1997	Nov CAHN

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP			ICU MEDICAL INC	10GM/100ML	N019603	002	Jan 08, 1987	Feb CAHN
			MANNITOL 15% IN PLASTIC CONTAINER					
AP			ICU MEDICAL INC	15GM/100ML	N019603	003	Jan 08, 1990	Feb CAHN
			MANNITOL 20% IN PLASTIC CONTAINER					
AP			ICU MEDICAL INC	20GM/100ML	N019603	004	Jan 08, 1990	Feb CAHN
			MANNITOL 5% IN PLASTIC CONTAINER					
AP			ICU MEDICAL INC	5GM/100ML	N019603	001	Jan 08, 1987	Feb CAHN

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

ICU MEDICAL INC 540MG/100ML;2.7GM/100ML

N018316	001		Feb CAHN
---------	-----	--	----------

MAPROTIline HYDROCHLORIDE

TABLET;ORAL

MAPROTIline HYDROCHLORIDE

@	WATSON LABS TEVA	25MG
@		50MG

A072162	001	Jun 01, 1988	May CAHN
A072163	001	Jun 01, 1988	May CAHN

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

EMVERM

! IMPAX LABS INC 100MG

A073580	001	Jan 04, 1995	Jun CAHN
---------	-----	--------------	----------

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL

MECAMYLAMINE HYDROCHLORIDE

! NEXGEN PHARMA 2.5MG

A204054	001	Mar 19, 2013	May CHRS
---------	-----	--------------	----------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	May CAHN
AA		25MG	A201451	002	Feb 23, 2011	May CAHN
	@	50MG	A201451	003	Feb 23, 2011	May CAHN
	@ PLIVA	25MG	A088734	001	Dec 11, 1985	Aug CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

@	WATSON LABS TEVA	EQ 100MG BASE	A071469	001	Apr 15, 1987	May CAHN
---	------------------	---------------	---------	-----	--------------	----------

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

>A>	AB	AMPHASTAR PHARMS INC	150MG/ML	A077235	001	Nov 28, 2017	Nov NEWA
>A>	AB		150MG/ML	A077334	001	Nov 28, 2017	Nov NEWA
		@ SANDOZ INC	150MG/ML	A078711	001	May 20, 2009	Jun DISC
	AB		150MG/ML	A078711	001	May 20, 2009	Mar CAHN
	AB	TEVA PHARMS USA	150MG/ML	A076553	001	Jul 28, 2004	Jan CAHN

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

@	USL PHARMA	10MG	A088484	001	Jul 26, 1984	Jun CAHN
---	------------	------	---------	-----	--------------	----------

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	VIVA HLTHCARE	250MG	A090562	001	Nov 19, 2010	Sep CAHN
----	---------------	-------	---------	-----	--------------	----------

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

+	@	ROCHE	250MG	N019591	001	May 02, 1989	Sep CRLD
---	---	-------	-------	---------	-----	--------------	----------

MEFLOQUINE HYDROCHLORIDE

AB	!	BARR	250MG	A076392	001	Dec 29, 2003	Apr CHRS
		@ SANDOZ	250MG	A076175	001	Feb 20, 2002	Apr DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

+	@	BRISTOL MYERS SQUIBB	40MG/ML	N020264	001	Sep 10, 1993	Feb DISC
---	---	----------------------	---------	---------	-----	--------------	----------

MEGESTROL ACETATE

>A>	AB	BRECKENRIDGE PHARM	125MG/ML	A204688	001	Dec 01, 2017	Nov NEWA
	AB	HI-TECH PHARMACAL	40MG/ML	A203960	001	Jun 09, 2017	May NEWA
	AB	! WEST-WARD PHARMS INT	40MG/ML	A075997	001	Feb 15, 2002	Feb CHRS

MELOXICAM

SUSPENSION; ORAL

MOBIC

+	@	BOEHRINGER INGELHEIM	7.5MG/5ML	N021530	001	Jun 01, 2004	Sep DISC
---	---	----------------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

MELOXICAM

		@	ANDA REPOSITORY	7.5MG	A077935	001	Jul 19, 2006	Sep CAHN
		@		15MG	A077935	002	Jul 19, 2006	Sep CAHN
>D>		@	COREPHARMA	7.5MG	A077930	001	Jul 19, 2006	Nov CAHN
>D>		@		15MG	A077930	002	Jul 19, 2006	Nov CAHN
>A>		@	IMPAX LABS INC	7.5MG	A077930	001	Jul 19, 2006	Nov CAHN
>A>		@		15MG	A077930	002	Jul 19, 2006	Nov CAHN

MELPHALAN

TABLET; ORAL

ALKERAN

AB	+	APOTEX INC	2MG	N014691	002		Mar CFTG
----	---	------------	-----	---------	-----	--	----------

MELPHALAN

AB		ALVOGEN MALTA	2MG	A207809	001	Mar 22, 2017	Mar NEWA
----	--	---------------	-----	---------	-----	--------------	----------

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

ALKERAN

+ @ APOTEX INC EQ 50MG BASE/VIAL

N020207 001 Nov 18, 1992 May DISC

MELPHALAN HYDROCHLORIDE

&gt;A&gt; AP + DR REDDYS LABS LTD EQ 50MG BASE/VIAL

A203655 001 Dec 08, 2017 Nov NEWA

AP ! MYLAN INSTITUTIONAL EQ 50MG BASE/VIAL

A090270 001 Jun 09, 2009 May CHRS

AP SAGENT PHARMS EQ 50MG BASE/VIAL

A201379 001 Feb 28, 2017 Feb NEWA

POWDER;IV (INFUSION)

EVOMELA

+! SPECTRUM PHARMS EQ 50MG BASE/VIAL

N207155 001 Mar 10, 2016 Aug CRLD

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

AB AMNEAL PHARMS 7MG

A205825 001 Oct 12, 2016 May CAHN

AB 14MG

A205825 002 Oct 12, 2016 May CAHN

AB 21MG

A205825 003 Oct 12, 2016 May CAHN

AB 28MG

A205825 004 Oct 12, 2016 May CAHN

AB ANCHEN PHARMS 7MG

A205784 001 Jun 09, 2017 May NEWA

AB 14MG

A205784 002 Jun 09, 2017 May NEWA

AB 21MG

A205784 003 Jun 09, 2017 May NEWA

AB 28MG

A205784 004 Jun 09, 2017 May NEWA

AB ZYDUS PHARMS USA INC 7MG

A203293 001 Aug 03, 2017 Jul NEWA

AB 14MG

A203293 002 Aug 03, 2017 Jul NEWA

AB 21MG

A203293 003 Aug 03, 2017 Jul NEWA

AB 28MG

A203293 004 Aug 03, 2017 Jul NEWA

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB AMNEAL PHARMS 5MG

A090041 001 Apr 10, 2015 May CAHN

AB 10MG

A090041 002 Apr 10, 2015 May CAHN

AB STRIDES PHARMA 5MG

A202350 001 May 23, 2017 May NEWA

AB 10MG

A202350 002 May 23, 2017 May NEWA

AB UPSHER-SMITH LABS 5MG

A090043 001 Jul 31, 2015 Jun CAHN

AB 10MG

A090043 002 Jul 31, 2015 Jun CAHN

AB ZYDUS PHARMS USA INC 5MG

A090961 001 Jul 10, 2017 Jun NEWA

AB 10MG

A090961 002 Jul 10, 2017 Jun NEWA

MEPENZOLATE BROMIDE

TABLET;ORAL

CANTIL

+ @ SANOFI AVENTIS US 25MG

N010679 003 Aug DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

AP WEST-WARD PHARMS INT 25MG/ML

A080445 001 Jan CAHN

AP 25MG/ML

A080455 007 Jan CAHN

AP 50MG/ML

A080445 002 Jan CAHN

AP 50MG/ML

A080455 008 Jan CAHN

AP 75MG/ML

A080445 003 Jan CAHN

AP 75MG/ML

A080455 009 Jan CAHN

AP 100MG/ML

A080445 004 Jan CAHN

AP 100MG/ML

A080455 010 Jan CAHN

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP ! ICU MEDICAL INC 10MG/ML

A088432 001 Aug 16, 1984 Apr CAHN

@ MALLINCKRODT INC 10MG/ML

A040163 001 May 12, 1997 Mar CAHN

AP WEST-WARD PHARMS INT 10MG/ML

A081002 001 Jul 30, 1993 Apr CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ISOCAINE HYDROCHLORIDE

AP ! SEPTODONT INC 3%

A080925 001 May CAHN

MEPIVACAINE HYDROCHLORIDE

@ BELMORA LLC 3%

A083559 001 Feb CAHN



MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

AB	DR REDDYS LABS SA	50MG	A040461	001	Feb 11, 2004	Jun CAHN
----	-------------------	------	---------	-----	--------------	----------

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP	AUROBINDO PHARMA LTD	500MG/VIAL	A205835	001	Mar 27, 2017	Mar NEWA
AP		1GM/VIAL	A205835	002	Mar 27, 2017	Mar NEWA

MERREM

AP	+! PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Jun CAHN
AP	+!	1GM/VIAL	N050706	001	Jun 21, 1996	Jun CAHN

MEROPENEM; VABORBACTAM

POWDER; IV (INFUSION)

VABOMERE

+!	REMPEX PHARMS MEDCNS	1GM/VIAL; 1GM/VIAL	N209776	001	Aug 29, 2017	Aug NEWA
----	----------------------	--------------------	---------	-----	--------------	----------

MESALAMINE

ENEMA; RECTAL

ROWASA

AB	+! MYLAN SPECIALITY LP	4GM/60ML	N019618	001	Dec 24, 1987	Mar CAHN
	SFROWASA					

AB	+ MYLAN SPECIALITY LP	4GM/60ML	N019618	002	Jun 20, 2008	Mar CAHN
----	-----------------------	----------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL

ASACOL HD

AB	+! APIL	800MG	N021830	001	May 29, 2008	Jul CFTG
	LIALDA					

AB	+! SHIRE	1.2GM	N022000	001	Jan 16, 2007	May CFTG
----	----------	-------	---------	-----	--------------	----------

MESALAMINE

AB	ZYDUS PHARMS USA INC	800MG	A203286	001	Jul 21, 2017	Jul NEWA
AB		1.2GM	A091640	001	Jun 05, 2017	May NEWA

MESNA

INJECTABLE; INTRAVENOUS

MESNA

@	MYLAN LABS LTD	100MG/ML	A203364	001	Jul 18, 2014	Oct DISC
---	----------------	----------	---------	-----	--------------	----------

METAXALONE

TABLET; ORAL

METAXALONE

AB	ACTAVIS LABS FL INC	800MG	A203695	001	Jun 15, 2017	Jun NEWA
	@ EPIC PHARMA LLC	640MG	N022503	001	Jun 01, 2015	May CAHN
	IMPAX LABS INC	400MG	A040486	001	Feb 27, 2015	Feb CAHN
AB	SCIEGEN PHARMS INC	800MG	A207466	001	Aug 31, 2017	Aug NEWA

SKELAXIN

	+ @ KING PHARMS	400MG	N013217	001		May CAHN
AB	+!	800MG	N013217	003	Aug 30, 2002	May CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	500MG	A205330	001	Oct 31, 2017	Oct NEWA
AB		850MG	A205330	002	Oct 31, 2017	Oct NEWA
AB		1GM	A205330	003	Oct 31, 2017	Oct NEWA
	@ MYLAN PHARMS INC	500MG	A075969	001	Jan 29, 2002	May DISC
	@	850MG	A075969	002	Jan 29, 2002	May DISC
	@	1GM	A075969	003	Jan 29, 2002	May DISC
	@ WATSON LABS FLORIDA	500MG	A075961	001	Jan 25, 2002	Mar DISC
	@	850MG	A075961	002	Jan 25, 2002	Mar DISC
	@	1GM	A075961	003	Jan 25, 2002	Mar DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1	INTELLIPHARMACEUTICS	500MG	A202306	001	Feb 23, 2017	Feb NEWA
AB		750MG	A202306	002	Feb 23, 2017	Feb NEWA
>D> AB1	MYLAN	500MG	A076650	001	Sep 13, 2005	Nov DISC
>A>	@	500MG	A076650	001	Sep 13, 2005	Nov DISC
	@	750MG	A077113	001	Sep 08, 2005	Oct DISC
AB1	TORRENT PHARMS LTD	500MG	A090014	001	Dec 30, 2009	Apr CAHN

METFORMIN HYDROCHLORIDE; REPAGLINIDETABLET; ORAL  
PRANDIMET

+ @ NOVO NORDISK INC	500MG; 1MG	N022386	001	Jun 23, 2008	Oct DISC
+ @	500MG; 2MG	N022386	002	Jun 23, 2008	Oct DISC
REPAGLINIDE AND METFORMIN HYDROCHLORIDE					
LUPIN LTD	500MG; 1MG	A200624	001	Jul 15, 2015	Oct CTEC
!	500MG; 2MG	A200624	002	Jul 15, 2015	Oct CHRS

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA	500MG; EQ 1MG BASE	A077337	005	May 19, 2017	May NEWA
------	--------------------	---------	-----	--------------	----------

METHACHOLINE CHLORIDEFOR SOLUTION; INHALATION  
PROVOCHOLINE

+ @ METHAPHARM	1600MG/VIAL	N019193	002	Aug 29, 2016	Sep DISC
----------------	-------------	---------	-----	--------------	----------

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADOSE

AA	+! MALLINCKRODT INC	10MG/ML	N017116	002		Apr CAHN
----	---------------------	---------	---------	-----	--	----------

INJECTABLE; INJECTION  
METHADONE HYDROCHLORIDE

AP	AKORN	10MG/ML	A208306	001	Oct 27, 2017	Oct NEWA
AP	+! MYLAN INSTITUTIONAL	10MG/ML	N021624	001		Oct CFTG

POWDER; FOR RX COMPOUNDING  
METHADONE HYDROCHLORIDE

@ MALLINCKRODT INC	50GM/BOT	N006383	002		Oct DISC
	50GM/BOT	N006383	002		Apr CAHN
@	100GM/BOT	N006383	003		Oct DISC
	100GM/BOT	N006383	003		Apr CAHN
@	500GM/BOT	N006383	004		Oct DISC
	500GM/BOT	N006383	004		Apr CAHN

SYRUP; ORAL

DOLOPHINE HYDROCHLORIDE

@ WEST-WARD PHARMS INT	10MG/30ML	N006134	004		Jan CAHN
------------------------	-----------	---------	-----	--	----------

TABLET; ORAL

DOLOPHINE HYDROCHLORIDE

AA	+! WEST-WARD PHARMS INT	5MG	N006134	002		Jan CAHN
AA	+!	10MG	N006134	010		Jan CAHN

METHADONE HYDROCHLORIDE

AA	EPIC PHARMA LLC	5MG	A090065	001	Aug 18, 2015	May CAHN
AA		10MG	A090065	002	Aug 18, 2015	May CAHN

TABLET, FOR SUSPENSION; ORAL  
METHADONE HYDROCHLORIDE

AA	+! WEST-WARD PHARMS INT	40MG	N017058	001		Jan CAHN
----	-------------------------	------	---------	-----	--	----------

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB	IMPAX LABS INC	1GM	A076411	001	Jun 20, 2003	Feb CAHN
----	----------------	-----	---------	-----	--------------	----------

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

@ ECI PHARMS LLC	15MG	A040619	003	Jul 12, 2005	May CAHN
------------------	------	---------	-----	--------------	----------

TAPAZOLE

AB	KING PHARMS LLC	5MG	A040320	001	Mar 31, 2000	Feb CAHN
AB		10MG	A040320	002	Mar 31, 2000	Feb CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP	LUITPOLD PHARMS INC	1GM/10ML (100MG/ML)	A207496	001	Jun 22, 2017	Jun NEWA
>A> AP	NAVINTA LLC	1GM/10ML (100MG/ML)	A206071	001	Nov 24, 2017	Nov NEWA
AP	RENAISSANCE PHARMA	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Jan NEWA
AP	RENAISSANCE SSA LLC	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Mar CAHN
AP	SAGENT PHARMS	1GM/10ML (100MG/ML)	A205404	001	Jul 18, 2017	Jul NEWA

## SOLUTION;IM-IV

## METHOCARBAMOL

AP	SOMERSET THERAPS LLC	1GM/10ML (100MG/ML)	A207522	001	Jul 31, 2017	Jul NEWA
	TABLET;ORAL					
	METHOCARBAMOL					
AA	ATLAS PHARMS LLC	500MG	A203550	001	Feb 08, 2017	Jan NEWA
AA		750MG	A203550	002	Feb 08, 2017	Jan NEWA
AA	BEXIMCO PHARMS USA	500MG	A208507	001	Jul 21, 2017	Jul NEWA
AA		750MG	A208507	002	Jul 21, 2017	Jul NEWA
	@ UPSHER SMITH	500MG	A087453	001		Jun CAHN
	@	750MG	A087454	001		Jun CAHN

METHOTREXATE

## SOLUTION;SUBCUTANEOUS

>D>	OTREXUP PFS					
>D>	+ ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Nov DISC
>A>	+ @	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Nov DISC
	+	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Jul NEWA
>D>	+	15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Nov DISC
>A>	+ @	15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Nov DISC
	+	15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Jul NEWA
>D>	+	17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Nov DISC
>A>	+ @	17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Nov DISC
	+	17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Jul NEWA
>D>	+	20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Nov DISC
>A>	+ @	20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Nov DISC
	+	20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Jul NEWA
>D>	+	22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Nov DISC
>A>	+ @	22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Nov DISC
	+	22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Jul NEWA
>D>	+	25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Nov DISC
>A>	+ @	25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Nov DISC
	+	25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Jul NEWA

METHOTREXATE SODIUM

## INJECTABLE;INJECTION

## METHOTREXATE SODIUM PRESERVATIVE FREE

AP	PHARMACHEMIE BV	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040843	002	Jan 11, 2010	Apr CMS1
AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012	Apr CMS1
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040843	004	Jan 11, 2010	Apr CMS1

## SOLUTION;ORAL

## XATMEP

+!	SILVERGATE PHARMS	EQ 2.5MG BASE/ML	N208400	001	Apr 25, 2017	Apr NEWA
----	-------------------	------------------	---------	-----	--------------	----------

## TABLET;ORAL

## METHOTREXATE SODIUM

AB	ORION CORP ORION	EQ 2.5MG BASE	A201749	001	May 21, 2015	Jul CAHN
AB	SUN PHARMA GLOBAL	EQ 2.5MG BASE	A201749	001	May 21, 2015	Oct CAHN
AB	ZYDUS PHARMS USA INC	EQ 2.5MG BASE	A207812	001	Jan 13, 2017	Jan NEWA

METHOXSALEN

## CAPSULE;ORAL

## 8-MOP

+	@ VALEANT PHARM INTL	10MG	N009048	001		Oct DISC
---	----------------------	------	---------	-----	--	----------

## LOTION;TOPICAL

## OXSORALEN

+	@ VALEANT PHARM INTL	1%	N009048	002		Oct DISC
---	----------------------	----	---------	-----	--	----------

METHYLDOPATE HYDROCHLORIDE

## INJECTABLE;INJECTION

## METHYLDOPATE HYDROCHLORIDE

!	LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987	Jan CTEC
---	----------	---------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATE

## INJECTABLE;INJECTION

## METHYLERGONOVINE MALEATE

AP	BRECKENRIDGE PHARM	0.2MG/ML	A040889	001	Sep 13, 2010	Sep CAHN
----	--------------------	----------	---------	-----	--------------	----------

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL  
COTEMPLA XR-ODT

+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017	Jun NEWA
+		17.3MG	N205489	002	Jun 19, 2017	Jun NEWA
+		25.9MG	N205489	003	Jun 19, 2017	Jun NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
METHYLPHENIDATE HYDROCHLORIDE

AB2	IMPAX LABS INC	10MG	A205105	001	Jul 28, 2016	Feb CAHN
AB2		20MG	A205105	002	Jul 28, 2016	Feb CAHN
AB2		30MG	A205105	003	Jul 28, 2016	Feb CAHN
AB2		40MG	A205105	004	Jul 28, 2016	Feb CAHN
AB2		50MG	A205105	005	Jul 28, 2016	Feb CAHN
AB2		60MG	A205105	006	Jul 28, 2016	Feb CAHN
!	MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	Feb CHRS

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	BRECKENRIDGE PHARM	5MG/5ML	A201466	001	Nov 12, 2013	Sep CAHN
AA		10MG/5ML	A201466	002	Nov 12, 2013	Sep CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ABHAI INC	5MG	A206932	001	May 11, 2017	Apr NEWA
AB		10MG	A206932	002	May 11, 2017	Apr NEWA
AB		20MG	A206932	003	May 11, 2017	Apr NEWA
AB	BRECKENRIDGE PHARM	5MG	A207587	001	Mar 03, 2017	Sep CAHN
AB		10MG	A207587	002	Mar 03, 2017	Sep CAHN
AB		20MG	A207587	003	Mar 03, 2017	Sep CAHN
AB	IMPAX LABS INC	5MG	A091159	001	Mar 12, 2014	Feb CAHN
AB		10MG	A091159	002	Mar 12, 2014	Feb CAHN
AB		20MG	A091159	003	Mar 12, 2014	Feb CAHN
AB	NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017	Feb NEWA
AB		10MG	A207587	002	Mar 03, 2017	Feb NEWA
AB		20MG	A207587	003	Mar 03, 2017	Feb NEWA

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	BRECKENRIDGE PHARM	2.5MG	A204954	001	Jan 26, 2017	Sep CAHN
AB		5MG	A204954	002	Jan 26, 2017	Sep CAHN
AB		10MG	A204954	003	Jan 26, 2017	Sep CAHN
AB	NOSTRUM LABS INC	2.5MG	A204954	001	Jan 26, 2017	Jan NEWA
AB		5MG	A204954	002	Jan 26, 2017	Jan NEWA
AB		10MG	A204954	003	Jan 26, 2017	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	IMPAX LABS INC	18MG	A208607	001	Jul 14, 2017	Jul NEWA
AB		27MG	A208607	002	Jul 14, 2017	Jul NEWA
AB		36MG	A208607	003	Jul 14, 2017	Jul NEWA
AB		54MG	A208607	004	Jul 14, 2017	Jul NEWA
AB	OSMOTICA	18MG	A205327	001	Jul 28, 2017	Jul NEWA
AB		27MG	A205327	002	Jul 28, 2017	Jul NEWA
AB		36MG	A205327	003	Jul 28, 2017	Jul NEWA
AB		54MG	A205327	004	Jul 28, 2017	Jul NEWA
		72MG	A205327	005	Jul 28, 2017	Jul NEWA

RITALIN-SR

AB	+	NOVARTIS	20MG	N018029	001	Mar 30, 1982	Feb CRLD
----	---	----------	------	---------	-----	--------------	----------

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

>D>	AB	+	PHARMACIA AND UPJOHN	2MG	N011153	002	Nov CTEC
>A>		+		2MG	N011153	002	Nov CTEC

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	SANDOZ INC	40MG/ML	A040719	001	Jan 29, 2009	Mar CAHN
AB		40MG/ML	A040794	001	Mar 05, 2009	Jul CAHN
AB		80MG/ML	A040719	002	Jan 29, 2009	Mar CAHN
AB		80MG/ML	A040794	002	Mar 05, 2009	Jul CAHN

METHYLTESTOSTERONETABLET;ORAL  
ANDROID 10

@ VALEANT PHARMS NORTH 10MG

A086450 001

May CAHN

METIPRANOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
METIPRANOLOL

AT SANDOZ INC 0.3%

A075720 001 Aug 06, 2001 Feb CAHN

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA PHARM ASSOC EQ 5MG BASE/5ML

A072744 001 May 28, 1991 May CAHN

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ SUN PHARM INDUSTRIES EQ 5MG BASE

A071536 002 Jan 16, 1997 May DISC

METOPROLOL SUCCINATETABLET, EXTENDED RELEASE;ORAL  
TOPROL-XL

AB + ARALEZ PHARMS EQ 25MG TARTRATE  
 AB +! EQ 50MG TARTRATE  
 AB + EQ 100MG TARTRATE  
 AB +! EQ 200MG TARTRATE

N019962 004 Feb 05, 2001 Jan CAHN  
 N019962 001 Jan 10, 1992 Jan CAHN  
 N019962 002 Jan 10, 1992 Jan CAHN  
 N019962 003 Jan 10, 1992 Jan CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP BAXTER HLTHCARE CORP 1MG/ML  
 AP SANDOZ INC 1MG/ML  
 AP WEST-WARD PHARMS INT 1MG/ML

A078950 001 Apr 29, 2013 Aug CAHN  
 A077360 001 Oct 02, 2007 Mar CAHN  
 A076495 001 Jul 07, 2003 Jan CAHN

TABLET;ORAL

LOPRESSOR

AB + US PHARMS HOLDINGS I 50MG  
 AB + 100MG

N017963 001 Sep CRLD  
 N017963 002 Sep CRLD

METOPROLOL TARTRATE

AB SUN PHARM INDUSTRIES 50MG

A073654 003 Dec 21, 1993 Jul CMS1

METRONIDAZOLE

CAPSULE;ORAL

METRONIDAZOLE

AB ALEMBIC PHARMS LTD 375MG

A079065 001 Jun 23, 2009 May CAHN

GEL;TOPICAL

METRONIDAZOLE

AB TARO PHARM 1%

A204651 001 Mar 14, 2017 Feb NEWA

GEL;VAGINAL

NUVESSA

+! CHEMO RESEARCH SL 1.3%

N205223 001 Mar 24, 2014 Aug CAHN

INJECTABLE;INJECTION

METRONIDAZOLE

@ WEST-WARD PHARMS INT 500MG/100ML

N018907 001 Mar 30, 1984 May CAHN

METRONIDAZOLE IN PLASTIC CONTAINER

AP BAXTER HLTHCARE CORP 500MG/100ML

A078084 001 Mar 31, 2008 Aug CAHN

AP MYLAN LABS LTD 500MG/100ML

A205531 001 May 09, 2017 Apr NEWA

TABLET;ORAL

METRONIDAZOLE

&gt;A&gt; AB CADILA PHARMS LTD 250MG

A209794 001 Dec 12, 2017 Nov NEWA

&gt;A&gt; AB 500MG

A209794 002 Dec 12, 2017 Nov NEWA

@ CHARTWELL MOLECULES 250MG

N018845 001 Aug 18, 1983 Jun CAHN

@ 500MG

N018930 001 Aug 18, 1983 Jun CAHN

AB INNOGENIX 250MG

A070772 001 Jul 16, 1986 Sep CAHN

AB 500MG

A070773 001 Jul 16, 1986 Sep CAHN

AB LUPIN LTD 250MG

A209096 001 Sep 12, 2017 Sep NEWA

AB 500MG

A209096 002 Sep 12, 2017 Sep NEWA

AB ORIT LABS LLC 250MG

A208681 001 Jun 20, 2017 Jun NEWA

AB 500MG

A208681 002 Jun 20, 2017 Jun NEWA

AB VIVIMED GLOBAL 250MG

A070040 001 Jan 29, 1985 Aug CAHN

AB 500MG

A070039 001 Jan 29, 1985 Aug CAHN

TABLET, EXTENDED RELEASE;ORAL									
METRONIDAZOLE									
AB	ALEMBIC PHARMS LTD	750MG		A090222	001	May 05, 2010	May	CAHN	
<u>MICONAZOLE NITRATE</u>									
SUPPOSITORY;VAGINAL									
MICONAZOLE NITRATE									
AB	ACTAVIS PHARMA	200MG		A073508	001	Nov 19, 1993	May	CAHN	
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE</u>									
OINTMENT;TOPICAL									
VUSION									
+	MYLAN PHARMS INC	0.25%;81.35%;15%		N021026	001	Feb 16, 2006	Jan	CAHN	
<u>MIDAZOLAM HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
MIDAZOLAM HYDROCHLORIDE									
	@ BAXTER HLTHCARE CORP	EQ 1MG BASE/ML		A075637	001	Oct 31, 2000	Aug	CAHN	
	@	EQ 5MG BASE/ML		A075637	002	Oct 31, 2000	Aug	CAHN	
	FRESENIUS KABI USA	EQ 5MG BASE/ML		A208878	001	Mar 28, 2017	Mar	NEWA	
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML		A075243	001	Jun 20, 2000	Jan	CAHN	
AP		EQ 1MG BASE/ML		A075247	002	Jun 23, 2000	Jan	CAHN	
AP		EQ 1MG BASE/ML		A075324	001	Jun 20, 2000	Mar	CAHN	
AP		EQ 1MG BASE/ML		A075421	002	Jun 20, 2000	Jan	CAHN	
AP		EQ 5MG BASE/ML		A075243	002	Jun 20, 2000	Jan	CAHN	
AP		EQ 5MG BASE/ML		A075247	001	Jun 23, 2000	Jan	CAHN	
AP		EQ 5MG BASE/ML		A075324	002	Jun 20, 2000	Mar	CAHN	
AP		EQ 5MG BASE/ML		A075421	001	Jun 20, 2000	Jan	CAHN	
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE									
AP	SAGENT AGILA LLC	EQ 1MG BASE/ML		A090315	001	Nov 29, 2010	May	CAHN	
AP		EQ 5MG BASE/ML		A090315	002	Nov 29, 2010	May	CAHN	
SYRUP;ORAL									
MIDAZOLAM HYDROCHLORIDE									
	@ SUN PHARM INDS LTD	EQ 2MG BASE/ML		A076058	001	Mar 15, 2002	May	DISC	
<u>MIDODRINE HYDROCHLORIDE</u>									
TABLET;ORAL									
MIDODRINE HYDROCHLORIDE									
BX	APOTEX INC	2.5MG		A077746	001	Sep 12, 2006	Sep	CTEC	
BX		5MG		A077746	002	Sep 12, 2006	Sep	CTEC	
BX		10MG		A077746	003	Sep 12, 2006	Sep	CTEC	
ORVATEN									
AB	UPSHER-SMITH LABS	2.5MG		A076725	001	Nov 03, 2004	Jun	CAHN	
AB		5MG		A076725	002	Nov 03, 2004	Jun	CAHN	
AB		10MG		A076725	003	Nov 03, 2004	Jun	CAHN	
PROAMATINE									
+	@ SHIRE LLC	2.5MG		N019815	001	Sep 06, 1996	Feb	CRLD	
+	@	5MG		N019815	002	Sep 06, 1996	Feb	CRLD	
+	@	10MG		N019815	003	Mar 20, 2002	Feb	CRLD	
<u>MIDOSTAURIN</u>									
CAPSULE;ORAL									
RYDAPT									
+	NOVARTIS PHARMS CORP	25MG		N207997	001	Apr 28, 2017	Apr	NEWA	
<u>MILNACIPRAN HYDROCHLORIDE</u>									
TABLET;ORAL									
MILNACIPRAN HYDROCHLORIDE									
	@ WINDLAS HLTHCARE	12.5MG		A205071	001	Jan 27, 2016	Sep	CAHN	
	@	25MG		A205071	002	Jan 27, 2016	Sep	CAHN	
	@	50MG		A205071	003	Jan 27, 2016	Sep	CAHN	
	@	100MG		A205071	004	Jan 27, 2016	Sep	CAHN	
SAVELLA									
AB	+ ALLERGAN SALES LLC	12.5MG		N022256	001	Jan 14, 2009	Feb	CAHN	
AB	+	25MG		N022256	002	Jan 14, 2009	Feb	CAHN	
AB	+	50MG		N022256	003	Jan 14, 2009	Feb	CAHN	
AB	+	100MG		N022256	004	Jan 14, 2009	Feb	CAHN	

MILRINONE LACTATE

## INJECTABLE;INJECTION

## MILRINONE LACTATE

	@ BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Aug CAHN
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jan CAHN
AP		EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan CAHN
	@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Mar CAHN
	MILRINONE LACTATE IN DEXTROSE 5%					
AP	RENAISSANCE SSA LLC	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Aug CAHN
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@ RENAISSANCE SSA LLC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Aug CAHN
	@ WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002	Mar CAHN
AP		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jan CAHN
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jan CAHN
	PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
	+ @ SANOFI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994	Jan CRLD
	+ @	EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan CRLD
	+ @	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan CRLD
	+ @	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan CRLD

MINOCYCLINE HYDROCHLORIDE

## CAPSULE;ORAL

## DYNACIN

AB	CNTY LINE PHARMS	EQ 50MG BASE	A063067	003	Aug 14, 1990	Sep CMFD
	MINOCIN					
>D> AB	PRECISION DERMAT	EQ 50MG BASE	N050649	001	May 31, 1990	Nov CRLD
>A> AB	+	EQ 50MG BASE	N050649	001	May 31, 1990	Nov CRLD
>D> AB		EQ 100MG BASE	N050649	002	May 31, 1990	Nov CRLD
>A> AB	+	EQ 100MG BASE	N050649	002	May 31, 1990	Nov CRLD
	MINOCYCLINE HYDROCHLORIDE					
AB	WATSON LABS TEVA	EQ 50MG BASE	A063181	001	Dec 30, 1991	May CAHN
	CAPSULE, EXTENDED RELEASE;ORAL					
	XIMINO					
	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr CMFD
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr CMFD
		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr CMFD
	TABLET, EXTENDED RELEASE;ORAL					
	MINOCYCLINE HYDROCHLORIDE					
	@ BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr DISC
		EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr NEWA
	@	EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr DISC
		EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr NEWA
	@ MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010	May DISC
	@	EQ 80MG BASE	A203443	002	Aug 22, 2014	May DISC
	@	EQ 90MG BASE	A090911	002	Jul 20, 2010	May DISC
	@	EQ 105MG BASE	A203443	003	Aug 22, 2014	May DISC
	@	EQ 135MG BASE	A090911	003	Jul 20, 2010	May DISC
AB	ZYDUS PHARMS USA INC	EQ 45MG BASE	A203553	001	Nov 16, 2017	Oct NEWA
AB		EQ 80MG BASE	A203553	004	Nov 16, 2017	Oct NEWA
AB		EQ 90MG BASE	A203553	005	Nov 16, 2017	Oct NEWA
AB		EQ 105MG BASE	A203553	006	Nov 16, 2017	Oct NEWA
AB		EQ 135MG BASE	A203553	008	Nov 16, 2017	Oct NEWA
	MINOLIRA					
	DR REDDYS LABS LTD	EQ 105MG BASE	N209269	001	May 08, 2017	May NEWA
		EQ 135MG BASE	N209269	002	May 08, 2017	May NEWA

MIRABEGRON

## TABLET, EXTENDED RELEASE;ORAL

## MYRBETRIQ

+	APGDI	25MG	N202611	001	Jun 28, 2012	Feb CHRS
---	-------	------	---------	-----	--------------	----------

MIRTAZAPINE

## TABLET; ORAL

## MIRTAZAPINE

>D>	AB	MYLAN PHARMS INC	15MG	A076176	001	Jun 19, 2003	Nov	DISC
>A>		@	15MG	A076176	001	Jun 19, 2003	Nov	DISC
>D>	AB		30MG	A076176	002	Jun 19, 2003	Nov	DISC
>A>		@	30MG	A076176	002	Jun 19, 2003	Nov	DISC
>D>	AB		45MG	A076176	003	Jun 19, 2003	Nov	DISC
>A>		@	45MG	A076176	003	Jun 19, 2003	Nov	DISC
		@ UPSHER-SMITH LABS	15MG	A076189	001	Jun 19, 2003	Jun	CAHN
	AB		15MG	A076219	001	Jun 19, 2003	Jun	CAHN
		@	30MG	A076189	002	Jun 19, 2003	Jun	CAHN
	AB		30MG	A076219	002	Jun 19, 2003	Jun	CAHN
		@	45MG	A076189	003	Jun 19, 2003	Jun	CAHN
	AB		45MG	A076219	003	Jun 19, 2003	Jun	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL  
MIRTAZAPINE

	AB	AUROBINDO PHARMA LTD	15MG	A077376	002	Dec 08, 2005	Jan	CAHN
	AB		30MG	A077376	003	Dec 08, 2005	Jan	CAHN
	AB		45MG	A077376	004	Feb 28, 2006	Jan	CAHN
	AB	ZYDUS PHARMS USA INC	15MG	A205798	001	Jun 01, 2017	May	NEWA
	AB		30MG	A205798	002	Jun 01, 2017	May	NEWA
	AB		45MG	A205798	003	Jun 01, 2017	May	NEWA

MITOMYCIN

## INJECTABLE; INJECTION

## MITOMYCIN

	AP	MYLAN LABS LTD	5MG/VIAL	A202670	001	Oct 13, 2017	Oct	NEWA
	AP		20MG/VIAL	A202670	002	Oct 13, 2017	Oct	NEWA
	AP		40MG/VIAL	A203386	001	Oct 13, 2017	Oct	NEWA
	AP	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	Jan	CAHN
	AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan	CAHN
	AP		20MG/VIAL	A064117	002	Apr 19, 1995	Jan	CAHN
	AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan	CAHN

## MUTAMYCIN

		+ @ BRISTOL	5MG/VIAL	N050450	001		Jan	CRLD
		+ @	20MG/VIAL	N050450	002		Jan	CRLD

MODAFINIL

## TABLET; ORAL

## MODAFINIL

	AB	ALEMBIC PHARMS LTD	100MG	A202700	001	Oct 18, 2012	May	CAHN
	AB		200MG	A202700	002	Oct 18, 2012	May	CAHN
	AB	APPCO PHARMA LLC	100MG	A207196	001	Aug 16, 2017	Aug	NEWA
	AB		200MG	A207196	002	Aug 16, 2017	Aug	NEWA
	AB	ZYDUS PHARMS USA INC	100MG	A209966	001	Sep 14, 2017	Sep	NEWA
	AB		200MG	A209966	002	Sep 14, 2017	Sep	NEWA

MOEXIPRIL HYDROCHLORIDE

## TABLET; ORAL

## MOEXIPRIL HYDROCHLORIDE

	AB	CHARTWELL RX	7.5MG	A077536	001	Nov 30, 2006	Apr	CAHN
	AB		15MG	A077536	002	Nov 30, 2006	Apr	CAHN

MOLINDONE HYDROCHLORIDE

## TABLET; ORAL

## MOLINDONE HYDROCHLORIDE

		EPIC PHARMA LLC	5MG	A090453	001	Mar 20, 2015	May	CAHN
			10MG	A090453	002	Mar 20, 2015	May	CAHN
		!	25MG	A090453	003	Mar 20, 2015	May	CAHN

MOMETASONE FUROATE

## LOTION; TOPICAL

## MOMETASONE FUROATE

	AB	PERRIGO ISRAEL	0.1%	A077180	001	Apr 06, 2005	Apr	CAHN
		SPRAY, METERED; NASAL						
		MOMETASONE FUROATE						
	AB	AMNEAL PHARMS	EQ 0.05MG BASE/SPRAY	A207989	001	Apr 03, 2017	Mar	NEWA



MONTELUKAST SODIUM

## TABLET;ORAL

## MONTELUKAST SODIUM

AB	CSPC OUYI PHARM CO	EQ 10MG BASE	A209012	001	Apr 24, 2017	Apr NEWA
AB	PERRIGO R AND D	EQ 10MG BASE	A206112	001	Apr 26, 2017	Apr NEWA
SINGULAIR						
AB	+! MSD MERCK CO	EQ 10MG BASE	N020829	002	Feb 20, 1998	Oct CAHN
TABLET, CHEWABLE;ORAL						
MONTELUKAST SODIUM						
AB	CSPC OUYI PHARM CO	EQ 4MG BASE	A209011	001	Apr 18, 2017	Apr NEWA
AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Apr NEWA
SINGULAIR						
AB	+ MSD MERCK CO	EQ 4MG BASE	N020830	002	Mar 03, 2000	Oct CAHN
AB	+!	EQ 5MG BASE	N020830	001	Feb 20, 1998	Oct CAHN

MORPHINE SULFATE

## CAPSULE, EXTENDED RELEASE;ORAL

## MORPHINE SULFATE

ACTAVIS ELIZABETH		30MG	A079040	001	Jan 16, 2013	Apr CAHN
		45MG	A079040	002	Jan 16, 2013	Apr CAHN
		60MG	A079040	003	Jan 16, 2013	Apr CAHN
		75MG	A079040	004	Jan 16, 2013	Apr CAHN
		90MG	A079040	005	Jan 16, 2013	Apr CAHN
!		120MG	A079040	006	Jan 16, 2013	Apr CAHN
AB	UPSHER-SMITH LABS	10MG	A202104	001	Jun 03, 2013	Jun CAHN
AB		20MG	A202104	002	Jun 03, 2013	Jun CAHN
AB		30MG	A202104	003	Jun 03, 2013	Jun CAHN
AB		50MG	A202104	004	Jun 03, 2013	Jun CAHN
AB		60MG	A202104	005	Jun 03, 2013	Jun CAHN
AB		80MG	A202104	006	Jun 03, 2013	Jun CAHN
AB		100MG	A202104	007	Jun 03, 2013	Jun CAHN

## INJECTABLE;INJECTION

## MORPHINE SULFATE

+ @ HOSPIRA INC		15MG/ML	N202515	005	Nov 14, 2011	Aug DISC
@ ICU MEDICAL INC		0.5MG/ML	N019917	001	Oct 30, 1992	Jun CAHN
AP	+!	1MG/ML	N019916	001	Oct 30, 1992	Apr CAHN
	+!	5MG/ML	N019916	002	Oct 27, 2006	Apr CAHN
@ MALLINCKRODT INC		1MG/ML	N020631	001	Jul 03, 1996	Apr CAHN
@		2MG/ML	N020631	002	Jul 03, 1996	Apr CAHN

## SOLUTION;ORAL

## MORPHINE SULFATE

AA	HI-TECH PHARMACAL	100MG/5ML	A208809	001	Jul 06, 2017	Jun NEWA
AA	RHODES PHARMS	10MG/5ML	A206308	001	Jun 22, 2017	Jun NEWA
AA		100MG/5ML	A206308	002	Jun 22, 2017	Jun NEWA
AA	+ WEST-WARD PHARMS INT	10MG/5ML	N022195	001	Mar 17, 2008	Jan CAHN
AA	+	20MG/5ML	N022195	002	Mar 17, 2008	Jan CAHN
AA	+!	100MG/5ML	N022195	003	Jan 25, 2010	Jan CAHN

## TABLET;ORAL

## MORPHINE SULFATE

+ WEST-WARD PHARMS INT		15MG	N022207	001	Mar 17, 2008	Jan CAHN
+!		30MG	N022207	002	Mar 17, 2008	Jan CAHN

## TABLET, EXTENDED RELEASE;ORAL

## ARYMO ER

+ EGALET		15MG	N208603	001	Jan 09, 2017	Jan NEWA
+		30MG	N208603	002	Jan 09, 2017	Jan NEWA
+		60MG	N208603	003	Jan 09, 2017	Jan NEWA

## MORPHABOND ER

+ DAIICHI SANKYO INC		15MG	N206544	001	Oct 02, 2015	Jan CTNA
+		30MG	N206544	002	Oct 02, 2015	Jan CTNA
+		60MG	N206544	003	Oct 02, 2015	Jan CTNA
+!		100MG	N206544	004	Oct 02, 2015	Jan CTNA

## MORPHINE SULFATE

AB	ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Apr CAHN
AB		30MG	A203849	002	Apr 06, 2015	Apr CAHN
AB		60MG	A203849	003	Apr 06, 2015	Apr CAHN
AB		100MG	A203849	004	Apr 06, 2015	Apr CAHN
AB		200MG	A203849	005	Apr 06, 2015	Apr CAHN
AB	EPIC PHARMA LLC	15MG	A091357	001	Jun 23, 2016	May CAHN
AB		30MG	A091357	002	Jun 23, 2016	May CAHN
AB		60MG	A091357	003	Jun 23, 2016	May CAHN
AB		100MG	A091357	004	Jun 23, 2016	May CAHN

TABLET, EXTENDED RELEASE;ORAL  
MORPHINE SULFATE

AB		200MG	A091357	005	Jun 23, 2016	May CAHN
AB	SUN PHARM INDUSTRIES	15MG	A205634	001	Aug 25, 2016	Mar CAHN
AB		30MG	A205634	002	Aug 25, 2016	Mar CAHN
AB		60MG	A205634	003	Aug 25, 2016	Mar CAHN
AB		100MG	A205634	004	Aug 25, 2016	Mar CAHN
AB		200MG	A205634	005	Aug 25, 2016	Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)  
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

AP	+! BAYER HLTHCARE	400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Apr CFTG
AP	MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Apr NEWA

SOLUTION/DROPS;OPHTHALMIC  
MOXIFLOXACIN HYDROCHLORIDE

AT1	AKORN	EQ 0.5% BASE	A202916	001	Nov 09, 2017	Oct NEWA
AT1	APOTEX INC	EQ 0.5% BASE	A090080	001	Jun 30, 2017	Jun NEWA
AT1	AUROBINDO PHARMA LTD	EQ 0.5% BASE	A206242	001	Oct 04, 2017	Sep NEWA

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB	MSN LABS PVT LTD	EQ 400MG BASE	A208682	001	Sep 22, 2017	Sep NEWA
AB	NOVEL LABS INC	EQ 400MG BASE	A207285	001	Feb 13, 2017	Jan NEWA

MUPIROCIN

OINTMENT;TOPICAL  
MUPIROCIN

AB	! PERRIGO NEW YORK	2%	A065123	001	Nov 07, 2003	May CHRS
----	--------------------	----	---------	-----	--------------	----------

MUPIROCIN CALCIUM

CREAM;TOPICAL  
MUPIROCIN

AB	GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	May CAHN
----	---------------------	------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL  
MYCOPHENOLATE MOFETIL

AB	@ JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014	Sep DISC
AB	ZHEJIANG HISUN PHARM	250MG	A204077	001	Nov 13, 2017	Oct NEWA

TABLET;ORAL

MYCOPHENOLATE MOFETIL

>A> AB	@ JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014	Sep DISC
	ZHEJIANG HISUN PHARM	500MG	A204076	001	Nov 16, 2017	Nov NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION  
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP	AKORN INC	500MG/VIAL	A204043	001	Feb 28, 2017	Feb NEWA
AP	MYLAN LABS LTD	500MG/VIAL	A203859	001	Mar 31, 2017	Mar NEWA
AP	ZYDUS PHARMS USA INC	500MG/VIAL	A204473	001	Aug 31, 2017	Aug NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL  
MYCOPHENOLIC ACID

AB	ACCORD HLTHCARE	180MG	A202555	001	Aug 23, 2017	Aug NEWA
AB		360MG	A202555	002	Aug 23, 2017	Aug NEWA

NABILONE

CAPSULE;ORAL  
CESAMET

+!	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985	Mar CAHN
----	---------------------	-----	---------	-----	--------------	----------

NADOLOL

TABLET;ORAL  
NADOLOL

AB	AMNEAL PHARMS CO	20MG	A208832	001	Jun 02, 2017	May NEWA
AB		40MG	A208832	002	Jun 02, 2017	May NEWA
AB		80MG	A208832	003	Jun 02, 2017	May NEWA
>A> AB	AUROBINDO PHARMA LTD	40MG	A201893	001	Sep 16, 2015	Nov CAHN
>A> AB		80MG	A201893	002	Sep 16, 2015	Nov CAHN
AB	LUPIN LTD	20MG	A209309	001	Oct 05, 2017	Sep NEWA

## TABLET; ORAL

## NADOLOL

	AB		40MG		A209309	002	Oct 05, 2017	Sep	NEWA
	AB		80MG		A209309	003	Oct 05, 2017	Sep	NEWA
>D>	AB	ORION CORP ORION	40MG		A201893	001	Sep 16, 2015	Nov	CAHN
>D>	AB		80MG		A201893	002	Sep 16, 2015	Nov	CAHN
	AB	ZYDUS PHARMS USA INC	20MG		A207761	001	Jul 28, 2017	Jul	NEWA
	AB		40MG		A207761	002	Jul 28, 2017	Jul	NEWA
	AB		80MG		A207761	003	Jul 28, 2017	Jul	NEWA

NAFTIFINE HYDROCHLORIDE

## CREAM; TOPICAL

## NAFTIFINE HYDROCHLORIDE

AB		TOLMAR	2%	A206960	001	Apr 10, 2017	Mar NEWA
----	--	--------	----	---------	-----	--------------	----------

NALDEMEDINE TOSYLATE

## TABLET; ORAL

## SYMPROIC

+	!	SHIONOGI INC	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Mar NEWA
---	---	--------------	---------------	---------	-----	--------------	----------

NALMEFENE HYDROCHLORIDE

## INJECTABLE; INJECTION

## REVEX

>D>		@ EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Nov CRLD
>A>	+	@	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Nov CRLD
>D>		@	EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Nov CRLD
>A>	+	@	EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Nov CRLD

NALOXONE HYDROCHLORIDE

## INJECTABLE; INJECTION

## NALOXONE

@	WEST-WARD PHARMS INT	0.4MG/ML	A070298	001	Sep 24, 1986	Jan CAHN
---	----------------------	----------	---------	-----	--------------	----------

@		0.4MG/ML	A070496	001	Sep 24, 1986	Jan CAHN
---	--	----------	---------	-----	--------------	----------

## NALOXONE HYDROCHLORIDE

AP		AKORN	0.4MG/ML	A208871	001	Feb 28, 2017	Feb NEWA
AP			0.4MG/ML	A208872	001	Mar 14, 2017	Feb NEWA
>D>	AP	!	INTL MEDICATION	A072076	001	Mar 24, 1988	Nov CTEC
>A>		!	1MG/ML	A072076	001	Mar 24, 1988	Nov CTEC
AP		SOMERSET THERAPS LLC	0.4MG/ML	A207633	001	Aug 08, 2017	Jul NEWA
AP			0.4MG/ML	A207634	001	Jul 26, 2017	Jul NEWA

## SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

## EVZIO

+	@	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014	Aug DISC
---	---	-----------	---------------------------	---------	-----	--------------	----------

## SPRAY, METERED; NASAL

## NARCAN

+		ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Jan NEWA
---	--	-------	-----------	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## TARGINIQ

+	@	PURDUE PHARMA LP	5MG; 10MG	N205777	001	Jul 23, 2014	Oct CRLD
+	@		10MG; 20MG	N205777	002	Jul 23, 2014	Oct CRLD
+	@		20MG; 40MG	N205777	003	Jul 23, 2014	Oct CRLD

NALTREXONE HYDROCHLORIDE

## TABLET; ORAL

## NALTREXONE HYDROCHLORIDE

AB		APOTEX INC	50MG	A207905	001	Jul 21, 2017	Jul NEWA
----	--	------------	------	---------	-----	--------------	----------

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## TROXYCA ER

@	PFIZER INC	1.2MG; 10MG	N207621	001	Aug 19, 2016	Oct DISC
@		2.4MG; 20MG	N207621	002	Aug 19, 2016	Oct DISC
@		3.6MG; 30MG	N207621	003	Aug 19, 2016	Oct DISC
@		4.8MG; 40MG	N207621	004	Aug 19, 2016	Oct DISC
@		7.2MG; 60MG	N207621	005	Aug 19, 2016	Oct DISC
@		9.6MG; 80MG	N207621	006	Aug 19, 2016	Oct DISC

NANDROLONE DECANOATEINJECTABLE; INJECTION  
NANDROLONE DECANOATE

! LUITPOLD PHARMS INC 200MG/ML

A091252 001 Aug 30, 2010 Jun CAHN

NAPROXEN

TABLET; ORAL

NAPROXEN

AB AUROBINDO PHARMA LTD 250MG

A200429 001 Nov 08, 2011 Jan CAHN

AB 375MG

A200429 002 Nov 08, 2011 Jan CAHN

AB 500MG

A200429 003 Nov 08, 2011 Jan CAHN

@ CHARTWELL MOLECULES 250MG

A074410 001 Apr 28, 1995 May CAHN

@ 375MG

A074410 002 Apr 28, 1995 May CAHN

@ 500MG

A074410 003 Apr 28, 1995 May CAHN

@ HIKMA INTL PHARMS 250MG

A076494 001 Jan 14, 2004 May DISC

@ 375MG

A076494 002 Jan 14, 2004 May DISC

@ 500MG

A076494 003 Jan 14, 2004 May DISC

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

@ MYLAN PHARMS INC 375MG

A075390 001 Apr 19, 2001 Oct DISC

@ 500MG

A075390 002 Apr 19, 2001 Oct DISC

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

AB GLENMARK PHARMS LTD EQ 250MG BASE

A078314 001 Apr 27, 2007 May CAHN

AB EQ 500MG BASE

A078314 002 Apr 27, 2007 May CAHN

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN

+! NOVARTIS PHARMS CORP 5%

N050514 001 Jan CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

AB @ GLENMARK PHARMS LTD EQ 2.5MG BASE

A203821 001 May 25, 2017 May DISC

EQ 2.5MG BASE

A203821 001 May 25, 2017 May NEWA

@ EQ 5MG BASE

A203821 002 May 25, 2017 May DISC

AB EQ 5MG BASE

A203821 002 May 25, 2017 May NEWA

@ EQ 10MG BASE

A203821 003 May 25, 2017 May DISC

AB EQ 10MG BASE

A203821 003 May 25, 2017 May NEWA

@ EQ 20MG BASE

A203821 004 May 25, 2017 May DISC

AB EQ 20MG BASE

A203821 004 May 25, 2017 May NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL

BYVALSON

+! FOREST LABS LLC EQ 5MG BASE; 80MG

N206302 001 Jun 03, 2016 May CRLD

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

&gt;D&gt; BX DR REDDYS LABS INC 50MG

A076309 001 Sep 16, 2003 Nov DISC

&gt;A&gt; @ 50MG

A076309 001 Sep 16, 2003 Nov DISC

&gt;D&gt; BX 100MG

A076309 002 Sep 16, 2003 Nov DISC

&gt;A&gt; @ 100MG

A076309 002 Sep 16, 2003 Nov DISC

&gt;D&gt; BX 150MG

A076309 003 Sep 16, 2003 Nov DISC

&gt;A&gt; @ 150MG

A076309 003 Sep 16, 2003 Nov DISC

&gt;D&gt; BX 200MG

A076309 004 Sep 16, 2003 Nov DISC

&gt;A&gt; @ 200MG

A076309 004 Sep 16, 2003 Nov DISC

&gt;D&gt; BX 250MG

A076309 005 Sep 16, 2003 Nov DISC

&gt;A&gt; @ 250MG

A076309 005 Sep 16, 2003 Nov DISC

&gt;D&gt; AB TEVA 50MG

A076037 001 Sep 16, 2003 Nov CTEC

&gt;A&gt; 50MG

A076037 001 Sep 16, 2003 Nov CTEC

&gt;D&gt; AB 100MG

A076037 002 Sep 16, 2003 Nov CTEC

&gt;A&gt; 100MG

A076037 002 Sep 16, 2003 Nov CTEC

&gt;D&gt; AB 150MG

A076037 003 Sep 16, 2003 Nov CTEC

&gt;A&gt; 150MG

A076037 003 Sep 16, 2003 Nov CTEC

&gt;D&gt; AB 200MG

A076037 004 Sep 16, 2003 Nov CTEC

&gt;A&gt; 200MG

A076037 004 Sep 16, 2003 Nov CTEC

TABLET;ORAL  
NEFAZODONE HYDROCHLORIDE

>D>	AB	!		250MG	A076037	005	Sep 16, 2003	Nov CTEC
>A>		!		250MG	A076037	005	Sep 16, 2003	Nov CTEC

NELFINAVIR MESYLATE

POWDER;ORAL  
VIRACEPT

@ AGOURON PHARMS EQ 50MG BASE/SCOOPFUL

N020778 001 Mar 14, 1997 Jan CAHN

TABLET;ORAL  
VIRACEPT

+! AGOURON PHARMS EQ 250MG BASE

N020779 001 Mar 14, 1997 Jan CAHN

+! EQ 625MG BASE

N021503 001 Apr 30, 2003 Jan CAHN

NEOMYCIN SULFATE

TABLET;ORAL  
NEOMYCIN SULFATE

AA BRECKENRIDGE PHARM 500MG

A065468 001 Mar 29, 2010 Sep CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION  
NEOSPORIN G.U. IRRIGANT

AT ! MONARCH PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML

A060707 001 Apr CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS  
NEOSTIGMINE METHYLSULFATE

AP AMPHASTAR PHARMS INC 5MG/10ML (0.5MG/ML)

A209933 001 Sep 25, 2017 Sep NEWA

AP 10MG/10ML (1MG/ML)

A209933 002 Sep 25, 2017 Sep NEWA

AP PAR STERILE PRODUCTS 5MG/10ML (0.5MG/ML)

A208405 001 Apr 26, 2017 Apr NEWA

AP 10MG/10ML (1MG/ML)

A208405 002 Apr 26, 2017 Apr NEWA

NERATINIB MALEATE

TABLET;ORAL  
NERLYNX

+! PUMA BIOTECH EQ 40MG BASE

N208051 001 Jul 17, 2017 Jul NEWA

NEVIRAPINE

SUSPENSION;ORAL  
NEVIRAPINE

AA CIPLA LTD 50MG/5ML

A207684 001 Aug 03, 2017 Jul NEWA

TABLET;ORAL  
NEVIRAPINE

AB TECH ORGANIZED 200MG

A203176 001 May 22, 2012 Sep CAHN

TABLET, EXTENDED RELEASE;ORAL  
NEVIRAPINE

AB AUROBINDO PHARMA LTD 400MG

A207698 001 Feb 28, 2017 Mar CAHN

AB AUROBINDO PHARMA USA 400MG

A207698 001 Feb 28, 2017 Feb NEWA

AB MACLEODS PHARMS LTD 400MG

A206879 001 Oct 06, 2017 Sep NEWA

AB SCIEGEN PHARMS INC 100MG

A207467 001 Jul 31, 2017 Jul NEWA

AB 400MG

A207467 002 Jul 31, 2017 Jul NEWA

AB TECH ORGANIZED 100MG

A207467 001 Jul 31, 2017 Sep CAHN

AB 400MG

A207467 002 Jul 31, 2017 Sep CAHN

NIACIN

TABLET;ORAL  
NIACOR

AA ! AVONDALE PHARMS 500MG

A040378 001 May 03, 2000 Oct CAHN

AA ! UPSHER-SMITH LABS 500MG

A040378 001 May 03, 2000 Jun CAHN

TABLET, EXTENDED RELEASE;ORAL  
NIACIN

AB LANNETT CO INC 500MG

A203899 001 Jun 16, 2017 Jun NEWA

AB 1GM

A203899 002 Jun 16, 2017 Jun NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION  
NICARDIPINE HYDROCHLORIDE

AP WEST-WARD PHARMS INT 25MG/10ML (2.5MG/ML)

A078714 001 Dec 28, 2009 Jan CAHN

INJECTABLE;INTRAVENOUS  
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE  
EXELA PHARMA SCIENCE 20MG/200ML (0.1MG/ML)

N022276 002 Apr 07, 2016 Feb NEWA

## INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE  
40MG/200ML (0.2MG/ML)

N022276 003 Apr 07, 2016 Feb NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL  
AFEDITAB CR

AB1	WATSON LABS TEVA	30MG	A075128	001	Mar 10, 2000	May CAHN
	NIFEDIPINE					
	@ MYLAN LABS LTD	30MG	A090602	001	Sep 13, 2010	May DISC
AB2		30MG	A090602	001	Sep 13, 2010	Mar CAHN
	@	60MG	A090602	002	Sep 13, 2010	May DISC
AB2		60MG	A090602	002	Sep 13, 2010	Mar CAHN
	@	90MG	A090602	003	Sep 13, 2010	May DISC
AB2		90MG	A090602	003	Sep 13, 2010	Mar CAHN
AB2	OSMOTICA PHARM US	90MG	A077410	001	Oct 03, 2007	Jun CAHN

NIRAPARIB TOSYLATE

CAPSULE;ORAL  
ZEJULA

+! TESARO INC EQ 100MG BASE

N208447 001 Mar 27, 2017 Mar NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL  
SULAR

AB	+! COVIS PHARMA BV	8.5MG	N020356	008	Jan 02, 2008	May CAHN
	+ @	10MG	N020356	001	Feb 02, 1995	May CAHN
AB	+!	17MG	N020356	007	Jan 02, 2008	May CAHN
	+ @	20MG	N020356	002	Feb 02, 1995	May CAHN
	+ @	25.5MG	N020356	006	Jan 02, 2008	May CAHN
	+ @	30MG	N020356	003	Feb 02, 1995	May CAHN
AB	+!	34MG	N020356	005	Jan 02, 2008	May CAHN
	+ @	40MG	N020356	004	Feb 02, 1995	May CAHN

NITISINONE

CAPSULE;ORAL  
ORFADIN

+ SWEDISH ORPHAN 10MG

N021232 003 Jan 18, 2002 Oct CHRS

TABLET;ORAL  
NITYR

+ CYCLE PHARMS LTD 2MG  
+ 5MG  
+! 10MG

N209449 001 Jul 26, 2017 Jul NEWA  
N209449 002 Jul 26, 2017 Jul NEWA  
N209449 003 Jul 26, 2017 Jul NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL  
NITROFURANTOIN

>A> AB ZYDUS PHARMS USA INC 50MG  
>A> AB 100MG

A205005 001 Dec 12, 2017 Nov NEWA  
A205005 002 Dec 12, 2017 Nov NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL  
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB AMNEAL PHARMS 75MG;25MG

A207372 001 May 15, 2017 May NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL  
NITRO-DUR

AB1	+! USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Jun CAHN
AB1	+!	0.2MG/HR	N020145	002	Apr 04, 1995	Jun CAHN
	+!	0.3MG/HR	N020145	003	Apr 04, 1995	Jun CAHN
AB1	+!	0.4MG/HR	N020145	004	Apr 04, 1995	Jun CAHN
AB1	+!	0.6MG/HR	N020145	005	Apr 04, 1995	Jun CAHN
	+!	0.8MG/HR	N020145	006	Apr 04, 1995	Jun CAHN

OINTMENT;TRANSDERMAL  
NITROGLYCERIN

! FOUGERA PHARMS INC 2%

A087355 001 Jul 08, 1988 Jan CAHN

TABLET;SUBLINGUAL  
NITROGLYCERIN

AB	ACTAVIS LABS FL INC	0.3MG	A203693	001	Oct 16, 2017	Oct NEWA
AB		0.4MG	A203693	002	Oct 16, 2017	Oct NEWA
AB		0.6MG	A203693	003	Oct 16, 2017	Oct NEWA

TABLET;SUBLINGUAL							
NITROGLYCERIN							
AB	GLENMARK PHARMS LTD	0.3MG	A206391	001	Sep 19, 2017	Sep	NEWA
AB		0.4MG	A206391	002	Sep 19, 2017	Sep	NEWA
AB		0.6MG	A206391	003	Sep 19, 2017	Sep	NEWA
<u>NOREPINEPHRINE BITARTRATE</u>							
INJECTABLE;INJECTION							
NOREPINEPHRINE BITARTRATE							
AP	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Aug	CAHN
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Jan	CAHN
<u>NORGESTREL</u>							
TABLET;ORAL							
OPILL							
	+ @ LABORATOIRE HRA	0.075MG	N017031	001		Oct	CTNA
	+ @	0.075MG	N017031	001		Oct	CRLD
<u>NORTRIPTYLINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
NORTRIPTYLINE HYDROCHLORIDE							
	@ MYLAN	EQ 10MG BASE	A074234	001	Jul 26, 1993	Jun	DISC
	@	EQ 25MG BASE	A074234	002	Jul 26, 1993	Jun	DISC
	@	EQ 50MG BASE	A074234	003	Jul 26, 1993	Jun	DISC
	@	EQ 75MG BASE	A074234	004	Jul 26, 1993	Jun	DISC
AB	TARO PHARM	EQ 10MG BASE	A075520	004	May 08, 2000	Mar	CAHN
AB		EQ 25MG BASE	A075520	003	May 08, 2000	Mar	CAHN
AB		EQ 50MG BASE	A075520	001	May 08, 2000	Mar	CAHN
AB		EQ 75MG BASE	A075520	002	May 08, 2000	Mar	CAHN
SOLUTION;ORAL							
NORTRIPTYLINE HYDROCHLORIDE							
AA	! PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	May	CAHN
<u>NYSTATIN</u>							
CREAM;TOPICAL							
NYSTATIN							
AT	CROWN LABS INC	100,000 UNITS/GM	A207733	001	Sep 26, 2017	Sep	NEWA
OINTMENT;TOPICAL							
NYSTATIN							
AT	G AND W LABS INC	100,000 UNITS/GM	A209114	001	Oct 06, 2017	Sep	NEWA
PASTILLE;ORAL							
MYCOSTATIN							
	@ DELCOR ASSET CORP	200,000 UNITS	N050619	001	Apr 09, 1987	Jun	CAHN
POWDER;TOPICAL							
NYSTATIN							
AT	LYNE	100,000 UNITS/GM	A208838	001	May 30, 2017	May	NEWA
AT	NESHER PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	May	NEWA
AT	UPSHER-SMITH LABS	100,000 UNITS/GM	A065183	001	May 03, 2005	Jun	CAHN
SUSPENSION;ORAL							
NYSTATIN							
	@ ALLIED PHARMA INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jul	CAHN
AA	FOUGERA PHARMS INC	100,000 UNITS/ML	A062517	001	Jun 07, 1984	Jan	CAHN
AA	PHARM ASSOC	100,000 UNITS/ML	A203621	001	Jan 07, 2016	May	CAHN
AA	TARO PHARM	100,000 UNITS/ML	A062876	001	Feb 29, 1988	Apr	CAHN
TABLET;ORAL							
NYSTATIN							
	@ USL PHARMA	500,000 UNITS	A062524	001	Nov 26, 1985	Jun	CAHN
<u>NYSTATIN; TRIAMCINOLONE ACETONIDE</u>							
CREAM;TOPICAL							
MYCOLOG-II							
	@ MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A062606	001	May 15, 1985	Jan	CAHN
NYSTATIN AND TRIAMCINOLONE ACETONIDE							
AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062599	001	Oct 08, 1985	Jan	CAHN
AT	PERRIGO UK FINCO	100,000 UNITS/GM;0.1%	A208479	001	Aug 14, 2017	Jul	NEWA
OINTMENT;TOPICAL							
MYCOLOG-II							
	@ MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985	Jan	CAHN
NYSTATIN AND TRIAMCINOLONE ACETONIDE							
AT	AKORN	100,000 UNITS/GM;0.1%	A207217	001	Aug 04, 2017	Jul	NEWA
AT	DR REDDYS LABS LTD	100,000 UNITS/GM;0.1%	A207741	001	Jan 31, 2017	Jan	NEWA

## OINTMENT;TOPICAL

## NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062602	001	Oct 09, 1985	Jan CAHN
----	--------------------	-----------------------	---------	-----	--------------	----------

OCTREOTIDE ACETATE

## INJECTABLE;INJECTION

## OCTREOTIDE ACETATE

@	SUN PHARM INDS	EQ 0.05MG BASE/ML	A077329	001	Mar 04, 2008	Sep DISC
@		EQ 0.1MG BASE/ML	A077329	002	Mar 04, 2008	Sep DISC
@		EQ 0.2MG BASE/ML	A077330	001	Mar 04, 2008	Oct DISC
@		EQ 0.5MG BASE/ML	A077329	003	Mar 04, 2008	Sep DISC
@		EQ 1MG BASE/ML	A077331	001	Mar 04, 2008	Oct DISC

OFLOXACIN

## SOLUTION/DROPS;OPHTHALMIC

## OFLOXACIN

AT	SANDOZ INC	0.3%	A076231	001	May 14, 2004	Feb CAHN
----	------------	------	---------	-----	--------------	----------

## SOLUTION/DROPS;OTIC

## OFLOXACIN

AT	SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Feb CAHN
----	------------	------	---------	-----	--------------	----------

OLANZAPINE

## TABLET;ORAL

## OLANZAPINE

@	AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016	Oct DISC
@		5MG	A206711	002	Aug 30, 2016	Oct DISC
@		7.5MG	A206711	003	Aug 30, 2016	Oct DISC
@		10MG	A206711	004	Aug 30, 2016	Oct DISC
@		15MG	A206711	005	Aug 30, 2016	Oct DISC
@		20MG	A206711	006	Aug 30, 2016	Oct DISC
AB	HIKMA PHARMS	2.5MG	A204866	001	Jun 16, 2017	Jun NEWA
AB		5MG	A204866	002	Jun 16, 2017	Jun NEWA
AB		7.5MG	A204866	003	Jun 16, 2017	Jun NEWA
AB		10MG	A204866	004	Jun 16, 2017	Jun NEWA
AB		15MG	A204866	005	Jun 16, 2017	Jun NEWA
AB		20MG	A204866	006	Jun 16, 2017	Jun NEWA
@	MYLAN PHARMS INC	2.5MG	A076866	001	Apr 23, 2012	Jun DISC
AB		2.5MG	A076866	001	Apr 23, 2012	Mar CAHN
@		5MG	A076866	002	Apr 23, 2012	Jun DISC
AB		5MG	A076866	002	Apr 23, 2012	Mar CAHN
@		7.5MG	A076866	003	Apr 23, 2012	Jun DISC
AB		7.5MG	A076866	003	Apr 23, 2012	Mar CAHN
@		10MG	A076866	004	Apr 23, 2012	Jun DISC
AB		10MG	A076866	004	Apr 23, 2012	Mar CAHN
@		15MG	A076866	005	Apr 23, 2012	Jun DISC
AB		15MG	A076866	005	Apr 23, 2012	Mar CAHN
@		20MG	A076866	006	Apr 23, 2012	Jun DISC
AB		20MG	A076866	006	Apr 23, 2012	Mar CAHN

## TABLET, ORALLY DISINTEGRATING;ORAL

## OLANZAPINE

AB	AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017	May NEWA
AB		10MG	A204320	002	May 30, 2017	May NEWA
AB		15MG	A204320	003	May 30, 2017	May NEWA
AB		20MG	A204320	004	May 30, 2017	May NEWA

OLAPARIB

## CAPSULE;ORAL

## LYNPARZA

+	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Mar CRLD
---	--------------------	------	---------	-----	--------------	----------

## TABLET;ORAL

## LYNPARZA

+	ASTRAZENECA PHARMS	100MG	N208558	001	Aug 17, 2017	Aug NEWA
+		150MG	N208558	002	Aug 17, 2017	Aug NEWA

OLIVE OIL; SOYBEAN OIL

## INJECTABLE;INJECTION

## CLINOLIPID 20%

+	@ BAXTER HLTHCARE CORP	16% (160GM/1000ML) ; 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jul DISC
---	------------------------	---------------------------------------	---------	-----	--------------	----------



OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	ACCORD HLTHCARE	5MG	A207662	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A207662	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A207662	003	Apr 24, 2017	Apr	NEWA
AB	ALEMBIC PHARMS LTD	5MG	A203012	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A203012	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A203012	003	Apr 24, 2017	Apr	NEWA
AB	ALKEM LABS LTD	5MG	A206763	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A206763	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A206763	003	Apr 24, 2017	Apr	NEWA
AB	AUROBINDO PHARMA LTD	5MG	A204798	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A204798	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A204798	003	Apr 24, 2017	Apr	NEWA
AB	GLENMARK PHARMS LTD	5MG	A203281	001	May 25, 2017	May	NEWA
AB		20MG	A203281	002	May 25, 2017	May	NEWA
AB		40MG	A203281	003	May 25, 2017	May	NEWA
AB	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A205482	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A205482	003	Apr 24, 2017	Apr	NEWA
AB	LUPIN LTD	5MG	A206631	001	Apr 27, 2017	Apr	NEWA
AB		20MG	A206631	002	Apr 27, 2017	Apr	NEWA
AB		40MG	A206631	003	Apr 27, 2017	Apr	NEWA
AB	MACLEODS PHARMS LTD	5MG	A204814	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A204814	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A204814	003	Apr 24, 2017	Apr	NEWA
AB	TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A091079	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A091079	003	Apr 24, 2017	Apr	NEWA
AB	TORRENT PHARMS LTD	5MG	A202375	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A202375	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A202375	003	Apr 24, 2017	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG	A205192	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A205192	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A205192	003	Apr 24, 2017	Apr	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

>A>	AT	AKORN	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Nov	NEWA
>A>	AT	APOTEX INC	EQ 0.2% BASE	A090918	001	Dec 05, 2017	Nov	NEWA
	AT	CIPLA LTD	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Jul	NEWA
>A>	AT		EQ 0.2% BASE	A206087	001	Dec 05, 2017	Nov	NEWA
	AT	WOCKHARDT LTD	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Jun	NEWA
	AT	ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015	Sep	CAHN

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB	PERRIGO ISRAEL	0.665MG/SPRAY	A202853	001	Jan 31, 2017	Jan	NEWA
----	----------------	---------------	---------	-----	--------------	-----	------

OLSALAZINE SODIUM

CAPSULE;ORAL

DIPENTUM

+	!	MYLAN SPECIALITY LP	250MG	N019715	001	Jul 31, 1990	Mar	CAHN
---	---	---------------------	-------	---------	-----	--------------	-----	------

OMACETAXINE MEPESUCCINATE

POWDER;SUBCUTANEOUS

SYNRIBO

+	!	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Apr	CAHN
---	---	------------------	------------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	May	CAHN
AB	STRIDES PHARMA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A203893	001	Sep 19, 2017	Sep	NEWA

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE;ORAL

OMTRYG

+ @ OSMOTICA	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Sep DISC
+!	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Sep CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB	AUROBINDO PHARMA LTD	10MG	A203270	001	Aug 19, 2015	Jan CAHN
AB		20MG	A203270	002	Aug 19, 2015	Jan CAHN
AB		40MG	A203270	003	Aug 19, 2015	Jan CAHN
AB	BRECKENRIDGE PHARM	10MG	A203481	001	Jul 03, 2017	Jun NEWA
AB		20MG	A203481	002	Jul 03, 2017	Jun NEWA
AB		40MG	A203481	003	Jul 03, 2017	Jun NEWA
AB	TEVA PHARMS USA	20MG	A204661	001	Jun 13, 2017	May NEWA
AB		40MG	A204661	002	Jun 13, 2017	May NEWA

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

+ COVIS PHARMA BV	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	May CAHN
+!	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	May CAHN

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jan CTEC
AB		40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jan CTEC
AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jan CMFD
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jan CMFD
	ZEGERID					
AB	+ SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jan CTEC
AB	+!	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jan CTEC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

@	CHARTWELL MOLECULES	4MG	A076506	001	Dec 26, 2006	Mar CAHN
@		8MG	A076506	002	Dec 26, 2006	Mar CAHN
@		16MG	A077406	001	Dec 26, 2006	Mar CAHN
@		24MG	A077406	002	Dec 26, 2006	Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP	!	BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Aug CAHN
>D>	AP	MYLAN LABS LTD	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	Nov DISC
>A>	@		EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	Nov DISC
AP			EQ 2MG BASE/ML	A204906	001	Jul 31, 2017	Jul NEWA
AP		SANDOZ INC	EQ 2MG BASE/ML	A077430	001	Jun 27, 2007	Mar CAHN
	@	SUN PHARM INDS (IN)	EQ 2MG BASE/ML	A077172	001	Dec 26, 2006	Oct DISC
AP		WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Jan CAHN
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	!	BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Aug CAHN
>D>	AP	MYLAN LABS LTD	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Nov DISC
>A>	@		EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Nov DISC
AP		SANDOZ INC	EQ 2MG BASE/ML	A077551	001	Jun 27, 2007	Mar CAHN
AP		WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Jan CAHN
AP			EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jan CAHN

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

NORFLEX

@	TELIGENT	30MG/ML	N013055	001		Apr CAHN
---	----------	---------	---------	-----	--	----------

TABLET, EXTENDED RELEASE;ORAL  
NORFLEX

+ @ MEDICIS 100MG N012157 001 Aug CRLD

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	AMNEAL PHARMS	EQ 30MG BASE	A209093	001	May 17, 2017	May NEWA
AB		EQ 45MG BASE	A209093	002	May 17, 2017	May NEWA
AB		EQ 75MG BASE	A209093	003	May 17, 2017	May NEWA
AB	MACLEODS PHARMS LTD	EQ 30MG BASE	A207211	001	Sep 14, 2017	Sep NEWA
AB		EQ 45MG BASE	A207211	002	Sep 14, 2017	Sep NEWA
AB		EQ 75MG BASE	A207211	003	Sep 14, 2017	Sep NEWA
AB	NESHER PHARMS	EQ 30MG BASE	A208578	001	Feb 24, 2017	Feb NEWA
AB		EQ 45MG BASE	A208578	002	Feb 24, 2017	Feb NEWA
AB		EQ 75MG BASE	A208578	003	Feb 24, 2017	Feb NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	ALVOGEN PINE BROOK	EQ 6MG BASE/ML	A208823	001	Oct 31, 2017	Oct NEWA
AB	NESHER PHARMS	EQ 6MG BASE/ML	A209113	001	Sep 14, 2017	Sep NEWA
TAMIFLU						
AB	+! ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Sep CFTG

OSPEMIFENE

TABLET;ORAL

OSPHEA

+! DUCHESNAY 60MG N203505 001 Feb 26, 2013 Mar CAHN

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

	@ MYLAN LABS LTD	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Oct DISC
	@	EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014	Oct DISC
AP	RENAISSANCE SSA LLC	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017	Aug NEWA
AP		EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017	Aug NEWA
AP		EQ 10GM BASE/VIAL	A206760	001	Oct 26, 2017	Oct NEWA
AP	WOCKHARDT BIO AG	EQ 1GM BASE/VIAL	A207147	001	Jul 31, 2017	Jul NEWA
AP		EQ 2GM BASE/VIAL	A207147	002	Jul 31, 2017	Jul NEWA
>A> AP		EQ 10GM BASE/VIAL	A207148	001	Nov 24, 2017	Nov NEWA

OXALIPLATIN

INJECTABLE;IV (INFUSION)

ELOXATIN

+ @ SANOFI AVENTIS US 200MG/40ML (5MG/ML) N021759 003 Nov 17, 2006 Jan CRLD

OXALIPLATIN

AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Mar NEWA
AP		100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Mar NEWA
AP		200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Mar NEWA
AP	CIPLA LTD	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Jan NEWA
AP		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Jan NEWA
AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Jan NEWA
AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Jan NEWA
AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Jan NEWA
AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jan NEWA
AP		50MG/VIAL	A207385	001	May 23, 2017	May NEWA
AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jan NEWA
AP		100MG/VIAL	A207385	002	May 23, 2017	May NEWA
AP		200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Oct NEWA
AP	LUITPOLD PHARMS INC	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017	May NEWA
AP		100MG/20ML (5MG/ML)	A204378	002	May 12, 2017	May NEWA
AP	MYLAN LABS LTD	200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Oct NEWA
AP	! QILU PHARM CO LTD	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jan CTEC
AP	SANJA PHARMS CO	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Aug NEWA
AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Aug NEWA

OXANDROLONE

TABLET;ORAL

OXANDROLONE

AB	UPSHER-SMITH LABS	2.5MG	A076761	001	Dec 01, 2006	Jun CAHN
AB		10MG	A078033	001	Mar 22, 2007	Jun CAHN

OXAPROZINTABLET;ORAL  
OXAPROZIN

AB	AMNEAL PHARMS CO	600MG	A208633	001	May 04, 2017	Apr NEWA
----	------------------	-------	---------	-----	--------------	----------

OXAZEPAMCAPSULE;ORAL  
OXAZEPAM

AB	ACTAVIS ELIZABETH	10MG	A072253	002	Apr 14, 1988	May CMS1
AB		15MG	A072253	003	Apr 14, 1988	May CMS1
	@ ANDA REPOSITORY	10MG	A071026	002	Aug 10, 1987	Sep CAHN
	@	15MG	A071026	003	Aug 10, 1987	Sep CAHN
	@	30MG	A071026	001	Aug 10, 1987	Sep CAHN
	@ WATSON LABS TEVA	10MG	A072952	001	Sep 28, 1990	May CAHN

TABLET;ORAL  
OXAZEPAM

	@ SUN PHARM INDUSTRIES	15MG	A070683	001	Jan 16, 1987	Jan CAHN
--	------------------------	------	---------	-----	--------------	----------

OXCARBAZEPINETABLET;ORAL  
OXCARBAZEPINE

AB	GLENMARK PHARMS LTD	150MG	A077802	001	Oct 09, 2007	May CAHN
AB		300MG	A077802	002	Oct 09, 2007	May CAHN
AB		600MG	A077802	003	Oct 09, 2007	May CAHN
	@ JUBILANT CADISTA	150MG	A090239	001	Jan 25, 2010	Sep DISC
AB		150MG	A090239	001	Jan 25, 2010	Apr CAHN
	@	300MG	A090239	002	Jan 25, 2010	Sep DISC
AB		300MG	A090239	002	Jan 25, 2010	Apr CAHN
	@	600MG	A090239	003	Jan 25, 2010	Sep DISC
AB		600MG	A090239	003	Jan 25, 2010	Apr CAHN

OXTRIPHYLLINETABLET, EXTENDED RELEASE;ORAL  
CHOLEDYL SA

	@ WARNER CHILCOTT LLC	600MG	A086742	001		Sep DISC
--	-----------------------	-------	---------	-----	--	----------

OXYBUTYNIN CHLORIDESYRUP;ORAL  
DITROPAN

	+ @ ORTHO MCNEIL JANSSEN	5MG/5ML	N018211	001		Jan CRLD
--	--------------------------	---------	---------	-----	--	----------

OXYBUTYNIN CHLORIDE

AA	PHARM ASSOC	5MG/5ML	A075137	001	Dec 18, 1998	May CAHN
----	-------------	---------	---------	-----	--------------	----------

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB	NOVITIUM PHARMA	5MG	A209823	001	Oct 23, 2017	Oct NEWA
AB	UPSHER-SMITH LABS	5MG	A074625	001	Jul 31, 1996	Sep CAHN
AB	USL PHARMA	5MG	A074625	001	Jul 31, 1996	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL  
OXYBUTYNIN CHLORIDE

AB	UNIQUE PHARM LABS	5MG	A206121	001	May 27, 2016	Aug CAHN
AB		10MG	A206121	002	May 27, 2016	Aug CAHN
AB		15MG	A206121	003	May 27, 2016	Aug CAHN
AB	ZYDUS PHARMS USA INC	5MG	A202332	001	Jun 26, 2017	Jun NEWA
AB		10MG	A202332	002	Jun 26, 2017	Jun NEWA
AB		15MG	A202332	003	Jun 26, 2017	Jun NEWA

OXYCODONE HYDROCHLORIDESOLUTION;ORAL  
OXYCODONE HYDROCHLORIDE

AA	ABHAI LLC	5MG/5ML	A208593	001	Jul 21, 2017	Jul NEWA
AA		100MG/5ML	A208593	002	Jul 21, 2017	Jul NEWA
AA	ANI PHARMS INC	100MG/5ML	A203447	001	Aug 30, 2017	Aug NEWA
AA	ASCENT PHARMS INC	5MG/5ML	A209021	001	Nov 09, 2017	Oct NEWA
AA		100MG/5ML	A209021	002	Nov 09, 2017	Oct NEWA
AA	HI-TECH PHARMACAL	5MG/5ML	A208817	001	Aug 10, 2017	Jul NEWA
AA		100MG/5ML	A208795	001	Aug 07, 2017	Jul NEWA
AA	PHARM ASSOC	100MG/5ML	A206822	001	Aug 15, 2017	Jul NEWA
AA	WES PHARMA INC	100MG/5ML	A209897	001	Sep 06, 2017	Aug NEWA

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB	ASCENT PHARMS INC	15MG	A207418	001	Aug 07, 2017	Jul NEWA
----	-------------------	------	---------	-----	--------------	----------

TABLET;ORAL									
OXYCODONE HYDROCHLORIDE									
AB		30MG	A207418	002	Aug 07, 2017	Jul	NEWA		
AB	EPIC PHARMA LLC	5MG	A090895	001	Aug 24, 2009	May	CAHN		
AB		15MG	A090895	002	Aug 24, 2009	May	CAHN		
AB		30MG	A090895	003	Aug 24, 2009	May	CAHN		
AB	NOVEL LABS INC	5MG	A204021	001	Jun 12, 2017	May	NEWA		
AB		10MG	A204021	002	Jun 12, 2017	May	NEWA		
AB		15MG	A204021	003	Jun 12, 2017	May	NEWA		
AB		20MG	A204021	004	Jun 12, 2017	May	NEWA		
AB		30MG	A204021	005	Jun 12, 2017	May	NEWA		
ROXYBOND									
	DAIICHI SANKYO INC	5MG	N209777	001	Apr 20, 2017	Aug	CAHN		
		15MG	N209777	002	Apr 20, 2017	Aug	CAHN		
		30MG	N209777	003	Apr 20, 2017	Aug	CAHN		
	INSPIRION DELIVERY	5MG	N209777	001	Apr 20, 2017	Apr	NEWA		
		15MG	N209777	002	Apr 20, 2017	Apr	NEWA		
		30MG	N209777	003	Apr 20, 2017	Apr	NEWA		
<u>OXYMETAZOLINE HYDROCHLORIDE</u>									
CREAM;TOPICAL									
RHOFADÉ									
+!	ALLERGAN INC	1%	N208552	001	Jan 18, 2017	Jan	NEWA		
<u>OXYMETHOLONE</u>									
TABLET;ORAL									
ANADROL-50									
+!	MYLAN SPECIALITY LP	50MG	N016848	001		Mar	CAHN		
<u>OXYMORPHONE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
OPANA									
+ @	ENDO PHARMS	1MG/ML	N011707	002		Aug	DISC		
TABLET;ORAL									
OXYMORPHONE HYDROCHLORIDE									
AB	EPIC PHARMA LLC	5MG	A201187	001	Dec 15, 2014	May	CAHN		
AB		10MG	A201187	002	Dec 15, 2014	May	CAHN		
TABLET, EXTENDED RELEASE;ORAL									
OPANA ER									
+ @	ENDO PHARMS	5MG	N201655	001	Dec 09, 2011	Aug	DISC		
+ @		7.5MG	N201655	002	Dec 09, 2011	Aug	DISC		
+ @		10MG	N201655	003	Dec 09, 2011	Aug	DISC		
+ @		15MG	N201655	004	Dec 09, 2011	Aug	DISC		
+ @		20MG	N201655	005	Dec 09, 2011	Aug	DISC		
+ @		30MG	N201655	006	Dec 09, 2011	Aug	DISC		
+ @		40MG	N201655	007	Dec 09, 2011	Aug	DISC		
OXYMORPHONE HYDROCHLORIDE									
AB	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Apr	CAHN		
AB		7.5MG	A079046	001	Dec 13, 2010	Apr	CAHN		
AB		10MG	A079046	004	Jul 11, 2013	Apr	CAHN		
AB		15MG	A079046	002	Dec 13, 2010	Apr	CAHN		
AB		20MG	A079046	005	Jul 11, 2013	Apr	CAHN		
AB		30MG	A079046	006	Jul 11, 2013	Apr	CAHN		
AB		40MG	A079046	007	Jul 11, 2013	Apr	CAHN		
	@ PAR PHARM	5MG	A200792	001	Oct 24, 2014	May	DISC		
	@	7.5MG	A200792	002	Oct 24, 2014	May	DISC		
	@	10MG	A200792	003	Oct 24, 2014	May	DISC		
	@	15MG	A200792	004	Oct 24, 2014	May	DISC		
	@	20MG	A200792	005	Oct 24, 2014	May	DISC		
	@	30MG	A200792	006	Oct 24, 2014	May	DISC		
	@	40MG	A200792	007	Oct 24, 2014	May	DISC		
<u>OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE</u>									
OINTMENT;OPHTHALMIC									
TERRAMYCIN W/ POLYMYXIN B SULFATE									
!	CASPER PHARMA LLC	EQ 5MG BASE/GM;10,000 UNITS/GM	A061015	001		Jul	CAHN		

PALONOSETRON HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

	@ DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Sep DISC
	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Sep DISC
>A>	+ FRESenius KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109	001	Nov 21, 2017	Nov NEWA

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

>D> AP	AREVA PHARMS	60MG/VIAL	A077433	002	Nov 26, 2008	Nov CTEC
>A>		60MG/VIAL	A077433	002	Nov 26, 2008	Nov CTEC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

PERTZYE

	+ DIGESTIVE CARE INC	90,750USP UNITS;24,000USP UNITS;86,250USP UNITS	N022175	004	Jul 13, 2017	Sep NEWA
--	----------------------	---	---------	-----	--------------	----------

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDE

>D> AP	! TEVA PHARMS USA	2MG/ML	A072760	001	Jul 31, 1990	Nov CTEC
>A>	!	2MG/ML	A072760	001	Jul 31, 1990	Nov CTEC

PANTOPRAZOLE SODIUM

POWDER;IV (INFUSION)

PANTOPRAZOLE SODIUM

EXELA PHARMA SCS LLC EQ 40MG BASE/VIAL

N209463 001 Jun 30, 2017 Jun NEWA

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

	@ SUN PHARM INDS LTD	EQ 20MG BASE	A077058	001	Sep 10, 2007	Sep DISC
AB		EQ 20MG BASE	A077058	001	Sep 10, 2007	Mar CAHN
	@	EQ 40MG BASE	A077058	002	Sep 10, 2007	Sep DISC
AB		EQ 40MG BASE	A077058	002	Sep 10, 2007	Mar CAHN

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB	AMNEAL PHARMS	1MCG	A204327	001	Jan 13, 2016	May CAHN
AB		2MCG	A204327	002	Jan 13, 2016	May CAHN
AB		4MCG	A204327	003	Jan 13, 2016	May CAHN
	ZEMPLAR					
AB	+ ABBVIE	1MCG	N021606	001	May 26, 2005	Oct CRLD
AB	+	2MCG	N021606	002	May 26, 2005	Oct CRLD
	+ @	4MCG	N021606	003	May 26, 2005	Oct CRLD

SOLUTION;INTRAVENOUS

PARICALCITOL

AP	AKORN	0.005MG/ML (0.005MG/ML)	A207692	001	Oct 16, 2017	Oct NEWA
AP	AMNEAL PHARMS CO	0.002MG/ML (0.002MG/ML)	A206699	001	Mar 09, 2017	Feb NEWA
AP		0.005MG/ML (0.005MG/ML)	A206699	002	Mar 09, 2017	Feb NEWA
AP		0.01MG/2ML (0.005MG/ML)	A206699	003	Mar 09, 2017	Feb NEWA
AP	MYLAN LABS LTD	0.002MG/ML (0.002MG/ML)	A203897	001	Nov 02, 2017	Oct NEWA
AP		0.005MG/ML (0.005MG/ML)	A203897	002	Nov 02, 2017	Oct NEWA
AP		0.01MG/2ML (0.005MG/ML)	A203897	003	Nov 02, 2017	Oct NEWA
AP	SANDOZ INC	0.002MG/ML (0.002MG/ML)	A091108	001	Jul 27, 2011	Apr CAHN
AP		0.005MG/ML (0.005MG/ML)	A091108	002	Jul 27, 2011	Apr CAHN
AP		0.01MG/2ML (0.005MG/ML)	A091108	003	Jul 27, 2011	Apr CAHN

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAXIL

	+! APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Sep CTEC
--	------------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

	@ MYLAN PHARMS INC	EQ 10MG BASE	A075716	001	Mar 08, 2004	Apr DISC
	@	EQ 20MG BASE	A075716	002	Mar 08, 2004	Apr DISC
	@	EQ 30MG BASE	A075716	003	Mar 08, 2004	Apr DISC
	@	EQ 40MG BASE	A075716	004	Mar 08, 2004	Apr DISC

## TABLET;ORAL

## PAROXETINE HYDROCHLORIDE

@ UPSHER-SMITH LABS EQ 10MG BASE  
 @ EQ 20MG BASE  
 @ EQ 30MG BASE  
 @ EQ 40MG BASE

A075566 001 Mar 08, 2004 Jun CAHN  
 A075566 002 Mar 08, 2004 Jun CAHN  
 A075566 003 Mar 08, 2004 Jun CAHN  
 A075566 004 Mar 08, 2004 Jun CAHN

## TABLET, EXTENDED RELEASE;ORAL

## PAROXETINE HYDROCHLORIDE

AB LUPIN LTD EQ 12.5MG BASE  
 AB EQ 25MG BASE  
 AB EQ 37.5MG BASE

A204134 001 Jan 20, 2017 Jan NEWA  
 A204134 002 Jan 20, 2017 Jan NEWA  
 A204134 003 Jan 20, 2017 Jan NEWA

PAROXETINE MESYLATE

## CAPSULE;ORAL

## BRISDELLE

AB +! SEBELA IRELAND LTD EQ 7.5MG BASE

N204516 001 Jun 28, 2013 Jun CFTG

## PAROXETINE MESYLATE

AB ACTAVIS LABS FL INC EQ 7.5MG BASE  
 AB PRINSTON INC EQ 7.5MG BASE

A207139 001 Jun 20, 2017 Jun NEWA  
 A207188 001 Aug 18, 2017 Aug NEWA

PENCICLOVIR

## CREAM;TOPICAL

## DENA VIR

+! MYLAN PHARMS INC 1%

N020629 001 Sep 24, 1996 Jan CAHN

PENICILLAMINE

## TABLET;ORAL

## DEPEN

+! MYLAN SPECIALITY LP 250MG

N019854 001 Mar CAHN

PENICILLIN G BENZATHINE

## INJECTABLE;INJECTION

## BICILLIN L-A

+! KING PHARMS LLC 300,000 UNITS/ML  
 BC +! 600,000 UNITS/ML

N050141 003 May CAHN  
 N050141 001 May CAHN

## PERMAPEN

BC CASPER PHARMA LLC 600,000 UNITS/ML

A060014 001 Jul CAHN

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

## INJECTABLE;INJECTION

## BICILLIN C-R

+! KING PHARMS LLC 150,000 UNITS/ML;150,000 UNITS/ML  
 +! 300,000 UNITS/ML;300,000 UNITS/ML

N050138 002 Apr CAHN  
 N050138 001 Apr CAHN

## BICILLIN C-R 900/300

+! KING PHARMS LLC 900,000 UNITS/2ML;300,000 UNITS/2ML

N050138 003 Apr CAHN

PENICILLIN G PROCAINE

## INJECTABLE;INJECTION

## PENICILLIN G PROCAINE

! KING PHARMS LLC 300,000 UNITS/ML  
 ! 600,000 UNITS/ML

A060101 002 Jun CAHN  
 A060101 001 Jun CAHN

PENTAMIDINE ISETHIONATE

## INJECTABLE;INJECTION

## PENTAM

AP +! FRESENIUS KABI USA 300MG/VIAL

N019264 001 Oct 16, 1984 Sep CTEC

## PENTAMIDINE ISETHIONATE

AP SETON PHARMS 300MG/VIAL

A206666 001 Sep 28, 2017 Sep NEWA

PENTOBARBITAL SODIUM

## INJECTABLE;INJECTION

## PENTOBARBITAL SODIUM

AP CUSTOPHARM INC 50MG/ML  
 >A> AP RENAISSANCE SSA LLC 50MG/ML  
 AP SAGENT PHARMS 50MG/ML

A203619 001 Nov 13, 2017 Oct NEWA  
 A206677 001 Nov 27, 2017 Nov NEWA  
 A206404 001 May 23, 2016 Apr CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL					
PENTOXIFYLLINE					
	@ PLIVA	400MG	A074874	001	May 25, 1999 Aug CAHN
PENTOXIL					
AB	UPSHER-SMITH LABS	400MG	A074962	001	Mar 31, 1999 Jun CAHN
TRENTAL					
	+ @ US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984 Jan CRLD

PERINDOPRIL ERBUMINE

TABLET;ORAL					
PERINDOPRIL ERBUMINE					
AB	! AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009 May CHRS
AB	!	4MG	A079070	002	Nov 10, 2009 May CHRS
AB	!	8MG	A079070	003	Nov 10, 2009 May CHRS

PERMETHRIN

CREAM;TOPICAL					
ELIMITE					
AB	+! MYLAN PHARMS INC	5%	N019855	001	Aug 25, 1989 Jan CAHN
PERMETHRIN					
AB	ACTAVIS LABS	5%	A074806	001	Jan 23, 1998 May CAHN

PERPHENAZINE

TABLET;ORAL					
PERPHENAZINE					
AB	MYLAN PHARMS INC	2MG	A206691	001	Apr 14, 2017 Apr NEWA
AB		4MG	A206691	002	Apr 14, 2017 Apr NEWA
AB		8MG	A206691	003	Apr 14, 2017 Apr NEWA
AB		16MG	A206691	004	Apr 14, 2017 Apr NEWA

PHENDIMETRAZINE TARTRATE

TABLET;ORAL					
PHENDIMETRAZINE TARTRATE					
	@ USL PHARMA	35MG	A084399	001	Jun CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL					
PHENOXYBENZAMINE HYDROCHLORIDE					
AB	PAR PHARM INC	10MG	A204522	001	Jan 24, 2017 Jan NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL					
PHENTERMINE HYDROCHLORIDE					
	@ ELITE LABS INC	30MG	A040227	001	Jun 18, 1997 May CAHN
	@	30MG	A040448	001	Jan 22, 2003 May CAHN
AA		37.5MG	A040228	001	Jun 19, 1997 May CAHN
	@ UPSHER-SMITH LABS	30MG	A084487	001	Apr 09, 1982 Jun CAHN
	@	30MG	A088430	001	Mar 27, 1984 Jun CAHN
TABLET;ORAL					
LOMAIRA					
>D>	! AVANTHI INC	8MG	A203495	001	Sep 12, 2016 Nov CTEC
>A> AA	!	8MG	A203495	001	Sep 12, 2016 Nov CTEC
PHENTERMINE HYDROCHLORIDE					
AA	ELITE LABS INC	37.5MG	A040190	001	May 30, 1997 May CAHN
AA	KVK TECH INC	8MG	A203436	001	Mar 17, 2017 Mar NEWA
AA	PRINSTON INC	37.5MG	A040377	001	Jan 04, 2002 Feb CAHN
TABLET, ORALLY DISINTEGRATING;ORAL					
PHENTERMINE HYDROCHLORIDE					
	ZYDUS PHARMS USA INC	15MG	A204663	001	Jun 28, 2017 Jun NEWA
		30MG	A204663	002	Jun 28, 2017 Jun NEWA
		37.5MG	A204663	003	Jun 28, 2017 Jun NEWA

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION					
PHENTOLAMINE MESYLATE					
AP	PRECISION DOSE INC	5MG/VIAL	A207686	001	Jul 14, 2017 Jul NEWA
AP	! WEST-WARD PHARMS INT	5MG/VIAL	A040235	001	Mar 11, 1998 Jul CTEC
	!	5MG/VIAL	A040235	001	Mar 11, 1998 May CHRS



## INJECTABLE; INJECTION

## REGITINE

+ @ NOVARTIS	5MG/VIAL	N008278	003		May	DISC
--------------	----------	---------	-----	--	-----	------

PHENYLEPHRINE HYDROCHLORIDE

## SOLUTION; IV (INFUSION)

## VAZCULEP

+ AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jan	CAHN
+	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jan	CAHN
+	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jan	CAHN

PHENYTOIN

## TABLET, CHEWABLE; ORAL

## DILANTIN

AB	!	PFIZER	50MG	A084427	001		Feb	CAHN
----	---	--------	------	---------	-----	--	-----	------

## PHENYTOIN

AB		EPIC PHARMA LLC	50MG	A040884	001	Nov 28, 2014	May	CAHN
----	--	-----------------	------	---------	-----	--------------	-----	------

PHENYTOIN SODIUM

## CAPSULE; ORAL

## DILANTIN

>D>	AB	!	PARKE-DAVIS	30MG EXTENDED	A084349	001		Nov	CTEC
>A>		!		30MG EXTENDED	A084349	001		Nov	CTEC
	AB	!		30MG EXTENDED	A084349	001		Feb	CAHN
	AB	!		100MG EXTENDED	A084349	002		Feb	CAHN

## INJECTABLE; INJECTION

## PHENYTOIN SODIUM

AP		ACELLA PHARMS LLC	50MG/ML	A040573	001	Sep 13, 2006	May	CAHN
----	--	-------------------	---------	---------	-----	--------------	-----	------

PHYTONADIONE

## INJECTABLE; INJECTION

## AQUAMEPHYTON

+ @ TELIGENT	1MG/0.5ML	N012223	002		Apr	CAHN
+ @	10MG/ML	N012223	001		Apr	CAHN

PILOCARPINE HYDROCHLORIDE

## SOLUTION; OPHTHALMIC

## ISOPTO CARPINE

AT	+	NOVARTIS PHARMS CORP	1%	N200890	001	Jun 22, 2010	Sep	CFTG
AT	+		2%	N200890	002	Jun 22, 2010	Sep	CFTG
AT	+	!	4%	N200890	003	Jun 22, 2010	Sep	CFTG

## PILOCARPINE HYDROCHLORIDE

AT		AKORN INC	1%	A204398	001	Sep 27, 2017	Sep	NEWA
AT			2%	A204398	002	Sep 27, 2017	Sep	NEWA
AT			4%	A204398	003	Sep 27, 2017	Sep	NEWA

## TABLET; ORAL

## PILOCARPINE HYDROCHLORIDE

AB		ALLIED PHARMA INC	5MG	A076963	001	Dec 22, 2004	Mar	CAHN
AB			7.5MG	A076963	002	Feb 27, 2007	Mar	CAHN
AB		INNOGENIX	5MG	A076963	001	Dec 22, 2004	Sep	CAHN
AB			7.5MG	A076963	002	Feb 27, 2007	Sep	CAHN
AB		PERRIGO PHARMA INTL	5MG	A076746	001	Nov 16, 2004	Apr	CAHN

PINDOLOL

## TABLET; ORAL

## PINDOLOL

AB		IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May	CMFD
AB			10MG	A073609	001	Mar 29, 1993	May	CMFD
AB		ZYDUS PHARMS USA INC	5MG	A209866	001	Aug 18, 2017	Aug	NEWA
AB			10MG	A209866	002	Aug 18, 2017	Aug	NEWA

PIOGLITAZONE HYDROCHLORIDE

## TABLET; ORAL

## PIOGLITAZONE HYDROCHLORIDE

AB		CIPLA LTD	EQ 15MG BASE	A076798	001	Oct 26, 2012	Jun	CAHN
AB			EQ 30MG BASE	A076798	002	Oct 26, 2012	Jun	CAHN
AB			EQ 45MG BASE	A076798	003	Oct 26, 2012	Jun	CAHN
AB		PURACAP PHARM LLC	EQ 15MG BASE	A206738	001	Oct 06, 2017	Sep	NEWA
AB			EQ 30MG BASE	A206738	002	Oct 06, 2017	Sep	NEWA
AB			EQ 45MG BASE	A206738	003	Oct 06, 2017	Sep	NEWA
AB		WATSON LABS TEVA	EQ 15MG BASE	A076798	001	Oct 26, 2012	May	CAHN
AB			EQ 30MG BASE	A076798	002	Oct 26, 2012	May	CAHN

TABLET;ORAL							
PIOGLITAZONE HYDROCHLORIDE							
AB	EQ 45MG BASE	A076798	003	Oct 26, 2012	May	CAHN	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM</u>							
INJECTABLE;INJECTION							
PIPERACILLIN AND TAZOBACTAM							
AP	APOLLO PHARMS INC EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan	NEWA	
AP	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan	NEWA	
AP	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan	NEWA	
AP	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan	NEWA	
AP	WOCKHARDT BIO AG EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Mar	NEWA	
AP	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Mar	NEWA	
AP	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Mar	NEWA	
AP	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207146	001	Mar 17, 2017	Mar	NEWA	
<u>PIRFENIDONE</u>							
TABLET;ORAL							
ESBRIET							
+	GENENTECH INC 267MG	N208780	001	Jan 11, 2017	Jan	NEWA	
+	@ 534MG	N208780	002	Jan 11, 2017	Jan	DISC	
+	! 801MG	N208780	003	Jan 11, 2017	Jan	NEWA	
<u>PIROXICAM</u>							
CAPSULE;ORAL							
PIROXICAM							
AB	HIKMA PHARMS 10MG	A209256	001	Aug 11, 2017	Jul	NEWA	
AB	20MG	A209256	002	Aug 11, 2017	Jul	NEWA	
	@ MYLAN 10MG	A074102	001	Jul 31, 1992	Jul	DISC	
	@ 20MG	A074102	002	Jul 31, 1992	Jul	DISC	
AB	PII 10MG	A206136	001	Jun 20, 2017	Jun	NEWA	
AB	20MG	A206136	002	Jun 20, 2017	Jun	NEWA	
AB	SUN PHARM INDUSTRIES 10MG	A073536	002	Jan 23, 2008	Oct	CMS1	
AB	20MG	A073536	001	Mar 12, 1993	Oct	CMFD	
AB	UNICHEM LABS LTD 10MG	A208340	001	Apr 13, 2017	Apr	NEWA	
AB	20MG	A208340	002	Apr 13, 2017	Apr	NEWA	
<u>PITAVASTATIN CALCIUM</u>							
TABLET;ORAL							
PITAVASTATIN CALCIUM							
AB	ORIENT PHARMA CO LTD EQ 1MG BASE	A205932	001	Feb 03, 2017	Jan	NEWA	
AB	EQ 2MG BASE	A205932	002	Feb 03, 2017	Jan	NEWA	
AB	EQ 4MG BASE	A205932	003	Feb 03, 2017	Jan	NEWA	
AB	SAWAI USA EQ 1MG BASE	A205955	001	Feb 03, 2017	Jan	NEWA	
AB	EQ 2MG BASE	A205955	002	Feb 03, 2017	Jan	NEWA	
AB	EQ 4MG BASE	A205955	003	Feb 03, 2017	Jan	NEWA	
<u>PITAVASTATIN MAGNESIUM</u>							
TABLET;ORAL							
ZYPITAMAG							
+	ZYDUS PHARMS USA INC EQ 1MG BASE	N208379	001	Jul 14, 2017	Jul	NEWA	
+	EQ 2MG BASE	N208379	002	Jul 14, 2017	Jul	NEWA	
+	! EQ 4MG BASE	N208379	003	Jul 14, 2017	Jul	NEWA	
<u>PITAVASTATIN SODIUM</u>							
TABLET;ORAL							
NIKITA							
+	@ LUPIN LTD EQ 1MG BASE	N209875	001	Aug 04, 2017	Sep	DISC	
+	EQ 1MG BASE	N209875	001	Aug 04, 2017	Aug	NEWA	
+	@ EQ 2MG BASE	N209875	002	Aug 04, 2017	Sep	DISC	
+	EQ 2MG BASE	N209875	002	Aug 04, 2017	Aug	NEWA	
+	@ EQ 4MG BASE	N209875	003	Aug 04, 2017	Sep	DISC	
+	! EQ 4MG BASE	N209875	003	Aug 04, 2017	Aug	NEWA	

PLECANATIDETABLET;ORAL  
TRULANCE

+! SYNERGY PHARMS 3MG N208745 001 Jan 19, 2017 Jan NEWA

PODOFILOXSOLUTION;TOPICAL  
PODOFILOX

@ BAUSCH AND LOMB INC 0.5% A090184 001 Jul 21, 2010 Aug DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

	@ MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A090409	001	Apr 02, 2010	Apr DISC
		.2GM/BOT				
AA	STRIDES PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A204559	001	Apr 13, 2015	Apr CAHN
		.2GM/BOT				
		PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE				
AA	BRECKENRIDGE PHARM	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A202060	001	Mar 08, 2017	Mar CAHN
		.2GM/BOT				
AA	BRECKENRIDGE PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A202060	001	Mar 08, 2017	Feb NEWA
		.2GM/BOT				
		TRILYTE				
AA	MYLAN PHARMS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A076491	001	Feb 05, 2004	Mar CAHN
		.2GM/BOT				

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATEANHYDROUS

FOR SOLUTION;ORAL

COLYTE

	@ MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Mar CAHN
	@	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Mar CAHN
	@	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Mar CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Mar CAHN
	@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Mar CAHN
		ET				
		COLYTE WITH FLAVOR PACKS				
AA	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Mar CAHN
		COLYTE-FLAVORED				
	@ MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Mar CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Mar CAHN
		PEG 3350 AND ELECTROLYTES				
	@ MYLAN	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Apr DISC

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT SANDOZ INC 10,000 UNITS/ML;EQ 1MG BASE/ML A064211 001 Apr 13, 1998 Feb CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

KLOR-CON

AB		UPSHER-SMITH LABS	8MEQ	A203106	001	Jul 10, 2015	Jun CAHN
AB			10MEQ	A203106	002	Jul 10, 2015	Jun CAHN
		MICRO-K					
>D>	AB	NESHER PHARMS	8MEQ	N018238	001		Nov CRLD
>A>	AB	+	8MEQ	N018238	001		Nov CRLD
		MICRO-K 10					
>D>	AB	NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	Nov CRLD
>A>	AB	+	10MEQ	N018238	002	May 14, 1984	Nov CRLD
		POTASSIUM CHLORIDE					
AB		ADARE PHARMS INC	8MEQ	A208864	001	Mar 17, 2017	Mar NEWA
AB			10MEQ	A208864	002	Mar 17, 2017	Mar NEWA

FOR SOLUTION;ORAL  
KLOR-CON

AA	UPSHER-SMITH LABS	20MEQ	A209662	001	Oct 23, 2017	Oct CAHN
AA		20MEQ	A209662	001	Oct 23, 2017	Oct NEWA
POTASSIUM CHLORIDE						
AA	+! PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Oct CFTG
INJECTABLE;INJECTION						
POTASSIUM CHLORIDE						
	@ BAXTER HLTHCARE	2MEQ/ML	A085499	001		Apr DISC
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER						
AP	+ ICU MEDICAL INC	14.9MG/ML	N020161	005	Nov 30, 1992	Feb CAHN
AP	+	745MG/100ML	N020161	001	Nov 30, 1992	Feb CAHN
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	29.8MG/ML	N020161	006	Aug 11, 1998	Feb CAHN
AP	+	1.49GM/100ML	N020161	002	Nov 30, 1992	Feb CAHN
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998	Feb CAHN
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	2.98GM/100ML	N020161	004	Aug 11, 1998	Feb CAHN
TABLET, EXTENDED RELEASE;ORAL						
KLOR-CON						
AB2	+ UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986	Jun CAHN
AB2	+!	10MEQ	N019123	002	Apr 17, 1986	Jun CAHN
KLOR-CON M10						
AB1	UPSHER-SMITH LABS	10MEQ	A074726	002	Aug 09, 2000	Jun CAHN
KLOR-CON M15						
	UPSHER-SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Jun CAHN
KLOR-CON M20						
AB1	! UPSHER-SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Jun CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP	ICU MEDICAL INC	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	Feb CAHN
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	ICU MEDICAL INC	149MG/100ML;900MG/100ML	N019686	001	Oct 17, 1988	Feb CAHN
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	ICU MEDICAL INC	298MG/100ML;900MG/100ML	N019686	002	Oct 17, 1988	Feb CAHN

POTASSIUM CITRATE

## TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE						
AB	IMPAX LABS INC	5MEQ	A077440	001	Jun 09, 2006	Feb CAHN
AB		10MEQ	A077440	002	Jun 09, 2006	Feb CAHN
AB	STRIDES PHARMA	5MEQ	A206813	001	Sep 11, 2017	Aug NEWA
AB		10MEQ	A206813	002	Sep 11, 2017	Aug NEWA
AB		15MEQ	A206813	003	Sep 11, 2017	Aug NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

## TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE						
	@ ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Jan DISC
	@	0.25MG	A091254	002	Nov 30, 2010	Jan DISC
	@	0.5MG	A091254	003	Nov 30, 2010	Jan DISC
	@	0.75MG	A091254	004	Nov 30, 2010	Jan DISC
	@	1MG	A091254	005	Nov 30, 2010	Jan DISC
	@	1.5MG	A091254	006	Nov 30, 2010	Jan DISC
AB	ALEMBIC PHARMS LTD	0.125MG	A078894	001	Oct 08, 2010	May CAHN
AB		0.25MG	A078894	002	Oct 08, 2010	May CAHN
AB		0.5MG	A078894	003	Oct 08, 2010	May CAHN
AB		1MG	A078894	004	Oct 08, 2010	May CAHN
AB		1.5MG	A078894	005	Oct 08, 2010	May CAHN

## TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE						
AB	ACTAVIS ELIZABETH	2.25MG	A203615	001	Oct 14, 2016	Apr CAHN
AB		3.75MG	A203615	002	Jan 03, 2017	Apr CAHN
AB	MACLEODS PHARMS LTD	3.75MG	A206156	007	Jan 23, 2017	Jan NEWA
>A> AB	ZYDUS PHARMS USA INC	0.375MG	A202891	001	Dec 12, 2017	Nov NEWA
>A> AB		0.75MG	A202891	002	Dec 12, 2017	Nov NEWA
>A> AB		1.5MG	A202891	003	Dec 12, 2017	Nov NEWA
>A> AB		2.25MG	A202891	004	Dec 12, 2017	Nov NEWA
>A> AB		3MG	A202891	005	Dec 12, 2017	Nov NEWA

TABLET, EXTENDED RELEASE;ORAL  
PRAMIPEXOLE DIHYDROCHLORIDE

>A>	AB		3.75MG	A202891	006	Dec 12, 2017	Nov NEWA
>A>	AB		4.5MG	A202891	007	Dec 12, 2017	Nov NEWA

PRASTERONE

INSERT;VAGINAL  
INTRAROSA

+	!	AMAG PHARMS INC	6.5MG	N208470	001	Nov 16, 2016	May CAHN
---	---	-----------------	-------	---------	-----	--------------	----------

PRASUGREL HYDROCHLORIDE

TABLET;ORAL  
EFFIENT

AB	+	ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009	Jun CFTG
AB	+	!	EQ 10MG BASE	N022307	002	Jul 10, 2009	Jun CFTG

PRASUGREL

AB		AUROBINDO PHARMA LTD	EQ 5MG BASE	A205888	001	Oct 16, 2017	Oct NEWA
AB			EQ 10MG BASE	A205888	002	Oct 16, 2017	Oct NEWA
AB		LIBERTY PHARMA INC	EQ 5MG BASE	A205790	001	Oct 16, 2017	Oct NEWA
AB			EQ 10MG BASE	A205790	002	Oct 16, 2017	Oct NEWA
AB		MYLAN PHARMS INC	EQ 5MG BASE	A205927	001	Jul 12, 2017	Jun NEWA
AB			EQ 10MG BASE	A205927	002	Jul 12, 2017	Jun NEWA
AB		PANACEA BIOTEC LTD	EQ 5MG BASE	A205897	001	Oct 16, 2017	Oct NEWA
AB			EQ 10MG BASE	A205897	002	Oct 16, 2017	Oct NEWA

PRAVASTATIN SODIUM

TABLET;ORAL  
PRAVASTATIN SODIUM

AB		AUROBINDO PHARMA LTD	10MG	A203367	001	Feb 02, 2017	Jan NEWA
AB			20MG	A203367	002	Feb 02, 2017	Jan NEWA
AB			40MG	A203367	003	Feb 02, 2017	Jan NEWA
AB			80MG	A203367	004	Feb 02, 2017	Jan NEWA

PRAZQUANTEL

TABLET;ORAL  
BILTRICIDE

>D>		+	!	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982	Nov CFTG
>A>	AB		+	!	600MG	N018714	001	Dec 29, 1982	Nov CFTG
>A>				PRAZQUANTEL					
>A>	AB			PAR PHARM INC	600MG	A208820	001	Nov 27, 2017	Nov NEWA

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL  
PRAZOSIN HYDROCHLORIDE

		IDT AUSTRALIA LTD	EQ 1MG BASE	A072577	002	May 16, 1989	May CMS1
			EQ 5MG BASE	A072577	003	May 16, 1989	May CMS1

PREDNISOLONE

SYRUP;ORAL  
PREDNISOLONE

AA		PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	May CAHN
AA		VISTAPHARM	15MG/5ML	A040323	001	May 13, 1999	Mar CAHN

TABLET;ORAL

		PREDNISOLONE					
	@	CHARTWELL RX	5MG	A084542	001		Apr CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL  
PREDNISOLONE SODIUM PHOSPHATE

	@	AMNEAL PHARMS	EQ 15MG BASE/5ML	A078345	001	Mar 10, 2009	May DISC
AA		CHARTWELL RX	EQ 5MG BASE/5ML	A075988	001	May 25, 2004	Jun CAHN
	@	PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	May CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC  
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb CAHN
AT		SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	Feb CAHN

PREDNISON

TABLET; ORAL									
PREDNISON									
	@	CHARTWELL RX	5MG	A083059	001			Apr	CAHN
AB		MYLAN PHARMS INC	5MG	A080292	001			Jan	CAHN
AB			10MG	A088832	001	Dec 04, 1985		Jan	CAHN
AB			20MG	A083677	001			Jan	CAHN
AB		SUN PHARM INDUSTRIES	10MG	A089246	001	Dec 04, 1985		May	CAHN
	@	UPSHER SMITH	5MG	A087471	001			Jun	CAHN
	@		20MG	A087470	001			Jun	CAHN
TABLET, DELAYED RELEASE; ORAL									
PREDNISON									
AB		ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017		Apr	NEWA
AB			2MG	A204867	002	Apr 25, 2017		Apr	NEWA
AB			5MG	A204867	003	Apr 25, 2017		Apr	NEWA
RAYOS									
AB	+	HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012		Apr	CFTG
AB	+		2MG	N202020	002	Jul 26, 2012		Apr	CFTG
AB	+	!	5MG	N202020	003	Jul 26, 2012		Apr	CFTG

PREGABALIN

TABLET, EXTENDED RELEASE; ORAL									
LYRICA CR									
	+	PFIZER INC	82.5MG	N209501	001	Oct 11, 2017		Oct	NEWA
	+		165MG	N209501	002	Oct 11, 2017		Oct	NEWA
	+	!	330MG	N209501	003	Oct 11, 2017		Oct	NEWA

PRIMIDONE

TABLET; ORAL									
PRIMIDONE									
AB		ANDA REPOSITORY	50MG	A040626	001	Sep 29, 2005		Sep	CAHN
AB			250MG	A040626	002	Sep 29, 2005		Sep	CAHN

PROBENECID

TABLET; ORAL									
BENEMID									
	+	@	MERCK	500MG	N007898	004		Jan	CRLD
PROBENECID									
AB		WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983		May	CAHN

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL									
PROCAINAMIDE HYDROCHLORIDE									
	@	IDT AUSTRALIA LTD	375MG	A089219	002	Jul 01, 1986		Aug	CMS1
	@		500MG	A089219	003	Jul 01, 1986		Aug	CMS1
INJECTABLE; INJECTION									
PROCAINAMIDE HYDROCHLORIDE									
AP		NEXUS PHARMS	100MG/ML	A206332	001	Oct 13, 2017		Oct	NEWA
AP			500MG/ML	A206332	002	Oct 13, 2017		Oct	NEWA
	@	WEST-WARD PHARMS INT	100MG/ML	A089029	001	Apr 17, 1986		Jan	CAHN
	@		500MG/ML	A089030	001	Apr 17, 1986		Mar	CAHN
TABLET, EXTENDED RELEASE; ORAL									
PROCAINAMIDE HYDROCHLORIDE									
	@	IDT AUSTRALIA LTD	500MG	A089369	002	Jan 09, 1987		Oct	DISC
			500MG	A089369	002	Jan 09, 1987		Aug	CMS1
	@		750MG	A089369	003	Aug 14, 1987		Oct	DISC
			750MG	A089369	003	Aug 14, 1987		Aug	CMS1

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL									
MATULANE									
	+	!	LEADIANT BIOSCI INC	EQ 50MG BASE	N016785	001		Feb	CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION									
PROCHLORPERAZINE EDISYLATE									
	@	ATHENEX INC	EQ 5MG BASE/ML	A040540	001	May 28, 2004		Mar	CAHN
	@	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A089523	001	May 03, 1988		Jan	CAHN
AP			EQ 5MG BASE/ML	A089903	001	Aug 29, 1989		Jan	CAHN

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

@ MONARCH PHARMS

2MG

N009818 005

Apr CAHN

@

5MG

N009818 003

Apr CAHN

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB AMNEAL PHARMS NY

100MG

A207724 001 Sep 07, 2017 Aug NEWA

AB 200MG

A207724 002 Sep 07, 2017 Aug NEWA

AB DR REDDYS LABS INC 100MG

A208801 001 Feb 28, 2017 Feb NEWA

AB 200MG

A208801 002 Feb 28, 2017 Feb NEWA

AB SANDOZ INC 100MG

A205229 001 Oct 20, 2017 Oct NEWA

AB 200MG

A205229 002 Oct 20, 2017 Oct NEWA

INJECTABLE; INJECTION

PROGESTERONE

AO +! ACTAVIS LABS UT INC 50MG/ML

N017362 002

Feb CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PHENERGAN

+ @ MYLAN PHARMS INC

50MG

N011689 001

Jan CAHN

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

IMPAX LABS

12.5MG

A040791 002 Feb 12, 2008 Aug CMS1

25MG

A040791 003 Feb 12, 2008 Aug CMS1

&gt;D&gt; AB MYLAN 12.5MG

A091054 001 Aug 30, 2011 Nov DISC

&gt;A&gt; @ 12.5MG

A091054 001 Aug 30, 2011 Nov DISC

&gt;D&gt; AB 25MG

A091054 002 Aug 30, 2011 Nov DISC

&gt;A&gt; @ 25MG

A091054 002 Aug 30, 2011 Nov DISC

&gt;D&gt; AB 50MG

A091054 003 Aug 30, 2011 Nov DISC

&gt;A&gt; @ 50MG

A091054 003 Aug 30, 2011 Nov DISC

AB PRINSTON INC 12.5MG

A040622 001 Jul 18, 2006 Feb CAHN

AB 25MG

A040622 002 Jul 18, 2006 Feb CAHN

AB 50MG

A040622 003 Jul 18, 2006 Feb CAHN

AB STRIDES PHARMA 12.5MG

A209177 001 Jun 30, 2017 Jun NEWA

AB 25MG

A209177 002 Jun 30, 2017 Jun NEWA

AB 50MG

A209177 003 Jun 30, 2017 Jun NEWA

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

AB GLENMARK PHARMS LTD 225MG

A205268 001 Sep 08, 2017 Aug NEWA

AB 325MG

A205268 002 Sep 08, 2017 Aug NEWA

AB 425MG

A205268 003 Sep 08, 2017 Aug NEWA

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

&gt;A&gt; AB AUROBINDO PHARMA LTD 150MG

A202445 001 May 11, 2016 Nov CAHN

&gt;A&gt; AB 225MG

A202445 002 May 11, 2016 Nov CAHN

&gt;A&gt; AB 300MG

A202445 003 May 11, 2016 Nov CAHN

&gt;D&gt; AB ORION CORP ORION 150MG

A202445 001 May 11, 2016 Nov CAHN

&gt;D&gt; AB 225MG

A202445 002 May 11, 2016 Nov CAHN

&gt;D&gt; AB 300MG

A202445 003 May 11, 2016 Nov CAHN

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

@ WEST-WARD PHARMS INT 20MG/ML

N012382 002

Jan CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INNOPRAN XL

BX ANI PHARMS INC 80MG

N021438 001 Mar 12, 2003 Mar CAHN

BX 120MG

N021438 002 Mar 12, 2003 Mar CAHN

PROPRANOLOL HYDROCHLORIDE

BX UPSHER SMITH 60MG

A078311 001 Mar 06, 2009 Apr CMFD

@ 60MG

A078311 001 Mar 06, 2009 Feb DISC

BX 80MG

A078311 002 Mar 06, 2009 Apr CMFD

@ 80MG

A078311 002 Mar 06, 2009 Feb DISC

BX 120MG

A078311 003 Mar 06, 2009 Apr CMFD

CAPSULE, EXTENDED RELEASE;ORAL						
PROPRANOLOL HYDROCHLORIDE						
BX	@	120MG	A078311	003	Mar 06, 2009	Feb DISC
		160MG	A078311	004	Mar 06, 2009	Apr CMFD
	@	160MG	A078311	004	Mar 06, 2009	Feb DISC
BX	@ UPSHER-SMITH LABS	60MG	A078311	001	Mar 06, 2009	Sep DISC
		60MG	A078311	001	Mar 06, 2009	Jun CAHN
	@	80MG	A078311	002	Mar 06, 2009	Sep DISC
BX		80MG	A078311	002	Mar 06, 2009	Jun CAHN
	@	120MG	A078311	003	Mar 06, 2009	Sep DISC
BX		120MG	A078311	003	Mar 06, 2009	Jun CAHN
BX	@	160MG	A078311	004	Mar 06, 2009	Sep DISC
		160MG	A078311	004	Mar 06, 2009	Jun CAHN
INJECTABLE;INJECTION						
PROPRANOLOL HYDROCHLORIDE						
AP	ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Mar CAHN
	@ SANDOZ INC	1MG/ML	A076400	001	Feb 26, 2003	Mar CAHN
TABLET;ORAL						
INDERAL						
	+ @ WYETH PHARMS INC	40MG	N016418	002		Jan CRLD
PROPRANOLOL HYDROCHLORIDE						
	@ ANDA REPOSITORY	10MG	A070319	001	Oct 22, 1985	Sep CAHN
	@	20MG	A070320	001	Oct 22, 1985	Sep CAHN
	@	40MG	A070103	001	Oct 22, 1985	Sep CAHN
	@	60MG	A070321	001	Sep 24, 1986	Sep CAHN
	@	80MG	A070322	001	Aug 04, 1986	Sep CAHN
	@ WATSON LABS TEVA	10MG	A070548	001	Jul 10, 1986	May CAHN
	@	20MG	A070549	001	Apr 11, 1986	May CAHN
	@	40MG	A070550	001	Apr 11, 1986	May CAHN
<u>PROPYLTHIOURACIL</u>						
TABLET;ORAL						
PROPYLTHIOURACIL						
	@ CHARTWELL RX	50MG	A084543	001		Apr CAHN
<u>PROTAMINE SULFATE</u>						
INJECTABLE;INJECTION						
PROTAMINE SULFATE						
	@ WEST-WARD PHARMS INT	10MG/ML	A089474	001	Nov 05, 1986	Mar CAHN
	@	10MG/ML	A089475	001	Nov 05, 1986	Jan CAHN
<u>PYRIDOSTIGMINE BROMIDE</u>						
INJECTABLE;INJECTION						
REGONOL						
AP	SANDOZ INC	5MG/ML	N017398	001		May CAHN
TABLET;ORAL						
PYRIDOSTIGMINE BROMIDE						
	@ IMPAX LABS INC	60MG	A040457	001	Dec 26, 2002	Feb CAHN
TABLET, EXTENDED RELEASE;ORAL						
PYRIDOSTIGMINE BROMIDE						
AB	KINEDEXE UK	180MG	A205464	001	Aug 15, 2017	Jul NEWA
<u>PYRIMETHAMINE</u>						
TABLET;ORAL						
DARAPRIM						
	+! TURING PHARMS LLC	25MG	N008578	001		May CAHN
<u>QUETIAPINE FUMARATE</u>						
TABLET;ORAL						
QUETIAPINE FUMARATE						
	@ MYLAN PHARMS INC	EQ 25MG BASE	A090323	001	Mar 27, 2012	May DISC
SEROQUEL						
AB	+! ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	Sep CAHN
AB	+	EQ 50MG BASE	N020639	007	Oct 04, 2005	Sep CAHN
AB	+	EQ 100MG BASE	N020639	002	Sep 26, 1997	Sep CAHN
	+ @	EQ 150MG BASE	N020639	004	Dec 20, 1998	Sep CAHN
AB	+	EQ 200MG BASE	N020639	003	Sep 26, 1997	Sep CAHN
AB	+!	EQ 300MG BASE	N020639	005	Jul 26, 2000	Sep CAHN
AB	+	EQ 400MG BASE	N020639	006	Oct 04, 2005	Sep CAHN



TABLET, EXTENDED RELEASE;ORAL  
QUETIAPINE FUMARATE

>A>	AB	ACCORD HLTHCARE	EQ 50MG BASE	A206252	001	Nov 29, 2017	Nov	NEWA
	AB		EQ 150MG BASE	A090681	001	May 09, 2017	Apr	NEWA
	AB		EQ 200MG BASE	A090681	002	May 09, 2017	Apr	NEWA
	AB		EQ 300MG BASE	A090681	003	May 09, 2017	Apr	NEWA
	AB		EQ 400MG BASE	A090681	004	Nov 01, 2016	Mar	CAHN
>A>	AB	ANCHEN PHARMS	EQ 150MG BASE	A090757	001	Dec 01, 2017	Nov	NEWA
>A>	AB		EQ 200MG BASE	A090757	002	Dec 01, 2017	Nov	NEWA
>A>	AB		EQ 300MG BASE	A090757	003	Dec 01, 2017	Nov	NEWA
>A>	AB		EQ 400MG BASE	A090757	004	Dec 01, 2017	Nov	NEWA
>A>	AB	AUROBINDO PHARMA LTD	EQ 50MG BASE	A207655	001	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 150MG BASE	A207655	002	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 200MG BASE	A207655	003	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 300MG BASE	A207655	004	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 400MG BASE	A207655	005	Nov 29, 2017	Nov	NEWA
	AB	INTELLIPHARMACEUTICS	EQ 50MG BASE	A202939	001	May 09, 2017	Apr	NEWA
	AB		EQ 150MG BASE	A202939	002	May 09, 2017	Apr	NEWA
	AB		EQ 200MG BASE	A202939	003	May 09, 2017	Apr	NEWA
	AB		EQ 300MG BASE	A202939	004	May 09, 2017	Apr	NEWA
	AB		EQ 400MG BASE	A202939	005	May 09, 2017	Apr	NEWA
	AB	LUPIN LTD	EQ 50MG BASE	A204203	001	May 17, 2017	May	NEWA
	AB		EQ 150MG BASE	A204203	002	May 17, 2017	May	NEWA
	AB		EQ 200MG BASE	A204203	003	May 17, 2017	May	NEWA
	AB		EQ 300MG BASE	A204203	004	May 17, 2017	May	NEWA
	AB		EQ 400MG BASE	A204203	005	May 17, 2017	May	NEWA
>A>	AB	MACLEODS PHARMS LTD	EQ 150MG BASE	A204253	001	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 200MG BASE	A204253	002	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 300MG BASE	A204253	003	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 400MG BASE	A204253	004	Nov 29, 2017	Nov	NEWA
>A>	AB	NOVAST LABS LTD	EQ 50MG BASE	A208947	001	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 150MG BASE	A208947	002	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 200MG BASE	A208947	003	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 300MG BASE	A208947	004	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 400MG BASE	A208947	005	Nov 29, 2017	Nov	NEWA
	AB	PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Apr	NEWA
	AB		EQ 150MG BASE	A090482	002	May 09, 2017	Apr	NEWA
	AB		EQ 200MG BASE	A090482	003	May 09, 2017	Apr	NEWA
	AB		EQ 300MG BASE	A090482	004	May 09, 2017	Apr	NEWA
	AB		EQ 400MG BASE	A090482	005	May 09, 2017	Apr	NEWA
	AB	PHARMADAX INC	EQ 50MG BASE	A206260	001	May 09, 2017	Apr	NEWA
	AB		EQ 150MG BASE	A206260	002	May 09, 2017	Apr	NEWA
	AB		EQ 200MG BASE	A206260	003	May 09, 2017	Apr	NEWA
	AB		EQ 300MG BASE	A206260	004	May 09, 2017	Apr	NEWA
	AB		EQ 400MG BASE	A206260	005	May 09, 2017	Apr	NEWA
>A>	AB	SCIEGEN PHARMS INC	EQ 150MG BASE	A209635	001	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 200MG BASE	A209635	002	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 300MG BASE	A209635	003	Nov 29, 2017	Nov	NEWA
>A>	AB		EQ 400MG BASE	A209635	004	Nov 29, 2017	Nov	NEWA
		SEROQUEL XR						
	AB	+	ASTRAZENECA	EQ 50MG BASE	N022047	001	May 17, 2007	Sep CAHN
	AB	+		EQ 50MG BASE	N022047	001	May 17, 2007	Apr CTEC
	AB	+		EQ 150MG BASE	N022047	005	Aug 11, 2008	Sep CAHN
	AB	+		EQ 150MG BASE	N022047	005	Aug 11, 2008	Apr CTEC
	AB	+		EQ 200MG BASE	N022047	002	May 17, 2007	Sep CAHN
	AB	+		EQ 200MG BASE	N022047	002	May 17, 2007	Apr CTEC
	AB	+		EQ 300MG BASE	N022047	003	May 17, 2007	Sep CAHN
	AB	+		EQ 300MG BASE	N022047	003	May 17, 2007	Apr CTEC
	AB	+		EQ 400MG BASE	N022047	004	May 17, 2007	Sep CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@	SUN PHARM INDS LTD	EQ 5MG BASE	A090800	001	Jun 18, 2009	Sep	DISC
@		EQ 10MG BASE	A090800	002	Jun 18, 2009	Sep	DISC
@		EQ 20MG BASE	A090800	003	Jun 18, 2009	Sep	DISC
@		EQ 40MG BASE	A090800	004	Jun 18, 2009	Sep	DISC

QUINIDINE GLUCONATE

>D>	INJECTABLE;INJECTION						
>D>	QUINIDINE GLUCONATE						
>D>	+! LILLY	80MG/ML	N007529	002	Feb 10, 1989	Nov	DISC
>A>	+ @	80MG/ML	N007529	002	Feb 10, 1989	Nov	DISC

RABEPRAZOLE SODIUM

	CAPSULE, DELAYED RELEASE;ORAL						
	ACIPHEX SPRINKLE						
	+ AVADEL PHARMS	5MG	N204736	001	Mar 26, 2013	Aug	CAHN
	+!	10MG	N204736	002	Mar 26, 2013	Aug	CAHN
	TABLET, DELAYED RELEASE;ORAL						
	RABEPRAZOLE SODIUM						
AB	AUROBINDO PHARMA LTD	20MG	A205761	001	Feb 17, 2017	Feb	NEWA
AB	KREMERS URBAN PHARMS	20MG	A090678	001	Nov 08, 2013	Jan	CAHN

RALTEGRAVIR POTASSIUM

	TABLET;ORAL						
	ISENTRESS HD						
	+ MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017	May	NEWA

RAMIPRIL

	CAPSULE;ORAL						
	ALTACE						
AB	+ KING PHARMS LLC	1.25MG	N019901	001	Jan 28, 1991	Jul	CAHN
AB	+	2.5MG	N019901	002	Jan 28, 1991	Jul	CAHN
AB	+	5MG	N019901	003	Jan 28, 1991	Jul	CAHN
AB	+!	10MG	N019901	004	Jan 28, 1991	Jul	CAHN
	RAMIPRIL						
AB	ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	Mar	CAHN
AB		2.5MG	A202392	002	Apr 15, 2014	Mar	CAHN
AB		5MG	A202392	003	Apr 15, 2014	Mar	CAHN
AB		10MG	A202392	004	Apr 15, 2014	Mar	CAHN

RANITIDINE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	ZANTAC						
AP	+! TELIGENT	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Apr	CAHN
AP	+! TELIGENT PHARMA INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan	CAHN
	ZANTAC IN PLASTIC CONTAINER						
	@ TELIGENT	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	May	CAHN
	@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	May	CAHN
	SYRUP;ORAL						
	RANITIDINE HYDROCHLORIDE						
AA	AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010	Jan	CAHN
AA	PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	May	CAHN
	TABLET;ORAL						
	RANITIDINE HYDROCHLORIDE						
>A> AB	ACIC PHARMS	EQ 150MG BASE	A203694	001	Nov 30, 2017	Nov	NEWA
>A> AB		EQ 300MG BASE	A203694	002	Nov 30, 2017	Nov	NEWA
AB	GLENMARK PHARMS INC	EQ 150MG BASE	A078542	001	Nov 19, 2008	May	CAHN
AB		EQ 300MG BASE	A078542	002	Nov 19, 2008	May	CAHN

RANOLAZINE

	TABLET, EXTENDED RELEASE;ORAL						
	RANEXA						
	+ GILEAD	500MG	N021526	002	Jan 27, 2006	Feb	CTEC
	+!	1GM	N021526	001	Feb 12, 2007	Feb	CTEC
	RANOLAZINE						
	@ LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb	DISC
	@	1GM	A201046	002	Jul 29, 2013	Feb	DISC

RASAGILINE MESYLATE

	TABLET;ORAL						
	RASAGILINE MESYLATE						
AB	ALKEM LABS LTD	EQ 0.5MG BASE	A201889	001	Oct 30, 2017	Oct	NEWA
AB		EQ 1MG BASE	A201889	002	Oct 30, 2017	Oct	NEWA
AB	MYLAN PHARMS INC	EQ 0.5MG BASE	A201971	001	May 15, 2017	Jul	CMFD
	@	EQ 0.5MG BASE	A201971	001	May 15, 2017	Jun	DISC
AB		EQ 0.5MG BASE	A201971	001	May 15, 2017	May	NEWA
AB		EQ 1MG BASE	A201971	002	May 15, 2017	Jul	CMFD

TABLET;ORAL							
RASAGILINE MESYLATE							
	@	EQ 1MG BASE		A201971	002	May 15, 2017	Jun DISC
AB		EQ 1MG BASE		A201971	002	May 15, 2017	May NEWA
<u>REPAGLINIDE</u>							
TABLET;ORAL							
PRANDIN							
AB	+ GEMINI LABS LLC	0.5MG		N020741	001	Dec 22, 1997	Feb CAHN
AB	+	1MG		N020741	002	Dec 22, 1997	Feb CAHN
AB	+	2MG		N020741	003	Dec 22, 1997	Feb CAHN
REPAGLINIDE							
AB	BOSCOGEN	0.5MG		A091517	001	Apr 24, 2015	Jun CAHN
AB		1MG		A091517	002	Apr 24, 2015	Jun CAHN
AB		2MG		A091517	003	Apr 24, 2015	Jun CAHN
<u>RESERPINE</u>							
TABLET;ORAL							
RESERPINE							
	+ @ SANDOZ	0.1MG		N009838	001		Apr DISC
	+ @	0.25MG		N009838	002		Apr DISC
<u>RIBAVIRIN</u>							
CAPSULE;ORAL							
RIBASPHERE							
AB	KADMON PHARMS LLC	200MG		A076203	001	Apr 06, 2004	Jan CAHN
TABLET;ORAL							
RIBAVIRIN							
AB	KADMON PHARMS LLC	200MG		A077456	001	Dec 05, 2005	Jan CAHN
AB		400MG		A077456	002	Dec 05, 2005	Jan CAHN
AB	!	600MG		A077456	003	Dec 05, 2005	Jan CAHN
<u>RIBOCICLIB SUCCINATE</u>							
TABLET;ORAL							
KISQALI							
	+! NOVARTIS PHARMS CORP	EQ 200MG BASE		N209092	001	Mar 13, 2017	Mar NEWA
<u>RIFAMPIN</u>							
INJECTABLE;INJECTION							
RIFAMPIN							
AP	WATSON PHARMS TEVA	600MG/VIAL		A206736	001	Jan 19, 2016	Feb CAHN
AP	WEST-WARD PHARMS INT	600MG/VIAL		A064217	001	Oct 29, 1999	Jan CAHN
<u>RILUZOLE</u>							
TABLET;ORAL							
RILUTEK							
AB	+! COVIS PHARMA BV	50MG		N020599	001	Dec 12, 1995	Aug CAHN
RILUZOLE							
AB	GLENMARK PHARMS LTD	50MG		A091394	001	Jun 18, 2013	May CAHN
<u>RIMANTADINE HYDROCHLORIDE</u>							
TABLET;ORAL							
FLUMADINE							
AB	+! SUN PHARM INDS INC	100MG		N019649	001	Sep 17, 1993	Oct CAHN
RIMANTADINE HYDROCHLORIDE							
	@ IMPAX LABS INC	100MG		A075916	001	Nov 02, 2001	Feb CAHN
<u>RISPERIDONE</u>							
TABLET;ORAL							
RISPERIDONE							
	@ JUBILANT CADISTA	0.25MG		A078828	001	Mar 23, 2009	Apr CAHN
	@	0.5MG		A078828	002	Mar 23, 2009	Apr CAHN
	@	1MG		A078828	003	Mar 23, 2009	Apr CAHN
	@	2MG		A078828	004	Mar 23, 2009	Apr CAHN
	@	3MG		A078828	005	Mar 23, 2009	Apr CAHN
	@	4MG		A078828	006	Mar 23, 2009	Apr CAHN
AB	PRINSTON INC	0.25MG		A078707	001	Dec 29, 2008	Feb CAHN
AB		0.5MG		A078707	002	Dec 29, 2008	Feb CAHN
AB		1MG		A078707	003	Dec 29, 2008	Feb CAHN
AB		2MG		A078707	004	Dec 29, 2008	Feb CAHN
AB		3MG		A078707	005	Dec 29, 2008	Feb CAHN
AB		4MG		A078707	006	Dec 29, 2008	Feb CAHN

RITONAVIRPOWDER;ORAL  
NORVIR

+! ABBVIE INC 100MG/PACKET N209512 001 Jun 07, 2017 Jun NEWA

RIVASTIGMINE TARTRATECAPSULE;ORAL  
RIVASTIGMINE TARTRATE

AB	AJANTA PHARMA LTD	EQ 1.5MG BASE	A207797	001	Sep 28, 2017	Sep NEWA
AB		EQ 3MG BASE	A207797	002	Sep 28, 2017	Sep NEWA
AB		EQ 4.5MG BASE	A207797	003	Sep 28, 2017	Sep NEWA
AB		EQ 6MG BASE	A207797	004	Sep 28, 2017	Sep NEWA
AB	CADILA PHARMS LTD	EQ 1.5MG BASE	A203844	001	Feb 13, 2017	Jan NEWA
AB		EQ 3MG BASE	A203844	002	Feb 13, 2017	Jan NEWA
AB		EQ 4.5MG BASE	A203844	003	Feb 13, 2017	Jan NEWA
AB		EQ 6MG BASE	A203844	004	Feb 13, 2017	Jan NEWA
AB	SUN PHARM INDS LTD	EQ 1.5MG BASE	A077131	001	Oct 22, 2007	Mar CAHN
AB		EQ 3MG BASE	A077131	002	Oct 22, 2007	Mar CAHN
AB		EQ 4.5MG BASE	A077131	003	Oct 22, 2007	Mar CAHN
AB		EQ 6MG BASE	A077131	004	Oct 22, 2007	Mar CAHN

RIZATRIPTAN BENZOATETABLET;ORAL  
RIZATRIPTAN BENZOATE

AB	ECI PHARMS LLC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Mar CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Mar CAHN
AB	UNICHEM LABS LTD	EQ 5MG BASE	A207836	001	Mar 07, 2017	Feb NEWA
AB		EQ 10MG BASE	A207836	002	Mar 07, 2017	Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL  
RIZATRIPTAN BENZOATE

AB	GLENMARK PHARMS LTD	EQ 5MG BASE	A201914	001	Jul 01, 2013	May CAHN
AB		EQ 10MG BASE	A201914	002	Jul 01, 2013	May CAHN
AB	PANACEA BIOTEC LTD	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jan NEWA
AB		EQ 10MG BASE	A204722	002	Jan 11, 2017	Jan NEWA
AB	UNICHEM LABS LTD	EQ 5MG BASE	A207835	001	Mar 07, 2017	Feb NEWA
AB		EQ 10MG BASE	A207835	002	Mar 07, 2017	Feb NEWA

ROCURONIUM BROMIDEINJECTABLE;INJECTION  
ROCURONIUM BROMIDE

AP	AUROBINDO PHARMA LTD	50MG/5ML (10MG/ML)	A206206	001	Apr 12, 2017	Mar NEWA
AP		100MG/10ML (10MG/ML)	A206206	002	Apr 12, 2017	Mar NEWA
AP	! SANDOZ INC	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Mar CAHN
AP	!	100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Mar CAHN
AP	WEST WARD PHARM CORP	50MG/5ML (10MG/ML)	A204679	001	Feb 28, 2017	Feb NEWA
AP		100MG/10ML (10MG/ML)	A204679	002	Feb 28, 2017	Feb NEWA

ROLAPITANT HYDROCHLORIDEEMULSION;IV (INFUSION)  
VARUBI

+! TESARO INC EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML) N208399 001 Oct 25, 2017 Oct NEWA

ROPINIROLE HYDROCHLORIDETABLET;ORAL  
ROPINIROLE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Apr CAHN
AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Apr CAHN
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Apr CAHN
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Apr CAHN
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Apr CAHN
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Apr CAHN
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Apr CAHN
AB	ACCORD HLTHCARE INC	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Feb NEWA
AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Feb NEWA
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Feb NEWA
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Feb NEWA
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Feb NEWA
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Feb NEWA
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Feb NEWA
	@ EPIC PHARMA LLC	EQ 0.25MG BASE	A078230	001	May 20, 2008	May CAHN
	@	EQ 0.5MG BASE	A078230	002	May 20, 2008	May CAHN

## TABLET;ORAL

## ROPINIROLE HYDROCHLORIDE

@	EQ 1MG BASE	A078230	003	May 20, 2008	May CAHN
@	EQ 2MG BASE	A078230	004	May 20, 2008	May CAHN
@	EQ 3MG BASE	A078230	005	May 20, 2008	May CAHN
@	EQ 4MG BASE	A078230	006	May 20, 2008	May CAHN
@	EQ 5MG BASE	A078230	007	May 20, 2008	May CAHN

## TABLET, EXTENDED RELEASE;ORAL

## ROPINIROLE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	May CAHN
AB		EQ 4MG BASE	A202786	002	Apr 22, 2013	May CAHN
AB		EQ 6MG BASE	A202786	003	Apr 22, 2013	May CAHN
AB		EQ 8MG BASE	A202786	004	Apr 22, 2013	May CAHN
AB		EQ 12MG BASE	A202786	005	Apr 22, 2013	May CAHN
	@ MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012	Apr DISC

ROPIVACAINE HYDROCHLORIDE

## SOLUTION;INJECTION

## ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	150MG/30ML (5MG/ML)	A203955	001	Apr 11, 2016	Jun CDFR
----	-----------	---------------------	---------	-----	--------------	----------

ROSUVASTATIN CALCIUM

## TABLET;ORAL

## ROSUVASTATIN CALCIUM

AB	ACCORD HLTHCARE	5MG	A206434	001	Oct 31, 2016	Mar CAHN
AB		10MG	A206434	002	Oct 31, 2016	Mar CAHN
AB		20MG	A206434	003	Oct 31, 2016	Mar CAHN
AB		40MG	A206434	004	Oct 31, 2016	Mar CAHN
AB	ALKEM LABS LTD	5MG	A206465	001	Mar 21, 2017	Mar NEWA
AB		10MG	A206465	002	Mar 21, 2017	Mar NEWA
AB		20MG	A206465	003	Mar 21, 2017	Mar NEWA
AB		40MG	A206465	004	Mar 21, 2017	Mar NEWA
AB	LUPIN LTD	5MG	A205587	001	Jul 31, 2017	Jul NEWA
AB		10MG	A205587	002	Jul 31, 2017	Jul NEWA
AB		20MG	A205587	003	Jul 31, 2017	Jul NEWA
AB		40MG	A205587	004	Jul 31, 2017	Jul NEWA
>A> AB	MSN LABS PVT LTD	5MG	A208898	001	Nov 22, 2017	Nov NEWA
>A> AB		10MG	A208898	002	Nov 22, 2017	Nov NEWA
>A> AB		20MG	A208898	003	Nov 22, 2017	Nov NEWA
>A> AB		40MG	A208898	004	Nov 22, 2017	Nov NEWA
AB	TORRENT PHARMS LTD	5MG	A201619	001	Oct 31, 2016	Apr CAHN
AB		10MG	A201619	002	Oct 31, 2016	Apr CAHN
AB		20MG	A201619	003	Oct 31, 2016	Apr CAHN
AB		40MG	A201619	004	Oct 31, 2016	Apr CAHN

RUCAPARIB CAMSYLATE

## TABLET;ORAL

## RUBRACA

+	CLOVIS ONCOLOGY INC	EQ 250MG BASE	N209115	003	May 01, 2017	May NEWA
---	---------------------	---------------	---------	-----	--------------	----------

SAFINAMIDE MESYLATE

## TABLET;ORAL

## XADAGO

+	NEWRON PHARMS US INC	50MG	N207145	001	Mar 21, 2017	Mar NEWA
+	!	100MG	N207145	002	Mar 21, 2017	Mar NEWA
+	US WORLDMEDS LLC	50MG	N207145	001	Mar 21, 2017	Apr CAHN
+	!	100MG	N207145	002	Mar 21, 2017	Apr CAHN

SECNIDAZOLE

## GRANULE;ORAL

## SOLOSEC

+	!	LUPIN	2GM/PACKET	N209363	001	Sep 15, 2017	Oct CAHN
+	!	SYMBIOMIX THERAP	2GM/PACKET	N209363	001	Sep 15, 2017	Sep NEWA

SELEGILINE HYDROCHLORIDE

## TABLET;ORAL

## SELEGILINE HYDROCHLORIDE

AB	BOSCOGEN	5MG	A074912	001	Apr 30, 1998	May CAHN
	@ CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996	Jan CAHN
	@	5MG	A074641	001	Aug 02, 1996	Jan CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL

SERTRALINE HYDROCHLORIDE

@ ALLIED PHARMA INC EQ 20MG BASE/ML

A076934 001 Jun 30, 2006 Mar CAHN

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@ ACI HEALTHCARE LTD EQ 25MG BASE

A076881 001 Feb 06, 2007 Jun CAHN

@ EQ 50MG BASE

A076881 002 Feb 06, 2007 Jun CAHN

@ EQ 100MG BASE

A076881 003 Feb 06, 2007 Jun CAHN

@ ALLIED PHARMA INC EQ 25MG BASE

A076881 001 Feb 06, 2007 Mar CAHN

@ EQ 50MG BASE

A076881 002 Feb 06, 2007 Mar CAHN

@ EQ 100MG BASE

A076881 003 Feb 06, 2007 Mar CAHN

@ ANDA REPOSITORY EQ 25MG BASE

A077818 001 Feb 06, 2007 Sep CAHN

@ EQ 50MG BASE

A077818 002 Feb 06, 2007 Sep CAHN

@ EQ 100MG BASE

A077818 003 Feb 06, 2007 Sep CAHN

@ MYLAN EQ 25MG BASE

A076671 001 Feb 06, 2007 Mar DISC

@ EQ 50MG BASE

A076671 002 Feb 06, 2007 Mar DISC

@ EQ 100MG BASE

A076671 003 Feb 06, 2007 Mar DISC

@ SUN PHARM INDS (IN) EQ 25MG BASE

A078108 001 Feb 06, 2007 Oct DISC

@ EQ 50MG BASE

A078108 002 Feb 06, 2007 Oct DISC

@ EQ 100MG BASE

A078108 003 Feb 06, 2007 Oct DISC

@ WATSON LABS TEVA EQ 25MG BASE

A077663 001 Feb 06, 2007 May CAHN

@ EQ 50MG BASE

A077663 002 Feb 06, 2007 May CAHN

@ EQ 100MG BASE

A077663 003 Feb 06, 2007 May CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

RENEVELA

AB + GENZYME 800MG/PACKET

N022318 001 Aug 12, 2009 May CFTG

AB +! 2.4GM/PACKET

N022318 002 Feb 18, 2009 May CFTG

SEVELAMER CARBONATE

AB AUROBINDO PHARMA LTD 800MG/PACKET

A207624 001 Jun 13, 2017 May NEWA

AB 2.4GM/PACKET

A207624 002 Jun 13, 2017 May NEWA

TABLET;ORAL

RENEVELA

AB +! GENZYME 800MG

N022127 001 Oct 19, 2007 Jul CFTG

SEVELAMER CARBONATE

&gt;A&gt; AB AMNEAL PHARMS CO 800MG

A207288 001 Nov 28, 2017 Nov NEWA

AB AUROBINDO PHARMA LTD 800MG

A207179 001 Jul 17, 2017 Jul NEWA

AB DR REDDYS LABS LTD 800MG

A206094 001 Sep 29, 2017 Sep NEWA

AB IMPAX LABS INC 800MG

A090975 001 Oct 23, 2017 Oct NEWA

AB INVAGEN PHARMS 800MG

A203860 001 Oct 26, 2017 Oct NEWA

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

&gt;D&gt; @ TEVA EQ 25MG BASE

A077342 001 Mar 09, 2016 Nov CMFD

&gt;A&gt; AB EQ 25MG BASE

A077342 001 Mar 09, 2016 Nov CMFD

&gt;D&gt; @ EQ 50MG BASE

A077342 002 Mar 09, 2016 Nov CMFD

&gt;A&gt; AB EQ 50MG BASE

A077342 002 Mar 09, 2016 Nov CMFD

&gt;D&gt; @ EQ 100MG BASE

A077342 003 Mar 09, 2016 Nov CMFD

&gt;A&gt; AB EQ 100MG BASE

A077342 003 Mar 09, 2016 Nov CMFD

VIAGRA

&gt;D&gt; + PFIZER INC EQ 25MG BASE

N020895 001 Mar 27, 1998 Nov CTEC

&gt;A&gt; AB EQ 25MG BASE

N020895 001 Mar 27, 1998 Nov CTEC

+ EQ 25MG BASE

N020895 001 Mar 27, 1998 May CAHN

&gt;D&gt; + EQ 50MG BASE

N020895 002 Mar 27, 1998 Nov CTEC

&gt;A&gt; AB + EQ 50MG BASE

N020895 002 Mar 27, 1998 Nov CTEC

+ EQ 50MG BASE

N020895 002 Mar 27, 1998 May CAHN

&gt;D&gt; +! EQ 100MG BASE

N020895 003 Mar 27, 1998 Nov CTEC

&gt;A&gt; AB +! EQ 100MG BASE

N020895 003 Mar 27, 1998 Nov CTEC

EQ 100MG BASE

N020895 003 Mar 27, 1998 May CAHN

SILODOSIN

CAPSULE;ORAL

RAPAFLO

AB +! ALLERGAN SALES LLC 4MG

N022206 001 Oct 08, 2008 Mar CFTG

AB + 8MG

N022206 002 Oct 08, 2008 Mar CFTG

SILODOSIN

AB SANDOZ INC 4MG

A204726 001 Mar 31, 2017 Mar NEWA

AB 8MG

A204726 002 Mar 31, 2017 Mar NEWA

SILVER SULFADIAZINECREAM; TOPICAL  
SILVADENE

AB	+	KING PHARMS LLC	1%	N017381	001		Aug	CAHN
----	---	-----------------	----	---------	-----	--	-----	------

SIMVASTATINSUSPENSION; ORAL  
FLOLIPID

+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016	Oct	CTNA
+	!	40MG/5ML	N206679	002	Apr 21, 2016	Oct	CTNA

TABLET; ORAL  
SIMVASTATIN

AB		HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	Oct	NEWA
AB			20MG	A206557	002	Nov 13, 2017	Oct	NEWA
AB			40MG	A206557	003	Nov 13, 2017	Oct	NEWA
AB			80MG	A206557	004	Nov 13, 2017	Oct	NEWA
	@	MYLAN PHARMS INC	5MG	A090868	001	Jun 08, 2010	May	DISC
	@		10MG	A090868	002	Jun 08, 2010	May	DISC
	@		20MG	A090868	003	Jun 08, 2010	May	DISC
	@		40MG	A090868	004	Jun 08, 2010	May	DISC
	@		80MG	A090868	005	Jun 08, 2010	May	DISC
AB		VIVA HLTHCARE	5MG	A090383	001	Sep 16, 2011	Sep	CAHN
AB			10MG	A090383	002	Sep 16, 2011	Sep	CAHN
AB			20MG	A090383	003	Sep 16, 2011	Sep	CAHN
AB			40MG	A090383	004	Sep 16, 2011	Sep	CAHN
AB			80MG	A090383	005	Sep 16, 2011	Sep	CAHN
AB		WATSON LABS TEVA	5MG	A076685	001	Dec 20, 2006	May	CAHN
AB			10MG	A076685	002	Dec 20, 2006	May	CAHN
AB			20MG	A076685	003	Dec 20, 2006	May	CAHN
AB			40MG	A076685	004	Dec 20, 2006	May	CAHN
AB			80MG	A076685	005	Dec 20, 2006	May	CAHN
		ZOCOR						
AB	+	MSD MERCK CO	5MG	N019766	001	Dec 23, 1991	Oct	CAHN
AB	+		10MG	N019766	002	Dec 23, 1991	Oct	CAHN
AB	+		20MG	N019766	003	Dec 23, 1991	Oct	CAHN
AB	+		40MG	N019766	004	Dec 23, 1991	Oct	CAHN
AB	+		80MG	N019766	005	Jul 10, 1998	Oct	CAHN

SODIUM ACETATEINJECTABLE; INJECTION  
SODIUM ACETATE

		FRESENIUS KABI USA	4MEQ/ML	A206687	001	Oct 30, 2017	Oct	NEWA
>A>	+	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Nov	CTNA

SODIUM ACETATE ANHYDROUSINJECTABLE; INJECTION  
SODIUM ACETATE IN PLASTIC CONTAINER

>D>	+	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Nov	CTNA
-----	---	---------	---------	---------	-----	--------------	-----	------

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION; IV (INFUSION)  
SODIUM PHENYLACETATE AND SODIUM BENZOATE

AP		AILEX PHARMS LLC	10%; 10% (5GM/50ML; 5GM/50ML)	A207096	001	Feb 24, 2016	Jul	CAHN
----	--	------------------	-------------------------------	---------	-----	--------------	-----	------

SODIUM BICARBONATEINJECTABLE; INJECTION  
SODIUM BICARBONATE

AP	!	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Feb	CTEC
AP	!		1MEQ/ML	A077394	002	Nov 09, 2005	Feb	CTEC
		HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Feb	NEWA
AP			0.9MEQ/ML	A202494	001	Mar 06, 2017	Feb	NEWA
AP			1MEQ/ML	A202432	001	Sep 26, 2017	Sep	NEWA
			1MEQ/ML	A202495	001	Mar 06, 2017	Feb	NEWA
AP			1MEQ/ML	A202494	002	Mar 06, 2017	Feb	NEWA
AP		INTL MEDICATION SYS	1MEQ/ML	A203449	001	Sep 19, 2017	Sep	NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION									
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER									
AP	+	ICU MEDICAL INC	450MG/100ML	N018090	001				Feb CAHN
SODIUM CHLORIDE 0.9%									
AP		SPECTRA MDCL DEVICES	9MG/ML	A206171	001	Jul 21, 2017			Jul NEWA
AP		WEST-WARD PHARMS INT	9MG/ML	A201850	001	Jan 20, 2012			Jan CAHN
SODIUM CHLORIDE 0.9%									
		WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013			Jan CAHN
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AP		FRESENIUS KABI USA	900MG/100ML	A207310	001	Sep 19, 2017			Sep NEWA
AP	+	ICU MEDICAL INC	900MG/100ML	N016366	001				Feb CAHN
AP		LABORATORIOS GRIFOLS	900MG/100ML	A207956	001	May 25, 2017			May NEWA
AP	!	TARO	9MG/ML	A077407	001	Aug 11, 2006			Apr CAHN
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER									
	+	@ ABRAXIS PHARM	234MG/ML	N019329	001	Apr 22, 1987			Jan CRLD
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER									
AP		B BRAUN	3GM/100ML	N019635	003	Mar 09, 1988			Jul CMFD
AP	+	BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983			Jul CTEC
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER									
AP		B BRAUN	5GM/100ML	N019635	004	Mar 09, 1988			Jul CMFD
AP	+	BAXTER HLTHCARE	5GM/100ML	N019022	002	Nov 01, 1983			Jul CTEC
SODIUM CHLORIDE IN PLASTIC CONTAINER									
	+	HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984			Mar CRLD
SOLUTION;IRRIGATION									
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AT		ICU MEDICAL INC	900MG/100ML	N017514	001				Feb CAHN
AT			900MG/100ML	N018314	001				Feb CAHN

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS									
SODIUM FLUORIDE F-18									
AP		JUBILANT DRAXIMAGE	10-200mCi/ML	A203968	001	Oct 23, 2015			Sep CAHN

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION									
SODIUM NITROPRUSSIDE									
AP		AKORN	25MG/ML	A208635	001	May 04, 2017			Apr NEWA
AP		AMNEAL PHARMS CO	25MG/ML	A209493	001	Nov 07, 2017			Oct NEWA
>A> AP		MICRO LABS	25MG/ML	A209352	001	Dec 08, 2017			Nov NEWA
AP		NEXUS PHARMS	25MG/ML	A207499	001	May 25, 2017			May NEWA
SOLUTION;IV (INFUSION)									
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%									
	+	!	EXELA PHARMA SCS LLC	50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017		Mar NEWA

SODIUM OXYBATE

SOLUTION;ORAL									
SODIUM OXYBATE									
AA		WEST-WARD PHARMS INT	500MG/ML	A202090	001	Jan 17, 2017			Jan NEWA

SODIUM PHENYLBUTYRATE

TABLET;ORAL									
SODIUM PHENYLBUTYRATE									
AB		ALVOGEN MALTA	500MG	A090910	001	Nov 18, 2011			Apr CAHN

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL									
KALEXATE									
AA	!	KVK TECH	454GM/BOT	A040905	001	Mar 30, 2009			Sep CHRS
KAYEXALATE									
	+	@ CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001				Sep DISC
SODIUM POLYSTYRENE SULFONATE									
AA		AILEX PHARMS LLC	454GM/BOT	A206815	001	Feb 18, 2016			Sep CAHN
AA		CMP PHARMA INC	454GM/BOT	A089910	001	Jan 19, 1989			Apr CAHN
AA		ECI PHARMS LLC	453.6GM/BOT	A090313	001	Dec 21, 2011			Mar CAHN
SUSPENSION;ORAL, RECTAL									
SPS									
AA	!	CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982			Apr CAHN



SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET; ORAL

VOSEVI

+	!	GILEAD SCIENCES INC	400MG;100MG;100MG	N209195	001	Jul 18, 2017	Jul NEWA
---	---	---------------------	-------------------	---------	-----	--------------	----------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

SEROSTIM

>D>	BX		EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997	Nov CTEC
>A>				4MG/VIAL	N020604	003	Jul 25, 1997	Nov CTEC

VALTROPIN

	BX		LG CHEM LTD	5MG/VIAL	N021905	001	Apr 19, 2007	Jun CAHN
--	----	--	-------------	----------	---------	-----	--------------	----------

ZOMACTON

>D>	BX	+	FERRING	10MG/VIAL	N019774	003	Mar 07, 2012	Nov CTEC
>A>		+		10MG/VIAL	N019774	003	Mar 07, 2012	Nov CTEC

SONIDEGIB PHOSPHATE

CAPSULE; ORAL

ODOMZO

+	!	SUN PHARM INDS INC	EQ 200MG BASE	N205266	001	Jul 24, 2015	Mar CAHN
+	!	SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015	May CAHN

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

AB1	+		COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May CAHN
AB1	+			120MG	N019865	005	Apr 20, 1994	May CAHN
AB1	+	!		160MG	N019865	002	Oct 30, 1992	May CAHN
AB1	+			240MG	N019865	003	Oct 30, 1992	May CAHN
			@	320MG	N019865	004	Oct 30, 1992	May CAHN

BETAPACE AF

			@	COVIS PHARMA BV	40MG	N021151	006	Apr 02, 2003	May CAHN
			@		60MG	N021151	007	Apr 02, 2003	May CAHN
AB2	+			80MG	N021151	001	Feb 22, 2000	May CAHN	
			@	100MG	N021151	005	Mar 14, 2003	May CAHN	
AB2	+			120MG	N021151	002	Feb 22, 2000	May CAHN	
AB2	+	!		160MG	N021151	003	Feb 22, 2000	May CAHN	

SORINE

AB1			UPSHER-SMITH LABS	80MG	A075500	001	Apr 27, 2001	Jun CAHN
AB1				120MG	A075500	004	Apr 27, 2001	Jun CAHN
AB1				160MG	A075500	002	Apr 27, 2001	Jun CAHN
AB1				240MG	A075500	003	Apr 27, 2001	Jun CAHN

SOTALOL HYDROCHLORIDE

			@	MYLAN	80MG	A075237	001	May 01, 2000	Jun DISC
			@		80MG	A075725	001	Dec 19, 2000	Jun DISC
			@		120MG	A075237	002	May 01, 2000	Jun DISC
			@		120MG	A075725	002	Dec 19, 2000	Jun DISC
			@		160MG	A075237	003	May 01, 2000	Jun DISC
			@		160MG	A075725	003	Dec 19, 2000	Jun DISC
			@		240MG	A075237	004	May 01, 2000	Jun DISC
			@		240MG	A075725	004	Dec 19, 2000	Jun DISC
AB1				UPSHER-SMITH LABS	80MG	A075366	001	May 01, 2000	Jun CAHN
AB1					120MG	A075366	002	May 01, 2000	Jun CAHN
AB1					160MG	A075366	003	May 01, 2000	Jun CAHN
AB1					240MG	A075366	004	May 01, 2000	Jun CAHN

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 30%

+	!	FRESENIUS	30%	N019942	001	Dec 30, 1993	Sep CTEC
---	---	-----------	-----	---------	-----	--------------	----------

SPIRONOLACTONE

SUSPENSION; ORAL

CAROSPIR

+	!	CMP DEV LLC	25MG/5ML	N209478	001	Aug 04, 2017	Sep CAHN
+	!	CMP PHARMA INC	25MG/5ML	N209478	001	Aug 04, 2017	Aug NEWA

TABLET; ORAL

SPIRONOLACTONE

AB			ACCORD HLTHCARE	25MG	A203512	001	Sep 19, 2016	Mar CAHN
AB				50MG	A203512	002	Sep 19, 2016	Mar CAHN
AB				100MG	A203512	003	Sep 19, 2016	Mar CAHN

## TABLET;ORAL

## SPIRONOLACTONE

AB	AMNEAL PHARMS	25MG	A091426	001	Jul 02, 2010	May CAHN
AB		25MG	A091426	001	Jul 02, 2010	May CMS1
AB		50MG	A091426	002	Jul 02, 2010	May CAHN
AB		50MG	A091426	002	Jul 02, 2010	May CMS1
AB		100MG	A091426	003	Jul 02, 2010	May CAHN
AB		100MG	A091426	003	Jul 02, 2010	May CMS1
>A> AB	AUROBINDO PHARMA LTD	25MG	A202187	001	Mar 06, 2014	Nov CAHN
>A> AB		50MG	A202187	002	Mar 06, 2014	Nov CAHN
>A> AB		100MG	A202187	003	Mar 06, 2014	Nov CAHN
>D> AB	ORION CORP ORION	25MG	A202187	001	Mar 06, 2014	Nov CAHN
>D> AB		50MG	A202187	002	Mar 06, 2014	Nov CAHN
>D> AB		100MG	A202187	003	Mar 06, 2014	Nov CAHN
	@ UPSHER SMITH	25MG	A087554	001		Jun CAHN

STAVUDINE

## CAPSULE;ORAL

## STAVUDINE

	@ MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009	May DISC
AB		30MG	A078775	001	Jan 05, 2009	Mar CAHN
	@	40MG	A078775	002	Jan 05, 2009	May DISC
AB		40MG	A078775	002	Jan 05, 2009	Mar CAHN

## FOR SOLUTION;ORAL

## STAVUDINE

	@ AUROBINDO PHARMA	1MG/ML	A077774	001	Dec 29, 2008	Jul DISC
--	--------------------	--------	---------	-----	--------------	----------

STERILE WATER FOR INJECTION

## LIQUID;N/A

## STERILE WATER FOR INJECTION

>A> AP	FRESENIUS KABI USA	100%	A209689	001	Nov 24, 2017	Nov NEWA
AP	WEST-WARD PHARMS INT	100%	A206369	001	Sep 02, 2015	Jan CAHN
	STERILE WATER FOR INJECTION IN PLASTIC CONTAINER					
AP	+! ICU MEDICAL INC	100%	N018233	001		Feb CAHN
AP	+!	100%	N019869	001	Dec 26, 1989	Apr CAHN
AP	TARO	100%	A077393	001	Aug 11, 2006	Apr CAHN

STERILE WATER FOR IRRIGATION

## LIQUID;IRRIGATION

## STERILE WATER IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	100%	N017513	001		Feb CAHN
AT		100%	N018313	001		Feb CAHN

SUCCINYLCHOLINE CHLORIDE

## INJECTABLE;INJECTION

## ANECTINE

AP	+! SANDOZ INC	20MG/ML	N008453	002		May CAHN
	@	50MG/ML	N008453	003		May CAHN
	@	500MG/VIAL	N008453	001		May CAHN
	@	1GM/VIAL	N008453	004		May CAHN

SULCONAZOLE NITRATE

## CREAM;TOPICAL

## EXELDERM

+!	SUN PHARM INDS INC	1%	N018737	001	Feb 28, 1989	Aug CAHN
----	--------------------	----	---------	-----	--------------	----------

## SOLUTION;TOPICAL

## EXELDERM

+!	SUN PHARM INDS INC	1%	N018738	001	Aug 30, 1985	Aug CAHN
----	--------------------	----	---------	-----	--------------	----------

SULFACETAMIDE SODIUM

## SOLUTION/DROPS;OPHTHALMIC

## SULFACETAMIDE SODIUM

AT	SANDOZ INC	10%	A089560	001	Oct 18, 1988	Feb CAHN
----	------------	-----	---------	-----	--------------	----------

SULFAMETHOXAZOLE; TRIMETHOPRIM

## INJECTABLE;INJECTION

## BACTRIM

+	@ MUTUAL PHARM	80MG/ML;16MG/ML	N018374	001		Sep CRLD
+	@ SUN PHARM INDS INC	80MG/ML;16MG/ML	N018374	001		Oct CAHN

## SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	MYLAN LABS LTD	80MG/ML;16MG/ML	A206607	001	Aug 30, 2017	Aug NEWA
AP	! TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991	Aug CTEC

## TABLET;ORAL

SEPTRA							
AB	MONARCH PHARMS	400MG;80MG	N017376	001		May	CAHN
SEPTRA DS							
AB	MONARCH PHARMS	800MG;160MG	N017376	002		May	CAHN
SULFAMETHOXAZOLE AND TRIMETHOPRIM							
AB	CHARTWELL MOLECULES	400MG;80MG	A078060	002	Jan 25, 2007	Mar	CAHN
AB		800MG;160MG	A078060	001	Jan 25, 2007	Mar	CAHN
AB	CHARTWELL PHARMS LLC	400MG;80MG	A078060	002	Jan 25, 2007	Jan	CAHN
AB		800MG;160MG	A078060	001	Jan 25, 2007	Jan	CAHN
	SUN PHARM INDUSTRIES	400MG;80MG	A071017	002	Aug 25, 1986	Oct	CMS1

SULFANILAMIDE

## CREAM;VAGINAL

## AVC

+! MYLAN SPECIALITY LP

15%

N006530 003 Jan 27, 1987 Mar CAHN

## SUPPOSITORY;VAGINAL

## AVC

@ MYLAN SPECIALITY LP

1.05GM

N006530 004 Jan 27, 1987 Mar CAHN

SULINDAC

## TABLET;ORAL

## SULINDAC

AB	EPIC PHARMA LLC	150MG	A073262	002	Sep 06, 1991	Aug	CAHN
AB		200MG	A073262	001	Sep 06, 1991	Aug	CAHN

SUMATRIPTAN SUCCINATE

## INJECTABLE;SUBCUTANEOUS

## SUMATRIPTAN SUCCINATE

>A>	AP	SAGENT AGILA LLC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Nov	CAHN
>D>	AP	SAGENT STRIDES	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Nov	CAHN
		@ SANDOZ INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078067	002	Feb 06, 2009	Mar	CAHN
		@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078067	001	Feb 06, 2009	Mar	CAHN
	AP	WEST-WARD PHARMS INT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jan	CAHN

## SYSTEM;IONTOPHORESIS

## ZECUITY

+ @ TEVA BRANDED PHARM

EQ 6.5MG BASE/4HR

N202278 001 Jan 17, 2013 Jan DISC

SUNITINIB MALATE

## CAPSULE;ORAL

## SUTENT

+ CPPI CV

EQ 12.5MG BASE

N021938 001 Jan 26, 2006 Mar CTEC

+

EQ 25MG BASE

N021938 002 Jan 26, 2006 Mar CTEC

+

EQ 37.5MG BASE

N021938 004 Mar 31, 2009 Mar CTEC

+!

EQ 50MG BASE

N021938 003 Jan 26, 2006 Mar CTEC

TACROLIMUS

## CAPSULE;ORAL

## TACROLIMUS

>A>	AB	BELCHER PHARMS LLC	EQ 0.5MG BASE	A206651	001	Nov 30, 2017	Nov	NEWA
>A>	AB		EQ 1MG BASE	A206651	002	Nov 30, 2017	Nov	NEWA
>A>	AB		EQ 5MG BASE	A206651	003	Nov 30, 2017	Nov	NEWA

## INJECTABLE;INJECTION

## PROGRAF

AP	+!	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Aug	CFTG
		TACROLIMUS						
AP		HOSPIRA INC	EQ 5MG BASE/ML	A203900	001	Aug 25, 2017	Aug	NEWA

TALC

## POWDER;INTRAPLEURAL

## STERITALC

+ NOVATECH SA

2GM/VIAL

N205555 001 May 01, 2017 Apr NEWA

+

3GM/VIAL

N205555 002 May 01, 2017 Apr NEWA

+!

4GM/VIAL

N205555 003 May 01, 2017 Apr NEWA

TAMOXIFEN CITRATE

TABLET;ORAL

TAMOXIFEN CITRATE

AB	!	MAYNE PHARMA	EQ 20MG BASE	A075797	002	Feb 20, 2003	Sep CMS1
AB		ZYDUS PHARMS USA INC	EQ 10MG BASE	A206694	001	Oct 27, 2017	Oct NEWA
AB			EQ 20MG BASE	A206694	002	Oct 27, 2017	Oct NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	0.4MG	A204645	001	Jan 20, 2017	Jan NEWA
AB		TAMSULOSIN HYDROCHLORIDE					
AB		ALKEM LABS LTD	0.4MG	A207405	001	Aug 11, 2017	Jul NEWA

TAZAROTENE

AEROSOL, FOAM;TOPICAL

FABIOR

	+	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012	Jan CAHN
		CREAM;TOPICAL					
		AVAGE					
AB	+	ALLERGAN	0.1%	N021184	003	Sep 30, 2002	Mar CFTG
		TAZAROTENE					
AB		TARO	0.1%	A208258	001	Apr 03, 2017	Mar NEWA
		TAZORAC					
AB	+	ALLERGAN	0.1%	N021184	002	Sep 29, 2000	Mar CFTG

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE;INJECTION

PULMOLITE

>D>	BS	JUBILANT DRAXIMAGE	N/A	N017776	001		Nov CRLD
>A>	BS	+	N/A	N017776	001		Nov CRLD
		TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT					
>D>	BS	DRAXIMAGE	N/A	N017881	001	Dec 30, 1987	Nov CRLD
>A>	BS	+	N/A	N017881	001	Dec 30, 1987	Nov CRLD

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE;INJECTION

NEUROLITE

>D>		LANTHEUS MEDCL	N/A	N020256	001	Nov 23, 1994	Nov CRLD
>A>		+	N/A	N020256	001	Nov 23, 1994	Nov CRLD

TECHNETIUM TC-99M EXAMETAZIME KIT

POWDER;INTRAVENOUS

DRAX EXAMETAZIME

		JUBILANT DRAXIMAGE	N/A	N208870	001	Aug 17, 2017	Aug NEWA
--	--	--------------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION

MDP-BRACCO

AP		CARDINAL HEALTH 414	N/A	N018107	001		Apr CAHN
----	--	---------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE;INJECTION

AN-DTPA

		@ JUBILANT DRAXIMAGE	N/A	N017714	001		Aug DISC
		DTPA					
>D>		DRAXIMAGE	N/A	N018511	001	Dec 29, 1989	Nov CRLD
>A>		+	N/A	N018511	001	Dec 29, 1989	Nov CRLD
			N/A	N018511	001	Dec 29, 1989	Aug CTEC

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE;INJECTION

ULTRATAG

>D>		MALLINKRODT NUCLEAR	N/A	N019981	001	Jun 10, 1991	Nov CRLD
>A>		+	N/A	N019981	001	Jun 10, 1991	Nov CRLD

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE;INJECTION

TECHNETIUM TC 99M SESTAMIBI

AP	CARDINAL HEALTH 414	N/A	A078809	001	Apr 28, 2009	Sep CAHN
AP	JUBILANT DRAXIMAGE	N/A	A078806	001	Apr 29, 2009	Jun CAHN

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE;INJECTION

MYOVUE

+	@ GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996	Jul DISC
---	-----------------	-----	---------	-----	--------------	----------

MYOVUE 30ML

+	! GE HEALTHCARE	N/A	N020372	002	Jul 07, 2005	Aug CMFD
---	-----------------	-----	---------	-----	--------------	----------

+	@	N/A	N020372	002	Jul 07, 2005	Jul DISC
---	---	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE;INJECTION

LYMPHOSEEK KIT

+	! CARDINAL HEALTH 414	N/A	N202207	001	Mar 13, 2013	Sep CAHN
---	-----------------------	-----	---------	-----	--------------	----------

+	! CARDINAL HLTH 414	N/A	N202207	001	Mar 13, 2013	Mar CAHN
---	---------------------	-----	---------	-----	--------------	----------

TELAVANCIN HYDROCHLORIDE

POWDER;IV (INFUSION)

VIBATIV

+	@ THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	Aug DISC
---	------------------------	--------------------	---------	-----	--------------	----------

+		EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	May CAHN
---	--	--------------------	---------	-----	--------------	----------

+	!	EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	May CAHN
---	---	--------------------	---------	-----	--------------	----------

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB	CADILA PHARMS LTD	20MG	A208605	001	Jul 25, 2017	Jul NEWA
AB		40MG	A208605	002	Jul 25, 2017	Jul NEWA
AB		80MG	A208605	003	Jul 25, 2017	Jul NEWA
AB	GLENMARK PHARMS LTD	20MG	A090032	001	Jul 07, 2014	May CAHN
AB		40MG	A090032	002	Jul 07, 2014	May CAHN
AB		80MG	A090032	003	Jul 07, 2014	May CAHN
AB	MICRO LABS	20MG	A207016	001	Oct 03, 2017	Sep NEWA
AB		40MG	A207016	002	Oct 03, 2017	Sep NEWA
AB		80MG	A207016	003	Oct 03, 2017	Sep NEWA
AB	PRINSTON INC	20MG	A207882	001	May 03, 2017	Apr NEWA
AB		40MG	A207882	002	May 03, 2017	Apr NEWA
AB		80MG	A207882	003	May 03, 2017	Apr NEWA

TELOTTRISTAT ETIPRATE

TABLET;ORAL

XERMELO

+	! LEXICON PHARMS INC	EQ 250MG BASE	N208794	001	Feb 28, 2017	Feb NEWA
---	----------------------	---------------	---------	-----	--------------	----------

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

AB	ACTAVIS ELIZABETH	15MG	A071620	002	Aug 07, 1987	May CMS1
AB	PRINSTON INC	7.5MG	A201781	001	Jun 04, 2015	Feb CAHN
AB		15MG	A201781	002	Jun 04, 2015	Feb CAHN
AB		22.5MG	A201781	003	Jun 04, 2015	Feb CAHN
AB		30MG	A201781	004	Jun 04, 2015	Feb CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB	ACCORD HLTHCARE	5MG	A201528	001	Feb 27, 2017	Feb NEWA
AB		20MG	A201528	002	Feb 27, 2017	Feb NEWA
AB		100MG	A201528	003	Feb 27, 2017	Feb NEWA
AB		140MG	A201528	004	Feb 27, 2017	Feb NEWA
AB		180MG	A201528	005	Feb 27, 2017	Feb NEWA
AB		250MG	A201528	006	Feb 27, 2017	Feb NEWA
AB	DEVA HOLDING AS	5MG	A207658	001	Apr 26, 2017	Apr NEWA
AB		20MG	A207658	002	Apr 26, 2017	Apr NEWA
AB		100MG	A207658	003	Apr 26, 2017	Apr NEWA
AB		140MG	A207658	004	Apr 26, 2017	Apr NEWA
AB		180MG	A207658	005	Apr 26, 2017	Apr NEWA

CAPSULE;ORAL							
TEMOZOLOMIDE							
AB		250MG	A207658	006	Apr 26, 2017	Apr	NEWA
AB	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Apr	NEWA
AB		20MG	A203959	002	Apr 18, 2017	Apr	NEWA
AB		100MG	A203959	003	Apr 18, 2017	Apr	NEWA
AB		140MG	A203959	004	Apr 18, 2017	Apr	NEWA
AB		250MG	A203959	005	Apr 18, 2017	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG	A206750	001	Jul 31, 2017	Jul	NEWA
AB		20MG	A206750	002	Jul 31, 2017	Jul	NEWA
AB		100MG	A206750	003	Jul 31, 2017	Jul	NEWA
AB		140MG	A206750	004	Jul 31, 2017	Jul	NEWA
AB		180MG	A206750	005	Jul 31, 2017	Jul	NEWA
AB		250MG	A206750	006	Jul 31, 2017	Jul	NEWA
<u>TENIPOSIDE</u>							
INJECTABLE;INJECTION							
VUMON							
	+ @ HQ SPECLT PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Aug	DISC
<u>TERAZOSIN HYDROCHLORIDE</u>							
CAPSULE;ORAL							
TERAZOSIN HYDROCHLORIDE							
AB	MYLAN PHARMS INC	EQ 1MG BASE	A075140	002	Feb 11, 2000	Mar	CAHN
AB		EQ 2MG BASE	A075140	003	Feb 11, 2000	Mar	CAHN
AB		EQ 5MG BASE	A075140	001	Feb 11, 2000	Mar	CAHN
AB		EQ 10MG BASE	A075140	004	Feb 11, 2000	Mar	CAHN
<u>TERBINAFINE HYDROCHLORIDE</u>							
GRANULE;ORAL							
LAMISIL							
	+ @ NOVARTIS	EQ 125MG BASE/PACKET	N022071	001	Sep 28, 2007	Aug	DISC
	+ @	EQ 187.5MG BASE/PACKET	N022071	002	Sep 28, 2007	Aug	DISC
TABLET;ORAL							
TERBINAFINE HYDROCHLORIDE							
	@ MYLAN	EQ 250MG BASE	A077195	001	Jul 02, 2007	Aug	DISC
<u>TERBUTALINE SULFATE</u>							
INJECTABLE;INJECTION							
TERBUTALINE SULFATE							
AP	! ATHENEX INC	1MG/ML	A076770	001	Apr 23, 2004	Mar	CAHN
TABLET;ORAL							
BRETHINE							
	+ @ ANI PHARMS INC	2.5MG	N017849	001		Feb	CAHN
	+ @	5MG	N017849	002		Feb	CAHN
TERBUTALINE SULFATE							
	! LANNETT	5MG	A077152	002	Mar 25, 2005	Jan	CHRS
<u>TESTOSTERONE</u>							
GEL;TRANSDERMAL							
ANDROGEL							
AB2	+ ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jun	CFTG
AB2	+!	1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jun	CFTG
TESTIM							
AB2	+! AUXILIUM PHARMS LLC	50MG/5GM PACKET	N021454	001	Oct 31, 2002	May	CAHN
TESTOSTERONE							
AB2	ACTAVIS LABS UT INC	50MG/5GM PACKET	A091073	001	Sep 18, 2017	Sep	NEWA
AB2	PERRIGO UK FINCO	1.62% (20.25MG/1.25GM PACKET)	A205781	001	Jul 12, 2017	Jun	NEWA
AB2		1.62% (40.5MG/2.5GM PACKET)	A205781	002	Jul 12, 2017	Jun	NEWA
VOGELXO							
AB2	UPSHER-SMITH LABS	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jun	CAHN
GEL, METERED;TRANSDERMAL							
TESTOSTERONE							
AB	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Mar	CAHN
VOGELXO							
BX	UPSHER-SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun	CAHN
SOLUTION, METERED;TRANSDERMAL							
AXIRON							
	+ @ ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Sep	DISC
AT	+!	30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Feb	CFTG

SOLUTION, METERED;TRANSDERMAL  
TESTOSTERONE

AT	ACTAVIS LABS UT INC	30MG/1.5ML ACTUATION	A205328	001	Aug 07, 2017	Jul NEWA
AT	LUPIN LTD	30MG/1.5ML ACTUATION	A208061	001	Oct 23, 2017	Oct NEWA
AT	! PERRIGO ISRAEL	30MG/1.5ML ACTUATION	A204255	001	Feb 28, 2017	Sep CHRS
AT		30MG/1.5ML ACTUATION	A204255	001	Feb 28, 2017	Feb NEWA

TABLET, EXTENDED RELEASE;BUCCAL  
STRIANT

+!	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	May CAHN
----	---------------------	------	---------	-----	--------------	----------

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION  
TESTOSTERONE CYPIONATE

AO	LUITPOLD PHARMS INC	200MG/ML	A207742	001	Jun 16, 2017	Jun NEWA
AO	SANDOZ INC	100MG/ML	A040615	001	Aug 10, 2006	Mar CAHN
AO		200MG/ML	A040615	002	Aug 10, 2006	Mar CAHN
AO	WATSON PHARMS INC	200MG/ML	A086030	001		Feb CAHN
AO	WEST-WARD PHARMS INT	100MG/ML	A090387	001	Jul 15, 2010	Jan CAHN
AO		200MG/ML	A090387	002	Jul 15, 2010	Jan CAHN

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION  
TESTOSTERONE ENANTHATE

AO	WATSON PHARMS INC	200MG/ML	A085598	001		Feb CAHN
----	-------------------	----------	---------	-----	--	----------

TETRABENAZINE

TABLET;ORAL  
TETRABENAZINE

AB	ACTAVIS LABS FL INC	25MG	A206686	001	Jul 07, 2017	Jun NEWA
AB	APICORE US	12.5MG	A207682	001	Jan 31, 2017	Jan NEWA
AB		25MG	A207682	002	Jan 31, 2017	Jan NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL  
ACHROMYCIN V

AB	+ HERITAGE PHARMA	250MG	N050278	003		Jan CAHN
AB	+!	500MG	N050278	001		Jan CAHN

TETRACYCLINE HYDROCHLORIDE

AB	CHARTWELL TETRA	250MG	A062752	001	Aug 12, 1988	Apr CAHN
AB		500MG	A062752	002	Aug 12, 1988	Apr CAHN
	@ IMPAX LABS	100MG	A060469	002		Jul DISC
	@	250MG	A060469	001		Jul DISC
	@	500MG	A060469	003		Jul DISC

THEOPHYLLINE

ELIXIR;ORAL  
THEOPHYLLINE

@	CHARTWELL RX	80MG/15ML	A085952	001		Apr CAHN
@	PHARM ASSOC	80MG/15ML	A086720	001		May CAHN

INJECTABLE;INJECTION

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	+! B BRAUN	80MG/100ML	N019826	002	Aug 14, 1992	Nov CTEC
>A>		+!	80MG/100ML	N019826	002	Aug 14, 1992	Nov CTEC

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	+! HOSPIRA INC	4MG/ML	N019211	007	Dec 14, 1984	Nov CTEC
>A>		+!	4MG/ML	N019211	007	Dec 14, 1984	Nov CTEC

TABLET, EXTENDED RELEASE;ORAL

THEOCHRON

AB	NOSTRUM PHARMS LLC	100MG	A088320	001	Feb 21, 1985	May CAHN
AB		200MG	A088321	001	Feb 21, 1985	May CAHN
	@	300MG	A087400	002	Jan 11, 1983	May CAHN

THEOPHYLLINE

!	ALEMBIC LTD	450MG	A090430	002	Oct 27, 2010	Apr CHRS
AB	ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	May CAHN
!		450MG	A090430	002	Oct 27, 2010	May CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

>A> AP	SAGENT PHARMS	100MG/ML	A206106	001	Dec 01, 2017	Nov NEWA
	@ WEST-WARD PHARMS INT	100MG/ML	A080575	001		Jan CAHN

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

THIORIDAZINE HYDROCHLORIDE

@ ANI PHARMS INC	30MG/ML	A089602	001	Nov 09, 1987	Jan CAHN
@ PHARM ASSOC	30MG/ML	A040187	001	Aug 28, 1997	May CAHN
@	100MG/ML	A040213	001	May 29, 1998	May CAHN

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

@ WATSON LABS TEVA	15MG	A088477	001	Nov 08, 1983	May CAHN
@	25MG	A088567	001	May 11, 1984	May CAHN
@	200MG	A088872	001	Apr 26, 1985	May CAHN

THIOTEPA

POWDER; IV (INFUSION)

TEPADINA

+! ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Jan NEWA
+!	100MG/VIAL	N208264	002	Jan 26, 2017	Jan NEWA

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

AB + CEPHALON	12MG	N020646	002	Sep 30, 1997	Oct CFTG
AB +	16MG	N020646	003	Sep 30, 1997	Oct CFTG

TIAGABINE HYDROCHLORIDE

>A> AB	AMNEAL PHARMS CO	2MG	A208181	001	Dec 08, 2017	Nov NEWA
>A> AB		4MG	A208181	002	Dec 08, 2017	Nov NEWA
>A> AB		12MG	A208181	003	Dec 08, 2017	Nov NEWA
>A> AB		16MG	A208181	004	Dec 08, 2017	Nov NEWA
AB	WILSHIRE PHARMS INC	2MG	A206857	001	Oct 13, 2017	Oct NEWA
AB		4MG	A206857	002	Oct 13, 2017	Oct NEWA
AB		12MG	A206857	003	Oct 13, 2017	Oct NEWA
AB		16MG	A206857	004	Oct 13, 2017	Oct NEWA

TICAGRELOR

TABLET; ORAL

BRILINTA

+ ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jan CAHN
+!	90MG	N022433	001	Jul 20, 2011	Jan CAHN

TIGECYCLINE

POWDER; IV (INFUSION)

TIGECYCLINE

AP	SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	Feb CDFR
AP	TYGACIL					
AP	+! PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Feb CDFR

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AB	SANDOZ INC	EQ 0.25% BASE	N020963	001	Oct 21, 1998	Feb CAHN
AB		EQ 0.5% BASE	N020963	002	Oct 21, 1998	Feb CAHN

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AT	! SANDOZ INC	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Feb CAHN
AT1	!	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Feb CAHN

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

AB	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Jan CTEC
AB		500MG	A202489	002	Oct 09, 2013	Jan CTEC



TIZANIDINE HYDROCHLORIDE

## CAPSULE;ORAL

## TIZANIDINE HYDROCHLORIDE

AB	JUBILANT GENERICS	EQ 2MG BASE	A209605	001	Aug 04, 2017	Jul	NEWA
AB		EQ 4MG BASE	A209605	002	Aug 04, 2017	Jul	NEWA
AB		EQ 6MG BASE	A209605	003	Aug 04, 2017	Jul	NEWA
AB	PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Feb	NEWA
AB		EQ 4MG BASE	A207199	002	Mar 14, 2017	Feb	NEWA
AB		EQ 6MG BASE	A207199	003	Mar 14, 2017	Feb	NEWA
AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A208622	001	Mar 03, 2017	Feb	NEWA
AB		EQ 4MG BASE	A208622	002	Mar 03, 2017	Feb	NEWA
AB		EQ 6MG BASE	A208622	003	Mar 03, 2017	Feb	NEWA
ZANAFLEX							
>D> AB	+ ACORDA	EQ 2MG BASE	N021447	001	Aug 29, 2002	Nov	CAHN
>D> AB	+	EQ 4MG BASE	N021447	002	Aug 29, 2002	Nov	CAHN
>D> AB	+	EQ 6MG BASE	N021447	003	Aug 29, 2002	Nov	CAHN
>A> AB	+ COVIS PHARMA BV	EQ 2MG BASE	N021447	001	Aug 29, 2002	Nov	CAHN
>A> AB	+	EQ 4MG BASE	N021447	002	Aug 29, 2002	Nov	CAHN
>A> AB	+	EQ 6MG BASE	N021447	003	Aug 29, 2002	Nov	CAHN
TABLET;ORAL							
TIZANIDINE HYDROCHLORIDE							
AB	EPIC PHARMA LLC	EQ 2MG BASE	A076347	001	Oct 11, 2002	May	CAHN
AB		EQ 4MG BASE	A076347	002	Oct 11, 2002	May	CAHN
AB	PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Jan	NEWA
AB		EQ 4MG BASE	A207170	002	Jan 26, 2017	Jan	NEWA
ZANAFLEX							
>D>	+ @ ACORDA	EQ 2MG BASE	N020397	002	Feb 04, 2000	Nov	CAHN
>D> AB	+	EQ 4MG BASE	N020397	001	Nov 27, 1996	Nov	CAHN
>A>	+ @ COVIS PHARMA BV	EQ 2MG BASE	N020397	002	Feb 04, 2000	Nov	CAHN
>A> AB	+	EQ 4MG BASE	N020397	001	Nov 27, 1996	Nov	CAHN

TOBRAMYCIN

## SOLUTION;INHALATION

## TOBRAMYCIN

AN	AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	May	CAHN
AN	LUPIN ATLANTIS	300MG/5ML	A208964	001	Mar 22, 2017	Mar	NEWA
AN	MYLAN PHARMS INC	300MG/5ML	A209554	001	Oct 13, 2017	Oct	NEWA

## SOLUTION/DROPS;OPHTHALMIC

## TOBRAMYCIN

AT	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Jun	NEWA
TOBREX							
AT	SANDOZ INC	0.3%	A062535	001	Dec 13, 1984	Feb	CAHN

TOBRAMYCIN SULFATE

## INJECTABLE;INJECTION

## TOBRAMYCIN SULFATE

AP	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Aug	CAHN
----	----------------------	-----------------	---------	-----	--------------	-----	------

TOLMETIN SODIUM

## TABLET;ORAL

## TOLMETIN SODIUM

>D> AB	! MYLAN	EQ 600MG BASE	A074473	001	Aug 30, 1994	Nov	CTEC
>A>	!	EQ 600MG BASE	A074473	001	Aug 30, 1994	Nov	CTEC

TOLTERODINE TARTRATE

## CAPSULE, EXTENDED RELEASE;ORAL

## TOLTERODINE TARTRATE

>A> AB	HETERO LABS LTD III	2MG	A206419	001	Dec 12, 2017	Nov	NEWA
>A> AB		4MG	A206419	002	Dec 12, 2017	Nov	NEWA

TOPIRAMATE

## CAPSULE;ORAL

## TOPIRAMATE

>D> AB	MYLAN	15MG	A078418	001	Oct 14, 2009	Nov	DISC
>A>	@	15MG	A078418	001	Oct 14, 2009	Nov	DISC
>D> AB		25MG	A078418	002	Oct 14, 2009	Nov	DISC
>A>	@	25MG	A078418	002	Oct 14, 2009	Nov	DISC

## CAPSULE, EXTENDED RELEASE;ORAL

## QUDEXY XR

+	UPSHER-SMITH LABS	25MG	N205122	001	Mar 11, 2014	Jun	CAHN
+		50MG	N205122	002	Mar 11, 2014	Jun	CAHN

CAPSULE, EXTENDED RELEASE;ORAL  
QUDEXY XR

+ 100MG  
+ 150MG  
+! 200MG

N205122 003 Mar 11, 2014 Jun CAHN  
N205122 004 Mar 11, 2014 Jun CAHN  
N205122 005 Mar 11, 2014 Jun CAHN

&gt;A&gt; TOPIRAMATE

>A> AB ZYDUS PHARMS USA INC 25MG  
>A> AB 50MG  
>A> AB 100MG

A207382 001 Nov 24, 2017 Nov NEWA  
A207382 002 Nov 24, 2017 Nov NEWA  
A207382 003 Nov 24, 2017 Nov NEWA

## TROKENDI XR

>D> + SUPERNUS PHARMS 25MG  
>A> AB + 25MG  
>D> + 50MG  
>A> AB + 50MG  
>D> + 100MG  
>A> AB + 100MG

N201635 001 Aug 16, 2013 Nov CFTG  
N201635 001 Aug 16, 2013 Nov CFTG  
N201635 002 Aug 16, 2013 Nov CFTG  
N201635 002 Aug 16, 2013 Nov CFTG  
N201635 003 Aug 16, 2013 Nov CFTG  
N201635 003 Aug 16, 2013 Nov CFTG

## TABLET;ORAL

## TOPIRAMATE

@ MYLAN 25MG  
@ 50MG  
@ 100MG  
@ 200MG  
AB UPSHER-SMITH LABS 25MG  
AB 50MG  
AB 100MG  
AB 200MG

A076314 001 Mar 27, 2009 May DISC  
A076314 002 Mar 27, 2009 May DISC  
A076314 003 Mar 27, 2009 May DISC  
A076314 004 Mar 27, 2009 May DISC  
A078499 001 Jan 07, 2010 Jun CAHN  
A078499 002 Jan 07, 2010 Jun CAHN  
A078499 003 Jan 07, 2010 Jun CAHN  
A078499 004 Jan 07, 2010 Jun CAHN

TOPOTECAN HYDROCHLORIDE

## INJECTABLE;INJECTION

## TOPOTECAN HYDROCHLORIDE

AP HONG KONG EQ 4MG BASE/VIAL  
AP NOVAST LABS LTD EQ 4MG BASE/VIAL  
@ SUN PHARM INDS LTD EQ 4MG BASE/VIAL

A201166 001 Aug 08, 2012 Sep CAHN  
A206962 001 Nov 30, 2016 Sep CAHN  
A202203 001 Aug 29, 2013 Sep DISC

## SOLUTION;INTRAVENOUS

## TOPOTECAN HYDROCHLORIDE

>D> AP ACCORD HLTHCARE EQ 1MG BASE/ML (EQ 1MG BASE/ML)  
>A> EQ 1MG BASE/ML (EQ 1MG BASE/ML)  
AP EQ 1MG BASE/ML (EQ 1MG BASE/ML)  
AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML)  
>A> AP MYLAN LABS LTD EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

A204406 001 Jul 06, 2017 Nov CTEC  
A204406 001 Jul 06, 2017 Nov CTEC  
A204406 001 Jul 06, 2017 Jun NEWA  
A204406 002 Jul 06, 2017 Jun NEWA  
A206074 001 Nov 24, 2017 Nov NEWA

TOREMIFENE CITRATE

## TABLET;ORAL

## FARESTON

+! KYOWA KIRIN EQ 60MG BASE

N020497 001 May 29, 1997 Jan CAHN

TORSEMIDE

## TABLET;ORAL

## DEMADEX

AB + MYLAN SPECIALITY LP 5MG  
AB + 10MG  
AB +! 20MG  
AB + 100MG

N020136 001 Aug 23, 1993 Mar CAHN  
N020136 002 Aug 23, 1993 Mar CAHN  
N020136 003 Aug 23, 1993 Mar CAHN  
N020136 004 Aug 23, 1993 Mar CAHN

## TORSEMIDE

@ SUN PHARM INDS 5MG  
@ 10MG  
@ 20MG  
@ 100MG

A078478 001 Feb 26, 2008 Sep DISC  
A078478 002 Feb 26, 2008 Sep DISC  
A078478 003 Feb 26, 2008 Sep DISC  
A078478 004 Feb 26, 2008 Sep DISC

TRAMADOL HYDROCHLORIDE

## TABLET;ORAL

## TRAMADOL HYDROCHLORIDE

@ ACCORD HLTHCARE 50MG  
AB 50MG  
AB AMNEAL PHARMS 50MG  
>D> AB MYLAN PHARMS INC 50MG  
>A> @ 50MG

A202390 001 May 16, 2013 Oct DISC  
A202390 001 May 16, 2013 Mar CAHN  
A076003 001 Jun 20, 2002 May CAHN  
A075980 001 Nov 21, 2002 Nov DISC  
A075980 001 Nov 21, 2002 Nov DISC

## TABLET, EXTENDED RELEASE;ORAL

## ULTRAM ER

+ @ VALEANT PHARMS 100MG  
+ @ 200MG  
+ @ 300MG

N021692 001 Sep 08, 2005 Mar CRLD  
N021692 002 Sep 08, 2005 Mar CRLD  
N021692 003 Sep 08, 2005 Mar CRLD

TRAMETINIB DIMETHYL SULFOXIDETABLET;ORAL  
MEKINIST

+ @ NOVARTIS PHARMS CORP EQ 1MG N204114 002 May 29, 2013 Jul DISC

TRANDOLAPRILTABLET;ORAL  
TRANDOLAPRIL

	@ EPIC PHARMA LLC	1MG	A 077256	001	Jun 12, 2007	May CAHN
	@	2MG	A 077256	002	Jun 12, 2007	May CAHN
	@	4MG	A 077256	003	Jun 12, 2007	May CAHN
	@ INVAGEN PHARMS	1MG	A 078320	001	Jun 12, 2007	Jun DISC
BX		1MG	A 078320	001	Jun 12, 2007	Apr CTEC
	@	2MG	A 078320	002	Jun 12, 2007	Jun DISC
BX		2MG	A 078320	002	Jun 12, 2007	Apr CTEC
	@	4MG	A 078320	003	Jun 12, 2007	Jun DISC
BX		4MG	A 078320	003	Jun 12, 2007	Apr CTEC
	@ MYLAN	1MG	A 078346	001	Apr 28, 2008	May DISC
	@	2MG	A 078346	002	Apr 28, 2008	May DISC
	@	4MG	A 078346	003	Apr 28, 2008	May DISC

TRANEXAMIC ACIDINJECTABLE;INJECTION  
TRANEXAMIC ACID

AP	AKORN	100MG/ML	A 206594	001	Sep 28, 2017	Sep NEWA
AP	AMNEAL PHARMS CO	100MG/ML	A 208840	001	Feb 28, 2017	Feb NEWA
AP	GLAND PHARMA LTD	100MG/ML	A 207239	001	Feb 13, 2017	Jan NEWA
AP	MICRO LABS	100MG/ML	A 206713	001	Jun 27, 2017	Jun NEWA
AP	VIRTUS PHARMS	100MG/ML	A 202755	001	Feb 25, 2016	Sep CAHN
AP	VIVA HLTHCARE	100MG/ML	A 206713	001	Jun 27, 2017	Sep CAHN
AP	ZYDUS PHARMS USA INC	100MG/ML	A 205228	001	Jul 17, 2017	Jul NEWA

TABLET;ORAL

LYSTEDA

>D>	AB	+!	FERRING PHARMS AS	650MG	N 022430	001	Nov 13, 2009	Nov CAHN
>A>	AB	+!	FERRING PHARMS INC	650MG	N 022430	001	Nov 13, 2009	Nov CAHN

TRAVOPROSTSOLUTION/DROPS;OPHTHALMIC  
TRAVOPROST

AT	MYLAN PHARMS INC	0.004%	A 205050	001	Jul 07, 2017	Jun NEWA
----	------------------	--------	----------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	50MG	A 206923	001	Sep 08, 2017	Aug NEWA
AB		100MG	A 206923	002	Sep 08, 2017	Aug NEWA
AB		150MG	A 206923	003	Sep 08, 2017	Aug NEWA
AB		300MG	A 206923	004	Sep 08, 2017	Aug NEWA
	@ MYLAN PHARMS INC	50MG	A 090514	001	Jun 02, 2009	May DISC
	@	100MG	A 090514	002	Jun 02, 2009	May DISC
	@	150MG	A 090514	003	Jun 02, 2009	May DISC
	@	300MG	A 090514	004	Jun 02, 2009	May DISC
AB	ZYDUS PHARMS USA INC	50MG	A 205253	001	Oct 10, 2017	Sep NEWA
AB		100MG	A 205253	002	Oct 10, 2017	Sep NEWA
AB		150MG	A 205253	003	Oct 10, 2017	Sep NEWA
AB		300MG	A 205253	004	Oct 10, 2017	Sep NEWA

TREPROSTINILINJECTABLE;IV (INFUSION), SUBCUTANEOUS  
REMODULIN

>D>		+	UNITED THERAP	1MG/ML	N 021272	001	May 21, 2002	Nov CFTG
>A>	AP	+		1MG/ML	N 021272	001	May 21, 2002	Nov CFTG
>D>		+		2.5MG/ML	N 021272	002	May 21, 2002	Nov CFTG
>A>	AP	+		2.5MG/ML	N 021272	002	May 21, 2002	Nov CFTG
>D>		+		5MG/ML	N 021272	003	May 21, 2002	Nov CFTG
>A>	AP	+		5MG/ML	N 021272	003	May 21, 2002	Nov CFTG
>D>		+		10MG/ML	N 021272	004	May 21, 2002	Nov CFTG
>A>	AP	+		10MG/ML	N 021272	004	May 21, 2002	Nov CFTG
>A>			TREPROSTINIL					
>A>	AP		SANDOZ INC	1MG/ML	A 203649	001	Nov 30, 2017	Nov NEWA
>A>	AP			2.5MG/ML	A 203649	002	Nov 30, 2017	Nov NEWA
>A>	AP			5MG/ML	A 203649	003	Nov 30, 2017	Nov NEWA

		INJECTABLE;IV (INFUSION), SUBCUTANEOUS						
>A>		TREPROSTINIL						
>A>	AP	10MG/ML	A203649	004	Nov 30, 2017	Nov	NEWA	
		<u>TRETINOIN</u>						
		CAPSULE;ORAL						
		TRETINOIN						
AB		GLENMARK PHARMS LTD 10MG	A208279	001	Dec 23, 2016	Jun	CAHN	
		VESANOID						
		+ @ CHEPLAPHARM 10MG	N020438	001	Nov 22, 1995	May	CAHN	
		CREAM;TOPICAL						
		TRETINOIN						
AB2		ZO SKIN HEALTH 0.05%	A076498	001	Sep 15, 2005	Feb	CAHN	
		GEL;TOPICAL						
		RETIN-A-MICRO						
		+! VALEANT INTL 0.06%	N020475	004	Oct 23, 2017	Oct	NEWA	
		TRETINOIN						
AB		MYLAN PHARMS INC 0.04%	A202567	001	Jul 17, 2013	Jun	CAHN	
AB		0.05%	A207955	001	Aug 13, 2015	Jun	CAHN	
AB		0.1%	A202026	001	Jul 17, 2013	Jun	CAHN	
		SOLUTION;TOPICAL						
		RETIN-A						
		+ @ VALEANT INTL 0.05%	N016921	001		Oct	DISC	
		<u>TRIAMCINOLONE ACETONIDE</u>						
		CREAM;TOPICAL						
		TRIAMCINOLONE ACETONIDE						
AT		LUPIN ATLANTIS 0.025%	A208763	001	Feb 01, 2017	Jan	NEWA	
AT		0.1%	A208763	002	Feb 01, 2017	Jan	NEWA	
AT		0.5%	A208763	003	Feb 01, 2017	Jan	NEWA	
AT		+ MYLAN PHARMS INC 0.025%	N011601	003		Jan	CAHN	
AT		+ 0.1%	N011601	006		Jan	CAHN	
		@ TARO 0.025%	A040038	001	Oct 26, 1994	Apr	CAHN	
AT		0.1%	A040039	001	Nov 26, 1997	Apr	CAHN	
AT		0.1%	A040039	001	Nov 26, 1997	Mar	CAHN	
AT		TELIGENT PHARMA INC 0.1%	A208848	001	Sep 18, 2017	Sep	NEWA	
		FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR						
		ZILRETTA						
		+! FLEXION THERAPS INC 32MG/VIAL	N208845	001	Oct 06, 2017	Oct	NEWA	
		INJECTABLE;INJECTION						
		KENALOG-10						
		+ APOTHECON 10MG/ML	N012041	001		Jun	CRLD	
		KENALOG-40						
>D>		+! APOTHECON 40MG/ML	N014901	001		Nov	CTEC	
>A>	AP	+! 40MG/ML	N014901	001		Nov	CTEC	
		TRIAMCINOLONE ACETONIDE						
>A>	AP	AMNEAL PHARMS CO 40MG/ML	A207550	001	Dec 11, 2017	Nov	NEWA	
		@ SANDOZ INC 10MG/ML	A090166	001	May 27, 2009	Apr	CAHN	
		@ 40MG/ML	A090164	001	Jun 01, 2009	Apr	CAHN	
		OINTMENT;TOPICAL						
		KENALOG						
		+ @ MYLAN PHARMS INC 0.025%	N011600	003		Sep	CRLD	
		@ 0.025%	N011600	003		Aug	DISC	
AT		0.025%	N011600	003		Jan	CAHN	
		+ @ 0.1%	N011600	001		Sep	CRLD	
		@ 0.1%	N011600	001		Aug	DISC	
AT		0.1%	N011600	001		Jan	CAHN	
		TRIAMCINOLONE ACETONIDE						
AT		G AND W LABS INC 0.5%	A208925	001	Oct 06, 2017	Sep	NEWA	
AT		GLENMARK PHARMS 0.1%	A208320	001	Aug 22, 2017	Aug	NEWA	
		@ TARO 0.025%	A040040	001	Sep 30, 1994	Apr	CAHN	
AT		0.1%	A040037	001	Sep 30, 1994	Apr	CAHN	
AT		TELIGENT PHARMA INC 0.5%	A208590	001	Mar 03, 2017	Feb	NEWA	
		TRIAMCINOLONE ACETONIDE IN ABSORBASE						
		! CMP PHARMA INC 0.05%	A089595	001	Mar 23, 1995	Apr	CAHN	
		PASTE;DENTAL						
		TRIAMCINOLONE ACETONIDE						
AT		G AND W LABS INC 0.1%	A205592	001	Jan 12, 2017	Jan	NEWA	
		SPRAY;TOPICAL						
		TRIAMCINOLONE ACETONIDE						
AT		RICONPHARMA LLC 0.147MG/GM	A206786	001	Sep 08, 2017	Aug	NEWA	

SPRAY, METERED;NASAL									
TRIAMCINOLONE ACETONIDE									
@	PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan	CAHN		
<u>TRIAMCINOLONE DIACETATE</u>									
INJECTABLE;INJECTION									
ARISTOCORT									
@	SANDOZ INC	25MG/ML	N011685	003		Jun	CAHN		
+	@	40MG/ML	N012802	001		Jun	CAHN		
<u>TRIAMCINOLONE HEXACETONIDE</u>									
INJECTABLE;INJECTION									
ARISTOSPAN									
+	!	SANDOZ INC	5MG/ML	N016466	001	Jun	CAHN		
+	!		20MG/ML	N016466	002	Jun	CAHN		
<u>TRIFLURIDINE</u>									
SOLUTION/DROPS;OPHTHALMIC									
TRIFLURIDINE									
AT	HI-TECH PHARMACAL	1%	A205438	001	Jul 28, 2017	Jul	NEWA		
AT	SANDOZ INC	1%	A074311	001	Oct 06, 1995	Feb	CAHN		
VIOPTIC									
AT	+	!	MONARCH PHARMS	1%	N018299	001	Feb	CAHN	
<u>TRIHEXYPHENIDYL HYDROCHLORIDE</u>									
ELIXIR;ORAL									
TRIHEXYPHENIDYL HYDROCHLORIDE									
AA	!	PHARM ASSOC	2MG/5ML	A040177	001	Apr 17, 1997	May	CAHN	
TABLET;ORAL									
TRIHEXYPHENIDYL HYDROCHLORIDE									
AA	VINTAGE PHARMS LLC	2MG	A040254	001	Dec 24, 1998	Mar	CAHN		
AA		5MG	A040254	002	Dec 24, 1998	Mar	CAHN		
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
TIGAN									
AB	+	!	KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	May	CAHN
<u>TRIMETHOPRIM HYDROCHLORIDE</u>									
SOLUTION;ORAL									
PRIMSOL									
+	!	ALLEGIS	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Oct	CAHN	
<u>TRIMIPRAMINE MALEATE</u>									
CAPSULE;ORAL									
TRIMIPRAMINE MALEATE									
AB	ELITE LABS INC	EQ 25MG BASE	A077361	001	Aug 02, 2006	May	CAHN		
AB		EQ 50MG BASE	A077361	002	Aug 02, 2006	May	CAHN		
AB		EQ 100MG BASE	A077361	003	Aug 02, 2006	May	CAHN		
<u>TRIPTORELIN PAMOATE</u>									
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR									
TRIPTODUR KIT									
+	!	ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017	Jun	NEWA	
<u>TROPICAMIDE</u>									
SOLUTION/DROPS;OPHTHALMIC									
MYDRIACYL									
AT	!	SANDOZ INC	0.5%	A084305	001		Feb	CAHN	
<u>TROSPIUM CHLORIDE</u>									
CAPSULE, EXTENDED RELEASE;ORAL									
TROSPIUM CHLORIDE									
@	UPSHER-SMITH LABS	60MG	A091635	001	Apr 29, 2015	Jun	CAHN		
<u>ULIPRISTAL ACETATE</u>									
TABLET;ORAL									
ELLA									
AB	+	!	LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010	Jan	CFTG
LOGILIA									
AB	TEVA PHARMS USA	30MG	A207952	001	Feb 13, 2017	Jan	NEWA		

URSODIOL

CAPSULE; ORAL							
URSODIOL							
	@ IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006	May	DISC
BX		300MG	A077895	001	Jul 27, 2006	Apr	CTEC
AB		300MG	A077895	001	Jul 27, 2006	Feb	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL							
VALACYCLOVIR HYDROCHLORIDE							
	@ MYLAN	EQ 500MG BASE	A078070	001	May 24, 2010	Jun	DISC
	@	EQ 1GM BASE	A078070	002	May 24, 2010	Jun	DISC

VALBENAZINE TOSYLATE

CAPSULE; ORAL							
INGREZZA							
+	NEUROCRINE	40MG	N209241	001	Apr 11, 2017	Apr	NEWA
+		80MG	N209241	002	Oct 04, 2017	Oct	NEWA

VALGANCICLOVIR HYDROCHLORIDE

TABLET; ORAL							
VALGANCICLOVIR HYDROCHLORIDE							
>A> AB	DR REDDYS LABS LTD	EQ 450MG BASE	A206876	001	Dec 12, 2017	Nov	NEWA

VALPROATE SODIUM

INJECTABLE; INJECTION							
VALPROATE SODIUM							
AP	ATHENEX INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Mar	CAHN

VALPROIC ACID

CAPSULE; ORAL							
VALPROIC ACID							
	@ USL PHARMA	250MG	A070631	001	Jun 11, 1987	Jun	CAHN
SYRUP; ORAL							
VALPROIC ACID							
AA	ECI PHARMS LLC	250MG/5ML	A090517	001	May 28, 2010	Mar	CAHN
AA	PHARM ASSOC	250MG/5ML	A075379	001	Dec 15, 2000	May	CAHN
AA	VISTAPHARM	250MG/5ML	A075782	001	Dec 22, 2000	Feb	CAHN

VALSARTAN

TABLET; ORAL							
VALSARTAN							
AB	AMNEAL PHARMS	40MG	A204011	001	Jan 11, 2016	May	CAHN
AB		80MG	A204011	002	Jan 11, 2016	May	CAHN
AB		160MG	A204011	003	Jan 11, 2016	May	CAHN
AB		320MG	A204011	004	Jan 11, 2016	May	CAHN
AB	MYLAN PHARMS INC	40MG	A090866	001	Jan 05, 2015	Feb	CAHN
AB		80MG	A090866	002	Jan 05, 2015	Feb	CAHN
AB		160MG	A090866	003	Jan 05, 2015	Feb	CAHN
AB		320MG	A090866	004	Jan 05, 2015	Feb	CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION							
VANCOMYCIN HYDROCHLORIDE							
AP	MUSTAFA NEVZAT ILAC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Aug	CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Aug	CAHN
	@ TEVA PHARMS USA	EQ 500MG BASE/VIAL	A201251	001	Dec 23, 2015	Oct	DISC
	@	EQ 1GM BASE/VIAL	A201251	002	Dec 23, 2015	Oct	DISC
	@	EQ 5GM BASE/VIAL	A201250	001	Dec 23, 2015	Oct	DISC
	@	EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015	Oct	DISC

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL									
LEVITRA									
>D>	AB	+	BAYER HLTHCARE	2.5MG	N021400	003	Aug 19, 2003	Nov	CTEC
>A>		+		2.5MG	N021400	003	Aug 19, 2003	Nov	CTEC
>D>	AB	+		5MG	N021400	001	Aug 19, 2003	Nov	CTEC
>A>		+		5MG	N021400	001	Aug 19, 2003	Nov	CTEC
>D>	AB	+		10MG	N021400	002	Aug 19, 2003	Nov	CTEC
>A>		+		10MG	N021400	002	Aug 19, 2003	Nov	CTEC
>D>	AB	+		20MG	N021400	004	Aug 19, 2003	Nov	CTEC

Product Name	Strength	Manufacturer	Lot Number	Expiration Date	Source
<b>TABLET;ORAL</b>					
<b>LEVITRA</b>					
>A>	+!	20MG	N021400	004 Aug 19, 2003	Nov CTEC
<b>VARDENAFIL HYDROCHLORIDE</b>					
	@ TEVA PHARMS	2.5MG	A091347	001 May 03, 2012	Sep DISC
	@	5MG	A091347	002 May 03, 2012	Sep DISC
	@	10MG	A091347	003 May 03, 2012	Sep DISC
	@	20MG	A091347	004 May 03, 2012	Sep DISC
<b>TABLET, ORALLY DISINTEGRATING;ORAL</b>					
<b>STAXYN</b>					
	+! BAYER HLTHCARE	10MG	N200179	001 Jun 17, 2010	Jun CTEC
<b>VASOPRESSIN</b>					
<b>SOLUTION;IV (INFUSION)</b>					
<b>VASOSTRICT</b>					
	+! PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001 Apr 17, 2014	May CMFD
	+ @	20UNITS/ML (20UNITS/ML)	N204485	001 Apr 17, 2014	Apr DISC
	+!	20UNITS/ML (20UNITS/ML)	N204485	002 Mar 18, 2016	Apr NEWA
	+!	200UNITS/10ML (20UNITS/ML)	N204485	002 Dec 17, 2016	May NEWA
<b>VECURONIUM BROMIDE</b>					
<b>INJECTABLE;INJECTION</b>					
<b>VECURONIUM BROMIDE</b>					
AP	@ WEST-WARD PHARMS INT	10MG/VIAL	A075218	001 Aug 23, 1999	Mar CAHN
		10MG/VIAL	A075549	001 Jun 13, 2000	Jan CAHN
	@	20MG/VIAL	A075218	002 Aug 23, 1999	Mar CAHN
AP		20MG/VIAL	A075549	002 Jun 13, 2000	Jan CAHN
<b>VENLAFAXINE HYDROCHLORIDE</b>					
<b>CAPSULE, EXTENDED RELEASE;ORAL</b>					
<b>VENLAFAXINE HYDROCHLORIDE</b>					
AB	MACLEODS PHARMS LTD	EQ 37.5MG BASE	A204889	001 Oct 05, 2017	Sep NEWA
AB		EQ 75MG BASE	A204889	002 Oct 05, 2017	Sep NEWA
AB		EQ 150MG BASE	A204889	003 Oct 05, 2017	Sep NEWA
	@ MYLAN	EQ 37.5MG BASE	A078789	001 Jun 01, 2011	Aug DISC
	@	EQ 75MG BASE	A078789	002 Jun 01, 2011	Aug DISC
	@	EQ 150MG BASE	A078789	003 Jun 01, 2011	Aug DISC
<b>TABLET;ORAL</b>					
<b>VENLAFAXINE HYDROCHLORIDE</b>					
AB	PRINSTON INC	EQ 25MG BASE	A090027	001 Aug 04, 2010	Feb CAHN
AB		EQ 37.5MG BASE	A090027	002 Aug 04, 2010	Feb CAHN
AB		EQ 50MG BASE	A090027	003 Aug 04, 2010	Feb CAHN
AB		EQ 75MG BASE	A090027	004 Aug 04, 2010	Feb CAHN
AB		EQ 100MG BASE	A090027	005 Aug 04, 2010	Feb CAHN
<b>TABLET, EXTENDED RELEASE;ORAL</b>					
<b>VENLAFAXINE HYDROCHLORIDE</b>					
AB	NOSTRUM LABS INC	EQ 150MG BASE	A205468	002 Mar 24, 2017	Mar NEWA
AB		EQ 225MG BASE	A205468	003 Mar 24, 2017	Mar NEWA
AB	+ OSMOTICA PHARM	EQ 225MG BASE	N022104	004 May 20, 2008	Mar CFTG
<b>VERAPAMIL HYDROCHLORIDE</b>					
<b>TABLET, EXTENDED RELEASE;ORAL</b>					
<b>CALAN SR</b>					
	+ @ PFIZER	180MG	N019152	002 Dec 15, 1989	Jan CRLD
<b>COVERA-HS</b>					
	@ GD SEARLE LLC	180MG	N020552	001 Feb 26, 1996	Jan DISC
	@	240MG	N020552	002 Feb 26, 1996	Jan DISC
<b>VERAPAMIL HYDROCHLORIDE</b>					
AB	CADILA PHARMS LTD	180MG	A206173	001 May 05, 2017	Apr NEWA
AB		240MG	A206173	002 May 05, 2017	Apr NEWA
<b>VIGABATRIN</b>					
<b>FOR SOLUTION;ORAL</b>					
<b>SABRIL</b>					
AA	+! LUNDBECK PHARMS LLC	500MG/PACKET	N022006	001 Aug 21, 2009	Apr CFTG
	+!	500MG/PACKET	N022006	001 Aug 21, 2009	Jan CAHN
<b>VIGABATRIN</b>					
AA	PAR PHARM INC	500MG/PACKET	A208218	001 Apr 27, 2017	Apr NEWA
<b>TABLET;ORAL</b>					
<b>SABRIL</b>					
	+! LUNDBECK PHARMS LLC	500MG	N020427	001 Aug 21, 2009	Jan CAHN

VINORELBINE TARTRATEINJECTABLE; INJECTION  
VINORELBINE TARTRATE

	@ MYLAN LABS LTD	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Oct DISC
AP	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Mar CAHN
AP		EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Jan CAHN

VORICONAZOLE

POWDER; IV (INFUSION)

VORICONAZOLE

	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar NEWA
--	-------------------	------------	---------	-----	--------------	----------

WARFARIN SODIUM

TABLET; ORAL

JANTOVEN

AB	USL PHARMA	1MG	A040416	001	Oct 02, 2003	Jun CAHN
AB		2MG	A040416	002	Oct 02, 2003	Jun CAHN
AB		2.5MG	A040416	003	Oct 02, 2003	Jun CAHN
AB		3MG	A040416	004	Oct 02, 2003	Jun CAHN
AB		4MG	A040416	005	Oct 02, 2003	Jun CAHN
AB		5MG	A040416	006	Oct 02, 2003	Jun CAHN
AB		6MG	A040416	007	Oct 02, 2003	Jun CAHN
AB		7.5MG	A040416	008	Oct 02, 2003	Jun CAHN
AB		10MG	A040416	009	Oct 02, 2003	Jun CAHN

WARFARIN SODIUM

	@ MYLAN	1MG	A040415	001	Sep 27, 2004	Apr DISC
	@	2MG	A040415	002	Sep 27, 2004	Apr DISC
	@	2.5MG	A040415	003	Sep 29, 2004	Apr DISC
	@	3MG	A040415	004	Sep 27, 2004	Apr DISC
	@	4MG	A040415	005	Sep 27, 2004	Apr DISC
	@	5MG	A040415	006	Sep 27, 2004	Apr DISC
	@	6MG	A040415	007	Sep 27, 2004	Apr DISC
	@	7.5MG	A040415	008	Sep 27, 2004	Apr DISC
	@	10MG	A040415	009	Sep 27, 2004	Apr DISC
AB	TARO PHARM	1MG	A040301	002	Jul 15, 1999	Mar CAHN
AB		2MG	A040301	003	Jul 15, 1999	Mar CAHN
AB		2.5MG	A040301	004	Jul 15, 1999	Mar CAHN
AB		3MG	A040301	005	Jul 15, 1999	Mar CAHN
AB		4MG	A040301	006	Jul 15, 1999	Mar CAHN
AB		5MG	A040301	007	Jul 15, 1999	Mar CAHN
AB		6MG	A040301	008	Jul 15, 1999	Mar CAHN
AB		7.5MG	A040301	009	Jul 15, 1999	Mar CAHN
AB		10MG	A040301	001	Jul 15, 1999	Mar CAHN

ZALEPLON

CAPSULE; ORAL

ZALEPLON

	@ MYLAN	5MG	A077238	001	Jun 06, 2008	Jul DISC
	@	10MG	A077238	002	Jun 06, 2008	Jul DISC
	@ UPSHER-SMITH LABS	5MG	A078095	001	Jun 06, 2008	Jun CAHN
	@	10MG	A078095	002	Jun 06, 2008	Jun CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

	@ HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	May CAHN
--	---------------------	-------	---------	-----	--------------	----------

ZILEUTON

TABLET, EXTENDED RELEASE; ORAL

ZILEUTON

AB	PACK PHARMS LLC	600MG	A204929	001	Mar 17, 2017	Mar NEWA
AB	RISING PHARMS INC	600MG	A204929	001	Mar 17, 2017	Mar CAHN
	ZYFLO CR					
AB	+! CHIESI USA INC	600MG	N022052	001	May 30, 2007	Mar CFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204375	001	Feb 17, 2017	Feb NEWA
AB		EQ 40MG BASE	A204375	002	Feb 17, 2017	Feb NEWA
AB		EQ 60MG BASE	A204375	003	Feb 17, 2017	Feb NEWA



## CAPSULE;ORAL

## ZIPRASIDONE HYDROCHLORIDE

AB		EQ 80MG BASE	A204375	004	Feb 17, 2017	Feb	NEWA
AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A208988	001	Aug 22, 2017	Aug	NEWA
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Aug	NEWA
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Aug	NEWA
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Aug	NEWA

ZOLEDRONIC ACID

## INJECTABLE;IV (INFUSION)

## ZOLEDRONIC ACID

>A>	AP	AUROBINDO PHARMA LTD	EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Nov	NEWA
	AP	BRECKENRIDGE PHARM	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Sep	CAHN
	AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Sep	CAHN
	AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Sep	CAHN
	AP	CIPLA LTD	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Oct	NEWA
	AP	MYLAN LABS LTD	EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Jan	NEWA
	AP		EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Oct	NEWA
	AP	PII	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	May	CAHN
	@	SUN PHARMA GLOBAL	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Oct	DISC

ZOLMITRIPTAN

## TABLET;ORAL

## ZOLMITRIPTAN

AB		APPCO PHARMA LLC	2.5MG	A206973	001	Jun 30, 2017	Jun	NEWA
AB			5MG	A206973	002	Jun 30, 2017	Jun	NEWA
AB		PLD ACQUISITIONS LLC	2.5MG	A207867	001	Feb 27, 2017	Feb	NEWA
AB			5MG	A207867	002	Feb 27, 2017	Feb	NEWA
	@	SUN PHARMA GLOBAL	2.5MG	A203476	001	Nov 13, 2014	Oct	DISC
	@		5MG	A203476	002	Nov 13, 2014	Oct	DISC

ZOLPIDEM TARTRATE

## SPRAY, METERED;ORAL

## ZOLPIMIST

+	!	MAGNA PHARMS	5MG/SPRAY	N022196	001	Dec 19, 2008	Aug	CAHN
---	---	--------------	-----------	---------	-----	--------------	-----	------

## TABLET;ORAL

## ZOLPIDEM TARTRATE

AB		ALLIED PHARMA INC	5MG	A077214	001	Apr 23, 2007	Mar	CAHN
AB			10MG	A077214	002	Apr 23, 2007	Mar	CAHN
	@	VIVIMED GLOBAL	5MG	A076062	001	Apr 23, 2007	Aug	CAHN
	@		10MG	A076062	002	Apr 23, 2007	Aug	CAHN

## TABLET;SUBLINGUAL

## EDLUAR

AB	+	MYLAN SPECIALITY LP	5MG	N021997	001	Mar 13, 2009	Mar	CAHN
AB	+		10MG	N021997	002	Mar 13, 2009	Mar	CAHN

## ZOLPIDEM TARTRATE

AB		PAR PHARM INC	1.75MG	A204229	001	Sep 11, 2017	Aug	NEWA
AB			3.5MG	A204229	002	Sep 11, 2017	Aug	NEWA

## TABLET, EXTENDED RELEASE;ORAL

## ZOLPIDEM TARTRATE

AB		SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017	Jan	NEWA
AB			12.5MG	A204170	002	Jan 24, 2017	Jan	NEWA

ZONISAMIDE

## CAPSULE;ORAL

## ZONISAMIDE

@		EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007	May	CAHN
@			50MG	A077876	002	Feb 21, 2007	May	CAHN
@			100MG	A077876	003	Feb 21, 2007	May	CAHN
@		MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005	Jun	DISC
@			50MG	A077647	002	Dec 22, 2005	Jun	DISC
@			100MG	A077647	003	Dec 22, 2005	Jun	DISC
@		UPSHER-SMITH LABS	25MG	A077644	001	Dec 22, 2005	Jun	CAHN
@			50MG	A077644	002	Dec 22, 2005	Jun	CAHN
@			100MG	A077644	003	Dec 22, 2005	Jun	CAHN

ACETAMINOPHENSUPPOSITORY; RECTAL  
ACETAMINOPHEN@ ACINO PRODS 120MG  
@ 650MGA071010 001 May 12, 1987 Oct CAHN  
A071011 001 May 12, 1987 Oct CAHNALUMINUM HYDROXIDE; MAGNESIUM TRISILICATETABLET, CHEWABLE; ORAL  
FOAMCOAT

@ GUARDIAN DRUG 80MG; 20MG

A071793 001 Sep 04, 1987 Sep DISC

AVOBENZONE; OCTINOXATE; OXYBENZONELOTION; TOPICAL  
SHADE UVAGUARD

+ @ BAYER HEALTHCARE LLC 3%; 7.5%; 3%

N020045 001 Dec 07, 1992 Jun DISC

BUTENAFINE HYDROCHLORIDECREAM; TOPICAL  
BUTENAFINE HYDROCHLORIDE  
TARO 1%

A205181 001 Nov 16, 2017 Oct NEWA

BUTOCONAZOLE NITRATECREAM; VAGINAL  
FEMSTAT 3

+ @ BAYER 2%

N020421 001 Dec 21, 1995 Aug DISC

CETIRIZINE HYDROCHLORIDECAPSULE; ORAL  
CETIRIZINE HYDROCHLORIDE ALLERGY  
STRIDES PHARMA 10MG

A205291 001 Jul 21, 2017 Jul NEWA

SYRUP; ORAL  
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY  
ALLIED PHARMA INC 5MG/5ML

A091327 001 Oct 17, 2011 Apr CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF  
ALLIED PHARMA INC 5MG/5ML

A091327 002 Oct 17, 2011 Apr CAHN

TABLET; ORAL  
CETIRIZINE HYDROCHLORIDE ALLERGY  
JUBILANT CADISTA 5MG

A078933 001 Jun 15, 2010 Apr CAHN

10MG

A078933 002 Jun 15, 2010 Apr CAHN

UNIQUE PHARM LABS 5MG

A077829 001 Aug 26, 2009 Aug CAHN

10MG

A077829 004 Aug 26, 2009 Aug CAHN

CETIRIZINE HYDROCHLORIDE HIVES

JUBILANT CADISTA 5MG

A078933 003 Jun 15, 2010 Apr CAHN

10MG

A078933 004 Jun 15, 2010 Apr CAHN

UNIQUE PHARM LABS 5MG

A077829 003 Aug 26, 2009 Aug CAHN

10MG

A077829 002 Aug 26, 2009 Aug CAHN

TABLET, ORALLY DISINTEGRATING; ORAL  
CETIRIZINE HYDROCHLORIDE ALLERGY  
PERRIGO R AND D 10MG

A205490 001 Sep 02, 2015 Aug CAHN

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDETABLET; ORAL  
ADVIL MULTI-SYMPTOM COLD & FLU

+! PFIZER 4MG; 200MG; 10MG

N022113 002 Apr 28, 2017 Apr NEWA

CIMETIDINETABLET; ORAL  
CIMETIDINE@ CONTRACT PHARMACAL 200MG  
@ 200MG

A074961 001 Jun 19, 1998 Oct DISC

L PERRIGO CO 200MG

A074963 001 Jun 19, 1998 Oct DISC

@ SANDOZ INC 100MG

A075285 001 Oct 29, 1998 Apr CAHN

@ 200MG

A075122 001 Jun 19, 1998 Mar CAHN

@ WATSON LABS TEVA 200MG

A075122 002 Jun 19, 1998 Mar CAHN

A075425 001 Jul 29, 1999 May CAHN

CLEMASTINE FUMARATE

## TABLET; ORAL

## CLEMASTINE FUMARATE

L PERRIGO CO	1.34MG	A074512	001	Nov 22, 1995	Apr CAHN
TAVIST-1					
+! GLAXOSMITHKLINE CONS	1.34MG	N020925	001	Aug 21, 1992	Apr CAHN

CLOTRIMAZOLE

## CREAM; VAGINAL

## CLOTRIMAZOLE

! ACTAVIS MID ATLANTIC	1%	A074165	001	Jul 16, 1993	Jun CHRS
TARO	1%	A072641	001	Dec 04, 1995	Apr CAHN
GYNE-LOTTRIMIN					
+ @ BAYER HEALTHCARE LLC	1%	N018052	002	Nov 30, 1990	Jun DISC
GYNE-LOTTRIMIN 3					
+ @ BAYER HEALTHCARE LLC	2%	N020574	001	Nov 24, 1998	Jun DISC
CREAM, TABLET; TOPICAL, VAGINAL					
GYNE-LOTTRIMIN 3 COMBINATION PACK					
+ @ BAYER HEALTHCARE LLC	1%, 200MG	N020526	002	Jul 29, 1996	Jun DISC
GYNE-LOTTRIMIN COMBINATION PACK					
+ @ BAYER HEALTHCARE LLC	1%, 100MG	N020289	002	Apr 26, 1993	Jun DISC
TABLET; VAGINAL					
GYNE-LOTTRIMIN					
+ @ BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990	Jun DISC
GYNE-LOTTRIMIN 3					
+ @ BAYER HEALTHCARE LLC	200MG	N020525	001	Jul 29, 1996	Jun DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

## TABLET, EXTENDED RELEASE; ORAL

## GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

ACTAVIS LABS FL	30MG; 600MG	A091070	001	Aug 31, 2015	Mar CAHN
	60MG; 1.2GM	A091070	002	Aug 31, 2015	Mar CAHN
AUROBINDO PHARMA LTD	30MG; 600MG	A206941	001	Mar 17, 2017	Mar NEWA
	60MG; 1.2GM	A206941	002	Mar 17, 2017	Mar NEWA

DEXTROMETHORPHAN POLISTIREX

## SUSPENSION, EXTENDED RELEASE; ORAL

## DEXTROMETHORPHAN POLISTIREX

AMNEAL PHARMS LLC	EQ 30MG HBR/5ML	A203133	001	Jul 28, 2017	Jul NEWA
-------------------	-----------------	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

## CAPSULE, DELAYED RELEASE; ORAL

## ESOMEPRAZOLE MAGNESIUM

AUROBINDO PHARMA LTD	EQ 20MG BASE	A209339	001	Oct 16, 2017	Oct NEWA
PERRIGO R AND D	EQ 20MG BASE	A207193	001	Aug 18, 2017	Aug NEWA

FAMOTIDINE

## TABLET; ORAL

## FAMOTIDINE

PERRIGO R AND D	20MG	A077351	001	Sep 25, 2006	Apr CAHN
-----------------	------	---------	-----	--------------	----------

FEXOFENADINE HYDROCHLORIDE

## SUSPENSION; ORAL

## CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

TARO PHARM	30MG/5ML	A208123	001	Nov 09, 2017	Oct NEWA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES					
TARO PHARM	30MG/5ML	A208123	002	Nov 09, 2017	Oct NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	60MG; 120MG	A209116	001	Oct 30, 2017	Oct NEWA
----------------------	-------------	---------	-----	--------------	----------

FLUTICASONE FUROATE

## SPRAY, METERED; NASAL

## FLONASE SENSIMIST ALLERGY RELIEF

+! GLAXOSMITHKLINE CONS	0.0275MG/SPRAY	N022051	002	Aug 02, 2016	Jun CAHN
-------------------------	----------------	---------	-----	--------------	----------

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL  
GUAIFENESIN

ACTAVIS LABS FL	1.2GM	A091009	002	Sep 03, 2015	Mar CAHN
GUARDIAN PHARMS	600MG	A209215	001	Sep 06, 2017	Aug NEWA
	1.2GM	A209215	002	Sep 06, 2017	Aug NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL	600MG; 60MG	A091071	001	May 27, 2015	Mar CAHN
	1.2GM; 120MG	A091071	002	May 27, 2015	Mar CAHN

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300	001	Dec 23, 2011	May CAHN
@ CONTRACT PHARMACAL	200MG	A074782	001	Jul 06, 1998	Oct DISC

SUSPENSION; ORAL

IBUPROFEN

ARISE PHARMS	100MG/5ML	A200457	001	Aug 18, 2011	Oct CAHN
TARO	100MG/5ML	A209207	001	Jun 27, 2017	Jun NEWA

SUSPENSION/DROPS; ORAL

IBUPROFEN

L PERRIGO CO	40MG/ML	A075217	001	Dec 16, 1998	Apr CAHN
--------------	---------	---------	-----	--------------	----------

TABLET; ORAL

IBUPROFEN

AIPING PHARM INC	200MG	A207095	001	May 05, 2017	Apr NEWA
AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Apr CAHN
AUROBINDO PHARMA LTD	200MG	A208865	001	Nov 08, 2017	Oct NEWA
@ CONTRACT PHARMACAL	200MG	A071735	001	Sep 10, 1987	Oct DISC
@	200MG	A074931	001	Jul 20, 1998	Oct DISC
STRIDES PHARMA	200MG	A207052	001	May 30, 2017	Jun CMS2
	200MG	A207052	001	May 30, 2017	May NEWA
JUNIOR STRENGTH IBUPROFEN					
L PERRIGO CO	100MG	A075367	001	Apr 22, 1999	Apr CAHN

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A>	AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT; 30MG	A209235	001	Dec 01, 2017	Nov NEWA
-----	----------------------	---	---------	-----	--------------	----------

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ CONTRACT PHARMACAL	200MG; 30MG	A075588	001	Apr 08, 2002	Oct DISC
----------------------	-------------	---------	-----	--------------	----------

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

KREMERS URBAN PHARMS	15MG	A207157	001	Sep 29, 2017	Sep NEWA
----------------------	------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

XYZAL ALLERGY 24HR

+	SANOFI-AVENTIS US	2.5MG/5ML (0.5MG/ML)	N209090	001	Jan 31, 2017	Feb CAHN
+	UCB INC	2.5MG/5ML (0.5MG/ML)	N209090	001	Jan 31, 2017	Jan NEWA

TABLET; ORAL

XYZAL ALLERGY 24HR

+	SANOFI-AVENTIS US	5MG	N209089	001	Jan 31, 2017	Feb CAHN
+	UCB INC	5MG	N209089	001	Jan 31, 2017	Jan NEWA

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

>A>	@ FDN CONSUMER	0.75MG	A078665	001	Aug 28, 2009	Nov CAHN
>A>		1.5MG	A200670	001	Jul 12, 2012	Nov CAHN
	RECKITT BENCKISER	1.5MG	A202246	001	Jun 05, 2015	Apr CAHN
>D>	WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012	Nov CAHN

	TABLET;ORAL						
	PLAN B						
>A>	+ @ FDN CONSUMER	0.75MG	N021045	002	Aug 24, 2006	Nov	CAHN
	PLAN B ONE-STEP						
>A>	+! FDN CONSUMER	1.5MG	N021998	001	Jul 10, 2009	Nov	CAHN
>D>	+! TEVA BRANDED PHARM	1.5MG	N021998	001	Jul 10, 2009	Nov	CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

ALLIED PHARMA INC 1MG/5ML

A073079 001 Apr 30, 1992 Mar CAHN

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE

@ CONTRACT PHARMACAL 2MG

A073254 001 Jul 30, 1993 Oct DISC

L PERRIGO CO 2MG

A075232 001 Jan 06, 2000 Apr CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

! PERRIGO 2MG;125MG

A076029 001 Aug 30, 2002 Jan CHRS

LORATADINE

SYRUP;ORAL

LORATADINE

TARO PHARM 1MG/ML

A201865 001 Jul 31, 2015 Mar CAHN

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

TARO 2%

A074444 001 Jan 13, 1997 Apr CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

ACTAVIS MID ATLANTIC 2%,200MG

A074926 001 Apr 16, 1999 Jun CAHN

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

ACTAVIS PHARMA 100MG

A073507 001 Nov 19, 1993 May CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL (FOR MEN)

WATSON LABS INC 5%

A208092 001 Feb 17, 2017 Feb NEWA

MINOXIDIL (FOR WOMEN)

WATSON LABS INC 5%

A208092 002 Jul 27, 2017 Jul NEWA

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

L PERRIGO CO 2%

A075357 001 Jul 30, 1999 Apr CAHN

MINOXIDIL (FOR WOMEN)

L PERRIGO CO 2%

A075357 002 Jul 30, 1999 Apr CAHN

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

@ CONTRACT PHARMACAL EQ 200MG BASE

A074789 001 Feb 27, 1997 Oct DISC

LNK INTL INC EQ 200MG BASE

A204872 001 Jan 23, 2017 Jan NEWA

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

+ DR REDDYS LABS SA 7MG/24HR

N020076 004 Nov 12, 1999 Jun CAHN

+ 14MG/24HR

N020076 005 Nov 12, 1999 Jun CAHN

+! 21MG/24HR

N020076 006 Nov 12, 1999 Jun CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE

&gt;D&gt; +! GLAXOSMITHKLINE EQ 2MG BASE

N018612 002 Feb 09, 1996 Nov CHRS

&gt;A&gt; + EQ 2MG BASE

N018612 002 Feb 09, 1996 Nov CHRS

NICOTINE POLACRILEX

L PERRIGO CO EQ 2MG BASE

A076775 001 Sep 16, 2004 Apr CAHN

EQ 2MG BASE

A076776 001 Sep 16, 2004 Apr CAHN

EQ 2MG BASE

A076777 001 Sep 16, 2004 Apr CAHN

GUM, CHEWING;BUCCAL  
NICOTINE POLACRILEX

EQ 4MG BASE	A076778	001	Sep 16, 2004	Apr CAHN
EQ 4MG BASE	A076779	001	Sep 16, 2004	Apr CAHN
EQ 4MG BASE	A076789	001	Sep 16, 2004	Apr CAHN

OMEPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL  
OMEPRAZOLE

+ DEXCEL PHARMA	20MG	N209400	001	Jul 05, 2017	Jul NEWA
-----------------	------	---------	-----	--------------	----------

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
OCUCLEAR

@ BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	May DISC
------------------------	--------	---------	-----	--------------	----------

PERMETHRIN

LOTION;TOPICAL  
PERMETHRIN

ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000	May CAHN
----------------------	----	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL  
POLYETHYLENE GLYCOL 3350

AILEX PHARMS LLC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Sep CAHN
------------------	---------------	---------	-----	--------------	----------

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	120MG	A209008	001	Jun 09, 2017	May NEWA
L PERRIGO CO	120MG	A075153	001	Feb 26, 1999	Apr CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL  
RANITIDINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	EQ 75MG BASE	A207579	001	Nov 13, 2017	Oct NEWA
	EQ 150MG BASE	A207578	001	Nov 13, 2017	Oct NEWA
@ CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999	Oct DISC
STRIDES PHARMA	EQ 150MG BASE	A200536	001	Jun 28, 2011	Jan CAHN

ZANTAC 150

+! SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004	Mar CAHN
+	EQ 150MG BASE	N021698	002	Mar 13, 2007	Mar CAHN

ZANTAC 75

>D> SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995	Nov CRLD
>A> +	EQ 75MG BASE	N020520	001	Dec 19, 1995	Nov CRLD
	EQ 75MG BASE	N020520	001	Dec 19, 1995	Mar CAHN

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL  
LAMISIL

+! GLAXOSMITHKLINE	1%	N020980	001	Mar 09, 1999	Jul CAHN
--------------------	----	---------	-----	--------------	----------

TIOCONAZOLE

OINTMENT;VAGINAL  
VAGISTAT-1

+! COMBE	6.5%	N020676	001	Feb 11, 1997	Jul CAHN
----------	------	---------	-----	--------------	----------

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL  
TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL	0.055MG/SPRAY	A078104	002	Nov 14, 2014	Jan CAHN
----------------	---------------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER 2017**

NO NOVEMBER 2017 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>



**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO NOVEMBER 2017 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ABACAVIR SULFATE</u>						
A 201107 001					PC	Mar 14, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001					>A> D-147	Mar 23, 2018
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	7803770	Mar 26, 2028	U-2009		NCE	Apr 28, 2022
	8148333	Nov 08, 2027	DP			
	8748382	Oct 03, 2027	U-2009			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2135			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2135			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2135			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2135			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027	U-1579			
	8822438	Aug 24, 2027	U-1580			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	>A> 9290504	Jul 11, 2032	DS DP		NCE	Oct 31, 2022
	>A> 9758524	Jul 11, 2032	U-2145			
	>A> 9796721	Jul 01, 2036	DS DP U-2145			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	9610265	Nov 13, 2028	U-2000		M-196 PED	Jan 27, 2020 Jul 27, 2020
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	9561204	May 08, 2032	U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	9561204	May 08, 2032	U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	RE46417	Sep 05, 2020	DS DP U-1263			
<u>ADAPALENE; BENZOYL PEROXIDE - ADAPALENE AND BENZOYL PEROXIDE</u>						
A 203790 001					PC	Jan 23, 2018
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8445543	Dec 23, 2022	U-1078			
	>A> 9814690	Dec 23, 2022	DP U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	9539258	Nov 09, 2026	U-1950			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	9539258	Nov 09, 2026	U-1950			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001 >A>	9808587	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	9731087	May 18, 2031	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	8733341	Oct 16, 2030	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001				>A> I-756		Nov 06, 2020
<u>ALISKIREN HEMIFUMARATE - TEKTRUNA</u>						
N 021985 001	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE - TEKTRUNA</u>						
N 021985 002	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 001	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 002	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 003	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 004	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029			U-2104	
	8283369	Nov 26, 2028			U-2104	
	8357713	Nov 26, 2028	DP		U-2104	
	8546436	Feb 29, 2032	DS			
	8546437	Apr 29, 2029			U-2104	
	9216179	Aug 01, 2031			U-2104	
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029			U-2104	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	8283369	Nov 26, 2028	U-2104			
	8357713	Nov 26, 2028	DP U-2104			
	8546436	Feb 29, 2032	DS			
	8546437	Apr 29, 2029	U-2104			
	9216179	Aug 01, 2031	U-2104			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	6329404	Jun 19, 2021	DP U-1334			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8112290	Jul 31, 2030	U-1443	Y		
	8645160	Jun 18, 2029	U-1485	Y		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	8389578	Jan 22, 2028	U-2105		NP	Aug 24, 2020
	8741343	Dec 02, 2030	U-2106		ODE	Aug 24, 2024
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	8389578	Jan 22, 2028	U-2105		NP	Aug 24, 2020
	8741343	Dec 02, 2030	U-2106		ODE	Aug 24, 2024
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	9549926	Oct 14, 2031	U-1965			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	9549926	Oct 14, 2031	U-1965			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN</u>						
N 208630 001					ODE	Jun 06, 2024
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 001					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 002					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 003					NP	Jan 21, 2018
<u>AMPHETAMINE - ADZENYS ER</u>						
N 204325 001	8709491	Jun 28, 2032	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - DYANAVAL XR</u>						
N 208147 001	9675703	Mar 15, 2027	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 001	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 002	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 003	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 004	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Nov 21, 2026	DS DP U-1167			
	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1502			
	6967208	Nov 21, 2026	DS DP U-1729			
	6967208	Nov 21, 2026	DS DP U-1730			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1323			
<u>APREPITANT - CINVANTI</u>						
N 209296 001	>A> 9561229	Sep 18, 2035	DP U-2161			
	>A> 9808465	Sep 18, 2035	U-2161			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001					I-746	Jul 27, 2020
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002					I-746	Jul 27, 2020
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003					I-746	Jul 27, 2020
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004					I-746	Jul 27, 2020
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001					>A> I-746	Jul 27, 2020
					>A> M-150	Dec 05, 2017
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002					>A> I-746	Jul 27, 2020
					>A> M-150	Dec 05, 2017
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003					>A> I-746	Jul 27, 2020
					>A> M-150	Dec 05, 2017
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004					>A> I-746	Jul 27, 2020
					>A> M-150	Dec 05, 2017
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005					>A> I-746	Jul 27, 2020
					>A> M-150	Dec 05, 2017
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006					>A> I-746	Jul 27, 2020
					>A> M-150	Dec 05, 2017
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9526726	Mar 19, 2035	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9526726	Mar 19, 2035	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9526726	Mar 19, 2035	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-543			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASCORBIC ACID - ASCOR</u>						
N 209112	001				>A> ODE	Oct 02, 2024
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	001	5763476	Jun 09, 2020	DP U-326	D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1960	I-597	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1961		
		5763476	Jun 09, 2020	DP U-1962		
		5763476	Jun 09, 2020	DP U-1963		
		5763476*PED	Dec 09, 2020			
		7741358	Apr 06, 2026	DS DP U-1064		
		7741358	Apr 06, 2026	DS DP U-1960		
		7741358	Apr 06, 2026	DS DP U-1961		
		7741358	Apr 06, 2026	DS DP U-1962		
		7741358	Apr 06, 2026	DS DP U-1963		
		7741358*PED	Oct 06, 2026			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	002	5763476	Jun 09, 2020	DP U-326	D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1960	I-597	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1961		
		5763476	Jun 09, 2020	DP U-1962		
		5763476	Jun 09, 2020	DP U-1963		
		5763476*PED	Dec 09, 2020			
		7741358	Apr 06, 2026	DS DP U-1064		
		7741358	Apr 06, 2026	DS DP U-1960		
		7741358	Apr 06, 2026	DS DP U-1961		
		7741358	Apr 06, 2026	DS DP U-1962		
		7741358	Apr 06, 2026	DS DP U-1963		
		7741358*PED	Oct 06, 2026			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	003	5763476	Jun 09, 2020	DP U-1893	D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1966	I-597	Jan 13, 2020
		5763476*PED	Dec 09, 2020			
		7741358	Apr 06, 2026	DS DP U-1893		
		7741358	Apr 06, 2026	DS DP U-1966		
		7741358*PED	Oct 06, 2026			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103	001	9539214	Mar 13, 2033	U-1902		
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103	002	9539214	Mar 13, 2033	U-1902		
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353	001				NCE	Aug 27, 2017
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	001				M-204	Jun 23, 2020
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	002				M-204	Jun 23, 2020
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494	001	9284314	Jun 15, 2032	DS		
		9695122	Jun 15, 2032	DS		
<u>AXITINIB - INLYTA</u>						
N 202324	001	8791140	Dec 14, 2030	DS		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AXITINIB - INLYTA</u>						
N 202324 002	8791140	Dec 14, 2030	DS			
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A 065488 001					PC	Mar 26, 2018
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A 065488 002					PC	Mar 26, 2018
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2018	DS DP U-594		NCE	Oct 13, 2018
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001 >A>	9808587	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002 >A>	9808587	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	6446627	Dec 18, 2017	DP			
	7637260	Aug 25, 2020	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	6446627	Dec 18, 2017	DP			
	7637260	Aug 25, 2020	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Dec 01, 2026	DS DP U-1321			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 001					NCE	Aug 29, 2022
					ODE	Aug 29, 2024



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570	002				NCE ODE	Aug 29, 2022 Aug 29, 2024
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819	002	9561208	Jun 03, 2029	DP U-916		
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079	001	9655907	Aug 31, 2030	DP U-1858		
		9775851	Aug 31, 2030	DP U-1858		
<u>BETRIXABAN - BEVYXXA</u>						
N 208383	001	6376515	Sep 15, 2020	DS DP U-1167	NCE	Jun 23, 2022
		6376515	Sep 15, 2020	DS DP U-1502		
		6376515	Sep 15, 2020	DS DP U-2029		
		6376515	Sep 15, 2020	DS DP U-2030		
		6835739	Sep 15, 2020	DS DP		
		7598276	Nov 08, 2026	DS		
		8404724	Mar 29, 2031	DP U-2034		
		8518977	Sep 15, 2020	DS		
		8557852	Sep 08, 2028	U-1167		
		8557852	Sep 08, 2028	U-2030		
		8691847	Sep 15, 2020	DS DP U-2029		
		8691847	Sep 15, 2020	DS DP U-2035		
		8987463	Dec 28, 2030	DP		
		9555023	Nov 07, 2026	U-1502		
		9629831	Sep 15, 2020	U-1167		
		9629831	Sep 15, 2020	U-1502		
		9629831	Sep 15, 2020	U-2030		
		9629831	Sep 15, 2020	U-2035		
<u>BETRIXABAN - BEVYXXA</u>						
N 208383	002	6376515	Sep 15, 2020	DS DP U-1167	NCE	Jun 23, 2022
		6376515	Sep 15, 2020	DS DP U-1502		
		6376515	Sep 15, 2020	DS DP U-2029		
		6376515	Sep 15, 2020	DS DP U-2030		
		6835739	Sep 15, 2020	DS DP		
		7598276	Nov 08, 2026	DS		
		8404724	Mar 29, 2031	DP U-2034		
		8518977	Sep 15, 2020	DS		
		8557852	Sep 08, 2028	U-1167		
		8557852	Sep 08, 2028	U-2030		
		8691847	Sep 15, 2020	DS DP U-2029		
		8691847	Sep 15, 2020	DS DP U-2035		
		8987463	Dec 28, 2030	DP		
		9555023	Nov 07, 2026	U-1502		
		9629831	Sep 15, 2020	U-1167		
		9629831	Sep 15, 2020	U-1502		
		9629831	Sep 15, 2020	U-2030		
		9629831	Sep 15, 2020	U-2035		
<u>BIMATOPROST - LATISSE</u>						
N 022369	001	9579270	Jan 31, 2021	U-1975		
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 205004	001	>A> 8962572	Nov 03, 2032	DP		
<u>BOSENTAN - TRACLEER</u>						
N 021290	001				NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 021290	002				NPP	Sep 05, 2020

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSENTAN - TRACLEER</u>						
N 209279 001	7959945	Dec 28, 2027	DP		NP	Sep 05, 2020
	8309126	May 15, 2026	DP		>A> ODE	Sep 05, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	6002008	Mar 27, 2018	DS DP U-1284		ODE	Sep 04, 2019
	7417148	Jan 23, 2026	U-1283			
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Apr 13, 2024	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9687443	Jul 10, 2021	DP			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	9770453	Apr 19, 2022	DP U-2131			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9352025	Jun 07, 2030	U-2111			
	9352025	Jun 07, 2030	U-2112			
	9352025	Jun 07, 2030	U-2113			
	9352025	Jun 07, 2030	U-2114			
	9352025	Jun 07, 2030	U-2115			
	9352025	Jun 07, 2030	U-2116			
	9352025	Jun 07, 2030	U-2117			
	9352025	Jun 07, 2030	U-2118			
	9352025	Jun 07, 2030	U-2119			
	9522117	Apr 30, 2032	DP U-976			
	9522117	Apr 30, 2032	DP U-1939			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9532954	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	6123924	Sep 26, 2017	DP		M-210	Sep 11, 2020
	7367333	Nov 11, 2018	DP		NPP	Jan 27, 2020
	7367333*PED	May 11, 2019			PED	Jul 27, 2020
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	6123924	Sep 26, 2017	DP		M-210	Sep 11, 2020
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	7897646	Sep 09, 2018	U-2002			
	7897646	Sep 09, 2018	U-2122			
	7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8461211	Sep 09, 2018	U-2002			
	8461211	Sep 09, 2018	U-2122			
	8461211*PED	Mar 09, 2019				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	9585838	Dec 24, 2021	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	9585838	Dec 24, 2021	DP			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	9642850	Sep 29, 2017	U-1556			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	9655843	Jul 23, 2027	DP U-2017			
<u>CABAZITAXEL - JEV TANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP		M-201	May 17, 2020
	5847170*PED	Sep 26, 2021			M-209	Sep 14, 2020
	7241907	Dec 10, 2025	DS		PED	Nov 17, 2020
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	9724342	Jul 09, 2033	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	9724342	Jul 09, 2033	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	9724342	Jul 09, 2033	DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					M-197	Feb 01, 2020
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	9700575	Jul 10, 2035	DP			
<u>CAPSAICIN - QUTENZA</u>						
N 022395 001	6239180	Jun 04, 2021	DP			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	9493582	Feb 27, 2033	DP			
	9629797	Nov 10, 2028		U-2004		
	9629797	Nov 10, 2028		U-2005		
	9629797	Nov 10, 2028		U-2006		
	9750822	Mar 13, 2029	DP			
	9770407	Nov 10, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	9533046	Dec 26, 2028	DP U-219			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	9522191	Jun 15, 2027	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	9493582	Feb 27, 2033	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	9493582	Feb 27, 2033	DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001					>A> M-213	Nov 09, 2020
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002					>A> M-213	Nov 09, 2020
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003					>A> M-213	Nov 09, 2020
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004					>A> M-213	Nov 09, 2020
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132 001					>A> PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132 002					>A> PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132 003					>A> PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132 004					>A> PC	May 07, 2018
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 001	9636407	Dec 21, 2032	DP			
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 002	9636407	Dec 21, 2032	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	9629861	Sep 21, 2030	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	9629861	Sep 21, 2030	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	8188276	Jan 31, 2023	DS DP		M-199	May 26, 2020
	8399450	Nov 20, 2027	DS DP		ODE	May 26, 2024
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIAE</u>						
N 208694 001	8829005	Mar 15, 2030		U-1680	NDF	May 30, 2020
	8829005*PED	Sep 15, 2030			PED	Nov 30, 2020
	9254286	Jul 09, 2032	DP			
	9254286*PED	Jan 09, 2033				
	9750684	Mar 15, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791 001					NP	Sep 26, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003					M-200	May 23, 2020
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	>A> 9827231	Jun 23, 2034	DP U-2162			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001					>A> NP	Nov 28, 2020
<u>CLOFARABINE - CLOFARABINE</u>						
A 204029 001					PC	Nov 05, 2017
<u>COBICISTAT - TYBOST</u>						
N 203094 001					NCE	Aug 27, 2017
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001					NCE	Aug 27, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7176220	Aug 27, 2026	DS DP U-257		NCE NPP	Aug 27, 2017 Sep 25, 2020
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
	9744181	Jan 13, 2024	DP U-257		NPP	Jan 27, 2020
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9555029	Aug 22, 2033	U-1020			
	9675613	Aug 22, 2033	U-1020			
	9789108	Aug 22, 2033	U-1020			
<u>COPANLISIB DIHYDROCHLORIDE - ALIQOPA</u>						
N 209936 001	7511041	May 13, 2024	DS DP		NCE	Sep 14, 2022
	8466283	Oct 22, 2029	DS DP U-2124		ODE	Sep 14, 2024
	9636344	Mar 29, 2032	U-2124			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8168614	Jan 20, 2030	U-1932			
	8501712	Feb 16, 2027	U-1932			
	9682092	Feb 16, 2027	U-1932			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	9585868	Oct 31, 2031	DS U-1319			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8292129	Feb 25, 2031	DP			
	8561859	Apr 16, 2032	DP			
	9669974	May 11, 2034	DP			
	9676525	Feb 07, 2034	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	7850990	Jan 23, 2027	DP U-2090		NP	Aug 03, 2020
	8022279	Sep 14, 2027	DP U-2090			
	8092828	Apr 01, 2029	U-2090			
	8431806	Apr 22, 2025	DP U-2090			
	8518437	Jun 07, 2026	DP			
	9271931	Jan 23, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
	7994185	Jan 20, 2030	DS DP U-2031		ODE	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8835443	Sep 13, 2025	U-2026			
	8835443	Sep 13, 2025	U-2027			
	8952018	Oct 15, 2030	U-2027			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
	7994185	Jan 20, 2030	DS DP U-2031		ODE	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8835443	Sep 13, 2025	U-2026			
	8835443	Sep 13, 2025	U-2027			
	8952018	Oct 15, 2030	U-2027			
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001	6414126	Oct 04, 2020	DS DP U-493		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-2139			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6515117	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-2139			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 11, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8329648	Aug 18, 2026	U-2153			
	8329648	Aug 18, 2026	U-2155			
	8329648	Aug 18, 2026	U-2156			
	8361972	Mar 21, 2028	U-493			
	8361972	Mar 21, 2028	U-2139			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8690837	May 19, 2029	DP			
	8712615	Jan 18, 2030	DP			
	8758292	Nov 12, 2027	DP			
	8827963	Feb 04, 2029	DP			
	8906851	Aug 18, 2026	U-1313			
	8998876	Jan 07, 2030	DP			
	9198925	Oct 04, 2020	U-493			
	9198925	Oct 04, 2020	U-2139			
	9238076	Apr 15, 2024	DP U-412			
	9320853	Mar 25, 2028	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001	6414126	Oct 04, 2020	DS DP U-493		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-2139			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6515117	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-2139			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 11, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8329648	Aug 18, 2026	U-2153			
	8329648	Aug 18, 2026	U-2155			
	8329648	Aug 18, 2026	U-2156			
	8361972	Mar 21, 2028	U-493			
	8361972	Mar 21, 2028	U-2139			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8690837	May 19, 2029	DP			
	8712615	Jan 18, 2030	DP			
	8758292	Nov 12, 2027	DP			
	8827963	Feb 04, 2029	DP			
	8906851	Aug 18, 2026	U-1313			
	8998876	Jan 07, 2030	DP			
	9198925	Oct 04, 2020	U-493			
	9198925	Oct 04, 2020	U-2139			
	9238076	Apr 15, 2024	DP U-412			
	9320853	Mar 25, 2028	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002	6414126	Oct 04, 2020	DS DP U-493		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-2139			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6515117	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-2139			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 11, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8329648	Aug 18, 2026	U-2153			
	8329648	Aug 18, 2026	U-2155			
	8329648	Aug 18, 2026	U-2156			
	8361972	Mar 21, 2028	U-493			
	8361972	Mar 21, 2028	U-2139			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8690837	May 19, 2029	DP			
	8712615	Jan 18, 2030	DP			
	8758292	Nov 12, 2027	DP			
	8827963	Feb 04, 2029	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002	8906851	Aug 18, 2026	U-1313			
	8998876	Jan 07, 2030	DP			
	9198925	Oct 04, 2020	U-493			
	9198925	Oct 04, 2020	U-2139			
	9238076	Apr 15, 2024	DP U-412			
	9320853	Mar 25, 2028	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-1976		M-175	Apr 05, 2019
	6414126	Oct 04, 2020	DS DP U-1977		NC	Feb 27, 2020
	6515117	Oct 04, 2020	DS DP U-1976		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-1977			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	RE44186	Jul 31, 2023	DS DP U-1976			
	RE44186	Jul 31, 2023	DS DP U-1977			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002					M-211 NPP	Sep 01, 2020 Mar 29, 2020
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003					M-211 NPP	Sep 01, 2020 Mar 29, 2020
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	9629841	Oct 18, 2033	DP U-1753			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	9744170	Jan 02, 2035	DP U-1889			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					>A> NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					>A> NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					>A> NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					>A> NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					>A> NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 006					>A> NPP	Nov 09, 2020
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003	6465504	Apr 05, 2019	DS DP			
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 001					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 002					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	9579359	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	9579359	Feb 10, 2029	U-1978			
<u>DELAFLORACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	7728143	Nov 20, 2027	DS		NCE	Jun 19, 2022
	8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	8273892	Aug 06, 2026	DS			
	8497378	Dec 28, 2029	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DELAFLORACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	8969569	Oct 07, 2025	DP U-2028			
	9539250	Oct 07, 2025	DS DP U-2028			
<u>DELAFLORACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	7728143	Nov 20, 2027	DS		NCE	Jun 19, 2022
	8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	8273892	Aug 06, 2026	DS			
	8497378	Dec 28, 2029	DS			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	9539250	Oct 07, 2025	DS DP U-2028			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9522155	Feb 21, 2028	DP U-1940			
	9636349	Feb 21, 2028	U-1940			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	9539302	Jun 15, 2030	DP			
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 001					PC	Jan 25, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 003					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204082 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204083 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 001					PC	Aug 28, 2017

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095	002				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172	002				PC	Aug 28, 2017
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	001	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846		
		9550780	Sep 18, 2033	DS DP U-1995		
	>A>	9814708	Sep 18, 2033	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	002	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846		
		9550780	Sep 18, 2033	DS DP U-1995		
	>A>	9814708	Sep 18, 2033	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	003	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846		
		9550780	Sep 18, 2033	DS DP U-1995		
	>A>	9814708	Sep 18, 2033	DP		
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315	001	9592242	Oct 20, 2020	U-1989		
		9592242	Oct 20, 2020	U-1990		
		9775849	Oct 20, 2020	U-1989		
		9775849	Oct 20, 2020	U-1990		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	002	9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	003	9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	004	9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165	001	>A> 9827197	Jun 16, 2026	DP		
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202	001	9561200	Feb 24, 2029	U-1482		
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623	001	9539335	Oct 17, 2027	U-1614		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001					>A> I-758	Nov 21, 2020
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002					>A> I-758	Nov 21, 2020
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003					>A> I-758	Nov 21, 2020
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001					>A> NC >A> NCE	Nov 21, 2020 Aug 12, 2018
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661 001	7560122	Jan 25, 2019	DP			
	9089489	Feb 18, 2033	DP U-1382			
	9375404	Feb 18, 2033	DP U-1382			
	9526703	Feb 18, 2033	DP U-1382			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	8222292	Aug 06, 2028	DS DP			
	9345771	Aug 06, 2028	DS DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 001	6933310	Nov 13, 2020	U-2013		NCE ODE	May 05, 2022 May 05, 2024
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	8598185	Apr 28, 2029	DP			
	9545414	Jun 13, 2026	DP U-750			
	9545414	Jun 13, 2026	DP U-1170			
	9744181	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9566272	Jan 03, 2028	U-1969			
	9662394	Oct 02, 2034	DP			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	>A> 8062665	Aug 01, 2027	DP U-930			
	>A> 8062665	Aug 01, 2027	DP U-1306			
	>A> 8062665	Aug 01, 2027	DP U-1575			
	>A> 8062665	Aug 01, 2027	DP U-1714			
	>A> 8062665*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	6280959	Oct 30, 2018	DS DP U-1736		ODE	Aug 26, 2021
	6280959*PED	Apr 30, 2019			PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	7547719	Jul 13, 2025	DS DP U-1736			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 24, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	8772325	Mar 14, 2025	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8772325	Mar 14, 2025	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	8673927	May 04, 2027	U-1652			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	8673927	May 04, 2027	U-1652			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001					M-206 M-207	Aug 21, 2020 Aug 21, 2020
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	9744181	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001					NPP	Sep 25, 2020
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	9744181	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	9669008	Mar 25, 2036	DP			
	>A> 9808442	Mar 25, 2036	U-3			
	>A> 9808442	Mar 25, 2036	U-71			
	>A> 9808442	Mar 25, 2036	U-185			
	>A> 9808442	Mar 25, 2036	U-1723			
	>A> 9808442	Mar 25, 2036	U-1892			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	9512107	Jan 07, 2033	DS DP U-2087		NCE	Aug 01, 2022
	9732062	Sep 16, 2034	DS		ODE	Aug 01, 2024
	9738625	Aug 01, 2034	DS			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	9512107	Jan 07, 2033	DS DP U-2087		NCE	Aug 01, 2022
	9732062	Sep 16, 2034	DS		ODE	Aug 01, 2024
	9738625	Aug 01, 2034	DS			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - ADRENALICK</u>						
N 020800 003	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENALICK</u>						
N 020800 004	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9295657	Mar 13, 2035	U-1829			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9707181	May 31, 2022	DP		NPP	Jul 06, 2020
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	9707181	May 31, 2022	DP		NPP	Jul 06, 2020
<u>ESTRADIOL - ESTRADIOL</u>						
A 205256 001					PC	Apr 15, 2017
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	9730900	Jul 10, 2028	U-2086			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	9730900	Jul 10, 2028	U-2086			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	9730900	Jul 10, 2028	U-2086			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	9730900	Jul 10, 2028	U-2086			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	9724310	Jul 10, 2028	DS DP			
	9730900	Jul 10, 2028	DP U-2086			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
>A>	9820938	Jun 27, 2034	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
>A>	9820938	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
>A>	9820938	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
>A>	9820938	Jun 27, 2034	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	8486907	Jun 28, 2025	U-1904	Y		
	9243245	Oct 27, 2028	DS U-2097			
	9243245	Oct 27, 2028	DS U-2098			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	8486907	Jun 28, 2025	U-1904	Y		
	9243245	Oct 27, 2028	DS U-2097			
	9243245	Oct 27, 2028	DS U-2098			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - FAYOSIM</u>						
A 205943 001					PC	Sep 30, 2017
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE</u>						
A 206287 001					PC	Sep 11, 2017
<u>ETONOGESTREL - IMPLANON</u>						
N 021529 001	9757552	Jul 28, 2030	DP U-1			
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002	9757552	Jul 28, 2030	DP U-1			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	6239124	Jul 29, 2017	U-1049			
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	6239124	Jul 29, 2017	U-1049			
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	6239124	Jul 29, 2017	U-1049			
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002					ODE	Feb 26, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	003				ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	004				ODE	Feb 26, 2023
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210	001	6479065	Aug 10, 2020	DP	NP	Oct 20, 2020
		6667061	May 25, 2020	DP		
		6824822	Oct 09, 2022	DP		
		6872700	Jan 14, 2020	U-654		
		6956026	Jan 07, 2018	U-687		
		7223440	Aug 31, 2021	DP		
		7456254	Jun 30, 2025	DP U-1223		
		7563871	Apr 15, 2024	DP		
		7612176	Apr 13, 2025	DP U-1223		
		7741269	Jan 07, 2018	U-1224		
		8329648	Aug 18, 2026	U-1313		
		8329648	Aug 18, 2026	U-2154		
		8329648	Aug 18, 2026	U-2155		
		8329648	Aug 18, 2026	U-2156		
		8431685	Apr 13, 2025	DP U-412		
		8461105	Apr 13, 2025	DP U-412		
		8895033	Oct 04, 2030	DP U-1313		
		8895033	Oct 04, 2030	DP U-2157		
		8895033	Oct 04, 2030	DP U-2158		
		8906851	Aug 18, 2026	U-1313		
		9238076	Apr 15, 2024	DP U-412		
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200	001	>A> 6414126	Oct 04, 2020	DS DP U-493	M-212	Oct 20, 2020
		>A> 6414126	Oct 04, 2020	DS DP U-2139		
		>A> 6515117	Oct 04, 2020	DS DP U-493		
		>A> 6515117	Oct 04, 2020	DS DP U-2139		
		>A> 6936590	Oct 04, 2020	U-493		
		>A> 7851502	Aug 19, 2028	DP		
		>A> 7919598	Dec 16, 2029	DS		
		>A> 8221786	Mar 21, 2028	DP		
		>A> 8361972	Mar 21, 2028	U-493		
		>A> 8361972	Mar 21, 2028	U-2139		
		>A> 8501698	Jun 20, 2027	DP U-493		
		>A> 8685934	May 26, 2030	U-1522		
		>A> 8716251	Mar 21, 2028	DP		
		>A> 9198925	Oct 04, 2020	U-493		
		>A> 9198925	Oct 04, 2020	U-2139		
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200	002	6414126	Oct 04, 2020	DS DP U-493		
		6414126	Oct 04, 2020	DS DP U-2139		
		6515117	Oct 04, 2020	DS DP U-493		
		6515117	Oct 04, 2020	DS DP U-2139		
		6936590	Oct 04, 2020	U-493		
		7851502	Aug 19, 2028	DP		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8361972	Mar 21, 2028	U-493		
		8361972	Mar 21, 2028	U-2139		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		
		8690837	May 19, 2029	DP		
		8716251	Mar 21, 2028	DP		
	>A>	8721615	Jan 18, 2030	DP		
		8758292	Nov 12, 2027	DP		
		8827963	Feb 04, 2029	DP		
		8998876	Jan 07, 2030	DP		
		9198925	Oct 04, 2020	U-493		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	9198925	Oct 04, 2020	U-2139			
	9320853	Mar 25, 2028	DP			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001					M-205	Aug 15, 2020
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002					M-205	Aug 15, 2020
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	9597288	Jul 23, 2027	DP U-767			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9731869	Jan 26, 2032	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9731869	Jan 26, 2032	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9731869	Jan 26, 2032	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	9731121	Oct 17, 2031	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	9757416	Feb 18, 2024	DS DP U-1577			
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 001					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 002					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 003					NCE	Jul 13, 2021
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	5808146	Nov 09, 2018	DS			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	6537983	Aug 03, 2021	DP U-2125		NCE	May 10, 2018
	6759398	Aug 03, 2021	DP U-2125		NCE	Dec 18, 2018
	6878698	Aug 03, 2021	U-2134			
	7101866	Aug 03, 2021	DS DP U-2126			
	7439393	May 21, 2025	DS DP U-2127			
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-2128			
	8309572	Apr 27, 2025	U-2129			
	8511304	Jun 14, 2027	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	9750762	Nov 29, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-2127			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	7439393	May 21, 2025	DS DP U-1401		M-202	May 15, 2020
	7439393	May 21, 2025	DS DP U-1691		NCE	May 10, 2018
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	7439393	May 21, 2025	DS DP U-1691		M-202	May 15, 2020
	7439393	May 21, 2025	DS DP U-2099		NCE	May 10, 2018
	7439393	May 21, 2025	DS DP U-2100			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	6715485	Mar 03, 2020	DP		NP	Sep 18, 2020
	7975690	Dec 29, 2025	U-2133			
	8327844	Oct 08, 2023	U-2133			
	8522778	May 11, 2022	DP			
	8550073	Oct 22, 2029	DP			
	8555878	Mar 20, 2020	DP			
	8978647	Aug 06, 2030	DP			
	9072857	Apr 10, 2021	DP			
	9468727	Jul 30, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	>A> 6774122	Jan 09, 2021	U-596		I-749	Aug 25, 2020
	>A> 6774122	Jan 09, 2021	U-1826			
	>A> 6774122	Jan 09, 2021	U-2108			
	>A> 6774122	Jan 09, 2021	U-2163			
	>A> 6774122*PED	Jul 09, 2021				
	>A> 7456160	Jan 09, 2021	U-596			
	>A> 7456160	Jan 09, 2021	U-1826			
	>A> 7456160	Jan 09, 2021	U-2108			
	>A> 7456160	Jan 09, 2021	U-2163			
	>A> 7456160*PED	Jul 09, 2021				
	>A> 8329680	Jan 09, 2021	U-596			
	>A> 8329680	Jan 09, 2021	U-1826			
	>A> 8329680	Jan 09, 2021	U-2108			
	>A> 8329680	Jan 09, 2021	U-2163			
	>A> 8329680*PED	Jul 09, 2021				
	>A> 8466139	Jan 09, 2021	U-596			
	>A> 8466139	Jan 09, 2021	U-1826			
	>A> 8466139	Jan 09, 2021	U-2108			
	>A> 8466139	Jan 09, 2021	U-2163			
	>A> 8466139*PED	Jul 09, 2021				



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 005					NCE NPP	Mar 20, 2018 Aug 25, 2020
<u>GANCICLOVIR - GANCICLOVIR</u>						
N 209347 001	9486530	Sep 02, 2034	DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	>A> 8648037	Jan 19, 2032	DS DP U-2141		NCE	Aug 03, 2022
	>A> 8937150	May 18, 2032	DS DP			
	>A> 9321807	Jun 05, 2035	DS			
	>A> 9586978	Jun 10, 2030	U-2141			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	9561197	Sep 22, 2030	U-1383		NPP	Apr 28, 2020
<u>GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON</u>						
N 205474 001	9549907	Nov 13, 2035	DS DP U-2023			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA PRESERVATIVE FREE</u>						
N 021945 002					ODE	Feb 03, 2018
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-741	Jan 18, 2020
	8476284	Dec 28, 2026	U-1650		I-753	Aug 02, 2020
	8476284	Dec 28, 2026	U-1946		ODE	Jan 18, 2024
	8476284	Dec 28, 2026	U-1947		ODE	Aug 02, 2024
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	>A> 9814721	Jun 03, 2031	U-1947			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9649284	Sep 30, 2029	U-2018			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8188146	Jan 27, 2020	DS DP		NCE	Jul 26, 2017
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1287			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	9789078	May 15, 2033	U-2138			
	>A> 9820959	Dec 18, 2026	DP U-1440			
	>A> 9833428	Dec 18, 2026	DP			
	>A> 9833429	Dec 18, 2026	DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	>A> 9820959	Dec 18, 2026	DP U-1440			
	>A> 9833428	Dec 18, 2026	DP			
	>A> 9833429	Dec 18, 2026	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART RECOMBINANT - FIASP</u>						
N 208751 001	8324157	Jun 25, 2030	DP		NP	Sep 29, 2020
<u>INSULIN ASPART RECOMBINANT - FIASP FLEXTOUCH</u>						
N 208751 002	6899699	Jan 02, 2022	DP		NP	Sep 29, 2020
	7686786	Aug 03, 2026	DP			
	8324157	Jun 25, 2030	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Jan 20, 2026	DP			
	9486588	Jan 02, 2022	DP			
	9687611	Feb 27, 2027	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART RECOMBINANT - FIASP FLEXTOUCH</u>						
N 208751 002	9775953	Jul 17, 2026	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
>A>	9827379	Mar 02, 2024	DP U-2146			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
>A>	9827379	Mar 02, 2024	DP U-2146			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9526764	Oct 09, 2029	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9707176	Nov 11, 2030	DP			
	9775954	Mar 02, 2024	DP			
>A>	9827379	Mar 02, 2024	DP U-2146			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003 >A>	9827379	Mar 02, 2024	DP U-2146			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1621			
	8623817	Sep 18, 2029	U-1537			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	9192675	Jun 12, 2029	DP U-1788			
	9358352	Feb 15, 2031	DP U-1861			
	9446133	Jun 12, 2029	DP U-1861			
	9597374	Oct 08, 2031	U-1987			
	9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1621			
	8623817	Sep 18, 2029	U-1537			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	9192675	Jun 12, 2029	DP U-1788			
	9358352	Feb 15, 2031	DP U-1861			
	9446133	Jun 12, 2029	DP U-1861			
	9597374	Oct 08, 2031	U-1987			
	9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1621			
	8623817	Sep 18, 2029	U-1537			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	9192675	Jun 12, 2029	DP U-1788			
	9358352	Feb 15, 2031	DP U-1861			
	9446133	Jun 12, 2029	DP U-1861			
	9597374	Oct 08, 2031	U-1987			
	9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			

IODIXANOL - VISIPAQUE 320

N 020351 002

I-752

Apr 05, 2020

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020808	002				I-752	Apr 05, 2020
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793	001	9717724	Jun 12, 2033	U-1848		
		9717724	Jun 12, 2033	U-2091		
		9724303	May 02, 2025	DS DP		
		9730891	May 02, 2025	U-1848		
		9782349	May 02, 2025	DS DP		
<u>IVACAFTOR - KALYDECO</u>						
N 203188	001	9670163	Dec 28, 2026	DP U-1311	NPP	Jul 31, 2020
<u>IVACAFTOR - KALYDECO</u>						
N 207925	001	9670163	Dec 28, 2026	DP U-1311	NPP	Jul 31, 2020
<u>IVACAFTOR - KALYDECO</u>						
N 207925	002	9670163	Dec 28, 2026	DP U-1311	NPP	Jul 31, 2020
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	001	7973038	Nov 08, 2026	U-1973		
		9670163	Dec 28, 2026	DP U-1911		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	002	7973038	Nov 08, 2026	U-1973		
		9670163	Dec 28, 2026	DP U-1911		
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388	001	>A> 8173707	Jul 30, 2023	U-1518		
		>A> 8173707*PED	Jan 30, 2024			
		>A> 8586633	Jul 30, 2023	DP		
		>A> 8586633*PED	Jan 30, 2024			
		>A> 9066856	Oct 23, 2033	DP		
		>A> 9066856*PED	Apr 23, 2034			
		>A> 9278101	Jul 30, 2023	U-1518		
		>A> 9278101*PED	Jan 30, 2024			
		>A> 9399040	Jul 30, 2023	DP		
		>A> 9399040*PED	Jan 30, 2024			
		>A> 9486406	Oct 23, 2033	DP		
		>A> 9486406*PED	Apr 23, 2034			
<u>L-GLUTAMINE - ENDARI</u>						
N 208587	001				I-748 ODE	Jul 07, 2020 Jul 07, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	001	>A> RE38551	Mar 17, 2022	DS	U-1567	
		>A> RE38551	Mar 17, 2022	DS	U-2140	
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	002	>A> RE38551	Mar 17, 2022	DS	U-1567	
		>A> RE38551	Mar 17, 2022	DS	U-2140	
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	003	>A> RE38551	Mar 17, 2022	DS	U-1567	
		>A> RE38551	Mar 17, 2022	DS	U-2140	
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	004	>A> RE38551	Mar 17, 2022	DS	U-1567	
		>A> RE38551	Mar 17, 2022	DS	U-2140	



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001	>A> RE38551	Mar 17, 2022	DS U-1567			
	>A> RE38551	Mar 17, 2022	DS U-2140			
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022			U-1663	
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022			U-1663	
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-1663			
	7754731*PED	Sep 11, 2029				
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 001					I-754 ODE	Sep 15, 2020 Sep 15, 2024
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 002					I-754 ODE	Sep 15, 2020 Sep 15, 2024
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 003					I-754 ODE	Sep 15, 2020 Sep 15, 2024
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	>A> 6211233	Jun 17, 2018	DS DP			
	>A> 7273946	Oct 03, 2025	DS DP U-2144			
	>A> 7629345	Jan 05, 2025	DP U-2144			
	>A> 7910767	Jan 05, 2025	DS DP U-2144			
	>A> 8058467	Jan 05, 2025	DS U-2144			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	>A> 7196086	May 22, 2024	DS DP		>A> NCE	Nov 08, 2022
	>A> 8513255	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	>A> 7196086	May 22, 2024	DS DP		>A> NCE	Nov 08, 2022
	>A> 8513255	May 22, 2024	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	>A> 7196086	May 22, 2024	DS DP		>A> NCE	Nov 08, 2022
	>A> 8513255	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	>A> 7196086	May 22, 2024	DS DP		>A> NCE	Nov 08, 2022
	>A> 8513255	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	>A> 7196086	May 22, 2024	DS DP		>A> NCE	Nov 08, 2022
	>A> 8513255	May 22, 2024	DS DP			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-1981			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-1981			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	9254307	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090 001	8633194	Oct 16, 2027	DP			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	9708371	Aug 16, 2033	DP U-1515			
	9708371	Aug 16, 2033	DP U-1516			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	9708371	Aug 16, 2033	DP U-1515			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	7304036	Aug 30, 2026	DS DP U-1516		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS		NS	Jan 25, 2020
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1516			
	8933030	Feb 17, 2031	DP U-1516			
	9708371	Aug 16, 2033	DP U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001					I-750	Aug 25, 2020
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-8			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
	>A> 9814751	Nov 06, 2035	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	9707176	Nov 11, 2030	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	9707176	Nov 11, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	9770455	Aug 31, 2031	U-2110			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	9770455	Aug 31, 2031	U-2110			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9687487	Oct 26, 2021	DS DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jan 18, 2020	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
	>A> 9815827	Feb 20, 2024	U-543		NPP	Jan 27, 2020
	>A> 9815827	Feb 20, 2024	U-2166		PED	Jul 27, 2020
					PED	Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9555027	May 26, 2026	DP U-543		NPP	Jan 27, 2020
	>A> 9815827	Feb 20, 2024	U-543		PED	Jul 27, 2020
	>A> 9815827	Feb 20, 2024	U-2166			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
	>A> 9815827	Feb 20, 2024	U-543		NPP	Jan 27, 2020
	>A> 9815827	Feb 20, 2024	U-2166		PED	Jul 27, 2020
					PED	Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9555027	May 26, 2026	DP U-543			
	>A> 9815827	Feb 20, 2024	U-543			
	>A> 9815827	Feb 20, 2024	U-2166			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
	>A> 9815827	Feb 20, 2024	U-543		NPP	Jan 27, 2020
	>A> 9815827	Feb 20, 2024	U-2166		PED	Jul 27, 2020
					PED	Jul 27, 2020
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001					NPP	Nov 04, 2019
					NS	Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002					NPP	Nov 04, 2019
					NS	Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001					NP	Nov 04, 2019
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001	9649318	Mar 31, 2035	DP			
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002	9649318	Mar 31, 2035	DP			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	9493582	Feb 27, 2033	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	8680136 9694025	Aug 17, 2031 Aug 08, 2031	DS DP U-2120			
<u>MESALAMINE - MESALAMINE</u>						
A 091640 001					PC	Jan 14, 2018
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6303661 6890898 7078381 7459428	Apr 24, 2017 Feb 02, 2019 Feb 02, 2019 Feb 02, 2019	U-1996 U-1996 U-1996 U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6303661 6890898 7078381 7459428	Apr 24, 2017 Feb 02, 2019 Feb 02, 2019 Feb 02, 2019	U-1996 U-1996 U-1996 U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6303661 6890898 7078381 7459428	Apr 24, 2017 Feb 02, 2019 Feb 02, 2019 Feb 02, 2019	U-1996 U-1996 U-1996 U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6303661 6890898 7078381 7459428	Apr 24, 2017 Feb 02, 2019 Feb 02, 2019 Feb 02, 2019	U-1996 U-1996 U-1996 U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6303661 6890898 7078381 7459428	Apr 24, 2017 Feb 02, 2019 Feb 02, 2019 Feb 02, 2019	U-1996 U-1996 U-1996 U-1996			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9533102 9629959	Jan 24, 2026 Jan 24, 2026	DP DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9259427	Jan 02, 2033	DP		ODE	Apr 25, 2024
					ODE	Apr 25, 2024
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	9492445	Sep 30, 2029	DP U-1185			
	9724343	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9668981	Oct 07, 2025	U-2024			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001 >A>	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002 >A>	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003 >A>	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004 >A>	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005 >A>	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006 >A>	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007 >A>	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	9545399	Aug 14, 2033	DP U-1827			
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
	8222244	Oct 29, 2022	U-2007		ODE	Apr 28, 2024
	8575146	Dec 02, 2030	U-2008		ODE	Apr 28, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001 >A>	9829495	Aug 15, 2036	U-1643			
<u>MITOMYCIN - MITOSOL</u>						
N 022572 001	9539241	Jan 02, 2028	DS DP U-2095			
	9649428	May 21, 2029	U-2095			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	9108975	Nov 11, 2031	DS DP		NCE	Mar 23, 2022
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP U-1185			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9211253	Mar 16, 2035	DP			
	9561177	Mar 16, 2035	DP U-1903			
	9629965	Mar 16, 2035	DP U-1903			
	9775838	Mar 16, 2035	U-1903			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	9480644	Mar 16, 2035	DP U-1903			
	9707226	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 209862 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9555000	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9555000	Apr 04, 2023	DP U-1556			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	9693978	Mar 03, 2026	DP			
	9693979	Mar 03, 2026	DP			
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	9662398	Dec 01, 2030	DP			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	6288082	Sep 24, 2019	DS DP U-2043		NCE	Jul 17, 2022
	7399865	Dec 29, 2025	DS DP			
	7982043	Oct 08, 2025	U-2043			
	8518446	Nov 20, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-2043			
	9139558	Oct 15, 2028	U-2043			
	9211291	Mar 24, 2030	U-2043			
	9630946	Oct 15, 2028	U-2043			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	8071623	Mar 22, 2030	DS DP		NCE	Mar 27, 2022
	8436185	Apr 24, 2029	DS		ODE	Mar 27, 2024
<u>NITISINONE - ORFADIN</u>						
N 021232 001					>A> D-169	Sep 01, 2020

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITISINONE - ORFADIN</u>						
N 021232 002					>A> D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232 003					>A> D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232 004					>A> D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 206356 001					>A> D-169	Sep 01, 2020
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	>A> 9770570	May 03, 2036	U-2148		M-167	Oct 09, 2018
	>A> 9770570*PED	Nov 03, 2036				
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	6166197	Dec 26, 2017	DS		ODE	Dec 23, 2023
	6210892	Oct 07, 2018		U-1942		
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025		U-1942		
	8110560	Dec 05, 2025		U-1943		
	8110560	Dec 05, 2025		U-1944		
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030		U-1941		
	9717750	Jun 17, 2030		U-1942		
	9717750	Jun 17, 2030		U-1943		
	9717750	Jun 17, 2030		U-2093		
	9717750	Jun 17, 2030		U-2094		
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	7151102	Apr 29, 2022	DS DP		NCE	Dec 19, 2019
	7449464	Oct 11, 2024	DS DP		NP	Aug 17, 2020
	7981889	Oct 11, 2024	DS DP		ODE	Dec 19, 2021
	8143241	Aug 12, 2027		U-2101		
	8143241	Aug 12, 2027		U-2102		
	8143241	Aug 12, 2027		U-2103		
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031		U-2101		
	8859562	Aug 04, 2031		U-2102		
	8912187	Mar 12, 2024		U-2101		
	8912187	Mar 12, 2024		U-2102		
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	7151102	Apr 29, 2022	DS DP		NCE	Dec 19, 2019
	7449464	Oct 11, 2024	DS DP		NP	Aug 17, 2020
	7981889	Oct 11, 2024	DS DP		ODE	Dec 19, 2021
	8143241	Aug 12, 2027		U-2101		
	8143241	Aug 12, 2027		U-2102		
	8143241	Aug 12, 2027		U-2103		
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031		U-2101		
	8859562	Aug 04, 2031		U-2102		
	8912187	Mar 12, 2024		U-2101		
	8912187	Mar 12, 2024		U-2102		
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	8733341	Oct 16, 2030	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	6149054	Dec 19, 2016	DP			
	6149054*PED	Jun 19, 2017				
	6846413	Aug 28, 2018	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP			
<u>OLOPATADINE HYDROCHLORIDE - OLOPATADINE HYDROCHLORIDE</u>						
A 090848 001					PC	Dec 05, 2017
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	9533053	May 19, 2032	DP			
<u>OMACETAXINE MEPESUCCINATE - SYNTRIBO</u>						
N 203585 001	6987103	Oct 26, 2026	U-1300			
<u>OMBITASVIR; PARITAPREVR; RITONAVIR - TECHNIVIE</u>						
N 207931 001					I-743	Jul 24, 2018
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2018	DP			
	5948818	May 13, 2018	DP			
<u>OMEPRazole MAGNESIUM - OMEPRazole MAGNESIUM</u>						
A 204152 001					>A> PC	May 30, 2018
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	9649352	Jul 16, 2035	DP			
	9682061	Apr 26, 2030	U-1569			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	9732058	Jul 25, 2032	DS DP U-1777			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	9732058	Jul 25, 2032	DS DP U-1777			
<u>OSPemIFENE - OSPHENA</u>						
N 203505 001 >A>	6245819	Jul 21, 2025	U-1370			
	9566252	Jul 21, 2020	U-1370			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	7955619	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552 001	7812049	May 02, 2028	U-1959		NP	Jan 18, 2020
	8420688	Aug 02, 2024	U-1959			
	8883838	Dec 01, 2031	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Mar 04, 2032	U-1290			
	9511046	Jan 12, 2034	U-1434			
	9597409	Mar 04, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 001	7473761	Dec 14, 2026	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 002	7473761	Dec 14, 2026	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 003	7473761	Dec 14, 2026	DS DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 001	7473761	Dec 14, 2026	DS DP			
	9351923	May 23, 2028	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 002	7473761	Dec 14, 2026	DS DP			
	9351923	May 23, 2028	DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 003	7473761	Dec 14, 2026	DS DP			
	9351923	May 23, 2028	DP			
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001					NPP	Sep 20, 2020
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	9545457	Jan 13, 2019	U-665			
	9789210	Mar 16, 2037	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9566271	Jan 15, 2024	U-1974			
	9765053	Jul 27, 2022	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001					>A> NCE	Oct 15, 2019
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	7566729	Apr 22, 2029	U-2077		>A> NCE	Oct 15, 2019
	7566729	Apr 22, 2029	U-2078		ODE	Oct 15, 2021
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2017	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002				>A> NCE ODE		Oct 15, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	7566729	Apr 22, 2029	U-2077	>A> NCE ODE		Oct 15, 2019 Oct 15, 2021
	7566729	Apr 22, 2029	U-2078			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2017	U-2079			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
	7799897	Jun 09, 2022	DS			
	8637451	Mar 28, 2022	U-1964			
	9610321	Sep 11, 2031	U-1999			
	9616097	Jul 02, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Dec 22, 2026	DS DP			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001 >A>	9750822	Mar 13, 2029	DP			
<u>PRASUGREL HYDROCHLORIDE - PRASUGREL</u>						
A 205927 001					PC	Feb 11, 2018
<u>PRASUGREL HYDROCHLORIDE - PRASUGREL</u>						
A 205927 002					PC	Feb 11, 2018
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9504699	Aug 03, 2027	U-1362			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 001	6197819	Dec 30, 2018	DS DP		NP	Oct 11, 2020
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	9144559	Nov 02, 2026	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA CR</u>						
N 209501 001	RE41920	Dec 30, 2018	U-2136			
	RE41920	Dec 30, 2018	U-2137			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 002	6197819	Dec 30, 2018	DS DP		NP	Oct 11, 2020
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	9144559	Nov 02, 2026	DP			
	RE41920	Dec 30, 2018	U-2136			
	RE41920	Dec 30, 2018	U-2137			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 003	6197819	Dec 30, 2018	DS DP		NP	Oct 11, 2020
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	9144559	Nov 02, 2026	DP			
	RE41920	Dec 30, 2018	U-2136			
	RE41920	Dec 30, 2018	U-2137			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	7169780	Oct 03, 2023	DS DP		D-167	May 26, 2020
	7169780*PED	Apr 03, 2024			>A> NPP	Nov 22, 2020
	7217713	Oct 21, 2022	U-257		PED	Nov 26, 2020
	7217713*PED	Apr 21, 2023			>A> PED	May 22, 2021
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	7169780	Oct 03, 2023	DS DP		>A> NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			NS	May 26, 2020
	7217713	Oct 21, 2022	U-257		PED	Nov 26, 2020
	7217713*PED	Apr 21, 2023			>A> PED	May 22, 2021
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
	9649311	Oct 21, 2030	DP			
	9649311*PED	Apr 21, 2031				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 001	7169780	Oct 03, 2023	DS DP		>A> NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			>A> PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	7169780	Oct 03, 2023	DS DP		>A> NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			>A> PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP		>A> NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			>A> PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 002					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 002					PC	Jul 01, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001					M-194	Jan 17, 2020
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	7351834	Jun 28, 2022	DS		I-744 ODE	Apr 27, 2020 Apr 27, 2024
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-1981			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-1981			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9629828	Jul 24, 2029	U-1994			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	>A> 7592339	Dec 11, 2020	U-1167		D-168	Oct 27, 2020
	>A> 7592339	Dec 11, 2020	U-1200			
	>A> 7592339	Dec 11, 2020	U-1301			
	>A> 7592339	Dec 11, 2020	U-1302			
	>A> 7592339	Dec 11, 2020	U-1303			
	>A> 7592339	Dec 11, 2020	U-2142			
	>A> 9415053	Nov 13, 2024	DP U-1167			
	>A> 9415053	Nov 13, 2024	DP U-1200			
	>A> 9415053	Nov 13, 2024	DP U-1301			
	>A> 9415053	Nov 13, 2024	DP U-1302			
	>A> 9415053	Nov 13, 2024	DP U-1303			
	>A> 9415053	Nov 13, 2024	DP U-2142			
	>A> 9539218	Feb 17, 2034	U-1953			
	>A> 9539218	Feb 17, 2034	U-1954			
	>A> 9539218	Feb 17, 2034	U-1955			
	>A> 9539218	Feb 17, 2034	U-1956			
	>A> 9539218	Feb 17, 2034	U-1957			
	>A> 9539218	Feb 17, 2034	U-2143			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	>A> 7592339	Dec 11, 2020	U-1167	Y		
	>A> 7592339	Dec 11, 2020	U-1200	Y		
	>A> 7592339	Dec 11, 2020	U-1301	Y		
	>A> 7592339	Dec 11, 2020	U-1302	Y		
	>A> 9415053	Nov 13, 2024	DP U-1167			
	>A> 9415053	Nov 13, 2024	DP U-1200			
	>A> 9415053	Nov 13, 2024	DP U-1301			
	>A> 9415053	Nov 13, 2024	DP U-1302			
	>A> 9415053	Nov 13, 2024	DP U-1303			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001					M-208	Aug 31, 2020
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	8404702	Apr 04, 2027	U-1741			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399 001	>A> 7049320	Dec 08, 2023	DS DP U-1741		NCE	Sep 01, 2020
	>A> 7981905	Apr 04, 2027	U-1741			
	>A> 8178550	Apr 04, 2027	DS DP U-1741			
	>A> 8404702	Apr 04, 2027	U-1741			
	>A> 8470842	Jan 18, 2029	U-1741			
	>A> 8796299	Dec 17, 2022	U-1741			
	>A> 9101615	Jul 14, 2032	U-1741			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 001					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 002					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 003					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 004					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 005					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 006					M-203	Mar 23, 2020
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	6495541	Jan 10, 2020	DS DP		NCE	Dec 19, 2021
	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	9045487	Feb 10, 2031	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	9662335	Dec 12, 2026	DS			
<u>SACROSIDASE - SUCRAID</u>						
N 020772 001	9469847	Feb 07, 2034	DS DP			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-198	Feb 27, 2020
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-198	Feb 27, 2020
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001					NCE GAIN	Sep 15, 2022 Sep 15, 2027
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9623022	Jul 28, 2026	U-1467			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 001	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 002	9597289	Feb 23, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	9770406	Jul 12, 2025	DP U-172			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	9539330	Dec 22, 2019	DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9549941	Mar 26, 2029	U-1958		NPP	Apr 07, 2020
					ODE	Apr 07, 2024
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	9757406	Jan 30, 2034	DP		>A> NCE	Dec 06, 2018
					NPP	Aug 01, 2020
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	7964580	Mar 26, 2029	DS DP U-2039		NCE	Dec 06, 2018
	7964580	Mar 26, 2029	DS DP U-2040		NCE	Jun 28, 2021
	8334270	Mar 21, 2028	DS DP U-2039		NCE	Jul 18, 2022
	8334270	Mar 21, 2028	DS DP U-2040			
	8575135	Nov 05, 2033	DS DP U-2039			
	8575135	Nov 05, 2033	DS DP U-2040			
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9284342	Sep 13, 2030	DS DP U-2039			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	9284342	Sep 13, 2030	DS DP U-2040			
	9296782	Jul 17, 2034	DS DP			
	9585906	Mar 21, 2028	DS DP U-2039			
	9585906	Mar 21, 2028	DS DP U-2040			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 001	6017927	Nov 19, 2018	DS DP			
	6017927*PED	May 19, 2019				
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 002	6017927	Nov 19, 2018	DS DP			
	6017927*PED	May 19, 2019				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	9737488	Sep 10, 2028	DP U-1480			
	9737488	Sep 10, 2028	DP U-1696			
	9737488	Sep 10, 2028	DP U-2107			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	9724297	Aug 31, 2035	DP U-2096			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	9757394	Oct 28, 2036	DP U-2109			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	6174442	Dec 19, 2018	DS U-1468			
	9561251	Jan 23, 2030	DP U-1468			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	5686060	Nov 11, 2019	DS DP			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	9649456	Oct 21, 2030	DP U-1719			
	9649456	Oct 21, 2030	DP U-2010			
	9649456	Oct 21, 2030	DP U-2011			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001					>A> I-755	Nov 16, 2020

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002					>A> I-755	Nov 16, 2020
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003					>A> I-755	Nov 16, 2020
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004					>A> I-755	Nov 16, 2020
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	9549918	May 30, 2028	DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 001	>A> 5859006	Nov 21, 2017	DS DP	Y		
	>A> 5859006*PED	May 21, 2018				
	>A> 6821975	Nov 19, 2020	DS DP U-533			
	>A> 6821975	Nov 19, 2020	DS DP U-614			
	>A> 6821975	Nov 19, 2020	DS DP U-1184			
	>A> 6821975*PED	May 19, 2021				
	>A> 6943166	Apr 26, 2020	U-155			
	>A> 6943166	Apr 26, 2020	U-614			
	>A> 6943166	Apr 26, 2020	U-1184			
	>A> 6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155			
	7182958	Apr 26, 2020	DP U-1184			
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 002	>A> 5859006	Nov 21, 2017	DS DP			
	>A> 5859006*PED	May 21, 2018				
	>A> 6821975	Nov 19, 2020	DS DP U-533			
	>A> 6821975	Nov 19, 2020	DS DP U-614			
	>A> 6821975*PED	May 19, 2021				
	>A> 6943166	Apr 26, 2020	U-155			
	>A> 6943166	Apr 26, 2020	U-614			
	>A> 6943166*PED	Oct 26, 2020				
	>A> 7182958	Apr 26, 2020	DP U-155			
	>A> 7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 003	>A> 5859006	Nov 21, 2017	DS DP			
	>A> 5859006*PED	May 21, 2018				
	>A> 6821975	Nov 19, 2020	DS DP U-533			
	>A> 6821975	Nov 19, 2020	DS DP U-614			
	>A> 6821975*PED	May 19, 2021				
	>A> 6943166	Apr 26, 2020	U-614			
	>A> 6943166*PED	Oct 26, 2020				
	>A> 7182958	Apr 26, 2020	DP U-155			
	>A> 7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 004	>A> 5859006	Nov 21, 2017	DS DP			
	>A> 5859006*PED	May 21, 2018				
	>A> 6821975	Nov 19, 2020	DS DP U-533			
	>A> 6821975	Nov 19, 2020	DS DP U-614			
	>A> 6821975*PED	May 19, 2021				
	>A> 6943166	Apr 26, 2020	U-155			
	>A> 6943166*PED	Oct 26, 2020				



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - CIALIS</u>						
N 021368 004	>A> 7182958	Apr 26, 2020	DP U-155			
	>A> 7182958*PED	Oct 26, 2020				
<u>TADALAFIL - ADCIRCA</u>						
N 022332 001	>A> 5859006	Nov 21, 2017	DS DP U-975			
	>A> 5859006*PED	May 21, 2018				
	>A> 6821975	Nov 19, 2020	DS DP			
	>A> 6821975*PED	May 19, 2021				
	>A> 7182958	Apr 26, 2020	DP			
	>A> 7182958*PED	Oct 26, 2020				
<u>TALC - STERITALC</u>						
N 205555 001					ODE	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 002					ODE	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 003					ODE	May 01, 2024
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	5856529	Dec 09, 2018	DS DP U-2149			
	9539234	Jan 25, 2033	U-1934			
	9549913	Jan 25, 2033	U-1486			
	9730910	May 17, 2034	U-2085			
	>A> RE46604	Jan 25, 2033	U-2147			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027	U-2016			
	9549938	Feb 16, 2026	U-1951			
	9566289	Feb 16, 2026	DP			
	9566290	Feb 16, 2026	U-1970			
	9572823	Feb 16, 2026	U-1970			
<u>TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVUE 30ML</u>						
N 020372 002	>A> 9549999	Mar 10, 2030	DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9539310	Nov 01, 2025	U-1320			
	9545434	Nov 01, 2025	U-1320			
	9545435	Nov 01, 2025	U-1320			
	9555079	Nov 01, 2025	U-1320			
	9572867	Nov 01, 2025	U-1320			
	9592273	Nov 01, 2025	U-1320			
	9592274	Nov 01, 2025	U-1320			
<u>TELOTRISTAT ETIPRATE - XERMELO</u>						
N 208794 001	7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
	7709493	Dec 11, 2027	DS	U-1979	ODE	Feb 28, 2024
	7968559	Dec 11, 2027		U-1979		
	8193204	Feb 27, 2031	DS			
	8653094	Dec 19, 2028	U-1979			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9662340	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9662340	Feb 11, 2034	DP U-1531			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THIOTEPA - TEPADINA</u>						
N 208264 001					I-747 ODE	Jan 26, 2020 Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 002					I-747 ODE	Jan 26, 2020 Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9694078	Mar 13, 2026	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6777423*PED	Mar 24, 2022				
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				
	7309707	Sep 24, 2021	DS DP			
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS DP			
	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	9010323	Apr 19, 2030	DP			
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
	RE39820	Jan 30, 2018	DS DP U-566			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	5964416*PED	Apr 04, 2017			PED	Aug 15, 2020
	6149054	Dec 16, 2016	DP			
	6149054*PED	Jun 16, 2017				
	6176442*PED	Dec 01, 2016				
	6453795	Dec 05, 2016	DP			
	6453795*PED	Jun 05, 2017				
	6726124	Oct 04, 2016	DP			
	6726124*PED	Apr 04, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7104470*PED	Apr 04, 2017				
	7246615*PED	Dec 01, 2016				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP U-1593			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	6149054	Dec 16, 2016	DP		PED	Aug 15, 2020
	6149054*PED	Jun 16, 2017				
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP			
	RE39820*PED	Jul 30, 2018				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026		U-1751		
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026		U-1751		
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	RE41783	Dec 08, 2025	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9555005	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024			U-2036	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024			U-2036	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024			U-2036	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024			U-2036	
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024				
	8252839	May 24, 2024		DP		
	8349892	Jan 22, 2031		DP		
	8410169	Feb 13, 2030		DP		
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029		DP		
	9050311	May 24, 2024		DS DP		
	9278901	May 24, 2024			U-1475	
	9393203	Apr 27, 2026		DP	U-1877	
	9422223	May 24, 2024		DP		
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TRIAMCINOLONE ACETONIDE - ZILRETTA</u>						
N 208845 001	8828440	Aug 04, 2031		DP		
	9555048	Aug 04, 2031			NP	Oct 06, 2020
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001					NP	Jun 29, 2020
					ODE	Jun 29, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001					NP ODE	Jun 29, 2020 Jun 29, 2024
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	7488827	Dec 18, 2027	DS DP		NCE	Dec 18, 2018
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	7439393	May 21, 2025	DS DP U-1476		NCE	May 10, 2018
	7488827	Dec 18, 2027	DS DP		NCE	Dec 18, 2018
	9750726	Nov 29, 2030	DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	8039627	Oct 06, 2029	DS DP		NCE	Apr 11, 2022
	8357697	Nov 08, 2027	U-1995			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	8039627	Oct 06, 2029	DS DP		NCE	Apr 11, 2022
	8357697	Nov 08, 2027	U-1995			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001	8889109	Dec 11, 2027	DP			
	9642911	Dec 11, 2027	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9687526	Jan 30, 2035	U-1857			
	9744209	Jan 30, 2035	U-1857			
	9744239	Jan 30, 2035	U-1857			
	9750785	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9375478	Jan 30, 2035	U-1857			
	9687526	Jan 30, 2035	U-1857			
	9744209	Jan 30, 2035	U-1857			
	9744239	Jan 30, 2035	U-1857			
	9750785	Jan 30, 2035	DP			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	>A> 8470818	Aug 02, 2026	U-1418		>A> I-757	Nov 06, 2020
	>A> 8470818	Aug 02, 2026	U-2164			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	7144884	Oct 02, 2022	DS DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	7144884	Oct 02, 2022	DS DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	7144884	Oct 02, 2022	DS DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	7144884	Oct 02, 2022	DS DP U-1439			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	9707270	Oct 01, 2024	U-2084			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	9707270	Oct 01, 2024	U-2084			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			

## Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.



## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at  
[http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at  
[http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)